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SUMMARY 
Peptides represent a source of novel therapeutics for recalcitrant human diseases, 
but screening for bioactivity from natural or synthetic sources can be uneconomic. 
In contrast, in vivo expression of peptides from DNA libraries in a heterologous host 
such as Escherichia coli may combine production with screening. This dissertation 
aimed to use such an approach to discover novel bioactive peptides in a 
high-throughput and cost-effective manner, with a focus on antimicrobials and 
antiaggregants as proof-of-principle. 
 
Antimicrobial peptides (AMPs) are innate defence effectors that may combat 
antibiotic-resistant pathogens. An inducible, autocleaving fusion tag was utilised to 
produce the model murine cathelicidin K2C18, along with a number of variants, 
which exhibited varying degrees of antimicrobial activity against a panel of 
microbes. Importantly, K2C18 also exhibited a bacteriostatic effect in vivo when 
secreted to the periplasm. This allowed for the implementation of an in vivo 
whole-cell screen for novel AMPs, using genomic DNA libraries as an input. One 
putative hit, the peptide S-H4, showed similar in vivo behaviour to K2C18 and was 
active when added exogenously to microbial cultures. 
 
A second in vivo screen was constructed to search for inhibitors of A!42 
aggregation, a process implicated in Alzheimer’s disease. The aggregation state of 
A!42 was coupled to the fluorescence of a chromophore fusion partner, and used 
to screen co-expressed peptides from a random DNA library for putative 
antiaggregants. Additionally, the system incorporated an internal fluorescent 
reference to allow ratiometric comparison between samples. Several hits were 
identified and further validated using flow cytometry, with work ongoing to assess 
their activity in vitro. 
 
Proof-of-principle of these two screens was achieved, indicating that such in vivo 
approaches to bioactive peptide discovery could lead to the development of new 
and useful therapeutics. 
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1 
CHAPTER 1 – GENERAL INTRODUCTION 
1.1 Bioactive peptides 
1.1.1 Brief history 
Peptides are ubiquitous in living systems. In their simplest form, these constitute 
oligomers that are ribosomally synthesised from a pool of 20 common amino acids. 
The particular sequence order is encoded via a universal genetic code specified by 
nucleic acid templates. Organisms typically use peptides as signalling molecules to 
convey information regarding cellular state between one another at a unicellular 
level, or to coordinate global tissue responses to physiological cues at a 
multicellular level. Sewald & Jakube (2009) have written an excellent textbook that 
serves as an introduction to the peptide field. 
 
The development of novel therapeutics is a driver of interest in these common, yet 
key, compounds. Whether it is the dysregulation of a normal biological process in 
humans, treatment of a pathogenic or undesired species, or a more cosmetic 
application, being able to remediate or alter such processes underpins modern 
medicine. Peptides exhibiting bioactivity (that is, provoking a biological response) 
are a relatively new class of therapeutics (Sewald & Jakubke, 2009). Rather it is 
small molecule drugs, typically with a molecular mass of 500 daltons or less, that 
have traditionally been used as medicines. For example, Hippocrates mentions the 
use of willow bark preparations as an analgesic in the 5th century BC, and the active 
ingredient, salicylic acid, has now been in use for two centuries as aspirin (Awtry & 
Loscalzo, 2000). 
 
Medicine had to wait until the 20th century, however, for peptides to become 
feasible therapeutics, due to the greater technical capabilities required to synthesise 
or purify these compounds in comparison to small molecule drugs. Insulin is the 
most famous example of a bioactive peptide. Used by the body as a global 
hormone to promote the uptake of blood glucose in liver, muscle and adipose 
tissue, this 51 amino acid entity (5.8 kDa; two subunits joined by disulphide bonds) 
is produced by the islets of Langerhans (!-cells) in the pancreas of humans via 
processing of the proinsulin precursor (Steiner & Oyer, 1967). Lack of insulin 
production through autoimmune destruction of these cells, or an insufficient 
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signalling response to insulin itself, are the underlying physiological causes of 
diabetes mellitus (Steiner et al., 2009). 
 
Diabetes, and the discovery of insulin, pioneered much peptide research last 
century (Sneader, 2001). Fredrick Banting and Charles Best first isolated extracts of 
the mature peptide while experimenting on canine pancreases, and successfully 
used natively purified insulin (sourced from foetal calf pancreas) to treat paediatric 
patients for the then fatal disease in 1922 (Best, 1962). Porcine insulin was soon 
found to be a better heterologous match for humans, but due to immunogenic 
concerns and source limitations, deriving a human version of this life-saving peptide 
became a goal. Insulin became the first protein to have its amino acid sequence 
elucidated in 1951 (Sanger, 1959) and was subsequently chemically-synthesised in 
its human form in the 1960s (Katsoyannis & Tometsko, 1966). Finally, in 1978 
human biosynthetic insulin was successfully produced recombinantly in Escherichia 
coli by Genentech Inc. (Genentech, 1978), and its improved variants have been 
mass-produced economically for medical use from the 1980s onwards (Johnson, 
1983). 
 
More modern examples of useful bioactive peptides include Eli Lilly and Company’s 
teriparatide (trade name Forteo, 34 aa, 4.1 kDa), a truncated recombinant version 
of the human hormone parathyroid which is used to treat some forms of 
osteoporosis via regulating calcium metabolism and stimulating osteoblast activity 
(Saag et al., 2007); and Hoffmann-La Roche Ltd.’s enfuvirtide (trade name Fuzeon, 
36 aa, 4.5 kDa), a human immunodeficiency virus fusion inhibitor which is employed 
as a therapy of last resort and acts as an antagonist of the viral transmembrane 
protein gp41 to inhibit its activation by other key viral entry proteins (Kilby et al., 
1998). 
 
Although peptides and proteins are both composed of amino acids, they are 
differentiated on the basis of molecular size. It is commonly accepted that the 
peptide label may be applied to proteinaceous compounds with 100 or fewer amino 
acid residues (Lax, 2010). However, short peptides (e.g. 2 aa) are more akin to 
small molecule drugs in overall size, while large peptides (e.g. greater than 50 aa) 
are more similar to small proteins. Both are peptides, and although this appears to 
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be a semantic issue, it has regulatory implications. Small molecule drugs and 
proteins are approved for therapeutic use in different manners by safety authorities 
(Lax, 2010), resulting in a fuzziness with regards to exact peptide size definition. 
 
Because of amino acid diversity, even short peptides allow an enormous number of 
possible sequence variations. For instance, if just the natural complement of 
20 amino acids is considered (non-natural residues are discussed in 
Section 1.1.4.2), a 4-residue peptide has 204 possible permutations (i.e. ~160,000 
distinct compounds), while a 14 residue peptide has 2014 (~1.64 x 1018 
compounds). In practice these theoretical compounds will not be as diverse as the 
numbers suggest, as some amino acids exhibit similar properties e.g. the 
hydrophobicity of leucine, isoleucine and valine. The use of random combinations of 
residues in a short peptide will typically lead to a linear, unstructured and 
consequently unconstrained compound. A lot of bioactive peptides, however, 
possess some form of structure (Watt, 2006). Secondary structures, such as 
"-helix, !-sheet, disulfide bonds and cyclisation are possible in even short chains of 
amino acids (Sewald & Jakubke, 2009). Dimerisation and oligomerisation is also 
possible (Sato et al., 2006a). For example, insulin is a two-chain compound cleaved 
from a single precursor, possessing three disulphide bonds and a large amount of 
"-helix (Steiner et al., 2009). The significance of secondary structure is discussed 
later in Sections 1.1.2.2 and 1.2.2.2.  
 
1.1.2 Properties of bioactive peptides 
Bioactive peptide research focuses on therapeutic applications. The following 
sections introduce some of the properties, advantages and challenges of using 
peptides as therapeutic drugs. 
 
1.1.2.1 Specificity 
A number of bioactive peptides are truncations derived from the most active part of 
a parent protein. For instance, the peptide therapeutics teriparatide (34 aa) and 
enfuvirtide (36 aa) mentioned earlier are the effector regions of their parent proteins 
– parathyroid hormone (84 aa) and gp41 (345 aa) respectively (Watt, 2006). 
Because of their large number of hydrogen bond donor/acceptor moieties, these 
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peptide truncations offer greater specificity than a small molecule drug, and so 
consequently exhibit less off-target binding (Vlieghe et al., 2010). An advantage of 
this higher specificity is that typically only a low amount of peptide (!g to a few mg 
per day) needs to be administered to a patient for an effective outcome (Lax, 2010), 
which may reduce toxicity (see Section 1.1.2.4).  
 
1.1.2.2 Stability 
A significant drawback of using natural peptides is their short half-life in vivo. Firstly, 
their small size means they are susceptible to being removed from the blood stream 
via filtration in the kidneys (McGregor, 2008). Secondly, their unstructured linear 
form makes them particularly labile to the activity of peptidases present in the blood 
stream, liver and kidney, giving them a typical half-life of only minutes in the blood 
stream (Werle & Bernkop-Schnürch, 2006). Overcoming protease susceptibility is 
important for parenterally administered peptides, and is especially relevant if a 
peptide is delivered orally. Even if the acidic pH of the stomach is safely traversed, 
the lumen of the small intestine poses the greatest challenge – the pancreas 
secretes peptidases such as chymotrypsin, trypsin, elastase and carboxypeptidases 
in large quantities for the purpose of complete protein digestion (Vlieghe et al., 
2010). 
 
Peptide instability can be both an advantage and disadvantage: if treatment only 
requires a short systemic residency time, a rapid turnover of the bioactive peptide 
gives less opportunity for undesirable side-effects to occur (Loffet, 2002). This is 
mostly applicable to hormonal analogues (e.g. insulin), whose continued systemic 
presence is undesirable with regards to bodily homeostasis. Despite this, most 
bioactive peptides would be preferred in a more stable, long-lasting format. The use 
of polyethylene glycol (PEG) as a conjugate is one way of increasing peptide half-
life, as protease function may be inhibited via conferred steric hindrance near the 
catalytic site (Lien & Lowman, 2003). Furthermore, PEG exhibits high solubility, low 
immunogenicity and a lack of toxicity, and seems to confer these properties on its 
conjugates (Werle & Bernkop-Schnürch, 2006). For example, the use of PEGylation 
increased the half-life of glucagon-like peptide-1 (a gut hormone to promote insulin 
production) by 16-fold in rat models (Lee et al., 2005a), and 330-fold when 
conjugated to interferon "-2-b (a hepatitis C anti-viral) (Ramon et al., 2005). 
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Polymer chains, typically ranging from 5 to 40 kDa in molecular mass, may be 
attached at a specific peptide residue, or spread over multiple sites (Sato et al., 
2006a). However, using multiple PEGylation sites complicates the task of creating a 
homogenous peptide batch, something which is desirable for therapeutic 
compounds (McGregor, 2008). Another positive side-effect of bulking the peptide 
mass up is the reduction of clearance from the bloodstream via the kidneys, as 
molecules with a mass over 50 kDa generally require alternative routes of 
breakdown (i.e. by the liver) before being disposed of (Sato et al., 2006a). Adding 
carbohydrate chains such as glucose or xylose moieties is an alternative to 
PEGylation (Vlieghe et al., 2010).  
 
A simpler modification to improve protease resistance is to acetylate the N-terminal 
residue or amidate the C-terminus of a peptide. Such measures have been shown 
to reduce susceptibility to exopeptidases in particular (Werle & Bernkop-Schnürch, 
2006). Another approach involves the swapping of one or more natural L-amino 
acids with their D-amino enantiomers. For example, Novartis Pharmaceuticals AG’s 
octreotide (trade name Sandostatin, a somatostatin mimetic to inhibit growth 
hormone release) is an 8-residue truncated version of human somatostatin, with a 
key tryptophan in the D configuration: half-life in blood circulation was increased 
from a few minutes to 1.5 hours (Harris, 1994). Because such enantiomer swapping 
changes the structure of the peptide, it may no longer properly fit a protease active 
site and thus confers proteolytic resistance (McGregor, 2008). Fully “retroinverso” 
peptides, where the original peptide is produced in reverse with residues in the 
D-form, have also been explored (Watt, 2009). 
 
Structurally constraining the peptide is another method of reducing susceptibility to 
protease action. Introducing cross-linking disulfide bonds through cysteine 
side-chains, or cyclising the peptide head-to-tail (i.e. chemically-ligating the N- and 
C-terminals) may prevent it from fitting the cleaving site of a protease (Vlieghe et 
al., 2010). Providing a more rigid structure in this manner may also help constrain 
residue side-chains in a more “active” conformation, which may not be 
thermodynamically favoured in the linear form (Sato et al., 2006a). This potentially 
results in a higher binding affinity for the desired target. 
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Lastly, a peptide may be attached to a scaffold that already possesses innate 
stability. The FC region of an antibody is one such candidate, which has a serum 
retention time of several days, thanks in part to its systemic recycling via the 
neonatal FC receptor (Roopenian & Akilesh, 2007). Another scaffold that may be 
harnessed is the abundant serum protein albumin, which has a half-life of 19 days 
in humans (Lien & Lowman, 2003). Several companies, such as Genentech Inc. 
and Dyax Corp., are investigating using these well-described proteins as scaffolds 
to carry bioactive peptides (McGregor, 2008). Steric hindrance is a concern with 
regards to interfering with peptide activity, especially considering that such a 
scaffold will be 10 to 30 times greater in size than its cargo (Sato et al., 2006a). 
 
Finally, it should be emphasised that no matter what approach to improving peptide 
stability is used, any structural change to the active peptide may of course affect 
function. Such modifications need to be empirically validated. 
 
1.1.2.3 Bioavailability 
A major caveat to using peptides as therapeutics is that their targets should be in or 
exposed to the extracellular milieu – it is much more difficult for a peptide to access 
intracellular targets, as this involves crossing one or more biological membranes. 
While cell-penetrating peptides are being developed (Sebbage, 2009) and are 
discussed as a potential application in Section 1.1.3.1, any fusions of this sort are 
context-specific and need to be evaluated as such. Small molecule drugs, 
depending on their solubility and lipophilicity, seem to have a greater innate ability 
to passively diffuse into cells (McGregor, 2008). Endocytosis of peptides by cells 
still fails to solve the problem, as this merely traps them in another biological 
compartment (endosomes) (Foerg & Merkle, 2008). Even assuming that the peptide 
can escape this vesicle and its associated proteases, it may still have to cross 
additional biological membranes if the target is located inside an organelle e.g. a 
mitochondrion. However, there are many extracellular receptors that may be 
targeted, and activating or suppressing their particular signal cascades is one 
manner of influencing intracellular events. This is reflected in the targets of current 
peptides on the market (see Section 1.1.3.2). 
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Delivery of a peptide to its site of action, even if it is extracellular, may still pose 
difficulties. Parenteral injection is the most common form of delivery – the examples 
of insulin, teriparatide and enfuvirtide presented earlier are all administered in this 
manner. However, patient discomfort and compliance are issues when it comes to 
injections. The most desirable route of administration is oral (Vlieghe et al., 2010). 
Despite the severe stability issues that face a peptide traversing the gut as well as 
poor penetration of the intestinal mucosa to enter systemic circulation, many 
researchers have spent the last decade trying to develop an orally-compatible form 
of insulin (Lien & Lowman, 2003). It is envisaged that solving this problem will allow 
the oral delivery of other peptides in a generic manner. However, to date nothing 
has appeared on the market as trials continue. Alternative delivery approaches to 
the oral route include transdermal patches for passive diffusion through the skin; 
iontophroesis for active electromotive administration; sonophoresis for ultrasound-
mediated administration; and aerosols for inhalation and subsequent access to the 
blood stream through the pulmonary system (Lien & Lowman, 2003; Pichereau & 
Allary, 2006). The successful and mainstream employment of one of these methods 
will be a boon to the development of future bioactive peptides, as delivery remains 
one of the key obstacles to pharmaceutical development (Lax, 2010). One current 
solution, if the bioavailability of a peptide is low through either poor stability or 
delivery, is to increase the dosage (if safe to do so) via more frequent administration 
– or more preferably, through a sustained delivery system (i.e. slow constant 
release) (Werle & Bernkop-Schnürch, 2006). However, this leads to an increased 
cost of treatment (Lien & Lowman, 2003). 
 
1.1.2.4 Toxicity 
Bioactive peptides are usually composed of natural amino acids or their 
enantiomers, and thus seem more natural to the body than some synthetic small 
molecule drugs (Vlieghe et al., 2010). Metabolic break-down products are amino 
acids, and will be dealt with by the body just as normal protein turnover is, thus 
limiting undesired side-reactions. Where side-effects are seen it is usually related to 
dosage amounts, or, if injected, as a localised effect around the site of 
administration (Lax, 2010). This lack of systemic toxicity is seen as one of the key 
strengths of bioactive peptides (Vlieghe et al., 2010). 
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Despite this, potential immunogenicity and eventual hypersensitivity to the 
therapeutic remain as concerns (Sato et al., 2006a). However, it is postulated that 
peptides, because of their short length, do not exhibit major histocompatibility 
complex class II epitopes (i.e. are not recognised by key lymphocytes such as 
macrophages or B cells), and thus fail to invoke an adaptive immune response 
(Vlieghe et al., 2010). PEGylation might also be used to confer the non-
immunogenic properties of PEG to a peptide (Werle & Bernkop-Schnürch, 2006). 
Non-human derived peptide examples exist that have proven their lack of 
immunogenicity in clinical trials, such as enfuvirtide (39 aa, a HIV fusion inhibitor 
described earlier) and salmon calcitonin (31 aa, used to treat osteoporosis) (Loffet, 
2002). Monitoring of potential immunogenicity, however, should remain standard 
practice during the development of systemically administered peptides. 
 
1.1.3 Potential uses and market 
1.1.3.1 Potential uses 
The earliest therapeutic use of bioactive peptides fell in the hormonal category, e.g. 
insulin to remedy insulin deficiency in diabetes mellitus type 1, or insulin-like growth 
factor 1 to treat growth deficiencies in children having an imbalance in this hormone 
(Rosenbloom, 2006). While hormonal mimetics are the most popular class of 
bioactive peptides, now that stability and bioavailability issues are being addressed 
there is a large range of other potential applications: allergies, analgesics, asthma, 
arthritis, baldness, cardiovascular diseases, diabetes, gastrointestinal dysfunction, 
growth problems, haemostasis, immune disorders, impotence, incontinence, 
infective diseases, inflammation, obesity, oncology, and osteoporosis (Vlieghe et 
al., 2010). 
 
Vaccines are another potential use of peptides, but represents conflicting aims. The 
short length of peptides is thought responsible for their low immunogenicity 
(discussed previously) (Vlieghe et al., 2010), but with vaccines a peptide of longer 
length (>69 aa; Watt [2006]) is meant to serve as an epitope to train the acquired 
immune system. An example is the experimentation with peptides as an anti-cancer 
vaccine, not only prophylactically, but also to treat pre-existing cancerous cells 
(Reichert & Wenger, 2008). This may be problematic if the immune system is 
already tolerant of these rogue cells. Although some clinical trials have been 
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performed with little report of peptide toxicity, any significant anti-cancer effect has 
yet to be found (Lien & Lowman, 2003). To overcome a lack of immune response, it 
may be that coupling the desired epitope to a larger scaffold protein may be a 
solution (see Section 1.1.2.2). However, this approach risks raising antibodies that 
do not recognise the native cancer epitope when it presents itself independently. 
 
In relation to the above, peptides could be used to modulate the immune system in 
other ways. For example, LL-37 (an antimicrobial peptide; see Section 1.3.1) was 
found to enhance the adaptive immune response when added as a co-translated 
adjuvant to a DNA vaccine against tumour cells in mice (An et al., 2005). This is 
likely related to the ability of the peptide to bind DNA and allow its subsequent 
recognition and processing by dendritic cells (primarily responsible for antigen 
presentation to T-cells) (Lande et al., 2007). As LL-37 has also been shown to 
manipulate dendritic cell activation and differentiation (Davidson et al., 2004), the 
use of analogues to therapeutically modulate the immune system could be possible. 
 
Cell-penetrating peptides (CPPs), while not strictly the active therapeutic, are a 
potential solution to poor peptide bioavailability. As mentioned earlier, peptides, as 
well as potentially therapeutic oligonucleotides, proteins and other large 
macromolecules, cannot readily cross the plasma membranes of cells. The 
hydrophobic nature of lipid-based membranes acts as a non-permeable barrier to 
hydrophilic and charged compounds (i.e. most soluble peptides), and this selectivity 
is vital for correct cellular function (Stewart et al., 2008). While membranes do 
contain active transport systems (e.g. membrane-spanning pore proteins) for the 
uptake and secretion of physiologically important products, these are hard to take 
advantage of in a manner generic enough to transport compounds of disparate size, 
charge and structure. It would be very beneficial if such generic trans-membrane 
transport were possible, as this would open the intracellular environment to 
therapeutic targeting. Research into CPPs has been ongoing since 1988, when a 
14-residue truncation of the Tat protein (a transcription-activating factor coded for 
by the human immunodeficiency virus type 1) was found to be sufficient to promote 
its uptake into HeLa cells in a potentially non-specific and non-toxic manner (Green 
& Loewenstein, 1988). Tat truncations and other CPPs, such as a 16-residue 
truncation of the Antennapedia transcription factor from Drosophila melanogaster 
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(Joliot et al., 1991), have since been fused or cross-linked to various proteins, 
peptides and oligonucleotides and trialled for mammalian intracellular delivery 
(Lindgren et al., 2000). There are some examples to prove their potential: the 
transport of small interfering RNA to inhibit translation of a luciferase reporter in 
mammalian cell cultures (Muratovska & Eccles, 2004); the successful transfer of 
Cre recombinase (38 kDa) to the nucleus to mediate DNA recombination via LoxP 
sites (Wadia et al., 2004); and the remarkable delivery of !-galactosidase (116 kDa) 
across the blood-brain barrier in a mouse model (Schwarze et al., 1999). Being able 
to deliver passenger compounds across the blood-brain barrier (via passive or 
active membrane uptake) is a key goal in itself (Vlieghe et al., 2010). While their 
exact mode of entry is still debated, i.e. direct penetration versus endocytosis and 
subsequent intracellular escape, it is most likely CPP-specific (Stewart et al., 2008). 
To complicate matters further, both modes could be utilised by a single peptide: 
LL-37 (mentioned previously) has not only been proposed to enter epithelial cells 
via specific receptors (Lau et al., 2005), but also to co-transport extracellular 
plasmid DNA via lipid raft endocytosis (Sandgren et al., 2004). More research is 
required on CPPs, as structure/function relationships are still unclear (Lindgren et 
al., 2000; Foerg & Merkle, 2008). It is worth noting, however, that the CPP field is 
moving away from the concept of a “generic” transporter (Foerg & Merkle, 2008). 
The development of cell- or organelle-specific penetrating peptides would be of 
value, especially with regards to partnering with other bioactive peptides that are 
membrane-impermeable on their own. 
 
One area where bioactive peptides could become important is against the so-called 
“undruggable” targets, i.e. protein-protein interactions (Watt, 2009). Small molecule 
drugs have been particularly successful against targets with defined binding 
pockets, such as cell membrane signal receptors e.g. the G-protein coupled 
receptor family, or enzyme active sites e.g. angiotensin-converting enzyme 
inhibitors for treatment of hypertension (Drews, 2000). They have not, however, had 
much success against targets lacking defined binding pockets, such as transcription 
factors or other intracellular global regulators (Drews, 1996). As a consequence, 
only 417 protein products have been therapeutically targeted in humans i.e. ~2% of 
the potential proteomic total (Drews, 1996). A number of protein-protein interactions 
occur over large, “flat” surfaces, as opposed to surface involution “hot-spots” which 
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small molecule drugs favour (Watt, 2009; Moellering et al., 2009). Bioactive 
peptides, which are typically an order of magnitude larger with respect to a small 
molecule drug, may be better suited to such binding – an increased number of 
potential hydrogen bond partners (i.e. increased avidity) can cumulatively overcome 
the unfavourable thermodynamics of a flat surface, leading to sufficient binding 
affinity for an effect (Sato, 2006a). Aileron Therapeutics Inc. has developed 
examples of peptides that disrupt protein-protein interactions. Chemically-
synthesised peptides that incorporate two non-natural side-chains are subsequently 
“stapled” together, locking the peptide into an "-helix secondary structure 
(Schafmeister, 2000). Such constrained peptides are then used to hit “undruggable” 
targets: one such example acts as an antagonist to disrupt the assembly of the 
NOTCH transcription factor complex (implicated to be over-active in T-cell acute 
lymphoblastic leukaemia) (Moellering et al., 2009), while another acts as an agonist 
to activate the pro-apoptotic BAX protein in mammalian cells to induce cell death 
(Gavathiotis et al., 2008). 
 
Another use for bioactive peptides is in the “cosmeceutical” industry – adding 
biologically active compounds to cosmetics. In 2006 the global anti-ageing 
cosmeceutical market was estimated to be worth US$3.5 billion (Pichereau & Allary, 
2006). Lipotec SA are developing peptide derivatives of the botulinum neurotoxin to 
treat wrinkles, and Therapeutic Peptides Inc. are developing peptides that stimulate 
collagen production (Pichereau & Allary, 2006). 
 
1.1.3.2 Market 
The market for bioactive peptides has slowly been growing over the past forty 
years. Research on hormonal homologues such as insulin in the 1970s and 1980s 
took 30 years to diversify into areas such as oncology, analgesics, osteopathy, 
haematology and virology (Reichert et al., 2008). Part of this slow development can 
be attributed to a dogma of pharmaceutical companies that entities with a molecular 
mass over 600 Da would not be useful as drugs due to poor bioavailability (Loffet, 
2002). Furthermore, peptides do not meet a number of other noted physiochemical 
criteria for drug-like properties formalised a decade ago by Lipinski and co-workers 
(i.e. size, lipophilicity, a limited number of hydrogen bond donors/acceptors) 
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(Lipinski et al., 2001). An increase in peptide therapeutic growth has been driven by 
both a demand for new treatments for conditions or diseases in which small 
molecules are underperforming, and by pharmaceutical companies looking for new 
molecular entities to replenish emptying development pipelines (Vlieghe et al., 
2010). The past decade has also seen a number of approaches taken to mitigate 
the perceived failures of bioactive peptides, such as overcoming bioavailability, 
stability and delivery issues (reviewed in Section 1.1.2). Production costs of 
chemically-synthesising short peptides (<50 aa) have also fallen as greater demand 
for contract manufacturing has lead to more competitive pricing. For instance, for 
large-scale production the cost may now be less than US$1 per gram per amino 
acid residue (Bray, 2003). 
 
Recently the Peptide Therapeutics Foundation (founded 2008; 
http://www.peptidetherapeutics.org/) has started to track peptide-based drugs from 
the pre-clinical stage through to approval by the relevant regulatory authority 
(usually the United States Food and Drug Administration or European Medicines 
Agency). Figure 1.1 shows the rapidly increasing number of peptides entering 
clinical trials each year. 
 
 
Figure 1.1: Average number of new peptide drug candidates per year, per decade. 
Numbers entering clinical trials, figure adapted from Reichert et al. (2010). 
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In 2001 there were approximately 150 peptide therapeutics under known 
development; in 2004, this increased to 400, with 30 peptides past clinical trials and 
approved for market (bringing in sales of US$6 billion) (Pichereau & Allary, 2006). 
As of 2010, 54 approved peptide drugs were on the market, and accounted for 
annual sales of approximately US$13 billion (Lax, 2010; Reichert et al., 2010). 
While this represents only ~1.5% of the total drug market in that year (~US$870 
billion), previous predictions estimated this would not be achieved until 2013 
(Pichereau & Allary, 2006). Growth in peptide drugs is progressing, and on current 
trends is projected to be at least 7% per annum for several years (Lax, 2010). In 
2010 approximately 140 bioactive peptides were in clinical trials (15 were at Phase 
3 or under regulatory review), with approximately 400 in the pre-clinical stage 
(Reichert et al., 2010; Lax, 2010). 
 
The success rate for peptides that enter clinical trials is relatively high, with 23-26% 
of candidate entries between 1984 and 2000 being approved (Reichert et al., 2010). 
This is approximately twice the success rate achieved by small molecule drugs 
(Reichert et al., 2008). However, as higher numbers of peptides have entered 
clinical trials over the last decade, this success percentage may decrease in the 
post-2000 cohort. The main failing of bioactive peptides during clinical trials seems 
to be a lack of efficacy at the Phase 2 stage. Only ~45% of peptide candidates 
proceed from Phase 2 to Phase 3 (Reichert et al., 2008). This issue of efficacy 
relates to the twin problems of stability and bioavailability, discussed in 
Sections 1.1.2.2 and 1.1.2.3. As these impediments are being addressed, it is 
predicted that interest in developing bioactive peptides will continue to grow 
(Reichert et al., 2010). 
 
Certain target classes are heavily favoured in the small number of entities already 
on the market (54 as of 2010). As outlined earlier, the vast majority are extracellular 
(>90%), reflecting the difficulties associated with getting a peptide across 
membrane(s) to access intracellular targets. For example, just under half of the total 
approved peptides are agonists for members of the G-protein coupled receptor 
family (Reichert et al., 2010). Of these, the gonadotropin-releasing hormone 
receptor (a global regulator for controlling sexual hormone levels, manipulated to 
treat breast and prostate cancers among other indications) is a favoured target 
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(Loffet, 2002). Other targets include somatostatin receptors (to inhibit growth 
hormone release), calcitonin receptors (to lower blood calcium levels), platelet 
aggregate inhibitors (to prevent blood clotting) and viral proteins (Pichereau & 
Allary, 2006). 
 
There is potential for some of these peptides to be worth a great deal economically, 
with a number already generating sales reaching US$1 billion per year. In 2008, 
Teva Pharmaceutical Industries Ltd.’s glatiramer acetate (trade name Copaxone, a 
random polymer of glutamic acid, lysine, alanine and tyrosine used to treat multiple 
sclerosis by acting as a decoy myelin basic protein to the immune system) had 
sales of US$3.18 billion; Novartis Pharmaceuticals AG’s octreotide acetate (trade 
name Sandostatin, a somatostatin mimetic to inhibit growth hormone release) had 
sales of US$1.12 billion; Eli Lilly and Company’s teriparatide (trade name Forteo, a 
parathyroid hormone analogue to treat varieties of osteoporosis) had sales of 
US$780; and Amylin’s exenatide (trade name Byetta, an incretin mimetic to aid 
insulin production) had sales of US$751 million (Reichert et al., 2010). This proof 
that bioactive peptides are capable of earning substantial revenue will help drive 
further interest in developing new peptides. The peptides listed above are all 
administered via injection (i.e. uncomfortably), so the pharmaceutical industry 
seems to accept that there is still a viable market for drugs that cannot be taken 
orally (Loffet, 2002; Lax, 2010). 
 
In comparison to well-described small molecule and antibody scaffolds, an 
additional advantage of bioactive peptides is that the intellectual property space is 
relatively unrestricted. While these alternative two classes rely on tweaking variant 
moieties as part of defined scaffolds, which are heavily patented, de novo peptide 
sequences are free to explore (Watt, 2008). A newcomer to the market provides an 
example of this. Bicycle Therapeutics Ltd. screens 17 amino acid motifs 
(12 residues are randomised) that are structurally constrained through subsequent 
chemical crosslinking by 3 cysteine residues (Heinis et al., 2009). The aim is to 
mimic the structural conformation constraints of an antibody’s complementarity 
determining region (responsible for antigen recognition) while avoiding the 
associated intellectual property. 
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1.1.4 Sources 
Bioactive peptides are obtained from three primary sources: naturally occurring 
products, chemical synthesis, or recombinant biosynthesis. 
 
1.1.4.1 Natural products 
Proteins play an essential role in the plethora of different activities a cell performs 
on a daily basis. These include cell signalling, enzymatic catabolism and anabolism, 
cellular replication, and homeostasis and repair. Because different organisms cope 
with the selection pressures placed on them by varying environments in different 
ways, it follows that many organisms will possess proteins with functions that are 
novel and perhaps useful as therapeutics e.g. antimicrobial peptides (see 
Section 1.3.1). While Section 1.2.2 goes into more detail, it is sufficient to note that 
most bioactive peptides have historically been sourced natively from plants, animals 
or insects. In particular, bioactive peptides have been isolated from the active 
domains of various hormones or other proteins that possess the desired biological 
activity (McGregor, 2008). 
 
Recent examples include The Medicines Company’s bivalirudin (trade name 
Angiomax, 20 aa, 2.2 kDa), a thrombin inhibitor, which is a variant of the 
anticoagulant hirudin found in the saliva of medicinal leeches (Warkentin et al., 
2008); and Amylin Pharmaceuticals Inc.’s exenatide (trade name Byetta, 39 aa, 
4.2 kDa), found in the saliva of the Gila monster (Heloderma suspectum), a 
homologue of human glucagon-like peptide 1 that is used to stimulate insulin 
production in diabetes mellitus type 2 patients (Leader et al., 2008). However, once 
these peptides have been isolated from their natural source and their activity 
profiled, they are typically produced commercially using either recombinant or more 
commonly chemical synthesis technology due to economies of scale. 
 
1.1.4.2 Chemical synthesis 
Solid-phase peptide synthesis (SPPS), pioneered in the 1960s (Merrifield, 1963), is 
still the gold-standard method for chemical synthesis of bioactive peptides today. 
Fmoc (9-fluorenylmethyloxycarbonyl) mediated chemistry allows for the sequential 
building of a peptide from protected amino acid residues starting at the C-terminus 
(attached to a solid resin support) and working “back” towards the N-terminus. In 
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brief, synthesis follows a cycle for the addition of each amino acid: coupling, wash 
(of unreacted compounds), deprotecting (of the amino group so the next residue 
can couple to the chain), and another wash (Guzmán et al., 2007). Such a process 
can be highly automated, and several peptides can be co-synthesised over a period 
of a few days (Bray, 2003). 
 
Peptides with a length of less than 30 amino acids are more economically 
manufactured in comparison to longer peptides using SPPS (Lax, 2010). This is 
because the longer the peptide chain desired, the lower the yield achieved: there is 
a greater chance of product side-reactions or racemisation (i.e. heterogeneity 
between individual peptides due to some residues adopting the D-enantiomer form) 
(Bray, 2003). In addition, some peptides are prone to aggregation during synthesis, 
or may fold to obscure access to the N-terminus, thus making further extension 
difficult (Bray, 2003). This is especially true for peptides containing a high proportion 
of hydrophobic residues, and thus the specific properties of the target sequence will 
determine the efficiency, purity and yield of peptide synthesis. One method for 
overcoming these difficulties is the use of microwaves. As the polar peptide 
backbone constantly tries to align itself to the applied electromagnetic field, it works 
against the aggregative forces imparted by various amino acid side-chains, allowing 
full-length product synthesis to be achieved (Palasek et al., 2007). 
 
For synthesis of longer peptides (typically >100 aa), two common approaches are 
taken (Bray, 2003). Convergent synthesis is a mixture of solid-phase and solution-
phase synthesis – amenable short sequences are built up using traditional solid-
phase synthesis, and these purified fragments are subsequently condensed 
together in a liquid-phase reaction (Vlieghe et al., 2010). Chemical ligation is a 
variation on this technique, occurring prior to fragment purification: specific N- or 
C-terminal residues (usually cysteine) are coupled chemoselectively, followed by 
rearrangement to form an amide bond prior to purification of the final product 
(Guzmán et al., 2007). 
 
One advantage of chemical synthesis over recombinant production (discussed 
below) is the ability to incorporate orthogonal residues into a peptide (McGregor, 
2008). Such peptidomimetics may include D-enantiomers, non-natural chemical 
17 
side-chains (such as norleucine or homoserine), and other labels such as 
chromophores (e.g. fluorescein isothiocyanate), chemical ligands for subsequent 
binding (e.g. biotin labels to be captured by streptavidin), or nucleic acid conjugates 
(Vlieghe et al., 2010). As discussed in Section 1.1.2, these non-natural peptides 
may exhibit improved stability, bioavailability and perhaps novel function. 
Orthogonal peptide backbones may also be used to produce protease-resistant 
products. Peptoids are perhaps the best described example of this, with the side-
chains coupled to the nitrogen atom of the peptide backbone instead of the usual 
"-carbon (Simon et al., 1992). 
 
Another advantage of chemical synthesis over other production routes is that quality 
assurance and regulatory compliance are simpler to achieve (Lax, 2010). Native or 
recombinant approaches involve purification from a heterogeneous mix that may 
include potentially toxic compounds that require removal (i.e. endotoxins in bacterial 
recombinant systems), whereas chemical synthesis starts clean from a set of 
known compounds. While removal of endotoxins and other contaminants is 
feasible, it does add to the production costs associated with native and recombinant 
peptide purification. 
 
Because of the mostly generic manner in which SPPS can occur, there are now a 
number of specialised contract manufacturers to which chemical synthesis of a lead 
bioactive peptide can be outsourced, freeing up researchers to concentrate on 
optimisation instead (Pichereau & Allary, 2006). The amounts of peptide 
synthesised can vary from anywhere in the mg range, typical for laboratory work, to 
~100 kg/year for drugs that are exceptionally popular (Lax, 2010). The cost of 
synthesis is also lower in comparison to recombinant production (Vlieghe et al., 
2010). In comparison to a 500 Da small molecule drug, however, the production 
costs of a 5,000 Da peptide will be approximately 10-fold higher (Bray, 2003). 
 
1.1.4.3 Biosynthetic approaches 
A biosynthetic approach to peptide production involves harnessing recombinant 
DNA technology (i.e. the coding sequence for a particular peptide) and inserting this 
into a production host, such as bacteria, yeast, insect cells, mammalian cells, plants 
or transgenic animals (Structural Genomics Consortium et al., 2008). Such systems 
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have been used extensively in the past thirty years to produce industrially or 
medically useful proteins, including proteases, amylases and lipases for laundry 
powders, and monoclonal antibodies for therapeutic use. This in vivo methodology 
is also complemented by in vitro transcription/translation techniques, which 
essentially use the required molecular machinery to produce a protein from a 
recombinant DNA template sans biological host (Katzen et al., 2005). While 
recombinant production approaches are suitable for proteins (i.e. over 10 kDa), it is 
important to note that SPPS (Section 1.1.4.2) has considerable advantage over 
recombinant techniques with regards to short peptides. 
 
Despite this, recombinant techniques are still widely used for some bioactive 
peptides, such as insulin (51 aa, 5.8 kDa), salmon calcitonin (31 aa, 3.4 kDa, used 
to treat osteoporosis) and glucagon (29 aa, 3.5 kDa, used to affect a raise in blood 
glucose levels) (Lax, 2010). Recombinant production is not readily amenable to the 
incorporation of non-natural amino acids, although some work has been carried out 
on freeing redundant codons to allow for such a possibility (Young & Schultz, 2010). 
Still, peptides that require glycosylation, phosphorylation or other post-translational 
modifications to create their active form are more suited to recombinant production. 
Given a suitable choice of production host, recombinant approaches can achieve 
such modifications in a more cost-effective manner than synthetic production 
(Vlieghe et al., 2010). 
 
While SPPS may be preferred for industrial production of bioactive peptides, 
recombinant techniques are of importance to this subject in two ways (Raventós et 
al., 2005). Firstly, recombinant production may be harnessed to produce a bioactive 
peptide and its variants on a small scale and in a short timeframe using common 
molecular biology resources. Secondly, and most importantly, the in vivo production 
of a peptide can potentially be coupled with a screen for a desired bioactivity in a 
high-throughput manner. Such concurrent production and screening may lead to the 
identification of novel bioactive peptides. 
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1.2 Screening for bioactivity 
1.2.1 Brief history 
The field of screening for bioactive peptides, interwoven with the rise of molecular 
biology over the past 40 years, can trace its roots back to the beginnings of drug 
discovery research in the 19th century (Sneader, 2005). During the industrial 
revolution, by-products such as coal-tar (rich in aromatic and aliphatic compounds) 
were studied as a source of useful products such as dyes. The specificity of some 
dyes for certain biological tissues was soon noted, with Paul Ehrlich postulating that 
these compounds bound cell-specific chemoreceptors and that this could form the 
basis of selective therapy (Bosch & Rosich, 2008). Research proceeded in a 
disparate manner, however, as university laboratories, pharmacies and industrial 
dye companies did not individually possess the required knowledge or skill set for 
drug development. As pharmacology became a distinct field, new ways of finding, 
characterising and developing drugs led the new industry of drug discovery. 
 
Moving forward, serendipity has played a large part in the discovery of new 
biological drugs (Kubinyi, 1999), the most famous example being Alexander 
Fleming’s discovery of penicillin after observing inhibition of a Staphylococcus 
culture’s growth on agar plates contaminated with a white mould (Fleming, 1929). 
Subsequent work on this secondary metabolite, and the microbiological and 
chemical engineering advances required for mass production during World War II, 
drove the screening of other microbes to see if they too produced antibiotics or 
other therapeutically valuable compounds (Li & Vederas, 2009). This provided one 
of the first instances of bioprospecting (Section 1.2.2). Work proceeded on a case-
by-case basis, with drugs like ivermectin (an antiparasitic to treat nematode worm 
infection) and cyclosporine (an immunosuppressant drug used in organ transplants) 
being identified (Drews, 2000). As research into the modes of action of successful 
drugs increased, biochemistry reinforced the notion that enzymes and cell signal 
receptors (which Ehrlich had postulated) were good drug targets, as well as 
elucidating more examples of them for target consideration (Sneader, 2005). 
Following this, the core scaffolds of drug compounds began to be produced 
synthetically and were subsequently derivatised by chemists to improve their 
activity, specificity and bioavailability (Kubinyi, 1999; Schreiber, 2000). 
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This core base of drug discovery knowledge led to an increased collaboration 
between chemists and biologists with an emphasis on understanding the 
relationship between the structure of a drug and its biological function. In turn, this 
led to the design and implementation of screens to identify new lead compounds of 
certain function from combinatorial libraries (Schreiber, 2000). These libraries 
consisted of a large number of different compounds in which the chemical 
composition or structure was subtly altered from a known natural compound. More 
random chemical libraries were also trialled to explore a larger chemical space 
(Bleicher, 2003). 
 
1.2.1.1 High-throughput screening 
The advent of high-throughput screening – cell-based or in vitro roboticised screens 
of combinatorial libraries on the microlitre scale – was predicted to revolutionise 
drug discovery, be it small molecule or peptide based (Drews, 2000). Initial 
compound “hits” would translate through into “leads” that exhibited the desired 
effect in more complicated models, such as in animal trials (Bleicher, 2003). 
Modification of this lead could in turn allow for further exploration of the sequence 
space and an increase in the number of novel bioactive compounds. High-
throughput screening, in combination with combinatorial compound libraries, led to 
a huge increase in data collection by pharmaceutical firms – from roughly 200,000 
discrete data points for a typical large trial in the early 1990s, to 50 million by the 
end of the decade (Drews, 2000). However, it soon became apparent that this large 
increase in numbers still needed to be matched by critical scientific analysis 
(Kubinyi, 2003). Many hits failed to translate into leads. Designs of combinatorial 
libraries focused on generating as much structural diversity as possible to explore 
the theoretical chemical space (Bleicher, 2003), but led to the generation of 
compounds that, while soluble and active in the solvents or dilute form tested during 
high-throughput screening, were too lipophilic or large to have any efficacy when 
subjected to a more intensive clinical test (Kubinyi, 2003). While some 
commentators heralded the lack of successful new drugs as a refutation of high-
throughput screening (Bleicher, 2003), it merely shows that inappropriate questions 
give meaningless answers (Drews, 2000). This is not only with reference to the poor 
choice of compounds tested, but also to the design of the screen itself. Screens 
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should be designed to be as close to physiologically relevant as possible, so that 
potential subtleties of drug action are not missed. 
 
1.2.1.2 In silico screening 
To rectify the initial problems with high-throughput screening, in silico methods have 
been employed to pre-screen members of a combinatorial library before synthesis 
(McInnes, 2007). Virtual screening is used to avoid structures that may have 
undesirable properties (such as solubility issues), and to focus on compounds that 
are predicted to have tight binding affinities for a particular target (Shoichet, 2004). 
In this manner a compound library may be targeted, and certain “privileged” 
structures enriched, i.e. those commonly found experimentally to interact with the 
target class in question (Bleicher, 2003). Problems with in silico screening are still 
common: an inability to estimate the strength of hydrogen bonds in different solvent 
conditions; the effect of freezing conformation/degrees of freedom of parts of a 
compound; and the effects of water molecules at hydrophobic residues can all lead 
to problems when the compound is tested in vivo (Kubinyi, 1999). Another 
application of in silico screening is to try to find potential structures that may fit a 
target’s binding site (usually modelled from nuclear magnetic resonance 
spectroscopy or x-ray crystallography data), and thus guide what a combinatorial 
library should look like when testing experimentally (McInnes, 2007). This approach 
still exhibits problems, as computer models usually accept compound structures as 
imported by the user. Thus the effect of compound and binding site flexibility may 
be dismissed, hydrogen bond donors and acceptors may be incorrectly assigned, 
and so poor in silico docking of a compound to the defined three-dimensional 
binding pocket may erroneously result (or vice versa) (Kubinyi, 2003). In silico 
screening of compounds and their potential interactions should therefore be used 
with a knowledge of its limitations. A “black-box” approach where compound 
structures are fed in, and a program predicts their potential as a drug, should only 
inform decisions along with other a priori knowledge about the potential target.  
 
1.2.1.3 Relevance to bioactive peptides 
The lessons learnt from early approaches to combinatorial chemical libraries, high-
throughput screening, and in silico modelling hold true for bioactive peptides. 
Nevertheless, screening for novel bioactive peptides started slowly. With the advent 
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of recombinant protein production in hosts such as E. coli in the late 1970s, 
molecular biology was initially only seen as a way to produce therapeutically 
desired proteins as opposed to purifying them from a native source (e.g. insulin) 
(Drews, 2000). But the power of coupling genotype with phenotype – i.e. DNA with 
its encoded protein product – soon led to recombinant protein libraries being 
screened for activity in their own right. This coupling of the nucleic acid input with a 
peptide output is an important strength. It enables high-throughput screening of 
libraries where, if a hit is found, the nucleotides coding for it are readily purified, and 
the active peptide composition hence deduced. The most well known example of 
this is phage display (Smith, 1985), where large peptide libraries (>109 entities) are 
screened for binding affinity to a target molecule (reviewed later in Section 1.2.3.1). 
Identification of new peptides, as well as optimisation of current peptides, is 
possible using the same technique. While interest in bioactive peptides from 
pharmaceutical companies waned in the 1990s as issues with delivery, 
bioavailability and stability became apparent (see Section 1.1.2), peptides as 
therapeutics are now making a comeback (see Section 1.1.3.2). As with 
combinatorial chemistry, random or rationally designed peptide libraries can be 
employed, but the technique of bioprospecting may also be used. 
 
1.2.2 Bioprospecting 
The term “bioprospecting” refers to the search for industrially or therapeutically 
useful compounds from natural sources in a systematic manner (Macilwain, 1998). 
At its simplest level, this may involve investigating and isolating the active 
component(s) of a traditional medicine (usually a plant extract). For example, the 
isolation of salicin (metabolised to salicylic acid [aspirin] when ingested) from 
meadowsweet or willow bark, and that of artemisinin (an anti-malarial agent) from 
the sweet wormwood plant, was achieved in this manner (Awtry & Loscalzo, 2000; 
Ro et al., 2006). Another approach is to bioprospect with no a priori information 
about potential compound function – this is akin to grinding up an organism, 
separating its constituent compounds as much as possible, and individually (or via 
compound pools) testing for the desired activity (Macilwain, 1998). One such 
example of this approach is the discovery of halichondrin B, a compound isolated 
from the sea sponge Halichondria okadai that showed potent anti-cancer activity 
when screened against murine tumour cells in vitro and also in vivo (Hirata & 
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Uemura, 1986). Unfortunately the yield of halichondrin B from this sponge is low at 
21 mg/tonne of animal. The yield of the same compound from another sponge 
species (Lissodendoryx) has been reported at 300 mg/metric ton of animal, but 
given that tens of grams of the compound are needed for clinical trials, and that the 
entire natural population of this sponge is estimated at 280 tons, progress has been 
hampered (Vogel, 2008).!
 
Because of such environmental and economic concerns, the biological source of an 
active compound and its actual production are usually separated where possible. In 
the above examples, salicylic acid (a relatively simple phenolic acid) was 
chemically-synthesised by Bayer AG in 1897 (Awtry & Loscalzo, 2000). Artemisinic 
acid (a precursor to artemisinin) has been produced biosynthetically in yeast by 
introducing two sweet wormwood (Artemisia annua) enzymes (amorphadiene 
synthase and a cytochrome P450 monooxygenase) into the precursor mevalonate 
biosynthesis pathway (Ro et al., 2006). Halichondrin B (a large polyether macrolide, 
1.1 kDa) was difficult to synthesise chemically, but eventually led to the 
commercialisation of the analogue eribulin (trade name Halaven; Eisai Inc.) (Towle 
et al., 2001). Artificial synthesis (either chemically or biosynthetically) is therefore 
usually desirable as the native host may not produce sufficient amounts of the 
natural compound, or even if it does, it may not be feasible to cultivate the organism 
commercially (Li & Vederas, 2009). 
 
1.2.2.1 Screening for bioactive peptides 
Bioprospecting for novel bioactive peptides can proceed as described in Section 
1.2.1 and 1.2.2, instead focusing on proteins and their peptide truncations. 
Furthermore, given that there is now a large knowledgebase concerning peptide 
synthesis and optimisation (see Section 1.1.4), final production problems are less of 
an issue than with complex small molecules (such as artemisinin and halichondrin B 
outlined in Section 1.2.2). 
 
The natural world, derived by millions of years of evolutionary selection pressure, 
provides the biggest rationally designed protein library known to man. This is the 
key advantage that bioprospecting for novel bioactive peptides offers. As noted 
earlier, bioactive peptides may be suitable candidates to address non-classical 
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targets such as protein-protein interactions, where small molecules are largely 
ineffective due to the thermodynamic barriers associated with binding “flat” surfaces 
(Watt, 2006). Successful examples of such peptides include interfacial peptides that 
inhibit dimerisation of human immunodeficiency virus 1 integrase (Zhao et al., 2003) 
and others that dissociate the same virus’s protease (Park & Raines, 2000). 
However, rather than screening peptides derived from other known interacting 
domains (as per the first example), the second example involved screening random 
peptides of 9 residues in length in vivo attached to a thioredoxin domain, giving a hit 
rate of 1 per million (Park & Raines, 2000). 
 
It is worth noting that naturally occurring peptides, rather than truly random ones, 
may have a higher hit rate due to residue combinations that are more 
physiologically relevant, i.e. selected for during evolution. This is referred to as the 
“stacked” deck of nature as opposed to the “straight” deck of random libraries (Watt, 
2006). For example, Phylogica Ltd. specialises in bioprospecting from such 
naturally-occurring peptides, and claims a 10-fold increased hit rate cf. Park & 
Raines (2000) above, e.g. in blocking the MyD88 adaptor-like protein which is 
involved in Toll-like receptor 2 signalling mediated inflammation (Watt, 2009). 
 
1.2.2.2 Advantages of bioprospecting 
Assuming that screens are suitably designed to have a negligible false-positive rate, 
what rationalises a 10-fold increase of natural versus random peptide hits? Random 
peptides may not be able to adopt stable secondary structures, which are frequently 
needed for a suitable interaction, if not just biostability. In contrast, peptides derived 
from existing proteins may form defined motifs, or “folds” (Watt, 2006). In this 
context it is also worth noting that divergent primary sequences can still lead to a 
similar secondary structure, e.g. amphipathicity, which may be more important for 
biological recognition of particular sizes, shapes and charges. This reduces the true 
structural diversity of random peptides with regards to pure numerical diversity. 
Following this, it has been predicted that the number of naturally occurring protein 
structural motifs (i.e. independent of primary residue sequence) is between 1,000 
and 10,000 (Wolf, 2000; Watt, 2006). Such motifs typically span a length of 15 to 30 
residues (Riechmann & Winter, 2000), thus fitting into the peptide category. 
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Furthermore, the overall structural diversity exhibited by peptides in isolation is 
greater than that from scaffolded entities (which are used in their entirety for 
therapeutic treatment), where only a small portion of the total structure is different 
between library members (Figure 2.1). Examples of commonly used scaffolds 
include antibodies, designed ankyrin repeat proteins and anticalins (Binz et al., 
2005). 
 
 
 
 
Figure 2.1: Structural diversity increases from antibodies (right) through to peptides 
(left). Antibodies exhibit diversity at their complementary determining regions, while smaller 
scaffolds such as designed ankyrin repeat proteins or anticalins are less sterically hindered 
by their constant regions. Peptides, which may form their own motifs, exhibit the highest 
diversity, and thus represent a good source of potential bioactive compounds. Figure 
adapted from Watt (2009). 
 
Peptides derived from bioprospecting, when used as therapeutics, are typically 
utilised out of context (Watt, 2006). Obviously, depending on the source organism, 
the majority of naturally occurring peptides are segregated in different biological 
compartments or habitats from the therapeutic target organism. For instance, it is 
hard to think of an occasion when peptides produced by an organism dwelling in a 
deep-sea vent would naturally come into contact with a human cancer. In addition, 
some peptide motifs may perhaps not be fully accessible for interaction in their 
native protein form (e.g. hidden in protein folds). Because of this segregation, novel 
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peptide-protein interactions may be found without regard for the original niche or 
function of a peptide (Watt, 2006). 
 
1.2.2.3 Use of DNA as an encoding source for peptides 
As discussed at the beginning of Section 1.2.2, the inability to harvest large 
amounts of protein/peptide from an organism during bioprospecting should not 
become an overall limiting factor, due to existing synthetic techniques of production 
(see Section 1.1.4). Problems with bioprospecting remain, however. Not all proteins 
will be expressed at all times in an organism, and given that a number of 
therapeutically valuable products may only be induced under particular stimuli (e.g. 
stress, the presence of pathogens), the harvested proteome of any given organism 
may be incomplete. Furthermore, while macroscopic organisms may be relatively 
easy to obtain in bulk, some microorganisms may not be sampled in significant 
quantities, and therefore not enough active compound will be present to be 
detected in a screen. There are probably millions of unidentified bacterial, fungal 
and protozoan species, but most of these are under-represented in environmental 
samples due to a small number of species dominating the biosphere (Sogin et al., 
2006). If the proteomes of species could be accessed without regard to their 
environmental abundance, an enormous universe of protein and peptide variation 
would become available. A method of providing such access involves the isolation 
of genomic DNA. 
 
Genomic DNA libraries, representing the nucleic acid blueprint of an organism, are 
a rich source of input for a recombinant bioactive peptide screen. Such DNA is 
easily purified from environmental samples, whether it is a jar of water containing 
microbes, a tissue sample or a single animal. Furthermore, genomic DNA will 
encode peptide motifs that have been sculpted by evolution, and are consequently 
biologically relevant (see Section 1.2.2.2). However, there is still an element of 
randomness in screening a genomic library. The source DNA is commonly sheared 
into fragments that are of peptide-encoding size, e.g. 45 to 300 bp to encode 
peptides of 15 to 100 amino acids, and inserted into a recombinant expression 
system. Usually the orientation of this insertion is uncontrolled, resulting in six 
possible reading frames, i.e. three forward and three reverse. In-frame stop codons 
may also occur. Even if a piece of DNA does code for a bioactive peptide, it is not 
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guaranteed that it will be expressed in its correct reading frame in the screen. 
However, when Watt (2009) screened a genomic library for peptides that bound the 
MyD88 adaptor-like protein (see Section 1.2.2.1), it was found that while only 
approximately 14% of the library was inserted in its natural reading frame (when 
compared to its annotated genomic sequence), ~41% of peptide hits were from this 
subsection. While this shows that naturally-encoded peptides from DNA libraries 
may be enriched in function, it also indicates that random, non-naturally occurring 
peptides from the same DNA template may also exhibit activity. Being unable to 
control DNA library insertion orientation or reading frame therefore combines the 
advantages of screening “evolved”, naturally occurring sequences with a more 
random selection of sequences, i.e. those from “unnatural” reading frames. 
 
The use of complementary DNA libraries may further enrich for peptide fragments 
that are produced by the organism in vivo. This DNA, which is derived from an 
organism’s messenger RNA (mRNA) transcripts, represents actively-transcribed 
parts of the genome (i.e. its transcriptome). Furthermore, cis (or even trans) splicing 
of such transcripts is possible in eukaryotes, revealing open reading frames that are 
not discernible from genomic DNA alone (Di Segni et al., 2008). While a large 
amount of this DNA will go on to be translated into protein in vivo, the same issues 
regarding the lack of control of orientation and reading frame when inserted into a 
recombinant expression screen still apply. In addition, not every mRNA transcript 
may be present at the time of library generation, as many proteins are not 
constitutively expressed but rather generated in response to environmental signals.  
 
In addition to using genomic or complementary DNA as an input source for 
recombinant peptide production, random synthetic DNA may also be used. Random 
single-stranded oligonucleotides may be obtained commercially, with defined 5’ and 
3’ terminal sequences so that they may be amplified into double-stranded DNA via 
polymerase chain reaction (PCR) techniques. A defined length of oligonucleotide 
allows for potential peptide length to be controlled. Discounting internal stop 
codons, this is typically up to 25 amino acids, depending on the maximum 
oligonucleotide length capable of being reliably synthesised. Furthermore, this 
approach is inexpensive, costing only tens of pence per base from a commercial 
synthesis company (see Section 2.1.2). 
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1.2.3 Biosynthetic approaches 
Once a nucleic acid source is identified, the question becomes how to express it as 
a peptide for screening. As outlined earlier in Section 1.2.1.3, a key requirement in 
using a DNA source to power a recombinant screen for bioactive peptides is that 
genotype and phenotype are linked. Each member of the peptide library must be 
discretely coupled to the DNA that coded for it, so that if a hit in the screen is 
observed, the active amino acid residue sequence can be inferred. In addition, the 
ease of DNA manipulation makes it straightforward to create mutants of any hit 
peptide for further structure/function studies. 
 
1.2.3.1 Recombinant peptide screens 
Phage display is one of the better-known techniques for screening, enriching and 
identifying bioactive peptides (Smith, 1985). The DNA library is inserted into a 
phage vector in-frame with the coding region for a capsid protein (typically pIII if the 
filamentous fd or M13 bacteriophage is used), so that when expressed in E. coli the 
corresponding peptide is fused to the capsid protein. When new phage are 
produced, they are assembled with the library-encoded peptide displayed on the 
outer tip of the virus. The DNA library plasmid also contains the necessary elements 
to ensure that it too is packaged in the new phage during virion assembly, thus 
ensuring that genotype and phenotype are physically linked – one phage, one 
peptide displayed, one genetic sequence coding for it. This library of phage is then 
washed over an immobilised target molecule. Those displaying a peptide that 
interacts are retained, and can then be recycled to infect fresh bacteria to multiply 
and enrich further for rare members with a high binding affinity to the target in 
question. Phage display libraries numbering 1011 different peptides have reportedly 
been produced (McGregor, 2008). This technique was used to discover bioactive 
peptides such as Amgen Inc.’s romiplostim (trade name Nplate, 41 aa scaffolded to 
a human IgG FC region), an agonist of the thrombopoietin receptor to promote blood 
platelet production, and Affymax Inc.’s peginesatide (trade name Hematide, 14 aa 
in a PEGylated and cyclic configuration, under clinical development [Wrighton et al., 
1996]), a mimetic of erythropoietin to treat anaemia. 
 
Another popular recombinant screen is the two-hybrid approach. Initially developed 
in the yeast Saccharomyces cerevisiae, two functionally separate domains of a 
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reporter protein are taken (e.g. the DNA binding domain and transcription activation 
region of the GAL4 transcription factor) and fused to a “bait” and “prey” protein 
respectively (Fields & Song, 1989). If the bait and prey interact, the biological circuit 
is complete and an output occurs. In the GAL4 system, the transcription/translation 
of a reporter gene such as !-galactosidase is used, which converts exogenous 
X-gal from a colourless compound into a blue product. Blue yeast colonies therefore 
indicate a successful interaction. A similar system utilising part of a native RNA 
polymerase has been used in E. coli (Joung et al., 2000). For bioactive peptide 
screening, the prey protein gene may be replaced by a DNA library to find potential 
peptides that interact with a defined bait protein; or an existing protein-protein (i.e. 
bait-prey) interaction may be targeted for disruption by an additionally expressed 
peptide library. Peptides found to bind the MyD88 adaptor-like protein (see Section 
1.2.2.3) were identified using such a two-hybrid approach (Watt, 2009). However, 
false positive rates are reportedly high, presumably due to non-specific bait-prey 
interactions (Brückner et al., 2009).  
 
Other recombinant screening techniques include mRNA display (Roberts & 
Szostak, 1997), ribosome display (Zahnd et al., 2007) and CIS display (Odegrip et 
al., 2004). All of these techniques involve in vitro transcription and translation as 
opposed to phage display. In mRNA display, a DNA library is used to generate an 
mRNA library (no stop codons included), which subsequently has a puromycin 
moiety (a mimic of tyrosyl-tRNA) ligated to its 3’ end. In vitro translation is then 
conducted, and once the ribosome reaches the incorporated puromycin, translation 
is disrupted (puromycin serves as an antibiotic in this manner). Crucially, the 
puromycin is ligated by the ribosome to the C-terminus of the peptide, thus 
physically coupling genotype with phenotype. Ribosome display proceeds in a 
similar manner, except that a spacer sequence is used instead of puromycin at the 
3’ end of the DNA library, and a lack of stop codon in the resulting transcript causes 
the ribosome to stall on this spacer. However, the peptide has enough “chaser” 
sequence to ensure it is properly displayed rather than being masked inside the 
ribosome exit tunnel. Finally, CIS display (CIS being derived from cis-acting) 
couples the peptide directly to its library DNA template via fusing the coding 
sequence upstream to that of the bacterial plasmid protein RepA, which when 
translated recognises and binds a particular sequence also included on the DNA 
30 
template. If transcription and translation are coupled in vitro, the nascent RepA 
protein is able to perform this function while the DNA template, RNA polymerase, 
mRNA and ribosome are in a complex; thus each library peptide is directly linked to 
its DNA template. An alternative library DNA/corresponding peptide association can 
also be achieved through in vitro compartmentalisation techniques such as water/oil 
droplet emulsions that encapsulate single library DNA members (Miller et al., 2006). 
Example uses of these in vitro approaches include screening for single-chain 
antibodies with improved target binding affinities (Hanes & Plückthun, 1997; Fukuda 
et al., 2006), as well as finding peptide ligands that bind enzymes such as lysozyme 
(Odegrip et al., 2004).  
 
Peptides produced by all of these methods may then be screened for specific 
binding or function, and their genotype recovered for further analysis or subsequent 
enrichment (i.e. screening again). It is possible to use such methods to isolate 
peptides with very low dissociation constants (<10 nM) to a particular target (Sato et 
al., 2006a). 
 
1.2.3.2 Advantages and disadvantages of recombinant peptide screens 
There are general problems to consider related to transcribing and translating 
peptide libraries: sequence length, promoter efficiency, codon bias, product 
solubility and activity in differing physiological conditions are all contributing factors 
(Ingham & Moore, 2007). The choice of expression system can help with this, as 
well as the use of larger protein scaffolds or tags in order to aid stability, solubility or 
downstream purification of a peptide. In addition, such a single-peptide approach 
necessarily limits the complexity of what may be identified. Any peptide requiring 
co-factors for activity (unless serendipitously provided by the expression system) or 
post-translation modification will be missed, as well as those that may show 
synergistic action with other peptides. Along with the limitations of uncontrolled 
insertion orientation and reading frame, this leads to a narrowed window of 
discovery when using DNA libraries to screen for bioactive peptides. Despite this, 
such an approach is still capable of finding useful peptides, as previous examples 
cited in Section 1.2.3.1 have illustrated. Screens will inherently ignore peptides that 
are poorly expressed or insoluble, which serves to remove entities unsuitable for 
further development. Any peptide that is identified as a hit should therefore be 
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physiochemically suitable for future production. It is also worth noting that discovery 
of even a single peptide with limited function may be an important first step in 
elucidating little-known or new pathways to do with the activity being assayed for. 
 
1.2.3.3 Screen considerations 
Because of a peptide’s limited bioavailability and stability (at least before 
optimisation; see Section 1.1.2), it may be more worthwhile pursuing peptide 
agonists than antagonists. An agonist of a particular receptor is typically only 
required at low concentration for activation, and a short half-life is not problematic 
due to the ensuing signal cascade that such an activation typical evokes (Lien & 
Lowman, 2003). In contrast, an antagonist is competing with the native ligand for its 
binding site, and thus requires higher concentrations and binding site residence 
time for efficacy. In general, an antagonist must occupy over 50% of the receptor 
population to have the desired effect, in comparison to 5-20% occupation for an 
agonist (Vlieghe et al., 2010). Despite this knowledge, many screens are targeted 
towards identifying antagonists rather than agonists because screening for 
inhibitors of natural ligand binding is more straightforward than the functional 
screens that agonists require (Lien & Lowman, 2003). Common antagonist targets 
are specific receptors or enzymes, which have ligand binding constants measured 
in vitro by utilising techniques such as surface-plasmon resonance or isothermal 
titration calorimetry (Rich & Myszka, 2000; Pierce et al., 1999). In contrast, finding 
peptides that provoke a desired response through other modes of action, like 
disrupting protein-protein interactions or allosteric activation/inhibition, require more 
complicated, whole-cell functional screens. This dissertation is concerned with 
whole-cell approaches. 
 
Whole-cell phenotypic screening is a more holistic way of looking for potential 
bioactive peptides. Much like classical forward genetic screens, such an approach 
looks for the desired phenotype/output and then studies the agent responsible 
(Watt, 2009). For recombinantly-produced bioactive peptides, where the input 
genotype is linked to an output phenotype in a discrete manner, identification of the 
casual agent is straightforward. If the interaction partner(s) of an active peptide is 
unknown, modern proteomic techniques such as chemical cross-linking, pull-down 
assays and mass spectrometry can be used to aid identification (Puig et al., 2001). 
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A screen relying on positive selection, i.e. an output is given or its level is increased, 
is more desirable than negative selection, i.e. a decrease in an output from an 
observed baseline, as this allows for rare peptides to be more easily identified from 
large pools. For instance, if the desired activity in an in vivo screen is coupled to an 
output of antibiotic resistance, organisms that can grow when challenged by this 
antibiotic represent hits – those that are negative fail to appear. Coupling the 
desired peptide activity to a selectable phenotype in this manner gives a screen 
enormous resolution power (cf. phage display in Section 1.2.3.1). In contrast, 
locating and isolating clones that fail to grow is more difficult. Such a positive 
selection approach may be required if the hit rate is low (i.e. less than one per 
million) (Watt, 2009). 
 
1.3 Proof of principle 
Potential screens for bioactive peptides are only limited by the ingenuity of the 
researcher and the resources available. In this dissertation, whole-cell in vivo 
assays are studied and employed to find novel bioactive peptides. In particular, 
peptides displaying antimicrobial or antiaggregation activity were sought, principally 
as a proof of principle to demonstrate the feasibility of the strategy adopted. 
 
1.3.1 Antimicrobial peptides 
The use of peptides as antimicrobials is a special focus of this research. Found in 
most species of life, antimicrobial peptides serve as part of the first line of defence 
against pathogens (Zasloff, 2002). Rather than acting as an agonist/antagonist 
against a specific target, they can exert their effect directly via lysis of microbial 
membranes, although also through other immunomodulatory functions (Bowdish et 
al., 2005a). Their broad-spectrum activity against non-proteinaceous targets 
suggests a low probability of target pathogens developing resistance (Peschel & 
Sahl, 2006). This makes them attractive candidates to treat “superbugs” such as 
methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus 
faecalis. The properties of antimicrobial peptides and their applicability to a 
biosynthetic screen will be discussed in detail in Chapter 3 and Chapter 4. 
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1.3.2 Antiaggregation peptides 
Another potential application of bioactive peptides may be as therapeutic 
antiaggregants. Inappropriate aggregation and subsequent amyloid formation (i.e. 
insoluble protein fibres) are characteristic of a number of human neuropathies 
(Treusch et al., 2009). In Alzheimer!s disease, the amyloid ! peptide, which is 
normally 40 residues in length, undergoes alternative cleavage from its amyloid 
precursor protein leading to two additional residues being retained at its C-terminus 
(Walsh & Selkoe, 2007). This mutant isoform is especially prone to aggregating via 
the formation of anti-parallel !-sheets (Hilbich et al., 1991). In Huntington’s disease, 
triplet repeat mutations in exon I of the huntingtin gene leads to an extended 
polyglutamine tract being coded for with 42-66 residues instead of the typical 11-35 
(Huntington's Disease Collaborative Research Group, 1993). This extended “sticky” 
repeat leads to fragments of the large huntingtin protein (348 kDa) forming 
aggregates with itself or other proteins (Cattaneo et al., 2005). For both amyloid ! 
and huntingtin, other peptides may be able to prevent their aggregation and 
potentially alleviate the disease state. For example, both the 15-residue Peptide 2 
(Baine et al., 2009) and 11-residue polyglutamine binding protein 1 (Nagai et al., 
2000) have been shown to inhibit aggregation of their target proteins in vitro. A 
screen to identify peptides able to interfere with amyloid ! aggregation will be 
discussed in detail in Chapter 5.  
 
1.3.3 Summary and aims 
Peptides and proteins are exquisitely tuned by evolution to perform a huge range of 
biological functions. Peptides, which consist of 100 amino acid residues or fewer, 
are often employed in vivo as cell signalling molecules and hence are implicated in 
a number of disease settings. After falling out of favour due to issues with delivery, 
stability and bioavailability, peptides are now being re-examined with increased 
interest by biotechnology and pharmaceutical companies. Some economically 
valuable peptide drugs now exist. Furthermore, it is clear that the potential uses for 
peptides can expand past traditional cell signal membrane receptors to more 
diverse bioactivities, such as antimicrobials and antiaggregants. The extraordinary 
diversity of organisms in the natural world represents a vast pool of different 
proteins, all of which have been optimised via evolutionary pressures to exhibit 
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particular activities. Tapping this diversity by using the DNA that encodes it to 
produce potentially bioactive peptides for screening may lead to the identification of 
bioactive peptides with novel therapeutic functions. 
 
The overall aim of this project is to explore the utility of in vivo systems to produce, 
screen and identify existing and novel bioactive peptides, focusing on antimicrobial 
and antiaggregation activities. For the first of these, the ability of E. coli to produce 
antimicrobial peptides will be assessed, with the aim of generating a recombinant 
system that can produce antimicrobials for further characterisation. The knowledge 
gained will then be used to design an in vivo screen of DNA libraries for novel 
peptides exhibiting antimicrobial function. For the second activity, another in vivo 
screen will be designed and tested in order to find peptides that possess 
antiaggregation activity against the amyloid ! peptide implicated in Alzheimer’s 
disease. 
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CHAPTER 2 – MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Chemicals 
Chemicals were purchased from Bio-Rad Laboratories Ltd. (Hemel Hempstead, 
UK), Melford Laboratories Ltd. (Ipswich, UK), MP Biomedicals Ltd. (Illkirch, France), 
Sigma-Aldrich Company Ltd. (Gillingham, UK) or Fisher Scientific UK Ltd. 
(Loughborough, UK). All other sources are as indicated. 
 
2.1.2 Oligonucleotides 
Oligonucleotides (i.e. primers) were obtained from Eurofins MWG Operon GmbH 
(Ebersberg, Germany) at the standard, salt-free purity. Long oligonucleotides (see 
Section 2.7.3) were obtained from Sigma-Aldrich Company Ltd. at a high purity 
(PAGE-extracted). When used for constructing genes, all oligonucleotide 
sequences were codon-optimised for use in Escherichia coli as per Nakamura et al. 
(2000).  
 
2.1.3 Bacterial expression strains and plasmids 
E. coli TOP10 chemically-competent cells were obtained from Invitrogen, a division 
of Life Technologies Ltd. (Paisley, UK), while DH10B chemically-competent cells 
were obtained from New England Biolabs (UK) Ltd. (Hitchin, UK). TOP10 and 
DH10B share the same genotype, being araBADC-, i.e. unable to metabolise the 
pBAD induction agent L-arabinose. E. coli Novagen BL21(DE3) Star and 
BL21(DE3)pLysS Rosetta cells were obtained from Merck KGaA (Darmstadt, 
Germany). Vibrio cholerae El Tor N16961 was kindly provided by Dr Gillian Fraser 
(Department of Pathology, University of Cambridge). Plasmid pET28a(+) was 
obtained from Merck KGaA; plasmids pBAD/gIII-A, pBAD/gIII-Calmodulin and 
pUC19 were Invitrogen-brand and obtained from Life Technologies Ltd.; plasmid 
pCC1FOS from Epicentre Biotechnologies Inc. (Madison, USA); plasmid pKG1010 
(Pecota et al., 2003) was kindly provided by Prof Kenn Gerdes (Institute for Cell and 
Molecular Biosciences, Newcastle University); plasmid pA!42-EGFP (Baine et al., 
2009) was kindly provided by Prof David Moffet (Department of Chemistry and 
Biochemistry, Loyola Marymount University, USA); plasmid pSALect-GM6 (Fisher 
et al., 2006) was kindly provided by Prof Matthew DeLisa (School of Chemical and 
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Biomolecular Engineering, Cornell University); plasmids pSB3K3-
mCherryGFP1plus3, pET28-A7-EGFP and pET15-AavLEA1 were previously made 
in the Tunnacliffe laboratory. Cultures of bacterial strains, and of those containing 
the various plasmids, were stored at -80ºC as glycerol stocks (15%) (Sambrook & 
Russell, 2001). 
 
2.1.4 Chemically-synthesised peptides and cell-permeabilizing reagent 
Table 2.1 lists the AMP-related peptides purchased during this work. Peptides came 
lyophilised in 1 mg aliquots. K2C18 and S-H4 were resuspended in sterile water; 
S-H1, S-H5, H4 and R13 in neat DMSO to aid solubility. Polymyxin B nonapeptide 
was purchased from Sigma-Aldrich Company Ltd. (catalogue #P2076). 
 
 
Table 2.1: Chemically-synthesised peptides purchased for this work. K2C18 
purchased from Proimmune Ltd. (Oxford, UK); rest from GenScript USA Inc. (Piscataway, 
USA). Hydrophobic, % of residues (F, I, L, N, V, W & Y); Purity, as measured by HPLC 
analysis (data not shown). 
 
2.2 General cloning methods 
Sambrook & Russell (2001) comprehensively outline the following molecular biology 
techniques.  
 
2.2.1 Common enzymatic manipulations of DNA 
To site-specifically digest DNA, restriction enzymes from New England Biolabs (UK) 
Ltd. or Fermentas GmbH (St. Leon-Rot, Germany) were used. To dephosphorylate 
the 5’ ends of linear DNA in order to prevent self-ligation during ligase treatment, 
calf intestinal alkaline phosphatase or Antarctic phosphatase from New England 
Biolabs (UK) Ltd. was used, or alternatively FastAP thermosensitive alkaline 
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phosphatase from Fermentas GmbH. To phosphorylate the 5’ ends of linear DNA to 
allow them to ligate during ligase treatment, T4 polynucleotide kinase from New 
England Biolabs (UK) Ltd. or Fermentas GmbH was used. To ligate ends of linear 
DNA together, T4 DNA ligase or a Quick Ligation kit from New England Biolabs 
(UK) Ltd. was used, or alternatively T4 DNA ligase from Fermentas GmbH. All 
enzymes were used according to the manufacturer’s instructions, with any 
modification indicated. 
 
2.2.2 Purification of DNA 
For plasmid purification, a QIAprep Spin Miniprep kit was used. For PCR product 
purification, a QIAquick PCR Purification kit was used, or alternatively a QIAquick 
Nucleotide Removal kit as indicated. For agarose gel extraction of DNA, a QIAquick 
Gel Extraction kit was used, with agarose gels lacking ethidium bromide being 
immersed for 10 min in a solution of 1 !g/mL ethidium bromide before visualisation 
at 365 nm (see Section 2.2.7). All kits were used according to the manufacturer’s 
instructions (QIAGEN Ltd., Crawley, UK). 
 
2.2.3 Determination of DNA concentration 
DNA concentration and purity was determined using a ND-1000 spectrophotometer 
as per the manufacturer’s instructions (NanoDrop Technologies Inc., Wilmington, 
USA). 
 
2.2.4 DNA sequencing 
To verify that a constructed plasmid contained the desired sequence, or to 
determine the sequence of an unknown insert, 1 !g of plasmid was analysed using 
appropriate sequencing primers (10 !M; indicated) on a 3730xl DNA Analyser 
(Applied Biosystems Inc., Foster City, USA) by the DNA Sequencing Facility, 
Department of Biochemistry, University of Cambridge. Sequence data was 
analysed using 4Peaks (v1.7.2) and EnzymeX (v3.1) software (Mekentosj BV, 
Amsterdam, Netherlands; accessed at http://www.mekentosj.com/).  
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2.2.5 Amplification of DNA using polymerase chain reaction (PCR) 
2.2.5.1 General PCR 
Advantage 2 polymerase mix (Takara Bio Inc., Otsu, Japan), Phusion High-Fidelity 
DNA polymerase (Finnzymes Oy, Espoo, Finland) or Taq DNA polymerase (Roche 
Diagnostics Ltd., Burgess Hill, UK) was used for PCR reactions (typically 20 !L) as 
indicated. PCR reaction compositions and cycling conditions were performed as per 
polymerase manufacturer’s instructions (typically 500 nM primer concentration), 
with primer-specific annealing temperatures indicated. In addition, touchdown PCR 
(Don et al., 1991) was sometimes performed over the first 10 cycles as indicated, 
with the remaining cycles (typically 20) using a constant annealing temperature. A 
PCR Express (Hybaid Ltd., Ashford, UK) or GS482 (G-Storm Ltd., Somerton, UK) 
thermocycler was used. 
 
2.2.5.2 Colony PCR of plasmid inserts 
To confirm correct plasmid construction, a bacterial colony swab was inoculated 
directly into 10 !L of 1x ReddyMix PCR master mix (Fisher Scientific UK Ltd.) 
containing the appropriate primers (see Table 2.2). Primers T7-Fwd and T7-Rev 
were used to PCR amplify (annealing at 51ºC) insert sequences from the multi-
cloning site region of pET28-based plasmids. Primers pBADmFWD and 
pBADgIII-reverse were used to PCR amplify (annealing at 57ºC) insert sequences 
from the araBAD multi-cloning site region of pBAD-based plasmids. Primers 
pAGLib-FWD and pAGLib-REV were used to PCR amplify (annealing at 54ºC) 
insert sequences from the Library cloning site region of pAG2-A!42-based 
plasmids. 
 
 
Table 2.2: Primers used for colony PCR. 
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2.2.6 Circular polymerase extension cloning (CPEC) 
A modified form of CPEC (Quan & Tian, 2009), named CPEC Viaduct, was 
developed to insert and/or delete DNA (ranging from single bp to kbp) from a 
circular plasmid, i.e. without requiring restriction enzyme treatment. This approach 
is analogous to site-directed mutagenesis (Sambrook & Russell, 2001). Figure 2.1 
outlines the approach. 
 
 
Figure 2.1: CPEC Viaduct may be used to insert and/or delete a sequence (1 bp to 
kbp) from a plasmid in a site-specific manner. Only one strand of the dsDNA 
insert/deletion product is shown for clarity. The inserted region is shown in blue, deleted in 
red. M, methyl groups on template plasmid that allow for selective digestion with DpnI, 
leading to only de novo plasmid being viable. 
 
In brief, the dsDNA sequence that was desired between two regions of a plasmid 
was constructed (typically by PCR amplification or annealing of complimentary 
oligonucleotides) so that its 5’ and 3’ ends contained at least 20 bp of homologous 
overlap with the upstream and downstream plasmid regions respectively. 100 ng of 
plasmid was mixed with dsDNA at a vector:dsDNA molar ratio of 1:3 in a 10 !L 
Phusion polymerase reaction (see Section 2.2.5.1). Typical cycling conditions were 
as follows: 98ºC for 30 s; 3x cycles 98ºC for 30 s, 55ºC for 60 s, 72ºC for 30 s/kbp 
final plasmid size; hold at 10ºC. The reaction was then treated with the methylation-
specific DpnI (2 U) to digest the template plasmid (de novo plasmid produced by 
CPEC Viaduct contains no GAmTC methyl motifs) at 37ºC for 15 min, and an 
aliquot subsequently transformed into E. coli. 
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2.2.7 Agarose gel electrophoresis 
To confirm approximate linear DNA size, electrophoresis of DNA was carried out 
using agarose gels (0.8 to 1.5%, containing 0.5 !g/mL ethidium bromide) in 
Tris-acetate-EDTA buffer (40 mM Tris, 20 mM acetic acid, 1 mM EDTA, pH 8.0). 
DNA samples were mixed with 5x GelPilot DNA loading dye (QIAGEN Ltd.) to 1x 
final concentration (typical final sample volume of 10 !L) and electrophoresed at 
between 60 to 110 V in a Mini-Sub Cell GT (Bio-Rad Laboratories Ltd.). DNA was 
visualised at 312 nm using a Doc-008.XD transilluminator system (UVItec Ltd., 
Cambridge, UK). 
 
2.2.8 Transformation of E. coli 
Aliquots of purchased chemically-competent TOP10 cells and DH10B cells were 
transformed as per the manufacturer’s instructions. For BL21(DE3) strains, 
chemically-competent cells were prepared using the calcium chloride method 
(Sambrook & Russell, 2001) and stored at -80ºC. Aliquots were thawed on ice and 
ligation mixture added to a maximum of 1/10th the cell aliquot volume (typically 0.5 
to 2 !L). Cells were incubated on ice for 30 min, heat-shocked at 42ºC for 30 s, 
returned to ice for 3 min, then 250 !L of lysogeny broth (LB) medium (171 mM 
NaCl; Sambrook & Russell [2001]) added and out-growth performed at 37ºC, 
~225 rpm for 1 h prior to plating aliquots on solid medium. 
 
2.2.9 Growth of E. coli 
To obtain colonies on solid medium, bacteria were typically grown on LB agar 
(1.5%) plates at 37ºC for ~16 h. For liquid culture, bacteria were typically grown in 
LB medium at 37ºC, ~225 rpm. Carbenicillin (100 !g/mL), kanamycin (50 !g/mL), 
chloramphenicol (34 !g/mL) or streptomycin (50 !g/mL) was added to the medium 
as appropriate for particular plasmid selection to give the indicated final 
concentrations. pBAD-, pKG-, pET15- and pSB3K3-based plasmids encoded 
carbenicillin resistance; pET28-based plasmids encoded kanamycin resistance; 
pCDF-based plasmids, i.e. pA!42-EGFP, encoded streptomycin resistance; and 
pSALect-based plasmids encoded chloramphenicol resistance. Chloramphenicol 
was also required to maintain the pLysS plasmid in the BL21(DE3)pLysS Rosetta 
cell line. 
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2.3 General protein methods 
2.3.1 Induction of protein expression in E. coli 
Starter cultures (grown overnight) were used to inoculate fresh medium at a dilution 
of 1:100. Cultures were grown to mid-log growth phase (OD600 = 0.4 to 0.6; using a 
path length of 10 mm in a DU 800 spectrophotometer [Beckmann Coulter Inc., 
Brea, USA]) and induced as appropriate (1 mM IPTG for pET plasmids; 0.05% 
L-arabinose for pBAD plasmids) at a defined temperature for a set time (indicated). 
 
2.3.2 Extraction of protein from E. coli 
All steps were carried out at 4ºC or on ice where possible. Induced cells were 
collected by centrifugation at ~13,700 rcf for 10 min, and the cell pellet resuspended 
in binding buffer (33 mM NaH2PO4, pH 8.0, 425 mM NaCl, 25 mM imidazole) to 
1/17th the original culture volume and subsequently frozen at -80ºC. Thawed 
resuspensions were further lysed by sonication (amplitude 10, 10x cycles of 15 s 
on, 30 s off, using a Soniprep 150 [SANYO Electric Ltd., Moriguchi, Japan]). Whole 
cell samples were taken at this point for SDS-PAGE analysis. Insoluble debris was 
removed by centrifugation at ~20,000 rcf for 30 min, and the supernatant retained. 
Clarified lysate samples were taken at this point for SDS-PAGE analysis. 
 
For lysis of cells in pAG2-A!42 experiments, cell pellets were resuspended in 1/15th 
culture volume of Genlantis SoluLyse (in 50 mM NaHPO4, pH7.4 [Gene Therapy 
Systems Inc., San Diego, USA]) and nutated at 23ºC for 10 min in lieu of sonication. 
 
2.3.3 Polyacrylamide gel electrophoresis (SDS-PAGE) 
2.3.3.1 Glycine-based SDS-PAGE 
Glycine-based SDS-PAGE (Laemmli, 1970), used to estimate protein size, was 
carried out in a Mini-PROTEAN 3 Cell (Bio-Rad Laboratories Ltd.) as per the 
manufacturer’s instructions. A 5% stacking gel was used, with resolving gel 
acrylamide concentration as indicated (typically 12% or 15%). Protein samples were 
mixed with 5x sample dye (60 mM Tris pH 6.8, 25% glycerol, 10% SDS, 0.1% 
bromophenol blue, 5% !-mercaptoethanol [freshly added]) to 1x final concentration, 
boiled in a water bath for 2 min, and allowed to cool prior to gel loading. PageRuler 
Plus Prestained Protein Ladder, Spectra Multicolor Low Range Protein Ladder 
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(Fermentas GmbH), Precision Plus Protein Dual Color (Bio-Rad Laboratories Ltd.) 
or MagicMark XP Western Protein Standard (Life Technologies Ltd.) was used as a 
molecular mass standard. Gels were typically electrophoresed at 60 V constant 
during the stacking phase, then 120 V constant during the resolving phase until the 
sample dye front had reached the bottom of the gel. 
 
2.3.3.2 Tricine-based SDS-PAGE 
Tricine-based SDS-PAGE (Schägger, 2006), used to estimate peptide size, was 
carried out in an Invitrogen XCell SureLock Mini-Cell (Life Technologies Ltd.) as per 
the manufacturer’s instructions. Invitrogen Novex tricine pre-cast gels were 
obtained from Life Technologies Ltd., using a 4% stacking gel with resolving gel 
acrylamide concentration as indicated (typically 10-20% gradient). Protein samples 
were mixed with Invitrogen 2x Novex tricine sample buffer (Life Technologies Ltd.; 
with 100 mM dithiothreitol [freshly added]) to 1x final concentration, then boiled and 
loaded as per Section 2.3.3.1. Gels were typically electrophoresed at 125 V 
constant until the sample dye front had reached the bottom. 
 
2.3.3.3 SDS-PAGE visualisation 
After electrophoresis, gels were fixed/stained in warm Coomassie stain (25% 
propan-2-ol, 10% acetic acid, 0.05% Coomassie brilliant blue R-250) for 30 min 
followed by destaining in destain solution (40% methanol, 10% acetic acid). Gels 
were subsequently scanned (Epson Perfection 3490 Photo flatbed scanner, Seiko 
Epson Corp., Nagano, Japan) or photographed (UVIdoc HD2/20LM transilluminator, 
UVItec Ltd.). 
 
2.3.3.4 Western blotting 
After SDS-PAGE (Section 2.3.3.1), the gel was washed in water and then 
equilibrated in transfer buffer (25 mM Tris pH 8.3, 192 mM glycine, 20% methanol) 
for 10 min. Amersham Hybond-P polyvinylidene fluoride membrane (GE Healthcare 
UK Ltd., Little Chalfont, UK) was equilibrated in methanol for 1 min, water for 5 min 
and then transfer buffer for 10 min. Proteins were transferred to the membrane 
using a Trans-Blot SD Semi-Dry Electrophoretic Transfer Cell (Bio-Rad 
Laboratories Ltd.) as per the manufacturer’s instructions (typically run at 15 V for 30 
min). After transfer, the membrane was blocked in 5% non-fat milk powder TBS-T 
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(Tris 50 mM pH 7.5, NaCl 150 mM, 0.1% Tween 20) for 1 h on a rocker, rinsed 
briefly with 1% non-fat milk powder TBS-T, and then 3.3 !L of Novagen 
Anti-His-Tag monoclonal mouse IgG antibody (Merck KGaA) was added to 5 mL 
fresh 1% non-fat milk powder TBS-T (1:1,500 dilution). After at least 1 h incubation 
with the primary antibody, the membrane was washed 5x with 1% non-fat milk 
powder TBS-T over 30 min. 1.3 !L of ECL Anti-mouse IgG horseradish-peroxidase-
linked sheep antibody (GE Healthcare UK Ltd.) was then added to 5 mL fresh 1% 
non-fat milk powder TBS-T (1:4,000 dilution) and the membrane incubated for 1 h, 
followed by 5x washes as above. Signal was visualised using ECL Plus Western 
Blotting Detection Reagents and Hyperfilm ECL (GE Healthcare UK Ltd.) as per the 
manufacturer’s instructions. Films were developed using a X-OMAT 1000 
Processor (Eastman Kodak Co., Rochester, USA). 
 
2.3.4 Amino acid analysis 
To verify peptide concentration, as well as qualitatively measure purity and 
composition, ion-exchange-ninhydrin analysis was carried out on 0.1 to 1 nmoles of 
sample hydrolysate on a Biochrom 30 amino acid analyser (Biochrom Ltd., 
Cambridge, UK) by the Protein & Nucleic Acid Chemistry Facility, Department of 
Biochemistry, University of Cambridge. 
 
2.3.5 Mass spectrometry analysis 
To determine the mass of a peptide for comparison to its expected mass, matrix-
assisted laser desorption/ionisation of 2 to 5 pmoles of sample was analysed by 
time-of-flight mass spectrometry using a Maldi Micro MX and Q-Tof micro (Waters 
UK Ltd., Elstree, UK) by the Protein & Nucleic Acid Chemistry Facility, Department 
of Biochemistry, University of Cambridge. 
 
2.4 Recombinant AMP production methods  
2.4.1 Construction of pET28-AMP-CPD vectors 
The oligonucleotides listed in Table 2.3 were used during vector construction as 
outlined in this section. 
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Table 2.3: Primers used to construct the various pET28-AMP-CPD vectors.  
 
2.4.1.1 Construction of pET28-CPD 
Primers CPD-Via1 and CPD-Via2 were used to PCR amplify (Phusion polymerase, 
annealing at 72ºC) the cysteine protease domain (CPD) from the rtxA gene (NCBI 
reference sequence NB_231094.1, amino acids 3440-3650) of V. cholerae El Tor 
N16961. The 667 bp product was inserted into pET28a by CPEC Viaduct (see 
Section 2.2.6) so that the CPD coding region was between the BamHI and XhoI 
sites of the plasmid, giving pET28-CPD. A C-terminal hexa-histidine tag was 
encoded in-frame by the pET28a vector downstream of the XhoI site. 
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2.4.1.2 Construction of pET28-K2C18-CPDW/T 
The 54 bp sequence of K2C18 (see Table 2.3) had been previously inserted into 
pET28a by CPEC Viaduct (see Section 2.2.6) so that it lay between the NcoI and 
NheI sites of the plasmid (pET28-K2C18). The CPD sequence was PCR amplified 
(as per Section 2.4.1.1) using primers CPD-Via2 and CPD-Via3. The 674 bp 
product was inserted into pET28-K2C18 by CPEC Viaduct so that the fused 
K2C18-CPD coding region was between the NcoI and XhoI sites of the plasmid. 
 
2.4.1.3 Construction of pET28-AMP-CPD variants 
The 54 bp sequences encoding the K2C18 and MCC18 variants were stitched 
together from oligonucleotides (Figure 2.2) using polymerase cycling assembly 
(Phusion polymerase, annealing at 59ºC) as per Stemmer et al. (1995), then 
subsequently inserted into pET28-CPD via the NcoI/BamHI sites. The assembly key 
was as follows: K2C18, Front#2, Mid#1a, Rear#1; K2C18(G8L), Front#1, Mid#1, 
Rear#1; K2C18(F14K), Front#2, Mid#2, Rear#2; K2C18(Q9K), Front#3, Mid#3, 
Rear#1; RC18, Front#4, Mid#4, Rear#3; K2C18-2, Front#5, Mid#5, Rear#4; 
K2C18-2(G8L), Front#6, Mid#6, Rear#4; MCC18, Front#7, Mid#7, Rear#5; 
MCC18(E2K), Front#2, Mid#8, Rear#5; MCC18(E2K,Q9K), Front#3, Mid#9, 
Rear#5.  
 
 
Figure 2.2: Schematic of the polymerase cycling assembly approach used to 
construct the K2C18 and MCC18 analogue sequences. Oligonucleotide sequences are 
outlined in Table 2.3. 
 
2.4.2 CPD on-column cleavage 
All steps were carried out at 4ºC or on ice where possible. Ni-NTA agarose beads 
(50% slurry, ~25 mg binding capacity/mL; QIAGEN Ltd.) were added to cell clarified 
lysate (see Section 2.3.2) at 1 mL per L original culture volume, and CPD-hexa-
histidine tagged protein allowed to bind for at least 1 h while agitating on a roller. 
Ni-NTA beads were collected by centrifugation at ~100 rcf for 2 min, placed in a 
disposable column, and washed with at least 15 bead volumes of wash buffer 
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(20 mM NaH2PO4, pH 8.0, 500 mM NaCl, 10 mM imidazole). On-column cleavage 
of CPD was induced via the addition of 1 bead volume wash buffer containing 1 mM 
IP6 (catalogue #593648, Sigma-Aldrich Company Ltd.), sealing the column, and 
incubating for at least 1 h while agitating on a rotating wheel. Free peptide was 
collected by washing the column with an additional 5 bead volumes of wash buffer 
in 1 bead volume fractions. The cleaved CPD-His tag was eluted by washing the 
column with 1 bead volume of wash buffer containing 500 mM imidazole. 
 
2.4.3 Further AMP purification 
2.4.3.1 C18 hydrophobic resin purification of AMPs 
TFA was added to pooled free AMP fractions (Section 2.4.2, typically ~4.5 to 
~5.5 mL) to a final concentration of 0.1% before application onto two Sep-Pak Vac 
C18 cartridges (50 mg resin, ~2 mg binding capacity [Waters UK Ltd.], pre-
equilibrated with 0.8 mL 65% acetonitrile/0.07% TFA followed by 1.6 mL 2% 
acetonitrile/0.07% TFA). A syringe was used to pull samples through. AMPs bound 
to the C18 resin were washed with 1.6 mL 2% acetonitrile/0.07% TFA, then eluted 
with 0.4 mL 15%/30%/45%/65% acetonitrile/0.07% TFA in a step-wise manner. 
Fractions were dried using a VacuFuge 5301 (Eppendorf AG, Hamburg, Germany) 
at ~30ºC and resuspended in sterile water, then stored at -80ºC. This procedure 
was performed in collaboration with Dr Tatsuya Yoshimi. 
 
2.4.3.2 Molecular weight cut-off (MWCO) purification of AMPs 
Pooled free AMP fractions (Section 2.4.2) were applied onto a Vivaspin 2 10 kDa 
MWCO polyethersulfone filtration spin column (Sartorius Stedim Biotech S.A., 
Aubagne, France) and filtered as per the manufacturer’s instructions. The low-
molecular mass flow-through was collected and dialysed using Spectra/Por 7 2 kDa 
MWCO regenerated cellulose membrane (Spectrum Laboratories Inc., Rancho 
Dominguez, USA) against 0.1 M ammonium acetate at 4ºC for ~16 h while stirring. 
Dialysate was lyophilised using a FTS Dura-Stop MP freeze dryer (SP Industries 
Inc., Warminster, USA) as per the manufacturer’s instructions, resuspended in 
sterile water, and stored at -80ºC. 
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2.4.4 Physical properties of peptides 
The charge (Q) of a peptide was determined by counting the number of positively-
charged amino acids (arginine, lysine and histidine) and subtracting the number of 
negatively-charged amino acids (aspartic acid and glutamic acid). The positively-
charged N-terminal and negatively-charged C-terminal negated each other. Cationic 
face angle (") of an #-helix was determined using a helical wheel plot, with 20º 
between each position assuming an ideal #-helix conformation. Mean 
hydrophobicity (H) was derived from Eisenberg’s consensus hydrophobicity scale 
(1984). The relative hydrophobic moment (!Rel) of an #-helix represented the vector 
sum of the hydrophobicities of all residues (assuming an ideal #-helix) expressed as 
a % of !max (0.80 – determined by an 18 residue peptide consisting of 9 arginines 
and 9 isoleucines in an ideal #-helix), and was calculated as per Eisenberg (1984). 
H and !Rel were calculated using HydroMCalc (Antimicrobial Peptides Laboratory, 
University of Trieste; accessed at http://www.bbcm.univ.trieste.it/~tossi/ 
HydroCalc/HydroMCalc.html). Molecular masses and other properties of proteins 
and peptides were predicted using ProtParam (Swiss Institute of Bioinformatics; 
Gasteiger et al. [2003]; accessed at http://web.expasy.org/protparam/). 
 
2.5 Antimicrobial activity assays  
2.5.1 Microbial test strains 
Escherichia coli (DH10B), Pseudomonas putida (American Type Culture Collection 
#47054), Bacillus subtilis (American Type Culture Collection #6051 derivative 
[#NZ8900, NIZO Food Research B.V., Ede, Netherlands]) and Candida albicans 
(laboratory strain) were used in antimicrobial activity assays. Starter cultures were 
grown overnight in LB medium at ~225 rpm, 37ºC for E. coli and P. putida; 30ºC for 
B. subtilis and C. albicans. The medium for C. albicans was supplemented with 
0.05% glucose. These cultures were used to inoculate fresh medium and grown as 
above for several hours until logarithmic growth was achieved (OD600 between 0.4 
to 0.6). An OD600 equivalent to 1 was assumed to equate to approximately 
5x108 cfu/mL for E. coli, P. putida and B. subtilis (Domínguez et al., 2001; Fraile et 
al., 2001; Garbisu et al., 1998), and was approximated experimentally by plating 
culture dilutions. For C. albicans, an OD600 of 1 was assumed to equate to 
approximately 3x107 cfu/mL (Jackson et al., 2007).  
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2.5.2 Agar radial diffusion assay 
5 mL of cooled molten LB top agar (0.7%) was inoculated with 15 !L overnight 
culture of E. coli TOP10 and poured over an LB agar plate. Wells (~2.5 mm 
diameter) were punched into agar and 10 !L of AMP fraction added. Plates were 
incubated for ~16 h upright at 37ºC. Zones of growth inhibition around a well 
indicated antimicrobial activity. 
 
2.5.3 Antimicrobial liquid culture assay 
Logarithmic stage cultures of test microbes (see Section 2.5.1) were diluted in fresh 
medium to achieve approximate cell concentrations of 5x104 cfu/mL (E. coli, 
P. putida [37ºC] and B. subtilis [30ºC]) or 6x103 cfu/mL (C. albicans [30ºC]). Unless 
otherwise indicated, nutrient broth (NB; 0.5% peptone, 0.3% meat extract) was 
used for E. coli and C. albicans, and LB for P. putida and B. subtilis. In a 96-well 
plate (Nunc brand, Nunclon $ surface; Fisher Scientific UK Ltd.), 90 !L of microbe 
was added to a duplicate dilution series of each AMP in sterile water. The plate was 
sealed with Parafilm (Pechiney Plastic Packaging Inc., Chicago, USA) and 
incubated (stationary) at the appropriate temperature for each microbe (see above), 
and OD600 measured periodically using an EnVision 2104 plate reader 
spectrophotometer (PerkinElmer Inc., Waltham, USA). Minimum inhibitory 
concentration (MIC) was determined as the concentration of peptide that completely 
inhibited microbial growth after 18 h (bacteria) or 23.5 h (yeast). 
 
2.6 Novel AMP screening methods 
2.6.1 Construction of AMP screen vectors 
The oligonucleotides listed in Table 2.4 were used during vector construction as 
outlined in this section. 
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Table 2.4: Primers used to construct the various pAMP vectors.  
 
2.6.1.1 Construction of pBADm 
Primers pBADmFWD and pBADmREV were used to PCR amplify (Advantage 2 
polymerase, annealing at 59ºC) a 100 bp product from pBAD/gIII-A spanning from 
the unique BamHI site to the start codon of the pIII secretion signal. This was 
subsequently digested with BamHI/NcoI and ligated into dephosphorylated 
pBAD/gIII-A via the same sites, resulting in the removal of the pIII-coding sequence 
from the plasmid. 
 
2.6.1.2 Insertion of K2C18 and K2C38 into pBAD/gIII-A and pBADm 
2.6.1.2.1 Cloning of K2C18 
Primers NcoI-CRAMP-FWD and BstBI-CRAMP-REV2 were used to PCR amplify 
(Advantage 2 polymerase, annealing at 54ºC) the K2C18 sequence from the 54 bp 
oligonucleotide K2C18 (see Table 2.3). In addition, primer BstBI-CRAMP-REV1 
was used in conjunction with primer NcoI-CRAMP-FWD to include a stop codon 
immediately after the C-terminal leucine of K2C18, thus preventing read-through to 
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the C-terminal hexa-histidine tag in the pBAD vectors. These PCR products were 
subsequently digested with NcoI/BstBI and ligated into dephosphorylated 
pBAD/gIII-A via the same sites, resulting in pBAD/gIII-K2C18-Tag and 
pBAD/gIII-K2C18* respectively. 
 
2.6.1.2.2 Cloning of K2C38 
The 114 bp sequence of K2C38 was stitched together using polymerase cycling 
assembly (Taq polymerase, annealing at 56ºC) as per Stemmer et al. (1995) from 
the overlapping oligonucleotides K2CF-A, K2CF-B, K2CF-C and K2CF-D(Tag). In 
addition, oligonucleotide K2CF-D(*) was used instead of K2CF-D(Tag) to include a 
stop codon immediately after the C-terminal glutamic acid of K2C38, thus 
preventing read-through to the C-terminal hexa-histidine tag in the pBAD vectors. 
These DNA products were subsequently digested with NcoI/BstBI and ligated into 
dephosphorylated pBAD/gIII-A and pBADm via the same sites, resulting in 
pBAD/gIII-K2C38-Tag, pBAD/gIII-K2C38*, pBADm-K2C38-Tag and 
pBADm-K2C38* respectively. See Section 4.2.2.1 for an overview of these 
plasmids. 
 
2.6.1.3 Insertion of hok and hokFS into pBAD/gIII-A and pBADm 
Primers Hok-FWD1 and Hok-REV were used to PCR amplify (Phusion polymerase, 
annealing at 60ºC) the hok sequence from pKG1010. In addition, primer Hok-FWD2 
was used in conjunction with primer Hok-REV to produce a frame-shift (FS) 
mutation immediately after the start codon. These ~160 bp PCR products were 
subsequently digested with NcoI/BstBI and ligated into dephosphorylated 
pBAD/gIII-A and pBADm via the same sites, resulting in pBAD/gIII-Hok, 
pBAD/gIII-HokFS, pBADm-Hok and pBADm-HokFS respectively. 
 
2.6.1.4 Construction of pAMP/S and pAMP 
Primers LacZ-FWD and LacZ-REV were used to PCR amplify (Advantage 2 
polymerase, annealing at 58ºC) the lacZ operon from pUC19. The 5’ ends of this 
757 bp product were phosphorylated and blunt-end ligated into BsaAI-
digested/dephosphorylated pBAD/gIII-A and pBADm, resulting in pBAD/gIII-LacZ 
and pBADm-LacZ respectively. For the new araBAD cloning site, complimentary 
oligonucleotides pBAD-AfeIstop-FWD and pBAD-AfeIstop-REV were designed to 
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have NcoI-compatible 5’ overhangs, and annealed by heating 100 !L of a 25 !M 
solution to 72ºC for 10 min and subsequently cooling to 53ºC over 10 min. This 
product was phosphorylated and ligated into NcoI-digested/dephosphorylated 
pBAD/gIII-LacZ and pBADm-LacZ, resulting in pAMP/S and pAMP respectively. 
See Section 4.2.3 for a schematic of these plasmids. 
 
2.6.2 Growth curves 
Growth curves were carried out in sterile 24-well plates (Nunc brand, non-treated 
surface; Fisher Scientific UK Ltd.). 2 mL of fresh LB (containing appropriate 
antibiotic) was inoculated with a 1:50 dilution of overnight starter culture, which was 
then split into duplicate 1 mL aliquots in separate wells. Plates were sealed using a 
sterile polydimethylsiloxane mat and binder clips, and incubated flat at 37ºC, 
~225 rpm for 1.5 h before L-arabinose (0.05%) was added to one of each duplicate 
well. OD600 was measured periodically using an EnVision 2104 plate reader 
spectrophotometer (PerkinElmer Inc., Waltham, USA). 
 
2.6.3 Preparation and insertion of genomic DNA (gDNA) into vectors 
2.6.3.1 Shearing of gDNA 
Genomic DNA extracts from human (Homo sapiens) and bdelloid rotifer (Adineta 
ricciae) sources were gifts from Prof Alan Tunnacliffe and Dr Chiara Boschetti 
respectively. 2 to 4 !g of gDNA was added to 500 !L nebulisation buffer (Tris-EDTA 
pH 8.0, 40% glycerol) and placed in an Invitrogen disposable nebuliser as per the 
manufacturer’s instructions (Life Technologies Ltd.). Nebulisation proceeded on ice 
in a fume hood using nitrogen gas at 3.45 bar for 2 min. The nebuliser was briefly 
centrifuged at 1000 rcf, and the sheared gDNA solution removed and concentrated 
via ethanol precipitation (Sambrook & Russell, 2001). To remove potential 5’ or 3’ 
overhangs from the sheared gDNA that may have resulted from nebulisation, and to 
ensure phosphorylation of 5’ ends prior to ligation, an End-It DNA End-Repair kit 
was used as per the manufacturer’s instructions (Epicentre Biotechnologies Inc.). 
Sheared and end-repaired gDNA was subsequently purified using a QIAquick 
Nucleotide Removal kit (see Section 2.2.2). 
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2.6.3.2 Insertion of gDNA into pAMP/S and pAMP  
Fragmented gDNA was ligated into 50 ng of AfeI-digested/dephosphorylated 
pAMP/S and pAMP at a vector:insert molar ratio of 1:5 using concentrated T4 DNA 
ligase (1000 U, New England Biolabs (UK) Ltd.) at 16ºC for ~16 h (10 !L total 
volume). Ligase was inactivated prior to transformation via storage of ligation 
mixture at -20ºC. For each desired agar plate, 1 !L of ligation mixture was 
transformed into ~25 !L of chemically-competent E. coli TOP10. 
 
2.6.4 Replica plate screening of pAMP/S and pAMP libraries 
Replica plating followed a modified version of that outlined by Sambrook & Russell 
(2001). In brief, transformations were plated on sterile 85 mm mixed cellulose ester 
membranes (0.45 !m pore size, white; Advantec MFS Inc. [Dublin, USA]) on LB 
agar (including 50 !g/mL X-gal) and incubated at 30ºC until pinhead-sized colonies 
were visible (typically 16 h). This master membrane was laid colony side up on 
Whatman 3MM Chr blotting paper (GE Healthcare UK Ltd.) on a thick glass plate, 
covered with a fresh membrane (pre-wetted on a fresh agar plate), followed by 
additional blotting paper and another glass plate. Pressure was evenly applied to 
ensure uniform colony transfer, the apparatus disassembled and the membranes 
asymmetrically keyed using a needle dipped in indelible ink before being separated 
by tweezers. This first replica filter was placed on LB agar containing 0.05% 
arabinose (+ara membrane). A second replica membrane was made and placed on 
LB agar lacking arabinose (-ara membrane). The master membrane was returned 
to its agar plate, and all plates were further incubated at 37ºC until large colonies 
appeared (typically 8 h). 
 
2.6.5 Identification of pAMP/S and pAMP library hits 
Replica membranes for each plate (master, +ara and -ara) were scanned (Epson 
Perfection 3490 Photo flatbed scanner) and the images imported into Photoshop 
v7.0.1 (Adobe Systems Inc., San Jose, USA) where they were converted to black & 
white via the “threshold” function: colonies became black, the background white. 
Each membrane was then colourised using the “screen” function: the master 
membrane blue, +ara black, and -ara red. The master and +ara images were 
overlaid on the -ara image as separate layers, aligned to the asymmetric key, and 
growth inhibition of colonies on the +ara membrane identified using the “darken” 
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function. Where no or little growth inhibition had occurred, the black colony on the 
+ara membrane obscured its red replica on the -ara membrane. Where growth was 
inhibited, the red -ara colony was visible and easily detected by eye. Any identified 
hits were then compared to the master membrane, and validated manually by 
inspecting the colonies themselves. 
 
2.6.6 Bioinformatic analysis of pAMP/S and pAMP library hits 
Insert gDNA sequences from selected pAMP/S and pAMP hits were compared to 
the National Centre for Biotechnology Information’s (NCBI, Bethesda, USA) nr 
database (all GenBank+EMBL+DDBJ+PDB sequences [but no EST, STS, GSS, 
environmental samples or phase 0, 1 or 2 HTGS sequences]) using NCBI’s 
translated query versus translated database basic local alignment search tool 
(tBLASTx v2.2.25+; Altschul et al. [1997]; accessed at http://blast.ncbi.nlm.nih.gov/). 
Default search settings were used, with low complexity regions left unfiltered. To 
search for putative antisense RNA partners to endogenous E. coli transcripts, the 
reverse complement of an insert sequence was compared against the E. coli 
DH10B genome (NCBI taxid:316385; Durfee et al. [2008]) using NCBI’s nucleotide 
query versus nucleotide database (BLASTn v2.2.25+; Altschul et al. [1997]). Default 
search settings were used, except the “expect” threshold was raised from 10 to 100, 
and low complexity regions left unfiltered. RNA secondary structure prediction was 
performed using RNAfold v2.0.0 (Hofacker [2003]; default options used, accessed 
at http://rna.tbi.univie.ac.at/). Peptide secondary structure prediction was performed 
using Multivariate Linear Regression Combination (SOPMA-GOR4-SIMPA) 
(Guermeur et al. [1999]; accessed at http://npsa-pbil.ibcp.fr/).  
 
2.6.7 Modification of pAMP/S library hits 
The oligonucleotides listed in Table 2.5 were used during vector modification as 
outlined in this section. 
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Table 2.5: Primers used to modify selected pAMP/S hit vectors.  
 
2.6.7.1 Site-directed mutagenesis to introduce a frame-shift 
Site-directed mutagenesis was carried out as per overlap extension PCR 
(Sambrook & Russell, 2001). For a frame-shift downstream of the start codon (ATG 
to ATGG), primers pAMP/S-SDM1 and pAMP/S-SDM6 were used to PCR amplify 
(Phusion polymerase, annealing at 56ºC) the region from the frame-shift upstream 
to the AgeI site of pAMP/S; primers pAMP/S-SDM5 and pAMP/S-SDM2 were used 
to PCR amplify the region from the frame-shift downstream to the XhoI site. 5 ng of 
the upstream and downstream product was then mixed and PCR amplified (as 
previously) using the flanking primers pAMP/S-SDM1 and pAMP/S-SDM2. The full-
length product was purified, digested with AgeI/XhoI, and ligated into pAMP/S that 
had been digested in the same manner and dephosphorylated. 
 
2.6.7.2 Antibiotic resistance cassette exchange 
The primers CamR-FWD2 and CamR-REV were used to PCR amplify (Phusion 
polymerase, annealing at 58ºC) the chloramphenicol acetyl transferase operon 
(chlR) from pCC1FOS. The product was purified, digested with BspHI, and ligated 
into pBADm (see Section 2.6.1.1) that had been digested in the same manner and 
dephosphorylated; this replaced the !-lactamase operon (ampR), giving the plasmid 
pBADmC. Flanking primers pAMP/S-SDM1 and pAMP/S-SDM2 were then used to 
PCR amplify (Phusion polymerase, annealing at 60ºC) selected pAMP/S hits; the 
products were purified, digested with AgeI/XhoI, and ligated into pBADmC that had 
been digested in the same manner and dephosphorylated. 
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2.6.7.3 Secretion tag removal 
CPEC Viaduct (see Section 2.2.6) was used to remove the 60 bp between the start 
codon of the pAMP/S araBAD site and the start of the insert sequence, i.e. the gIII 
secretion signal sequence and the downstream 9 bp encoding Thr-Met-Ser. Table 
2.6 outlines the primers used for each plasmid; reverse complements of each were 
also utilised, but are omitted for clarity. 
 
 
Table 2.6: Primers used to remove gIII sequence from several pAMP/S hits via CPEC 
Viaduct. Start codon in bold, hit insert sequence underlined. Reverse complements of each 
primer also used, not shown. 
 
2.6.8 Insertion and expression of AMP hits in pET28-CPD 
2.6.8.1 Insertion of selected AMP hits into pET28-CPD  
The primers outlined in Table 2.7 were used to PCR amplify (Phusion polymerase, 
annealing at 62ºC) the following pAMP/S hit sequences (primer combination in 
parentheses): pAMP/S-H2 (CPD-Via5/6), pAMP/S-H3 (CPD-Via7/8), pAMP/S-H4 
(CPD-Via9/10), pAMP/S-R17 (CPD-Via11/12), pAMP/S-R22 (CPD-Via22/23), 
pAMP/S-R25 (CPD-Via24/25), pAMP/S-R32 (CPD-Via32/33), pAMP/S-R33 
(CPD-Via34/35) and pAMP/S-R39 (CPD-Via42/43). CPEC Viaduct (see Section 
2.2.6; annealing at 51ºC) was then used to insert these products (all encoding 
C-terminal leucine codons) into pET28-CPD between the NcoI-provided start codon 
and the BamHI site. The resulting plasmids were named pET28-S-xxx-CPD 
accordingly. 
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Table 2.7: Primers used to transfer several pAMP/S hit sequences to pET28-CPD via 
CPEC Viaduct. Start codon (ATG) or critical CPD cleavage Leu codon (CAG, reverse 
complement) in bold, hit insert sequence underlined. Used in combination as outlined 
above. 
 
2.6.8.2 Expression of selected AMP hits from pET28-CPD 
Expression occurred as per Section 2.3.1, with pET28-S-H2-CPD, 
pET28-S-H3-CPD, pET28-S-H4-CPD, pET28-S-R17-CPD transformed into E. coli 
BL21(DE3) Star and 500 mL induced at 30ºC for 5 h; pET28-S-R22-CPD, 
pET28-S-R25-CPD, pET28-S-R32-CPD, pET28-S-R33-CPD and 
pET28-S-R39-CPD were transformed into BL21(DE3)pLysS Rosetta cells and 250 
mL induced at 16ºC for 18 h. 
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2.7 Novel antiaggregant screening methods 
2.7.1 Construction of pAG2-A!42 
The oligonucleotides listed in Table 2.8 were used during vector construction as 
outlined in this section; BioBrick part sequences (BBa; Canton et al. [2008]) are 
available at the Registry of Standard Biological Parts (accessed at 
http://partsregistry.org/). 
 
 
Table 2.8: Primers used to construct pAG2-A!42. 
 
2.7.1.1 Insertion of mCherry operon 
Primers pAG-Via1 and pAG-Via2 were used to PCR amplify (Phusion polymerase, 
touchdown 61ºC to 52ºC, then annealing at 65ºC) the mCherry operon 
(BBa_J06702, partnered with the medium-strength promoter BBa_J23101) from 
pSB3K3-mCherryGFP1plus3. This 958 bp product was inserted into pBADm near 
its BsaAI site by CPEC Viaduct (see Section 2.2.6) so that the mCherry coding 
region lay between the ampR operon and the origin of replication, resulting in 
pAG-A. 
 
2.7.1.2 Construction and insertion of Library operon 
The Library site consisted of the strong promoter BBa_J23119, ribosome binding 
site BBa_B0034, a start codon straddled by SpeI and AfeI sites, stop codons for all 
three reading frames, and the rrnB T1/T2 terminator region (for more detail see 
Appendix 8). Primers pAG-Via3 and pAG-Via4, which overlapped, were extended 
by PCR amplification (Phusion polymerase, touchdown 62ºC to 53ºC, then 
annealing at 72ºC), giving a 78 bp product (named A). Primers pAG-Via6 and 
pAG-Via7 were used to PCR amplify (as above) the rrnB T1/T2 terminator region 
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from pBADmC (see Section 2.6.7.2), giving a 249 bp product (named B). Product B 
was re-amplified (as above) using Primers pAG-Via19 and pAG-Via 7, giving a 
279 bp product (named C). Products A and C, which overlapped, were stitched 
together by PCR amplification (as above) using primers pAG-Via3 and pAG-Via7, 
giving the full-length Library site. This 335 bp product was inserted into pAG-A by 
CPEC Viaduct (see Section 2.2.6; annealing at 62.5ºC) between the end of the 
araBAD site’s transcriptional terminator and the start of the ampR operon, resulting 
in pAG2-B. 
 
2.7.1.3 Insertion of A!42-EGFP into the araBAD site 
Primers pAG-Via8 and pAG-Via9 were used to PCR amplify (Phusion polymerase, 
touchdown 62ºC to 53ºC, then annealing at 72ºC) A!42-EGFP from pA!42-EGFP. 
This 929 bp product was inserted into pAG2-B by CPEC Viaduct (see Section 2.2.6; 
annealing at 60ºC) between the araBAD site’s start codon and the PmeI site, 
resulting in pAG2-A!42. The linker between the A!42 and EGFP domains was 
GSAGSAAGSGESHMV (15 aa; as per Baine et al., [2009]). See Section 5.2.1.1 for 
a schematic of pAG2-A!42; the full annotated sequence is shown in Appendix 7. 
 
2.7.2 Construction of pAG2-A!42 controls 
The oligonucleotides listed in Table 2.9 were used during vector construction as 
outlined in this section. 
 
 
Table 2.9: Primers used to construct pAG2-A!42 controls. 
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2.7.2.1 Construction of pBADm-EGFP 
As a single (green) positive control, EGFP was inserted into the araBAD site of 
pBADm (see Section 2.6.1.1). Primers EGFP-Via1 and EGFP-Via2 were used to 
PCR amplify (Phusion polymerase, touchdown 65ºC to 56ºC, then annealing at 
72ºC) EGFP from pET28-A7-EGFP. This 744 bp product was inserted into pBADm 
by CPEC Viaduct (see Section 2.2.6; annealing at 65ºC) between the NcoI and 
XbaI sites of the araBAD region, resulting in pBADm-EGFP. The sequence ran on 
into the pBADm C-terminal hexa-histidine tag (17 aa extra). 
 
2.7.2.2 Insertion of EGFP into Library site of pAG2-A!42 
To test the activity of the Library site, EGFP was inserted as a reporter. Primers 
pAG-Via21 and Cherry-REV2 were used to PCR amplify (Phusion polymerase, 
touchdown 60ºC to 51ºC, then annealing at 58ºC) EGFP from pET28-A7-EGFP (the 
same sequence as Baine et al. [2009]), incorporating a 5’ SpeI and 3’ XbaI site. 
This 757 bp product was subsequently digested with SpeI/XbaI (which share 
compatible sticky ends) and ligated into dephosphorylated pAG2-B via the SpeI 
Library site, resulting in pAG2-B/EGFP. 
 
2.7.2.3 Construction of pAG2-GM6 
pAG2-A!42 was modified to incorporate the non-aggregating A!42 mutant GM6 
(Wurth et al., 2002) as a positive control. Primers pAG-Via8 and pAG-Via10 were 
used to PCR amplify (Phusion polymerase, touchdown 62ºC to 53ºC, then 
annealing at 72ºC) GM6 from pSALect-GM6. This 151 bp product was inserted into 
pAG2-A!42 by CPEC Viaduct (see Section 2.2.6; annealing at 51ºC) to replace the 
A!42 domain, resulting in pAG2-GM6. 
 
2.7.2.4 Insertion of Peptide 2 (Pep2) and AavLEA1 into pAG2-A!42 
The coding sequences for Pep2 (Baine et al., 2009) and AavLEA1 (Browne et al., 
2002) were inserted into the Library site of pAG2-A!42 to use as antiaggregant 
controls. To create the Pep2 coding sequence, complimentary oligonucleotides p2F 
and p2R were annealed by heating 20 !L of a 25 !M solution to 95ºC for 5 min and 
subsequently cooling from 80ºC to 60ºC at 0.5ºC/min. This 50 bp product was PCR 
amplified (Phusion polymerase, touchdown 62ºC to 53ºC, then annealing at 72ºC) 
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using primers pAG-Via23 and pAG-Via16. The resulting 92 bp product was inserted 
into pAG2-A!42 by CPEC Viaduct (see Section 2.2.6; annealing at 51ºC) between 
the Library site’s start codon and first stop codon, resulting in pAG2-A!42-Pep2. 
 
Primers pAG-Via25 and pAG-Via18 were used to PCR amplify (as above) AavLEA1 
from pET15-AavLEA1. This 476 bp product was inserted into pAG2-A!42 as per 
Pep2 above, resulting in pAG2-A!42-AavLEA1. 
 
2.7.3 Insertion of random DNA library into pAG2-A!42 
Oligonucleotides (see Table 2.10) coding for a maximum of either 12 or 24 random 
amino acids (13 or 25 including the initiating methionine) were PCR amplified (from 
10 pmol of template; Phusion polymerase, annealing at 57ºC) using primers 
pAGIns-FWD and pAGIns-REV. Only 15 amplification cycles were used in order to 
minimise any loss of product diversity. These 74 and 110 bp products were 
subsequently digested with SpeI/AfeI and ligated into 200 ng of dephosphorylated, 
gel extracted pAG2-A!42 via the same sites at a vector:insert molar ratio of 1:5 
using T4 DNA ligase (Fermentas GmbH) at 23ºC for 1 hour (40 !L total volume). 
Ligase was inactivated prior to transformation via storage of ligation mixture at 
-20ºC. The resulting libraries were named pAG2-A!42-74 (13 aa peptide) and 
pAG2-A!42-110 (25 aa peptide). For each desired agar plate, 1.25 !L of ligation 
mixture was transformed into ~12.5 !L of chemically-competent E. coli DH10B. 
Each transformation was plated on LB agar containing 0.05% arabinose. 
 
 
Table 2.10: Oligonucleotides used to create random DNA libraries. N, any base pair. 
 
2.7.4 Microscopy 
Bright field and fluorescence microscopy were undertaken on an Optiphot-2 
microscope with an EFD-3 epifluorescence system (Nikon Corp., Tokyo, Japan). 
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Images were captured using a DS-2Mv camera system (Nikon Corp.). EGFP had 
peak absorption and emission wavelengths of 488 nm and 509 nm, while mCherry 
was 587 nm and 610 nm respectively (Takara Bio Inc.). For EGFP, a B-2A filter 
block was used (excitation 470 +/- 20 nm, emission >520 nm); for mCherry, G-2A 
(excitation 535 +/- 25 nm, emission >590 nm). Bleed-through of mCherry 
fluorescence was observed when using the B-2A filter block for long exposure 
times; such excitation catches the extreme left-hand shoulder of mCherry’s 
absorption spectrum, and its full emission spectrum is able to transit the longpass 
emission filter. No bleed-through of EGFP fluorescence was observed using the 
G-2A filter block.  
 
2.7.5 Flow cytometry 
2.7.5.1 Flow cytometry analysis of E. coli fluorescence 
Cultures (3 mL) containing the various induced (see Section 2.3.1) constructs were 
diluted to approximately 2x107 cfu/mL in phosphate buffered saline (PBS; 10 mM 
Na2HPO4, 1.8 mM KH2PO4, 2.7 mM KCl, 137 mM NaCl, pH 7.4) and analysed using 
a DxP 8 FACScan II flow cytometer (Cytek Development Inc., Fremont, USA) as 
per the manufacturer’s instructions. Any cultures exhibiting cell clumping were 
thoroughly vortexed immediately prior to analysis to aid dispersion. Cells were 
initially gated on a dot plot by log Forward Scatter (FS) versus log Side Scatter (SS) 
to select for a homogenous cell population (G1), and G1 subsequently gated by log 
FS area versus log FS width to select for single cells only, i.e. doublet discrimination 
(G2). Cells selected by G1 and G2 were individually interrogated for EGFP or 
mCherry fluorescence using the appropriate single-positive control strains, and a 
compensation matrix applied to correct for any spectral overlap observed between 
the two (minimal). For EGFP, excitation at 488 nm was used, with emission 
monitored at 530 +/- 15 nm; for mCherry, excitation at 561 nm was used, with 
emission monitored at 615 +/- 12.5 nm. A total of 100,000 events were recorded per 
sample. Data was analysed using FlowJo v7.6.4 (Tree Star Inc., Ashland, USA). 
 
2.7.5.2 Preparation of libraries for fluorescence-activated cell sorting  
Approximately 25,000 colonies (30ºC incubation for ~16 h after transformation [as 
per Section 2.2.8]) from each of the pAG2-A!42-74 and pAG2-A!42-110 libraries 
were resuspended and pooled in 1 mL of LB medium, and the cell density 
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subsequently normalised by dilution to OD600 = 2.5 (Section 2.3.1). The same was 
performed for approximately 25,000 colonies containing pAG2-A!42, which was 
then split into three aliquots and spiked separately with 3 colonies of 
pAG2-A!42-Pep2, pAG2-A!42-AavLEA1 or pAG2-GM6. These five resuspensions 
were used as inoculums for induction of expression as per Section 2.3.1. 
 
2.7.5.3 Fluorescence-activated cell sorting (FACS) 
Cultures (3 mL) to be analysed were pelleted and resuspended in PBS prior to 
being diluted further as per Section 2.7.5.1, and sorted on a DakoCytomation MoFlo 
MLS cell sorter (Beckmann Coulter Inc., Brea, USA) as per the manufacturer’s 
instructions under the supervision of Mr Nigel Miller (Flow Cytometry Facility, 
Department of Pathology, University of Cambridge). Cell population gating was as 
per Section 2.7.5.1, with spectral compensation performed manually by adjusting 
photomultiplier tube (PMT) gain. For EGFP, excitation at 488 nm was used, with 
emission monitored at 530 +/- 15 nm; for mCherry, excitation at 568 nm was used, 
with emission monitored at 613 +/- 10 nm. At least 20,000 total events were 
recorded per sample. Data was analysed using Summit v4.3.02 (Beckmann Coulter 
Inc., Brea, USA). For cell sorting, approximately 1x104 positive events (indicated) 
from 1x106 cells were selected and pooled into 3 mL fresh LB medium. For further 
enrichment, these pooled cultures were directly grown and induced as per 
Section 2.3.1 before undergoing additional rounds of FACS (indicated). After the 
final round, cells were plated out on LB agar. 
 
2.7.5.4 Calculations 
To give a measure of the spread of data obtained during flow cytometry, the 
coefficient of variation (CV) was used (Huber, 2005). CV represents a normalised 
standard deviation, i.e. the standard deviation divided by the mean, and is 
commonly converted to a percentage. A more preferred statistic is the robust CV 
(rCV), which is not as skewed as CV by outlying data, and was calculated using 
Equation 2.1 using the flow cytometer manufacturer’s software (Section 2.7.5.1). 
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%rCV =100*
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Intensity [at 84.13 percentile] " Intensity [at 15.87 percentile]( ) Median  
 
Equation 2.1: %rCV, robust coefficient of variation (as a percentage). 
 
However, the rCV calculation was not available for the MoFlo MLS cell sorter 
(Section 2.7.5.3), so CV was used instead. 
 
2.7.6 Identification of pAG2-A!42 library hits on solid medium 
EGFP fluorescence from induced colonies was photographed (3 s exposure) using 
an ImageQuant LAS 4000 system (GE Healthcare UK Ltd.). Excitation was at 
~460 nm (blue epifluorescence), emission at 510 nm (510DF10 filter). Images were 
imported into ImageJ v1.41o (National Institutes of Health, Bethesda, USA), and the 
“threshold” function applied to highlight the colonies with the brightest fluorescence. 
Any colony hits identified were manually verified by microscopy for both EGFP and 
mCherry fluorescence. 
 
2.7.7 Bioinformatic analysis of pAG2-A!42 library hits 
Peptide sequences were interrogated for pairwise alignment to the A!42 sequence 
using the European Molecular Biology Open Software Suite (EMBOSS) Matcher 
v2.0u4 (Rice et al. [2000]; default options used, with 3 alternative matches shown; 
accessed at http://www.ebi.ac.uk/Tools/psa/emboss_matcher/), or for multiple 
sequence alignment to each other using ClustalW2 v2.1 (Larkin et al. [2007]; default 
options used; accessed at http://www.ebi.ac.uk/Tools/msa/clustalw2/). Open 
Reading Frame Finder (NCBI; bacterial genetic code used; accessed at 
http://www.ncbi.nlm.nih.gov/projects/gorf/) was used to search for alternate start 
codons in insert sequences with short open reading frames originating from the 
Library site start codon. To predict the percentage of sequences from a random 
DNA insert library that should incorporate an internal stop codon, Equation 2.2 was 
utilised (Walker et al., 2001). 
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Equation 2.2: n, number of amino acids in peptide. 
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CHAPTER 3 – BIOSYNTHETIC PRODUCTION OF BIOACTIVE 
PEPTIDES: ANTIMICROBIALS 
3.1 Introduction 
3.1.1 Brief history 
Antimicrobial peptides (AMPs) are evolutionarily ancient compounds harnessed by 
a wide variety of organisms to repel microbial infection. Insects, fish, plants, 
amphibians and mammals all use these gene-encoded antimicrobials as a first line 
of defence against pathogens (Zasloff, 2002). Bacteria and fungi may also produce 
AMPs to inhibit competing species (Rossi et al., 2007). While their presence is of no 
surprise in organisms that lack an adaptive immune system, AMPs are also 
commonly found in higher organisms (including humans) that possess more 
intricate defences (i.e. an adaptive immune system). Ever since extracts from 
human neutrophils in the 1950s revealed low molecular mass proteinaceous 
components with broad-spectrum antimicrobial activities (Skarnes & Watson, 1957), 
the AMP field has blossomed – to date, more than 1,700 AMPs and their derivatives 
have been described (Wang et al., 2009). 
 
The increasing prevalence of antibiotic resistance is a major cause of concern for 
healthcare systems worldwide. Methicillin-resistant Staphylococcus aureus, 
vancomycin-resistant Enterococcus faecalis, carbapenem-resistant Escherichia coli, 
multidrug-resistant Pseudomonas aeruginosa – all these examples of “superbugs” 
are resistant to “last resort” antibiotics, and can lead to increased incidences of 
mortality amongst the immuno-compromised (Mulvey & Simor, 2009; Fairlamb & 
Cole, 2011). The majority of new antimicrobials to combat this have been generated 
by derivatising existing drug scaffolds (Monaghan & Barrett, 2006). Unfortunately, 
further resistance may rapidly develop due to modifications of existing microbial 
resistance mechanisms, i.e. those that were effective against the parent scaffold 
(Fischbach & Walsh, 2009). Entirely new classes of antibiotics are required, but 
despite this pressing need only the oxazolidinones have come onto the market 
since 1962 (Rossi et al., 2007). Antimicrobial peptides exhibit a number of 
characteristics that may make them suitable as a new antibiotic class. 
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3.1.2 Structure and function 
3.1.2.1 Structures 
In general, mature AMP sequences consist of between 10 to 60 residues, in which 
cationic (i.e. lysine and arginine) and hydrophobic (e.g. leucine and isoleucine) 
amino acids are especially prominent (Zasloff, 2002; Brogden, 2005). While this 
leads to most AMPs having a positive charge of +2 or greater (Wang et al., 2009), 
the primary sequences of AMPs are varied, and do not contain conserved motifs, 
even between closely related species (Peschel & Sahl, 2006). As organisms 
produce more than one AMP species in certain tissues (Zasloff, 2002), it is thought 
that such variation is tolerated due to functional redundancy, thus leading to a 
greater evolutionary flexibility in the classical “arms race” with pathogens (Hancock 
& Sahl, 2006). What seems to matter more than primary AMP sequence is overall 
secondary structure. Three main structural classes are apparent: "-helical, with an 
amphipathic nature (i.e. hydrophobic and cationic side chains segregated to distinct 
faces of the helix); !-sheet, with a similar amphipathic nature but with multiple 
disulphide bonds acting as stabilisers; and an extended conformation, lacking clear 
secondary structure in which certain residues are favoured (e.g. tryptophan [39%] in 
indolicidin, proline [49%] and arginine [26%] in PR-39) (Gallo & Huttner, 1998; 
Brogden, 2005). Figure 3.1 gives examples of peptides from each of these classes. 
In addition, cyclic peptides in a head-to-tail circular configuration, such as the 
#-defensin RTD-1, have also been described (Tang et al., 1999). 
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Figure 3.1: Examples of various AMP structures. Common structural classes include A, 
!-helical; B, "-sheet; and C, extended. Cationic residues are shown in blue, while anionic 
are shown in red. Selected peptide details (amino acids [aa], origin, Protein Data Base 
entry [PDB ID]) are as follows: magainin 2 (23 aa, African clawed frog, PDB ID 2MAG), 
LL-37 (37 aa, human, PDB ID 2K6O), lactoferricin (25 aa, bovine, PDB ID 1LFC), protegrin 
1 (18 aa, porcine, PDB ID 1PG1), "-defensin-3 (45 aa, human, PDB ID 1KJ5), tritrpticin 
(13 aa, synthetic, PDB ID 1D6X), and indolicidin (13 aa, bovine, PDB ID 1G89). Figure 
modified from Nguyen et al. (2011), PDB accessible at http://www.pdb.org (Berman et al., 
2000). 
 
What unites many AMP molecules is their amphiphilicity when bound to lipid 
membranes. Positively charged and hydrophobic residues cluster in distinct regions 
of an AMP, be it on opposite sides of an "-helix or faces of a !-sheet (Toke, 2005). 
Of particular relevance to this work is the structure of cathelicidins, a class of 
mammalian AMPs (12 to 39 aa) so named because of the conserved pre-pro 
regions that they share prior to the cleavage event that gives rise to the active 
peptide (Gennaro & Zanetti, 2000; Ramanathan et al., 2002). Expressed in a variety 
of epithelial and lymphatic tissues (Dorschner et al., 2001; Nizet et al., 2001), a 
subgroup of these peptides are linear and unstructured in solution, but circular 
dichroism and nuclear magnetic resonance spectroscopy studies (Yu et al., 2002; 
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Park et al., 2003) have revealed that they form an "-helix when associated with 
model phospholipid membranes (e.g. the human LL-37, Figure 3.1) (Toke, 2005). 
 
3.1.2.2 Functions 
Traditional antibiotics often have well-defined targets: for example, the !-lactams 
bind bacterial cell wall transpeptidases, while macrolides bind bacterial 50S 
ribosome subunits to inhibit protein synthesis (Devasahayam et al., 2010). AMPs, 
on the other hand, predominantly act on less specific targets, such as biological 
membranes (van't Hof et al., 2001). Such a lytic mode of action has been elucidated 
by several in vitro studies (Saiman et al., 2001; Park et al., 2001; Fantner et al., 
2010), including examining the release of the contents of mimetic membranes and 
microbes themselves, as well as electron microscopy (Toke, 2005). The 
cytoplasmic membranes from both Gram-negative and Gram-positive bacteria 
contain anionic head groups in their phospholipid make up, resulting in an overall 
negative charge (Zasloff, 2002). In addition, Gram-positives possess a number of 
anionic teichoic and lipoteichoic acid moieties in their cell wall, while Gram-
negatives exhibit anionic lipopolysaccharides (LPS) on their outer membrane (Hale 
& Hancock, 2007; van't Hof et al., 2001). Both these features contribute to the 
electrostatic attraction of positively-charged AMPs, with LPS being especially 
important with regards to Gram-negatives. These negative moieties provide a 
passage to the inner cell membrane via a “self-mediated” uptake mechanism, in 
which the competitive displacement of LPS-associated divalent cations (e.g. Ca2+, 
Mg2+) allows outer membrane permeabilisation and subsequent AMP translocation 
to occur (Sawyer et al., 1988). 
 
Once associated with a bacterial membrane, unstructured AMPs typically undergo a 
conformational change such as the coil-helix transition exhibited by LL-37 
mentioned previously (Gennaro & Zanetti, 2000). For "-helical cathelicidins, this 
conformation is energetically favourable with regards to membrane insertion due to 
a reduced energy cost imparted by intramolecular NH-CO hydrogen bonding along 
the peptide backbone (Dathe & Wieprecht, 1999). The realignment of residues into 
an amphipathic configuration allows the hydrophobic face to insert into the 
membrane between the phospholipid head groups, while shielding the polar peptide 
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backbone from the lipid membrane interior (Oren & Shai, 1998; Brogden, 2005). 
Cationic AMP insertion events are further facilitated by the internally negative 
membrane potential of a bacterium (Toke, 2005). When a critical threshold peptide 
concentration is reached (which may be near complete saturation of the membrane 
[Melo et al., 2009]), the integrity of the bilayer is compromised. Several mechanisms 
for this have been proposed, none of which are mutually exclusive (see Figure 3.2) 
(Hale & Hancock, 2007). Bacterial death results within minutes due to the loss of 
membrane polarisation and overall integrity (Brogden, 2005). In silico molecular 
dynamics simulations have been performed to try to further understand such 
mechanisms of action, and may give additional insight as modelling times progress 
from nanosecond bursts to microseconds (Bond & Khalid, 2010). 
 
 
Figure 3.2: Cartoon of proposed mechanisms of AMP-mediated membrane 
destabilisation. Once a critical AMP threshold concentration has been reached, 
membrane lysis can occur via A, barrel-stave formation by multiple AMP molecules, where 
multiple hydrophilic faces associate to form a transmembrane pore; B, a “carpet” 
mechanism akin to the effect of a detergent; C, toroidal pore formation, where AMPs insert 
between phospholipid head groups and promote membrane curvature much like the inside 
of a doughnut; or D, disordered toroidal pore formation (less structured with respect to a 
conventional toroidal pore). Figure modified from Melo et al. (2009). 
 
In contrast to bacterial membranes, host membranes such as those of mammalian 
cells are more neutral in charge, containing zwitterionic outer leaflets that attract 
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and bind cationic AMPs poorly (Oren & Shai, 1998). In addition, their membranes 
are typically less fluid than bacterial membranes due to the “stiffening” properties 
conferred by cholesterol, further reducing the susceptibility to AMP-mediated lysis 
(Toke, 2005). It must be emphasised, however, that mammalian cells are not 
impervious to lytic activity – AMPs frequently exhibit undesirable haemolytic 
properties. For example, melittin, a 26 aa "-helical peptide from the honeybee, 
exhibits equal bactericidal and haemolytic activity at its minimum inhibitory 
concentration (MIC) due to possession of a hydrophobic N-terminal domain coupled 
with a cationic C-terminal domain (van't Hof et al., 2001). Mutational studies with 
different AMPs give conflicting evidence as to which property is most important 
(Shin et al., 2000; Travis et al., 2000; Yang et al., 2003; Hilpert et al., 2006; Chen et 
al., 2007; Jiang et al., 2008), but adjusting the charge, the proportion of 
hydrophobic/cationic residues, and the residue distribution over a peptide can 
abrogate haemolytic activity (Dathe & Wieprecht, 1999). Overall, haemolysis seems 
to be context dependent for each peptide, although high absolute hydrophobicity 
leads to greater haemolytic activity due to an increased affinity for zwitterionic 
membranes (van't Hof et al., 2001; Frecer et al., 2004; Toke, 2005; Matsuzaki, 
2009). It appears that there is a subtle balance between amino acid composition, 
charge, lipophilicity, amphipathicity and structure. 
 
AMPs have also been shown to have alternative (or concurrent) targets to the cell 
membrane (Brogden, 2005). Clues to this came from the observation that, when 
used at their MIC, some AMPs were able to kill a target without leading to obvious 
membrane disruption. For example, analogues of pleurocidin, a 25 aa "-helical 
peptide from the winter flounder, only lead to membrane depolarisation at 
concentrations ten-fold higher than its MIC (Patrzykat et al., 2002). It makes sense 
that intracellular-acting AMPs still exhibit lytic activity at higher concentrations, as 
they are required to cross the cell membrane to access potential targets. Because 
of their cationic properties, such targets are often anionic in nature (Hale & 
Hancock, 2007). Examples of AMPs with intracellular targets include PR-39 (39 aa, 
porcine origin, rich in proline and arginine, extended structure), which has been 
shown to inhibit protein synthesis in E. coli (Boman et al., 1993); indolicidin 
(mentioned previously), which caused filamentation of E. coli cells by altering 
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cytoplasmic membrane septum formation (Subbalakshmi & Sitaram, 1998); and 
buforin II (21 aa, toad origin, "-helix structure), which is able to accumulate in the 
E. coli cytoplasm and bind DNA (Park et al., 1998). 
 
Another alternative function of some AMPs is an ability to modulate a host’s 
immune response (e.g. LL-37; see Section 1.1.3.1) (Hancock & Sahl, 2006). As 
mentioned above, cationic AMPs bind LPS moieties during their self-mediated 
uptake in Gram-negative bacteria. Bacterial lysis results in liberation of these 
endotoxins, which provoke a strong systemic immune response in humans that may 
lead to septic shock (Zanetti, 2005). Among other AMPs, LL-37 has been shown to 
bind free LPS, and thus limit its ability to stimulate the production of pro-
inflammatory cytokines such as tumour necrosis factor-" (Bowdish et al., 2005b). 
Furthermore, the presence of serum seems to abrogate the membrane lytic activity 
of LL-37 (Gennaro & Zanetti, 2000; van't Hof et al., 2001). It has therefore been 
hypothesised that, although LL-37 shows good antimicrobial activity in vitro, its 
primary function in vivo may be as an immunomodulator (Bowdish et al., 2005b). In 
addition to endotoxin binding, LL-37 and other cationic AMPs (such as defensins) 
may also act as chemokines to attract macrophages; translocate into lymphocytes 
(presumably via their innate membrane penetration properties) to induce expression 
of anti-inflammatory genes; and promote wound healing in general (Bowdish et al., 
2005a). Because of the above, AMPs that possess an immunomodulatory function 
in addition to antimicrobial activity have been re-christened “host defence peptides” 
in order to reflect this increased functional workload (Bowdish et al., 2005a). 
 
There are concerns that the use of AMPs in a clinical setting may lead to the 
eventual rise of resistance, which may have the undesirable consequence of also 
promoting resistance to endogenously produced AMPs (Perron et al., 2006). 
However, because the primary mode of action of many AMPs is the general 
disruption of the cell membrane, it has been posited that resistance to such a broad 
mechanism of action is unlikely to arise in vivo, i.e. a fundamental membrane 
redesign would be required (Zasloff, 2002). Some specific resistance mechanisms 
do exist, however, such as the use of D-alanine amino groups by Staphylococcus 
aureus to reduce the negative charge of surface anionic teichoic acid molecules 
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(Peschel et al., 1999), and the use of outer membrane proteins as potential target 
decoys (e.g. adhesin A in the Gram-negative bacterium Yersinia enterocolitica 
[Visser et al., 1996]). The Gram-negative bacterium Burkholderia cepacia, an 
opportunistic pathogen involved in cystic fibrosis, is also extremely resistant to 
AMPs due to lipid A modifications (Mahenthiralingam et al., 2005). Other resistance 
strategies include protease production (particularly effective against linear AMPs), 
the use of capsule polysaccharides to prevent AMP access to the membrane, and 
increasing the rigidity of the membrane to make it more difficult for AMP insertion 
(Peschel & Sahl, 2006). Despite this, AMPs have remained effective antimicrobials 
over millions of years in many species, probably due to a multitude of targets and 
the production of several different peptides in a single organism (Zasloff, 2002). 
Consistent with this, it takes many passages of a microbe at sub-lethal AMP 
concentrations to induce resistance (Gennaro & Zanetti, 2000; Perron et al., 2006): 
cross-resistance to other AMPs is limited (Samuelsen et al., 2005), and animal 
models lacking certain endogenous AMPs have shown little increase in 
susceptibility to infection (Hancock & Sahl, 2006). 
 
In summary, the large number of different activities that AMPs can possess has 
lead to the idea that AMPs may be “dirty drugs”, i.e. hit multiple targets with varying 
affinities, and such a multifaceted approach could lead to new microbial treatments 
(Peschel & Sahl, 2006). 
 
3.1.3 Sources 
A wide variety of organisms including plants, animals and insects (see Section 
3.1.1) have been found to produce AMPs, and thus bioprospecting is well suited to 
their discovery (see Section 1.2.2). In addition, fragments of larger proteins have 
been shown to possess antimicrobial activity, e.g. lactoferricin (Figure 3.1), a 
naturally occurring pepsin digestion product from the 80 kDa lactoferrin, which is 
itself implicated in the immune response regarding the sequestration of iron (Gifford 
et al., 2005). Native purification, due to limitations such as source availability or 
amenability to cultivation (discussed in Section 1.2.2) is not economically viable 
(Hancock, 1997). Further to this, while a large number of mature AMPs are actively 
secreted, for example magainin 2 on the skin of the frog Xenopus laevis (Zasloff, 
1987), expression is usually only upregulated upon tissue damage or challenge by 
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a pathogen (Zanetti, 2005). Chemical synthesis or recombinant production is 
required instead (see Section 3.1.5 below). There is, however, one well-known 
exception – nisin, a lantibiotic (34 aa in length, post-translationally modified with 
lanthionine groups [thioester-linked alanine side chains]), is naturally produced in 
large quantities by Lactococcus lactis, and has been harnessed as a food 
preservative against Gram-positive bacteria for many years (Cotter et al., 2005). 
 
3.1.4 Therapeutic potential 
AMPs represent a potential new route to dealing with recalcitrant pathogens that 
current antibiotics are ineffective against. Synthetic "-helical AMPs have been 
shown to be active against “superbugs” in vitro (Tiozzo et al., 1998), and even 
protozoan parasites such as Plasmodium falciparum (the causative agent of 
malaria) and Leishmania species (involved in leishmaniasis) are being examined as 
targets (Bell, 2011; Luque-Ortega et al., 2008). However, despite initial promise in 
the 1990s (Hancock, 1997), the use of systemically-administered AMPs in the clinic 
has failed to materialise to date. For example, two non-ribosomally synthesised 
bacterial AMPs, gramicidin S (10 aa, produced by Bacillus brevis, cyclic structure 
incorporating D-phenylalanine and ornithine) and the polymyxins (B and E, 
produced by Bacillus polymyxa, cyclic cationic head with a lipid tail) have potent 
antimicrobial activity, but they both exhibit systemic toxicity, thus constraining their 
regular use to topical applications in wound creams, eye and eardrops (Marr et al., 
2006). Although most AMPs can be modified to reduce haemolytic activity (see 
Section 3.1.2 above), no such peptide has currently been approved for systemic 
administration, perhaps due to potential additional activities such as over-
stimulation of the immune system (e.g. induction of apoptosis or mast-cell 
degranulation) (Bowdish et al., 2005a; Hancock & Sahl, 2006). Despite these 
issues, topical use is still a worthy goal – gramicidin S and polymyxins are used for 
treatment of Pseudomonas aeruginosa in cystic fibrosis patients, and against 
Acinetobacter baumannii in other nosocomial incidences.  
 
Some AMPs have nearly made it into the clinic (Marr et al., 2006). Pexiganin, a 
magainin 2 derivative originally developed by Magainin Pharmaceuticals Inc., was 
denied Phase 3 clinical approval for the topical treatment of diabetic foot ulcers as it 
could not better the efficacy of current treatments (Lipsky et al., 2008). Omiganan, a 
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bovine bactenecin derivative (12 aa in length, linear as opposed to the native cyclic 
form) originally developed by Migenix Inc, also failed to pass Phase 3 clinical trials 
when used topically for the prevention of local catheter site infection due to trial 
inconsistencies. Other candidate AMPs are still in the pipeline, but their future is by 
no means certain (Marr et al., 2006). More work is required to accurately assess 
in vivo function, stability and side effects (Nguyen et al., 2011). 
 
Other alternative uses for AMPs are going forward. As mentioned above, many 
AMPs, such as LL-37, indolicidin and Bac2A (12 aa, a linear form of bovine 
bactenecin) possess immunomodulatory functions both in vitro and in vivo (Bowdish 
et al., 2005c). Future trials may focus on exploiting such properties, rather than 
innate antimicrobial activity per se (Yeung et al., 2011). One example of such an 
approach is the synthetic peptide IDR-1 (aka IMX00C1), which while devoid of 
direct antimicrobial activity in vitro is still able to invoke a successful immune 
response to Staphylococcus aureus and Salmonella typhimurium through 
monocytes and macrophages in mouse models (Scott et al., 2007). 
 
Finally, the use of AMPs to coat medical implants or other surfaces is also being 
explored. Derivatives of indolicidin and Bac2A successfully retained activity when 
tethered by their C-terminus to a cellulose support (Hilpert et al., 2009). While an 
analogue of Bac2A failed clinical trials when used to treat catheter-related infections 
in a gel format (Omiganan, mentioned above), further work by the Hancock 
laboratory is focusing on attaching similar peptides directly to the catheter itself – 
initial results seem promising (R. Hancock, unpublished data). Another approach 
has even looked at using AMPs in an antimicrobial paint (Fulmer & Wynne, 2011), 
with the aim of employing this on hospital walls or children’s toys.  
 
3.1.5 Production 
3.1.5.1 Chemical synthesis 
AMPs are well suited to solid-phase peptide synthesis (reviewed in Section 1.1.4.2). 
However, cyclic peptides, or those containing multiple disulphide bonds (such as 
defensins) will require more effort to ensure correct product formation. The cost of 
synthesis is not inconsequential, and numerous studies have indicated that a 
cheaper manufacturing alternative is desired (van't Hof et al., 2001; Marr et al., 
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2006; Hancock & Sahl, 2006; Rossi et al., 2007; Li et al., 2010). This is especially 
relevant to the initial research phase, as “good manufacturing practice” compliance 
of chemical synthesis for final production is not so relevant when the primary goal is 
to analyse a number of AMP variants cheaply and rapidly. Advances have allowed 
microarrays of short (6 to 18 aa) peptides to be produced on a cellulose solid 
support in !mol amounts, with subsequent release into soluble form being possible 
(Hilpert et al., 2007). This scaled-down approach has been used to synthesise and 
test single residue mutants of Bac2A (12 aa in length) (Hilpert et al., 2005). 
However, such an approach is technically demanding, and traditional solid-phase 
peptide synthesis is required to confirm any findings (Hilpert et al., 2007). 
 
3.1.5.2 Recombinant production 
In comparison with chemical synthesis, the input costs of microbe and feed are 
relatively small for recombinant production of a peptide, AMP or otherwise (Lax, 
2010). As long as only natural amino acids are required (i.e. the 20 common 
L-forms), it is relatively straightforward to build the short coding sequence 
necessary from synthetic oligonucleotides. This can then be inserted into an 
expression vector of a common heterologous host, such as the prokaryotes E. coli 
and L. lactis or the eukaryotes Saccharomyces cerevisiae and Pichia pastoris (Li et 
al., 2010). Secretion of a small number of AMPs into the culture medium has been 
shown in limited amounts, as has the ability for disulphide bonds to be correctly 
formed in the oxidising environment of the E. coli periplasm (i.e. for the production 
of defensins) (Raventós et al., 2005). Levels of expression and final production 
yields, however, depend on the AMP in question. It is also important to note that, 
because of an AMP’s intrinsic antimicrobial activity, it may be toxic to a microbial 
production host. Therefore AMPs are typically fused to larger carrier proteins in 
order to prevent or alleviate toxicity during expression, presumably through steric 
hindrance (Ingham & Moore, 2007). Additionally, the presence of a stable fusion 
partner could protect labile AMPs from native protease attack (Taguchi et al., 1994; 
Walker et al., 2001). Fusion partners are often also used as a target for affinity 
chromatography, thus also affording simple purification of the fusion protein. 
Common fusion partners include thioredoxin (12 kDa), glutathione S-transferase 
(26 kDa), and chitin-binding domain (6 kDa) (Baneyx, 1999). Linkers between the 
AMP and the fusion partner typically incorporate a chemical or enzymatic cleavage 
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site, which can be utilized to separate the two during subsequent downstream 
processing in vitro. Furthermore, given the small size of most AMPs and the 
difficulty in detecting low-level expression via SDS-PAGE, the fusion partner allows 
for expression levels to be more readily assessed. While recombinant production of 
AMPs may have drawbacks, such as a lack of host toleration of certain inserted 
nucleic acid sequences and final protein product solubility (Ingham & Moore, 2007), 
it represents a straightforward and rapid method for the production of crude peptide 
for initial analysis. 
 
3.1.5.2.1 K2C18 as a model AMP 
The murine-sourced CRAMP (cathelin-related AMP, expressed in neutrophils and 
bone marrow) is a typical cathelicidin, being unstructured in solution but forming an 
amphipathic "-helix when associated with membranes (Gallo et al., 1997). This 
38 aa peptide has been shown to have broad-spectrum activity against Gram-
negative (E. coli, S. typhimurium, P. aeruginosa) and Gram-positive (Bacillus 
subtilis, Streptococcus pyogenes, S. aureus) bacteria, as well as some yeast 
(Candida albicans and Aspergillus fumigatus), and displays low haemolytic activity 
(Shin et al., 2000). Furthermore, a series of 18-residue truncations of this AMP also 
exhibited similar properties to the full-length peptide, with circular dichroism and 
nuclear magnetic resonance studies confirming their ability to form amphipathic 
helixes upon interaction with membranes (Park et al., 2003). One of these 
truncations, K2C18 (including a glutamic acid to lysine mutation at position 2), was 
chosen as a model linear AMP to use as a positive control in this work (Shin et al., 
2000). 
 
3.1.5.2.2 Current recombinant production methods 
A number of approaches exist to produce linear AMPs recombinantly using E. coli 
in conjunction with fusion tags. Recent examples include fusion of the N-terminus of 
an AMP to a glutathione S-transferase domain (Moon et al., 2006); a split-
intein/chitin binding domain (Hong et al., 2010); a hexa-histidine-tagged thioredoxin 
domain (Krahulec et al., 2010); or the use of a hexa-histidine-tagged small ubiquitin-
like modifier domain (Bommarius et al., 2010). While these have been shown to be 
effective methods, overnight cleavage steps are required using expensive enzymes 
(like enterokinase) or other reagents to liberate the AMP from its fusion partner. 
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Furthermore, some of these protocols require additional chromatography steps to 
remove the cleaving enzyme or fusion partner prior to any further polishing of the 
desired AMP. 
 
3.1.5.2.3 Use of an inducible, autocleaving tag 
RtxA (~500 kDa), a virulence factor produced by the pathogen Vibrio cholerae, 
contains a 23 kDa cysteine protease domain (CPD) that is responsible for the 
autoprocessing of this large toxin into its active subunits via a cysteine/histidine 
catalytic dyad (Lin et al., 1999; Satchell, 2007). This 209 residue protein domain 
has been shown to cleave itself from an upstream (i.e. N-terminal) protein region 
when induced allosterically by the sugar inositol hexakisphosphate (IP6) 
(Prochazkova & Satchell, 2008). While IP6 is commonly found in eukaryotic cells as 
a storage unit of phosphate (Zhou & Erdman, 1995), it is lacking in prokaryotes 
such as E. coli. Bogyo and coworkers exploited these properties by using a hexa-
histidine (His) tagged version of CPD as a fusion partner for the recombinant 
production of a number of proteins (ranging from 14 to 35 kDa) in E. coli (Shen et 
al., 2009a). After expression of the full-length fusion product, cleavage of the 
CPD-His tag could successfully be performed in vitro via the addition of IP6. Such 
an inducible, autocleaving enzyme tag could be useful for linear AMP production. 
CPD is an order of magnitude larger than most AMPs and thus should afford some 
protection from toxicity towards the E. coli host. In addition, downstream purification 
of an AMP could be streamlined in comparison with current recombinant production 
techniques. 
 
3.1.6 Summary 
There is an increased need for new classes of antibiotics to combat the era of 
antibiotic resistance that clinicians find themselves in. The broad-spectrum, multi-
target activities of AMPs indicate a promising potential for their use as therapeutics, 
as does their proven worth in Nature over millions of years. While the first cohort of 
AMPs to enter clinical trials did not perform well, this setback should not be 
discouraging. Rather, it illustrates that additional fundamental research into their 
structure and function is required, as are larger numbers of candidates. In addition, 
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more straightforward recombinant production techniques are required in order to 
facilitate this in a cost-effective manner. 
 
To expand upon current knowledge, the use of E. coli to produce a model AMP, 
K2C18, was investigated. A CPD-His tag was used as an inducible, autocleaving 
fusion partner, and a number of K2C18 variants were produced. Furthermore, novel 
mammalian cathelicidin consensus sequences were produced, along with selected 
derivatives. This recombinant production system was explored, and the AMP 
products were tested against a number of bacterial strains to demonstrate efficacy, 
to ascertain their minimum inhibitory concentration, and to try to elucidate structure 
and function relationships. 
 
3.2 Results 
3.2.1 Construction of pET28-CPD 
The CPD sequence was cloned into the IPTG-inducible pET28a plasmid between 
its BamHI and XhoI sites so that the C-terminus was in-frame with the hexa-
histidine tag provided by the vector (see Section 2.4.1.1). Figure 3.3 outlines the 
properties of the plasmid, as well as the purification protocol designed for this work. 
 
 
Figure 3.3: The pET28-CPD expression vector and AMP purification protocol. A: The 
desired AMP coding sequence may be inserted upstream of the CPD domain between the 
NcoI and BamHI sites. The start codon is indicated in bold. The codon immediately 
preceding the BamHI site must code for a leucine to allow CPD cleavage to occur. B: 
Schematic of the AMP-CPD purification protocol. lacI, lac operon repressor; T7, RNA 
polymerase promoter; kanR, kanamycin resistance; ori, origin of replication. 
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pET28-CPD is similar in design to the pET2b-CPDBamHI vector created by Shen and 
co-workers (Shen et al., 2009a), except that the start codon is contained within an 
NcoI site. The wild-type cleavage recognition sequence of Leu^Ala-Asp was 
changed to Leu^Gly-Ser in order to incorporate a BamHI site to facilitate cloning of 
DNA inserts (^ denotes the scissile bond). As only the leucine residue is essential 
for cleavage (Shen et al., 2009b), it was not expected that such a change would 
affect CPD activity. The use of an NcoI site as the initiation codon requires that the 
second codon begins with a G, limiting the encoded amino acid to either a valine, 
alanine, aspartic acid, glutamic acid or glycine. However, the above constraints 
pose no problem for K2C18, as its N- and C-terminal residues are glycine and 
leucine respectively. 
 
3.2.2 Expression and activity of recombinant K2C18-CPD 
3.2.2.1 Construction of pET28-K2C18-CPDW/T 
The coding sequence for K2C18 was cloned into pET28-CPD via the NcoI and 
BamHI sites (see Section 2.4.1.3), as shown in Figure 3.3. In parallel to this, a 
version of pET28-K2C18-CPD was also constructed to incorporate the wild-type 
(W/T) CPD cleavage recognition sequence of Leu^Ala-Asp (named 
pET28-K2C18-CPDW/T; see Section 2.4.1.2). This version of the plasmid was used 
to initially explore the production of active K2C18. The N-terminal regions of these 
three plasmids are compared in Table 3.1. 
 
 
Table 3.1: N-terminal regions encoded by pET28-CPD vectors. Amino acids 
downstream of CPD cleavage site in bold; residues modified by incorporation of BamHI site 
are underlined. 
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3.2.2.2 Expression of pET28-K2C18-CPDW/T 
The pET28-CPD and pET28-K2C18-CPDW/T vectors were transformed into E. coli 
BL21(DE3) Star cells. Expression was induced by the addition of IPTG (see Section 
2.3.1), and protein products analysed using SDS-PAGE after 5 h (Figure 3.4). 
 
 
Figure 3.4: Expression from pET28-CPD and pET28-K2C18-CPDW/T. SDS-PAGE 
(glycine 15%) of induction trial in E. coli, CPD product expected to run at 26 kDa (arrowed). 
Equal volumes of cell culture were loaded (normalised to the same density via OD600). The 
clarified lysate (CL) fractions represent soluble protein. T0, uninduced (whole-cell); T5, 5 h 
induction (whole-cell); CL7.5x, 7.5x loaded; WM, molecular mass marker. 
 
K2C18-CPDW/T was found to express at both 30ºC and 37ºC, but not at the same 
level as CPD alone. In addition, the K2C18-CPDW/T fusion protein appears to be 
less soluble than CPD alone (compare lanes 13 & 14 with 5 & 6). An expression 
temperature of 30ºC was thus chosen for K2C18-CPDW/T in order to ensure 
maximal accumulation of soluble product. 
 
3.2.2.3 Initial purification and activity of recombinant K2C18 
The soluble fraction from induced pET28-K2C18-CPDW/T E. coli cells was applied to 
Ni-NTA agarose in a batch manner, and K2C18 eluted by autocatalytic CPD 
cleavage induced by the addition of IP6 as described in Section 2.4.2. Fractions 
from the purification process were analysed by SDS-PAGE (Figure 3.5). 
 
80 
 
Figure 3.5: Fractions from on-column cleavage of K2C18-CPDW/T. SDS-PAGE (tricine 
10-20%) of cleavage products shows that IP6 induces CPD cleavage to give a product band 
similar in size to chemically-synthesised K2C18. T0, uninduced E. coli; T5, 5 hours induction 
at 30ºC; CL, clarified lysate; FT, flow-through; W, wash, six in total with W1 to W3 prior to 
cleavage, W4 to W6 conducted post-cleavage; IP6, cleavage induced; K2C18, 2.5 !g 
synthetic peptide; WM, molecular mass marker; E, 250 mM imidazole elution. 
 
K2C18 was successfully cleaved from the CPD tag. Although both chemically-
synthesised (lane 11) and recombinantly-produced K2C18 (e.g. lane 7) have a 
molecular mass of ~2.2 kDa, assuming that E. coli removes the initiating methionine 
after translation (Hirel et al., 1989), they were seen to run near the 4.6 kDa marker. 
This apparent anomaly is most likely due to the highly charged nature of K2C18 
(+7), resulting in an altered migration towards the anode due to ineffective masking 
of charge by SDS moieties. Mass spectrometry analysis of purified recombinant 
K2C18 (see Appendix 1) confirmed the molecular mass to be ~2.2 kDa, as well as 
the removal of the initiating methionine. 
 
The cleaved K2C18 does not elute cleanly, being spread over all elution fractions 
(lane 7 onwards). It appears that this peptide “sticks” to the column after cleavage, 
requiring several washes to elute. Several higher molecular mass contaminants, 
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including CPD, also wash off the column after cleavage is induced. This indicates 
that additional purification is required for further studies; however, the peptide was 
pure enough for an initial analysis of antimicrobial activity with the appropriate 
controls. 
 
The fractions shown in Figure 3.5 were tested for antimicrobial activity against E. 
coli cells by agar radial diffusion assay (see Section 2.5.2) and liquid culture assay 
(see Section 2.5.3). Figure 3.6 shows that antimicrobial activity is observed in the 
cleaved fractions, i.e. those containing free K2C18. 
 
 
Figure 3.6: Antimicrobial activity of fractions from initial K2C18 purification. 10 !L of 
each fraction was added to: A, wells punched into E. coli TOP10 soft LB agar overlay; and 
B, 90 !L of ~5x104 cfu/mL E. coli TOP10 in LB medium. Photo/OD600 reading taken after 
18 h incubation at 37ºC. Pos., wash buffer including 100 !M IP6 and 225 !M synthetic 
K2C18; Neg., wash buffer including 100 !M IP6; Blank, LB medium only. 
 
Fraction E1 contains 250 mM imidazole, which is toxic to E. coli even when diluted 
to 25 mM in the liquid culture assay (Simonetti et al., 2001). The imidazole in the 
wash buffer was of sufficiently low concentration to be tolerated, however (see Neg. 
fraction; 2 mM final concentration when diluted in the assay). 
 
3.2.3 Design, construction and expression of AMP variants 
3.2.3.1 Design of AMP variants 
The experiments described in Section 3.2.2 showed that the CPD system can be 
used to produce K2C18 in an active form. Therefore a number of constructs 
containing variant AMPs were designed to further explore the potential of this 
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approach for producing recombinant AMPs for investigation of structure/function 
relationships. 
 
3.2.3.1.1 K2C18 analogues 
Using a helical wheel plot (Schiffer & Edmundson, 1967), several variants were 
designed to explore the relationship between the amphipathic nature of K2C18 and 
its antimicrobial activity (see Figure 3.7). Mutants were created that extended the 
hydrophobic face of the "-helix through a glycine to leucine mutation at residue 8, 
i.e. K2C18(G8L), while extension of the cationic face performed by a phenylalanine 
to lysine mutation at residue 14, i.e. K2C18(F14K). An increase of the positive 
charge on the cationic face was achieved by substituting glutamine with lysine at 
residue 9, i.e. K2C18(Q9K), and the effect of utilising arginine instead of lysine as 
the cationic residue was explored, i.e. RC18. To ascertain the effect of charge 
dispersal around the cationic face (as opposed to clumping lysine residues 
together), K2C18-2 was modelled on CRAMP-18-2, a peptide from a previous study 
(Kim & Cha, 2010). In addition, a mutant of this with an expanded hydrophobic face 
was designed, i.e. K2C18-2(G8L). As a negative control, a random mutant of 
K2C18 that did not exhibit antimicrobial activity was chosen, i.e. A6c (isolated in the 
Tunnacliffe laboratory by Dr Tatsuya Yoshimi, unpublished data). 
83 
 
Figure 3.7: Helical wheel projections of designed AMPs. Amino acids mutated from 
parent AMP are circled. A, K2C18 and derivatives. A6c serves as a negative control with an 
interrupted hydrophobic face. B, K2C18-2 and a derivative with dispersed cationic face. C, 
Mammalian consensus MCC18 and derivatives. The boundary between the cationic and 
hydrophobic faces is indicated by a dashed line, amino acids are colour coded: cationic 
(green), hydrophobic (yellow), anionic (purple) and uncharged hydrophilic (blue). 
Differences between variants and the type sequence are shown by a grey background. 
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3.2.3.1.2 MCC18 analogues 
As a further novelty, a consensus of mammalian CRAMP-18 sequences (MCC18) 
was generated from an alignment of 14 AMP sequence regions that are similar to 
K2C18 (Table 3.2 and Figure 3.8). Two mutants of MCC18 were created 
(Figure 3.7), in which the cationic face was altered sequentially in order to increase 
its charge, with a glutamic acid to lysine mutation at residue 2 (MCC18(E2K)), and a 
glutamine to lysine mutation at residue 9 (MCC18(E2K Q9K)). 
 
 
Table 3.2: Consensus sequences of mammalian !-helical cathelicidins. Fourteen 
mammalian cathelicidin sequences with !-helical propensity were collated from the 
Antimicrobial Peptide Database (ADP, Wang et al. [2009], accessible at 
http://aps.unmc.edu/AP/main.php). An 18-residue consensus region most similar to the 
K2C18 sequence was aligned (indicated in bold). 
 
 
Figure 3.8: Overall consensus sequence of mammalian !-helical cathelicidins. The 
14 mammalian cathelicidin consensus regions identified in Table 3.2 were used to generate 
an 18-residue consensus sequence (MCC18) using WebLogo (Crooks et al. [2004], 
accessible at http://weblogo.berkeley.edu/). The height of the letters indicates their relative 
frequency. Residue position is indicated. 
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3.2.3.2 Construction and expression of AMP variants 
The coding sequences for the K2C18 and MCC18 variants (Figure 3.7) were 
“stitched” together from oligonucleotides and cloned into pET28-CPD via the NcoI 
and BamHI sites (see Section 2.4.1.3), as shown in Figure 3.3. Expression in E. coli 
BL21(DE3) Star was induced by the addition of IPTG (see Section 2.3.1), and 
protein products analysed using SDS-PAGE. Expression levels of some AMP-CPD 
fusions was found to be poor at 30ºC (cf. Section 3.2.2.2). Induction temperature 
was reduced to 16ºC, induction time extended to ~16 h, and E. coli BL21 
Rosetta(DE3)pLysS cells were trialled in order to alleviate potential translational 
problems. Rosetta cells express six rare tRNAs to help overcome codon bias 
(Novagen User Protocol TB009). There was a marked increase in the expression of 
K2C18-CPD when induced under these conditions (see Figure 3.9). 
 
 
Figure 3.9: pET28-K2C18-CPDW/T versus pET28-K2C18-CPD expression. SDS-PAGE 
(tricine 16%) of E. coli whole-cell extract, induced at 16ºC for ~18 h at ~225 rpm. Equal 
volumes of cell culture were loaded (normalised to the same density via OD600). 
K2C18-CPD expression is not seen in BL21(DE3) Star cells (Star), but is in BL21 
Rosetta(DE3) pLysS cells (R). K2C18-CPD band size arrowed. WM, molecular mass 
marker. 
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While K2C18-CPDW/T expresses in BL21(DE3) Star cells (lane 1), K2C18-CPD 
does not (lane 2). It is unclear why there is such a disparity between the expression 
levels of K2C18-CPD in pET28-K2C18-CPDW/T versus pET28-K2C18-CPD under 
the conditions used. The only difference between the two constructs is the presence 
of a BamHI site (GGATCC) immediately downstream of the cleavage-critical leucine 
in pET28-K2C18-CPD (the wild-type sequence is GCGGAT). This 6 bp change 
alters the encoded CPD cleavage site from Leu^Ala-Asp to Leu^Gly-Ser (see 
Table 3.1). While the glycine (GGA) and serine (TCC) codons conferred by the 
incorporation of the BamHI site are not favoured for translation by E. coli 
(Nakamura et al., 2000), pET28-CPD alone, which also translates the BamHI site, is 
readily expressed (see Figure 3.4). The use of E. coli BL21 Rosetta(DE3)pLysS 
cells at 16ºC for ~18 h seems to alleviate this BamHI-related expression problem 
(lane 3), so these conditions were employed for subsequent experiments. 
 
K2C18 and MCC18 analogues were expressed in 1.5 L culture volumes to increase 
total protein yields, and purified as per Section 2.4.2. Figure 3.10 shows 
SDS-PAGE analysis of AMP-CPD fractions after on-column cleavage. 
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Figure 3.10: Expression and on-column cleavage of K2C18 and MCC18 analogues. 
SDS-PAGE (tricine 10-20%) of equivalent protein loads of purification fractions from the 11 
K2C18 and MCC18 analogues. *, peptides that are poorly expressed; CL, clarified lysate; 
E, cleaved CPD eluate (250 mM imidazole); WM, molecular mass marker; IP6, pooled 
cleaved AMP. 
 
Of the 11 K2C18 and MCC18 analogues that were expressed, 8 gave discrete AMP 
bands after cleavage was induced. K2C18(F14K) was expressed particularly well 
(lane 12). However, K2C18(G8L) and K2C18-2(G8L), while seen as a CPD fusion 
in the clarified lysate fractions (lanes 5 & 27), did not exhibit free AMP bands (lanes 
8 and 29). Faint cleaved CPD bands are seen in these samples (lanes 6 & 28), but 
it may be that the addition of the hydrophobic leucine at position 8 of both peptides 
leads to aggregation and a poor yield in general. Any free peptide may have been 
retained on the column during the post-cleavage wash steps, as all AMPs studied 
appeared to wash off the Ni-NTA column slowly over many column volumes (cf. 
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Figure 3.5). A6c, while seen in the cleaved AMP fraction (lane 22), aggregated into 
an unusable form when further purified. Finally, RC18-CPD expression was seen to 
be poor (lane 16), and no free RC18 post-cleavage was observed. Reasons for this 
are unclear. Due to these difficulties, the study of K2C18(G8L), K2C18-2(G8L), 
RC18 and A6c was discontinued. 
 
3.2.4 Purification of AMP variants 
3.2.4.1 Polishing of AMPs by C18 resin 
The seven cleaved and soluble K2C18 and MCC18 analogues (see Figure 3.10) 
were further purified using hydrophobic C18 resin as per Section 2.4.3.1. This 
served to desalt the peptides prior to vacuum drying, as well as removing larger 
protein contaminants that, due to a greater number of hydrophobic residues, 
remained bound to the C18 resin during peptide elution over an acetonitrile step 
gradient. Figure 3.11 shows this process for a typical purification, as well as 
samples of all the recombinant AMPs that were purified. 
 
 
Figure 3.11: C18 polishing of K2C18 and MCC18 analogues. SDS-PAGE (tricine 
10-20%) of A, acetonitrile elutions of K2C18 from C18 resin, from which pure fractions were 
pooled (30% and 45% in this example); and B, purified K2C18 and MCC18 analogues after 
drying and resuspension in water. K2C18syn, 0.5 !g chemically-synthesised K2C18. 
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All peptides appear to be relatively pure as observed by SDS-PAGE with 
Coomassie staining. MCC18 appears to have a low level of contamination, visible 
as faint protein bands running at higher molecular masses (lane 11). MCC18(E2K) 
may also be slightly contaminated (lane 12). Amino acid analysis confirms the 
presence of contaminating protein through the observed amino acid ratio diverging 
from that expected (see Section 3.2.4.2 below, and Appendix 2). In both cases, 
however, the AMP band is by far the most dominant, and the level of purity should 
be sufficient for activity studies. The AMP bands do not run at the same molecular 
mass; those that are more highly charged, such as MCC18(E2K Q9K) with a charge 
of +8 (lane 13), run higher than those with a lower net charge i.e. MCC18 with a 
charge of +5 (lane 11). This further confirms the anomalous SDS-PAGE running 
mass of these peptides as observed previously in Section 3.2.2.3. 
 
3.2.4.2 Assessment of purified AMP concentration and purity 
Samples of the K2C18 and MCC18 analogues were submitted for amino acid 
analysis (as per Section 2.3.4) in order to determine their concentration and to 
assess their purity. As an example, a comparison of recombinant and chemically-
synthesised K2C18 is shown in Figure 3.12. The remainder of the amino acid 
analysis results are shown in Appendix 2. 
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Figure 3.12: Amino acid analysis of recombinant and chemically-synthesised K2C18. 
Ion exchange ninhydrin analysis of hydrolysates of A, recombinant K2C18; and B, 
chemically-synthesised K2C18 peptide. The closeness of fit between the expected and 
observed amino acid mole ratios is used as a qualitative indication of purity; unexpected 
amino acids, i.e. those not in the peptide, were excluded from the analysis. Analyses were 
carried out in duplicate, single runs shown. 
 
Recombinant K2C18 is of an equivalent, if not greater purity than the chemically-
synthesised version (commercially obtained, 88.88% purity according to 
manufacturer’s HPLC analysis). If the majority of observed values are within 10% of 
the expected values, it indicates a peptide is relatively pure. The seven purified 
K2C18 and MCC18 analogues met this criteria, including the slightly contaminated 
MCC18 and MCC18(E2K) from Figure 3.11. 
 
3.2.4.3 Yields of purified AMPs 
The yield of each AMP from the CPD purification protocol was calculated from the 
amino acid analysis results, and is summarised in Table 3.3. 
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Table 3.3: Purification yields of K2C18 and MCC18 analogues. Mutated residues 
indicated in bold. MW, molecular mass in Daltons; !M, peptide concentration as determined 
by amino acid analysis; !L, resuspended peptide volume; !g, total yield from 1.5 L E. coli 
culture; *, K2C18(F14K) was not polished using C18 resin, rather filtered through 10 kDa 
MWCO membrane and dialysed against 0.1 M ammonium acetate before lyophilisation and 
resuspension (Section 2.4.3.2). 
 
Yields of peptide per litre of induced E. coli culture ranged from ~100 !g for 
MCC18(E2K Q9K) to ~1 mg for K2C18(F14K), but more typically fell into the 100 to 
150 !g/L range. As an example, the expression of K2C18-CPD in E. coli BL21 
Rosetta(DE3)pLysS cells was estimated at 20 mg/L (see Figure 3.9). Given that 
K2C18 comprises ~8% of the predicted mass of the fusion protein, a maximal yield 
of approximately 1.7 mg/L of AMP was estimated. The actual yield of 139 !g/L of 
K2C18 represents approximately 8% of this. Other peptides, such as K2C18(F14K), 
were expressed at higher levels (see Figure 3.10), and hence lead to a greater final 
yield. Although these final yields were not high, enough AMP was purified to assay 
for antimicrobial activity. 
 
3.2.5 Measurement of antimicrobial activity 
Laboratory strains of the Gram-negative bacteria E. coli and P. putida, the Gram-
positive bacterium B. subtilis, and the yeast C. albicans (see Section 2.5.1; in 
exponential-phase growth) were challenged with the K2C18 and MCC18 analogues 
at final concentrations ranging from 16 !M to 0.3 !M (~34 !g/mL to ~0.7 !g/mL). 
Minimum inhibitory concentration (MIC) was determined as the concentration of 
AMP that prevented microbial growth after an overnight incubation (Table 3.4). MIC 
is distinct from minimum bactericidal concentration (MBC), which requires 
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confirmation of cell death (i.e. not just the cessation of growth). The physical 
characteristics of each AMP i.e. charge (Q), cationic face angle of the "-helix ($), 
mean hydrophobicity (H) and relative hydrophobic moment (!Rel) were also 
determined for each peptide as per Section 2.4.4. These are common descriptors 
used to compare "-helical AMPs (Dathe & Wieprecht, 1999). 
 
 
Table 3.4: Structural characteristics and antimicrobial activities of K2C18 and MCC18 
analogues, ranked by relative hydrophobic moment. Minimum inhibitory concentration 
(MIC) was determined as the concentration of peptide that completely inhibited microbial 
growth after 18 h (bacteria) or 23.5 h (C. albicans). Values represent duplicate average. 
MICs reported in the literature are shown in italics: 1, Shin et al. (2000); 2, Kim & Cha 
(2010), no MIC data reported. Structural parameters: Q, charge; #, angle subtended on the 
helix by the cationic face; H, mean hydrophobicity; !Rel, relative hydrophobic moment. 
 
The K2C18 and MCC18 analogues, expressed and purified using the CPD system, 
all displayed varying degrees of antimicrobial activity. While recombinant and 
synthetic K2C18 had a very similar effective concentration against E. coli and 
P. putida, a ~2.5 fold difference in MIC was observed for B. subtilis and C. albicans. 
The reason for this discrepancy is unclear; racemisation or oxidation of residues in 
one of the peptides may be an explanation, but the most susceptible amino acids 
(e.g. methionine, cysteine, histidine, tryptophan and aspartic acid) are not found in 
K2C18 (Palasek et al., 2007; Sewald & Jakubke, 2009). Of the K2C18 variants, 
K2C18(Q9K) was the most effective overall against the microbes tested. MCC18 
was similar in potency to K2C18 against E. coli, but was ineffective at the 
concentrations tested against P. putida. Interestingly, the MCC18(E2K) and 
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MCC18(E2K Q9K) variants were more effective against P. putida, B. subtilis and C. 
albicans than their parent peptide MCC18. 
 
Although the active AMP variants all exhibit similarly low MIC values (i.e. same 
order of magnitude), some structure/function relationships are indicated. Peptides 
with a larger relative hydrophobic moment, i.e. a greater amphipathic propensity, 
show more potent activity. MCC18(E2K Q9K) exhibited the greatest antimicrobial 
activity in comparison to the other analogues tested, while K2C18(F14K) showed 
the lowest. A higher overall charge also correlated with a lower observed MIC. 
 
3.3 Discussion 
While solid-phase peptide synthesis remains the standard for commercial-level 
synthesis of bioactive peptides (Lax, 2010), there is still a place for recombinant 
production in a research and development setting. For AMPs, small-scale and rapid 
creation of a peptide and a variety of analogues for structure/function analysis is 
desirable (Hancock & Sahl, 2006). The use of the inducible, auto-cleaving CPD tag, 
first described by Shen et al. (2009a), is shown in this work to adequately suit this 
purpose. K2C18, a truncation of the extensively studied murine "-helical cathelicidin 
CRAMP (Gallo et al., 1997; Shin et al., 2000; Yu et al., 2002), was successfully 
produced and shown to exhibit antimicrobial activity. Several variants, including a 
novel consensus sequence of CRAMP-like mammalian AMPs, were also purified, 
with mutations made to the primary amino acid sequences in an attempt to 
ascertain basic information on structure/function relationships. 
 
The CPD purification approach is cost-effective, as the fusion tag is also the 
cleaving enzyme that releases free AMP. This negates the need to purchase a 
separate protease, and the cleavage-inducing compound IP6 is inexpensive (£9 per 
gram, Sigma-Aldrich Company Ltd.). In addition, because a 1:1 ratio of AMP to 
CPD is inherent, complete cleavage can occur rapidly within 1 h or less. This gives 
the CPD system an advantage over other recent recombinant AMP production 
techniques. The glutathione S-transferase tag approach utilised by Moon et al. 
(2006) requires buffer exchange prior to Factor Xa cleavage treatment over two 
days; the split-intein/chitin binding domain of Hong et al. (2010) requires overnight 
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incubation in !-mercaptoethanol to induce cleavage; the cleavage of the thioredoxin 
tag used by Krahulec et al. (2010) requires a day of incubation at 37ºC with an 
expensive enterokinase; and the small ubiquitin-like modifier domain harnessed by 
Bommarius et al. (2010) exhibited issues with the specificity and dissociation of the 
cleaving enzyme sumoase.  
 
Expression of the AMP-CPD fusions in E. coli did not appear to induce toxicity in 
the host cells. Although a slight depression in growth rate was generally observed in 
comparison to cells expressing pET28-CPD alone (data not shown), this varied for 
each AMP expressed, and showed no correlation with the MIC values that were 
finally determined. This lack of AMP-fusion toxicity during intracellular expression is 
in line with that seen in previous recombinant production methods (Moon et al., 
2006; Bommarius et al., 2010). 
 
The use of the modified CPD cleavage site, mutated by the introduction of a BamHI 
site from Leu^Ala-Asp to Leu^Gly-Ser, did not inhibit CPD cleavage. This confirms 
the work of Shen et al. (2009a). However, the expression level of identical AMP 
fusions was influenced by this change. The poor expression from 
pET28-K2C18-CPD (BamHI cleavage site) in E. coli BL21(DE3) Star cells in 
comparison to pET28-K2C18-CPDW/T (wild-type cleavage site) is not readily 
explainable, as pET28-CPD, which possesses the modified cleavage site in the 
correct reading frame, expresses well. However, using the wild-type cleavage 
sequence in the production of additional peptides did not guarantee significant 
expression (see Section 4.2.6.1). Use of E. coli BL21(DE3)pLysS Rosetta cells, 
along with a reduction of induction temperature and extended incubation time, 
alleviated the expression problem somewhat. It appears that, while the CPD domain 
is soluble and readily expressed, N-terminal fusions alter this in a context-
dependent manner. Indeed, some AMP-CPD fusions were not amenable to 
purification at all. These included RC18, which did not express; and K2C18(G8L) 
and K2C18-2(G8L), which expressed but did not produce free AMP. A6c, while 
expressed and readily cleaved by CPD, aggregated into an unusable form. 
 
The yields of purified K2C18 and MCC18 variants ranged from 0.1 to 1 mg/L. This 
represents 5 to 50% of the total estimated production level of 1.7 mg/L, i.e. 
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~20 mg/L AMP-CPD fusion is produced with the AMP portion forming ~8% of this. 
Initial purification protocols involved filtering the cleaved AMP through a 10 kDa 
MWCO membrane to remove larger protein contaminants, followed by dialysis to 
desalt and subsequent lyophilisation. However, allowing the peptides to adsorb to 
two sets of membranes reduced yields to an undesirable level. Apart from 
K2C18(F14K), which was strongly expressed, the yields of other peptides using this 
approach were less than 100 !g/L (data not shown). The use of hydrophobic C18 
resin, commonly used in HPLC for separating peptides, overcame this problem by 
allowing for desalting and contaminant removal in one step. Production yields might 
further be improved upon by harnessing FPLC and HPLC for the Ni-NTA and C18 
purification steps respectively. However, the aim of this work was to produce a 
system that produces linear AMPs such as K2C18 in a cheap, straightforward and 
timely manner. The use of Ni-NTA resin and C18 disposable columns is in line with 
this approach.  
 
While the AMP yields (0.1 to 1 mg/L) seem low, they are commensurate with the 
yields reported in previous studies that utilised E. coli. Moon et al. (2006) reported a 
yield of 0.3 mg/L for LL-37 (37 aa) expressed as a fusion to the C-terminus of 
glutathione S-transferase; Hong et al. (2010) did not report their yield of dermcidin 
(48 aa, an anionic AMP) from a fusion to the C-terminal of a split-intein/chitin 
binding domain, but did state that they purified a total of 10 mg of AMP. Krahulec et 
al. (2010) used a fermentor (as opposed to shake flask incubation used in this work 
and the other previously mentioned studies) to achieve 40 mg/L for LL-37 
expressed as a fusion to the C-terminal of thioredoxin. Bommarius et al. (2010) also 
used a fermentor to produce IDR-1 (13 aa, an artificial host defense peptide) from a 
C-terminal fusion to a small ubiquitin-like modifier domain at a yield of 45 mg/L, and 
E6 (12 aa, a bactenecin analogue) in the same manner at a yield of 8 mg/L. 
However, the use of a fermentor is not amenable to the straightforward production 
of multiple AMPs in parallel. 
 
Amino acid analysis was carried out on the purified AMPs to determine the net 
peptide content (i.e. concentration) of the resuspended peptide solutions. This is 
important as a dried peptide still contains residual salt, so calculating peptide 
concentration by resuspended dry-weight over-estimates the actual peptide 
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concentration (Bommarius et al., 2010). While HPLC analysis was not conducted on 
the recombinantly purified peptides, SDS-PAGE and amino acid analysis 
qualitatively showed that the AMPs were relatively pure. Although MCC18 exhibited 
some contamination, it was deemed sufficiently pure for use in the antimicrobial 
activity assay. 
 
The MICs of K2C18 in this work are comparable to those determined by Shin et al. 
(2000). Discrepancies may be explained by different experimental protocols. In this 
work, 90 !L of 5x104 cfu/mL bacteria (~4,500 cells) or 6x103 cfu/mL fungi (~540 
cells) were used as starting cultures for the antimicrobial assay; Shin and 
co-workers used 100 !L of 2x106 cfu/mL bacteria (~20,000 cells) and 2x104 cfu/mL 
fungi (~2,000 cells). Standardisation of antimicrobial assays is lacking in the 
antimicrobial field, with each lab adopting their own approach (Wiegand et al., 
2008). However, as long as assays are carried out in parallel under the same 
conditions, comparisons can be made between different AMPs under examination. 
 
The antimicrobial activity of the various purified K2C18 and MCC18 analogues 
confirms and extends previous studies of AMP structure/function relationships. Shin 
et al. (2000) showed K2C18 to have a potent MIC in the low !M range against a 
number of Gram-negative and Gram-positive bacteria, as well as against the fungus 
C. albicans. Extending the cationic face angle (K2C18(F14K)) appears to reduce 
overall effectiveness; in magainin variants, similar mutations lead to an abrogation 
of antimicrobial activity, alongside a reduction in overall hydrophobicity (Dathe & 
Wieprecht, 1999). It has been posited that this is due to peptides with wide cationic 
faces exhibiting a greater stability for associating with negative phospholipid heads, 
reducing membrane insertion and disruption; complete insertion becomes 
disfavoured due to electrostatic repulsion between adjacent peptide cationic faces 
(Toke, 2005). Furthermore, Park et al. (2003) showed that the removal of both 
phenylalanines (positions 14 and 15) from the K2C18 analogue CRAMP-18 by 
alanine substitution led to a decrease in antimicrobial activity against E. coli, 
indicating a key role for these hydrophobic moieties (Park et al., 2003). This broadly 
agrees with the results seen in this work, although K2C18(F14K) still retains a 
similar activity to K2C18 against P. putida. 
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The analogue K2C18-2 was designed to have the same amino acid composition as 
K2C18 but with the lysine residues interspersed (rather than clustered) around the 
cationic face. This was predicted to enhance the interaction of the cationic face of 
the "-helix with bacterial anionic phospholipids, and hence further promote 
membrane insertion (Kim & Cha, 2010). While Kim and Cha (2010) found that 
CRAMP-18-2 (similar to K2C18-2) exhibited a more potent lytic activity against 
E. coli than CRAMP-18 (similar to K2C18), the results presented here did not show 
any such improvement in MIC. This may be due to the different nature of the 
protocols, with the liquid culture assay used in this work proceeding overnight rather 
than for 30 min at a fixed concentration as per Kim & Cha (2010). 
 
MCC18, a consensus sequence derived from 14 mammalian cathelicidin 
K2C18-like sequences (the 18-residue consensus region from LL-37 correlated well 
with a previous investigation into its minimum active region [Li et al., 2006]), was 
examined for antimicrobial activity along with two variants. MCC18 possesses five 
amino acid changes in comparison to K2C18, of which three are non-homologous: 
glutamic acid at position 2 (replacing a lysine) and aspartic acid at position 13 
reduce the overall charge of the peptide, while lysine at position 16 replaces the 
uncharged glutamine. MCC18 shows antimicrobial activity at a MIC similar to 
K2C18 against E. coli, but is ineffective against P. putida, B. subtilis and C. albicans 
over the concentration range tested. While the Gram-negative bacterium P. putida 
has similar membrane compositions as E. coli (Pinkart & White, 1997; Ruiz et al., 
2006), the ability for P. putida to modify its membrane fatty acid and protein content 
in response to membrane-active substances may be responsible for the lack of 
effect seen by MCC18 at the concentrations tested (Heipieper & de Bont, 1994). 
However, when the overall charge of MCC18 (+5) is increased, i.e. to +7 in 
MCC18(E2K) and +8 in MCC18(E2K Q9K), activity is seen against P. putida. This is 
in line with previous studies regarding the importance of cationic charge (Dathe & 
Wieprecht, 1999; Jiang et al., 2008; Matsuzaki, 2009). However, the charge of 
these AMPs is not the only parameter to change between the MCC18 analogues. 
Overall hydrophobicity and relative hydrophobic moment are also altered 
concurrently, as it is very difficult to vary one parameter in isolation from others 
(Dathe & Wieprecht, 1999). This increase in relative hydrophobic moment, due to 
additional lysine residues on the cationic face, has been shown to enhance the 
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activity of an AMP against Gram-positive bacteria, as well as other microbes in 
general (Matsuzaki, 2009). Antimicrobial activity against all microbes thus increases 
for the MCC18 analogues, as their relative hydrophobic moment increases from 
0.56 to 0.62. 
 
The presence of the anionic aspartic acid at position 13 in the MCC18 consensus 
peptide is interesting, as this residue is situated in the middle of the AMP’s cationic 
face (see Figure 3.7). As mentioned previously, a dispersed cationic charge is also 
favourable to activity (Kim & Cha, 2010). Perhaps an anionic residue at this position 
is favourable as it simultaneously acts to reduce the overall positive charge while 
giving an interrupted and hence dispersed cationic face.  
 
While haemolytic activity of the K2C18 and MCC18 variants was not assessed in 
this study, some general comment may be made. Many AMPs that exhibit a high 
positive charge (+7 to +9; such as those studied here) do not tend to lyse red blood 
cells (Dathe & Wieprecht, 1999; Jiang et al., 2008). Confirmation of this, as well as 
observation of other effects on mammalian cells, would need to be conducted. 
Encouragingly, the K2C18 and MCC18 variants exhibited activity against the 
various microbes in high-salt medium (i.e. in LB containing 171 mM NaCl; data not 
shown), indicating that they may not be antagonised by the high ion concentrations 
found in human blood (Bowdish et al., 2005a). However, divalent ions such as 
magnesium and calcium, which may be more potent antagonists of AMP activity 
(Hancock & Sahl, 2006), were not tested, nor was a more complex medium 
mimicking physiological conditions (such as serum, which contains a number of 
peptidases [McGregor, 2008]) used. 
 
In conclusion, the utility of the inducible, autocleaving CPD-hexa-histidine tag as a 
fusion partner for recombinant production and purification of linear AMPs in E. coli 
has been shown. These AMPs were purified at small scale in an inexpensive and 
timely manner, and displayed varying antimicrobial activity when tested in vitro. It is 
hoped that this production technique will be useful for the future production of 
antimicrobials for structure/function studies. The next step is to try to utilise a similar 
recombinant system to screen for new AMPs. 
99 
CHAPTER 4 – SCREENING FOR BIOACTIVE PEPTIDES: 
ANTIMICROBIALS 
4.1 Introduction 
4.1.1 Brief history 
The identification of new antimicrobial peptides (AMPs; reviewed in Section 3.1) 
could prove a boon for the treatment of human pathogens that are recalcitrant to 
existing antibiotics (Rossi et al., 2007). However, identifying and investigating AMPs 
directly from environmental samples is both economically and environmentally 
unfavourable (see Section 1.2.2). Alternative screening strategies for novel AMPs 
are therefore desired. 
 
One screening approach is to use in silico techniques to identify likely candidates 
(Fjell et al., 2007). Although AMPs exhibit a large amount of structural diversity, a 
number contain largely conserved N-terminal pre-pro-regions that require enzymatic 
cleavage to release the active peptide (Hancock & Sahl, 2006). These conserved 
regions allow for new AMP sequences to be elucidated by reverse transcriptase 
PCR from mRNA transcripts, or by bioinformatic database mining as new 
transcriptome or genome sequences become available (Gennaro & Zanetti, 2000; 
Fjell et al., 2007). However, such identification of AMPs occurs piecemeal, and 
misses peptides that do not share similar pre-pro-regions. 
 
Other in silico approaches to identifying putative AMPs revolve around quantitative 
structure-activity relationships, in which descriptor values (such as charge, 
amphipathicity, hydrophobicity) are given to known peptides that have had their 
minimum inhibitory concentration validated experimentally (Frecer et al., 2004; 
Raventós et al., 2005). These data, along with more complicated descriptors (i.e. on 
the atomic scale for each specific amino acid position), can be fed into computer 
simulations in order to predict or design AMP sequences de novo (Loose et al., 
2006; Cherkasov et al., 2009; Fjell et al., 2009). After virtual libraries have been 
screened in such a manner, the best predictions can be synthesised and 
experimentally validated. While such in silico approaches show great promise 
(Blondelle & Lohner, 2010), they currently appear limited to the analysis of short 
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AMP lengths (10 or fewer residues), and their use falls outside the work presented 
here. 
 
Chemically-synthesised peptides may be harnessed as an input into a 
high-throughput screen for new AMPs (Blondelle & Lohner, 2010). The associated 
costs per peptide, however, make screening an unconstrained library uneconomic 
(see Section 1.4.1). Recent use has instead focused on optimising known “hit” 
peptides. For example, Rathinakumar et al. (2009) screened ~16,000 rationally 
designed peptides (5 to 9 aa in length) where just four residues were allowed to 
differ. To reduce cost, Hilpert & co-workers (2007) miniaturised peptide synthesis 
levels to the !mol level via microarrays, and were able to screen such small 
amounts for antimicrobial activity via the use of a Pseudomonas aeruginosa test-
strain expressing a luciferase cassette (Hilpert et al., 2006). In this sensitive setup, 
if bacterial energy levels are disturbed (i.e. through AMP toxicity), luminescent 
output falls commensurately. However, as outlined in Section 3.1.5.1, this peptide 
synthesis approach is technically demanding. 
 
In contrast to the natural-product, in silico and chemical synthesis screening 
approaches outlined above, recombinant screening for putative AMPs has the 
potential to be economically viable, technically straightforward and cost-effective 
respectively (Raventós et al., 2005). 
 
4.1.2 Recombinant screen approaches 
Most approaches to recombinant screening for AMPs have been concerned with 
optimising known peptides, rather than searching for de novo sequences (Blondelle 
& Lohner, 2010). Phage display (reviewed in Section 1.2.3.1) has been employed to 
select for peptide inhibitors of peptidoglycan synthesis enzymes in the microbial cell 
wall (El Zoeiby et al., 2003), and for peptide binding to bacterial mimetic liposomes 
(Tanaka et al., 2008). However, overall antimicrobial activity of isolated peptides 
when tested against microbial cultures was poor. A more holistic, whole-cell 
approach is required. 
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4.1.2.1 Whole-cell screening 
Whole-cell screening, where compounds are screened for their ability to provoke a 
specific phenotype in a cell culture without a priori knowledge of a particular target, 
is reviewed in Section 1.2.3.3. Because AMPs can act on generalised targets, such 
as bacterial membranes (van’t Hof et al., 2001), it seems logical to employ this 
technique as a screening method. The simplest approach is to add purified AMP 
aliquots to a microbial culture over a concentration gradient, i.e. as per Section 
3.2.5. Although such a negative selection screen is less desirable than a positive 
selection approach with regards to resolving power (see Section 1.2.3.3), it is the 
obvious route for novel AMP identification. But while robotisation can aid with the 
throughput of such a screen (Raventós et al., 2005), prior peptide production is still 
required. 
 
An alternative is to combine in vivo both the screening and peptide production 
functions. DNA libraries, utilised as a diverse input for subsequent transcription and 
translation into peptide (see Section 1.2.2.3 and Section 1.2.3), are contained within 
discrete host cells. Hence, the phenotypic effect that an encoded peptide may have 
is linked with its genotype, which is recoverable through isolation of the DNA. With 
regards to an in vivo whole-cell screen for AMPs, a novel hit will lead to a loss of 
growth in the host cell when induced in liquid or solid media. This approach is 
known as cis-screening (see Section 4.1.2.2). Past examples of this approach 
include the use of a vital staining methodology on cells expressing putative AMPs, 
whereby trypan blue only stains colonies with compromised cell membranes (Loit et 
al., 2008; Cheng et al., 2009). However, this method appears non-specific (giving a 
high false-positive rate of 67% to 75%), and does not differentiate between 
exogenous and endogenous hits (see Section 4.1.3.1 below). In addition, 
Novozymes A/S (Basævrd, Denmark) has compared the in vivo activity of mutants 
of a SMAP29 truncation (18 aa, !-helical cathelicidin) in order to optimize its 
potency (Steinstraesser et al., 2002; Raventós et al., 2005). 
 
4.1.2.2 Cis or trans screens 
In an in vivo whole-cell screen for novel AMPs, both cis and trans approaches are 
possible (Raventós et al., 2005). The cis-based screening approach, in which the 
producing organism is also the target of the AMP it produces, is outlined in Section 
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4.1.2.1. In a trans-based screen, the producing cell is largely immune to the AMP 
expressed, and an additional AMP-sensitive organism is used to evaluate activity. 
 
The optimisation of plectasin (40 aa, a defensin from the fungus Pseudoplectania 
nigrella) serves as a typical example of a trans-based screen (Mygind et al., 2005). 
Peptide variants were constructed and secreted from colonies of the yeast 
Saccharomyces cerevisiae, and activity assessed via radial diffusion assay using 
an agar overlay of the test organism Staphylococcus carnosus (Raventós et al., 
2005). Additional examples of cis-based screens using E. coli as the host include 
investigation of the critical residues of apidaecin 1b (Taguchi et al., 1994) and 
thantin (Taguchi et al., 2000), as well as those listed above in Section 4.1.2.1. The 
work described in this chapter is based around utilising E. coli as an AMP-sensitive 
production host in a cis-based screen.  
 
4.1.3 Use of an AMP-sensitive production host 
A cis-acting screen for novel AMPs requires that the producing organism is AMP-
sensitive. Previous work has shown that, when patch-plated on inductive medium, 
clones encoding AMPs, such as PR-39 and bactenecin 5 (43 aa, bovine source), 
with known intracellular targets fail to grow (Raventós et al., 2005). 
 
4.1.3.1 Exogenous versus endogenous hits 
AMPs with a known membrane-specific activity, such as LL-37 and indolicidin, only 
exhibited a reduction in colony growth when targeted to the periplasm (Raventós et 
al., 2005). This indicates that membrane localisation is necessary for their activity. 
Furthermore, it shows promise for an in vivo whole-cell screen. If constructed to 
ensure secretion to the periplasm, identification of novel AMPs that possess 
exogenous antimicrobial activity should be possible, i.e. activity is retained when 
purified and added exogenously to a microbe culture. 
 
This is an important detail, as the origin of an AMP produced in vivo is the 
cytoplasm, i.e. endogenous to the target cell. Thus, any AMP hit identified using an 
in vivo whole-cell screen may result from an interaction with a cytoplasmic target. 
An AMP that is added exogenously is more relevant, as it reflects the clinical reality 
for any putative drug. It is more than likely that identified intracellular AMP hits 
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would not possess the required cell-penetrating activity to access the cytoplasm if 
added exogenously, as the microbial cell membrane is a potent barrier (Stewart et 
al., 2008). While such hits may be modified to allow cell-penetration (Eriksson et al., 
2002), it makes greater sense to focus on isolating exogenous AMP hits in the first 
instance. 
 
4.1.3.2 Secretion systems 
Targeting of known membrane-active AMPs to the periplasm of E. coli during 
recombinant production has been shown to lead to toxicity (discussed in Section 
4.1.3.1). Although E. coli possesses several different secretion systems, most are 
protein-specific rather than generic in function, and true secretion through both the 
inner and outer membranes is a complex process (Saier, 2006). Furthermore, 
modification of these systems for heterologous protein secretion gives 
unpredictable results, with any success requiring a heuristic approach (Ni & Chen, 
2009). Nevertheless, the most commonly harnessed secretion system in E. coli is 
the Sec pathway (Choi & Lee, 2004). In this system, a short (10 to 20 aa) 
N-terminal tag is recognised by the SecA ATPase and threaded through the inner 
membrane via the SecYEG complex, where the secretion tag is subsequently 
cleaved by signal peptidase I (Natale et al., 2008). While there are a number of Sec 
secretion signals available (Choi & Lee, 2004), a truncation of the gIII gene, which 
encodes the 18 aa secretion signal of the minor capsid protein pIII from filamentous 
phage fd (Rapoza & Webster, 1993), was chosen for this work. This commonly 
used N-terminal tag is sufficient for peptide targeting to the Sec-translocase 
complex, but may also be aided by the chaperone SecB, which binds and keeps 
nascent peptides in an unfolded state prior to periplasmic translocation (Natale et 
al., 2008).  
 
Extracellular release once a pIII-tagged peptide reaches the periplasm is, however, 
not the norm. While a few recombinant proteins have been observed to accumulate 
in the extracellular milieu, this may be because of natural cell death and lysis, and 
seems dependent on culture conditions (Ni & Chen, 2009). Strategies to promote 
release exist, including: osmotic shock; chemical treatment, e.g. Triton X-100 
detergent; co-expression of a lysis promoting peptide, e.g. bacteriocin release 
protein; or the use of L-form cells, which lack an outer membrane (Gumpert & 
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Hoischen, 1998; Choi & Lee, 2004). However, such approaches result in a general 
loss of cell viability, and consequently would lead to an AMP effect being 
indistinguishable from the control. 
 
4.1.3.3 Replica plating 
Although the patch-plating approach discussed at the beginning of Section 4.1.3 
may be suitable for manual analysis of a small number of AMPs expressed by 
E. coli in vivo, a different method is required for high-throughput screening of a DNA 
library. Replica plating, commonly used for profiling microbial colony mutation 
libraries on different selective growth media (Lederberg & Lederberg, 1952), may be 
harnessed as a negative screen. This simple and robust technique may be used to 
transfer a library of putative AMP-encoding colonies to inductive medium; 
comparison of subsequent outgrowth colonies can isolate clones that fail to grow 
due to the toxic effect of a produced putative AMP. 
 
4.1.4 Other screen considerations 
As mentioned in Section 4.1.2.1, DNA is the input utilised for a recombinant in vivo 
AMP screen. For proof-of-principle in this work, genomic DNA (gDNA) extracts from 
human (Homo sapiens) and bdelloid rotifer (Adineta ricciae) were used. The haploid 
human genome contains approximately 3 billion bp, with 1.2% of this coding for 
approximately 20,000 to 25,000 discrete proteins (International Human Genome 
Sequencing Consortium, 2004). The A. ricciae genome is in the process of being 
annotated, but it has a predicted size of 120 to 135 million bp (C. Boschetti, 
personal communication). Both sources of gDNA should serve as good sources of 
sequence diversity, especially that of A. ricciae, as bdelloid rotifer genomes have 
been shown to contain large numbers of horizontally transferred genes (Gladyshev 
et al., 2008). 
 
Promoter selection and potential codon bias in the peptide expression vector should 
also be considered (Ingham & Moore, 2007). For the former, the tightly-regulated, 
arabinose-inducible araBAD promoter was chosen, as it is suitable for the cloning 
and expression of toxic genes such as AMPs (Guzman et al., 1995). For the latter, 
the codon bias (Nakamura et al., 2000) of the human and rotifer gDNA inserts may 
affect their translation, and hence final peptide yield, in E. coli. However, as the 
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screen will presumably “skip” such reticent sequences, codon bias should not be an 
issue for any putative AMP hits identified. 
 
Lastly, fusion partners to an AMP are commonly utilised during recombinant 
production, both in order to alleviate toxicity to their host and to aid in downstream 
purification (reviewed in Section 3.1.5.2). Results from Chapter 3 indicated that 
E. coli tolerates endogenous expression of an AMP-CPD fusion, and that active 
AMP can be successfully released upon addition of IP6. This property of inducible 
CPD cleavage could be utilised in an in vivo whole-cell screen. If truly inactive, an 
AMP-CPD fusion could be tagged for secretion in either a cis or trans-based 
screen, and once a critical threshold of AMP-CPD was reached, cleavage could be 
induced and active AMP released. Exogenous antimicrobial activity could then be 
observed, either against the host or by using the culture medium to challenge other 
microbes. To ascertain whether this would be possible, the first step is to establish if 
the positive control K2C18-CPDW/T lacks antimicrobial activity in its fusion state. 
 
4.1.5 Summary 
Natural-product and chemically-synthesised peptide library screens for new AMPs 
have issues with environmental sustainability, technical expertise required and cost-
effectiveness. Although only focusing on peptide-based entities, rather than the 
wide range of secondary metabolites that many organisms are capable of 
producing, screens for AMPs are inherently more amenable to high-throughput 
methodologies. While chemically-synthesised libraries have shown promise in 
recent years, recombinant whole-cell approaches can potentially couple AMP 
synthesis with assaying for activity in the same step and at a lower cost. Harnessing 
a cis-based screen, in which the microbial host is sensitive to the putative AMP 
produced, could lead to the rapid identification of novel AMPs. 
 
To demonstrate proof-of-principle, the effect of production in E. coli of the model 
AMP K2C18 was investigated for amenability with regards to a replica plate 
negative screen. Furthermore, genomic DNA libraries of human and rotifer origin 
were employed in a screen for novel AMPs with exogenous or endogenous activity. 
Identified hits were further investigated through bioinformatic and mutational means, 
and several hits produced recombinantly and synthetically. Their efficacy when 
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added exogenously back to their production host was also investigated in order to 
confirm the ability of the screen to identify novel AMPs that have bioactive potential. 
 
4.2 Results 
4.2.1 Analysis of K2C18-CPD activity as a fusion protein 
To determine if an AMP-CPD fusion was inactive when added exogenously to an 
E. coli culture, i.e. before cleavage and release of the active AMP, K2C18-CPDW/T 
(see Section 2.4.1.2) was utilised as a model control. 
 
4.2.1.1 Purification and activity of crude K2C18-CPDW/T 
Expression and purification of pET28-K2C18-CPDW/T in E. coli was carried out as 
described earlier in Section 3.2.2.2, except CPD cleavage was not induced; rather, 
3 bead volumes of wash buffer containing 500 mM imidazole were used for elution 
of the fusion protein. Imidazole, which is toxic to E. coli (Simonetti et al., 2001), was 
subsequently removed by dialysis (see Section 2.4.3.2) against wash buffer without 
imidazole. Dilutions of this K2C18-CPDW/T dialysate, with or without 500 !M IP6 
pre-treatment for 1 h to induce the release of free K2C18, were tested for 
antimicrobial activity against E. coli DHB10 by liquid culture assay (see Section 
2.5.3). 
 
 
Figure 4.1: K2C18-CPD fusion exhibits antimicrobial activity in liquid culture assay. 
A, SDS-PAGE (tricine 10-20%) of dialysed K2C18-CPDW/T Ni-NTA eluate; and B, 10 !L 
dialysate serially diluted (with/without 500 !M IP6 pre-treatment for 1 h) and added to 90 !L 
of 5x104 cfu/mL E. coli DH10B. OD600 reading taken after 24 h incubation at 37ºC, 
representative experiment shown from duplicate. WM, molecular mass marker; Blank, LB 
medium only; Pos., elution buffer (250 mM imidazole); Neg., wash buffer including 1 mM 
IP6; *, gel artefact. Representative experiment shown (n = 2). 
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Both cleaved and uncleaved K2C18-CPDW/T (Figure 4.1 A) showed an equivalent 
antimicrobial activity over the dilutions tested (Figure 4.1 B). There is an estimated 
500 ng/!L liberated K2C18 in the IP6 treated gel sample (lane 3, with reference to 
the molecular mass marker), which equates to an approximate final concentration of 
1.4 !M when diluted 160-fold (16-fold initially, then another 10-fold when added to 
the antimicrobial liquid culture assay). This is in line with the minimum inhibitory 
concentration (MIC) observed for purified K2C18 against E. coli (see Section 3.2.5). 
 
Even if the untreated K2C18-CPDW/T contained a small amount of liberated K2C18 
from unstimulated background CPD cleavage (not observed in lane 2), there would 
be at least a two-fold observable difference between the inhibitory concentration of 
the plus and minus IP6 samples if the free peptide was solely responsible for the 
antimicrobial effect. This was not observed. Overall, the use of “inactive” 
membrane-targeted AMP-CPD fusions appears unsuitable for E. coli, as the fusion 
may retain antimicrobial activity. 
 
4.2.2 Endogenous activity of K2C18 and K2C38 expressed in E. coli 
As the strategy of harnessing an “inactive” AMP-CPD fusion proved unfeasible, the 
use of an AMP’s innate toxicity (without a fusion partner) towards its production host 
was attempted as a screening approach instead (Raventós et al., 2005). K2C18, as 
well as K2C38, the full-length CRAMP parent from which K2C18 was derived (Shin 
et al., 2000), were used as model AMPs in order to validate this method and aid in 
the construction of a screen for novel AMPs. 
 
4.2.2.1 Construction of expression vectors 
The K2C18 and K2C38 sequences were cloned into the arabinose-inducible 
pBAD/gIII-A plasmid between the vector-encoded N-terminal pIII secretion tag and 
C-terminal hexa-histidine tag (see Section 2.6.1.2). pBAD/gIII-A was also modified 
to remove the pIII-encoding secretion tag, resulting in pBADm (see Section 2.6.1.1). 
K2C38 was cloned into pBADm in a similar manner as per pBAD/gIII-A. Versions of 
K2C18 and K2C38 were also constructed to incorporate a stop codon, so that the 
C-terminal hexa-histidine tag was not translated (see Section 2.6.1.2). Table 4.1 
summarises the plasmids constructed, which were transformed into E. coli TOP10 
for expression studies. 
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Table 4.1: pBAD plasmid constructs encoding K2C18 and K2C38. pBAD/gIII vectors 
encode the N-terminal pIII secretion signal (underlined), while pBADm vectors do not. 
Expression is induced by L-arabinose. K2C18/K2C38 indicated in bold, C-terminal hexa-
histidine tag region (Tag) also underlined. Asterisk, denotes the lack of hexa-histidine tag 
region; MW, molecular mass. 
 
4.2.2.2 Growth of E. coli expressing K2C18 and K2C38 on solid medium 
As replica plating was to be utilised as a screening methodology, the size of E. coli 
colonies expressing K2C18 and K2C38 on solid medium was assessed initially. 
Ideally, bacteria expressing toxic AMPs would fail to grow, although only partial 
growth inhibition has been reported previously (Raventós et al., 2005). E. coli 
TOP10 containing the plasmids outlined in Table 4.1 were streaked out on LB agar 
containing the inducing agent arabinose in concentrations ranging from 0.005% to 
2%, and the resulting colony morphology observed (see Figure 4.2).  
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Figure 4.2: Colonies of induced E. coli containing pBAD/gIII-K2C18-Tag and 
pBAD/gIII-K2C38-Tag are smaller in size than the controls. Photos taken after ~16 h at 
37ºC on LB medium, 0.05% arabinose. All uninduced cultures exhibited the same 
morphology, representative photo shown (- ara). Scale bar, 2 mm. Representative photos 
shown (n = 2). 
 
No AMP constructs failed to grow on arabinose-containing medium; rather, most of 
the induced K2C18 and K2C38 constructs exhibited a similar colony size to that of 
the pBAD/gIII-A and pBADm controls. Furthermore, all induced colonies were 
slightly smaller than their uninduced controls, indicating a general effect on growth 
by arabinose. However, the pIII/hexa-histidine tagged versions of K2C18 and 
K2C38 gave a discernible further reduction in colony size, with 
pBAD/gIII-K2C38-Tag being the most marked. All ranges of arabinose 
concentrations tested (0.005% to 2%) resulted in similar colony sizes to those 
shown in Figure 4.2. As 0.05% was seen to ensure maximal expression in the 
literature (Guzman et al., 1995), this concentration was utilised for subsequent 
experiments. 
 
Because the difference in size between the induced pBAD/gIII-A control and 
pBAD/gIII-K2C18-Tag colonies was not dramatic, colony PCR (see Section 2.2.5.2; 
using K2C18-specific primers) was used to confirm whether or not the smaller 
colonies did contain the K2C18 plasmid. A mixed culture of pBAD/gIII-A (~66%) and 
pBAD/gIII-K2C18-Tag (~33%) was plated on LB agar containing 0.05% arabinose, 
and the resultant small and large colonies analysed (see Figure 4.3). 
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Figure 4.3: Small colonies from induced mix of pBAD/gIII-A and pBAD/gIII-KC18-Tag 
E. coli are found to contain the pBAD/gIII-K2C18-Tag plasmid. A: Photos taken after 
~16 h at 37ºC on LB medium, example small colony arrowed. Scale bar, 2 mm. B: Colony 
PCR shows a K2C18-specific product (191 bp) in no large colonies but in 12 out of 14 small 
colonies assayed (arrowed). Ara, arabinose (0.05%); WM, DNA ladder. 
 
Figure 4.3 indicates that the size difference observed between the colonies of 
induced control and K2C18-containing E. coli can be used to identify colonies that 
contain the AMP-encoding plasmid. This shows that colony size may be used as a 
selection criterion in a screen for endogenously produced AMPs. 
 
4.2.2.3 Growth curves of E. coli expressing K2-CRAMP constructs 
The effect of induction of K2C18 and K2C38 expression in liquid LB was also 
explored. Cultures of E. coli TOP10 containing the various plasmids outlined in 
Table 4.1 were induced during early exponential-phase growth as per Section 2.3.1 
and OD600 monitored over time.  
 
 
Figure 4.4: K2C18 and K2C38, when targeted to the periplasm, inhibit E. coli growth. 
Arabinose (0.05%) added to induce cultures in LB medium at 0 h (dashed lines), incubated 
at 37ºC at ~225 rpm. Representative experiment shown (n = 3). 
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All uninduced strains grow uniformly (Figure 4.4), while the pBAD/gIII-A and 
pBADm controls (possessing or lacking the pIII secretion tag, respectively) show 
slightly reduced growth. This general induction effect on growth was seen to be 
typical for non-toxic products, such as pIII-tagged calmodulin (see Appendix 3). 
Both pBAD/gIII-K2C18-Tag and pBAD/gIII-K2C38-Tag exhibit a similar level of 
inhibition of growth. This planes out over the first 3 h of induction, but growth 
resumes after 10 h. Removal of the C-terminal hexa-histidine tag region, however, 
reduces the effect of K2C18 (and that of K2C38 slightly). This was also seen on 
solid medium (Figure 4.2). It may be that simply increasing the length of the 
encoded peptide confers stability and thus increases half-life, allowing more time for 
a deleterious effect to occur (Maurizi, 1992). Strikingly, removal of the N-terminal 
pIII secretion signal from K2C38 leads to complete removal of growth inhibition, 
indicating that this AMP needs to be targeted to the periplasm for its antimicrobial 
activity to be successfully exerted. 
 
4.2.2.4 Western blot of E. coli expressing K2-CRAMP constructs 
The expression of the pIII-K2C18-Tag, pIII-K2C38-Tag and K2C38-Tag peptides in 
liquid culture was analysed by Western blotting using an anti-hexa-histidine 
antibody (see Section 2.3.3.4).  
 
 
Figure 4.5: Western blotting confirms expression of K2C18 and K2C38 in E. coli. 
SDS-PAGE (glycine 15%) of hexa-histidine tagged constructs from Table 4.1. 
pBAD/gIII-Calm-Tag encodes calmodulin (22 kDa), used as a control. T0, uninduced; T3, 3 
h induction (0.05% arabinose); CL, clarified lysate; WM, molecular mass marker. 
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While Figure 4.5 confirms the production of K2C18 and K2C38 (lanes 2, 6 & 9), the 
corresponding bands were not visible on a Coomassie-stained polyacrylamide gel 
(data not shown). This indicates that overall expression levels are low, i.e. in the 
order of ng/mL culture. This is unsurprising, as such short peptides may be 
especially susceptible to proteases (Maurizi, 1992; Taguchi et al., 1994). Given that 
the MIC of recombinant K2C18 was observed to be 1 !M (~2.2 !g/mL, see Section 
3.2.5), it is likely that the AMP is being produced at sub-MIC levels. Lastly, although 
K2C18 and K2C38 run higher than their expected molecular masses (see Table 
4.1; explanation in Section 3.2.2.3), pIII-K2C38-Tag and K2C38-Tag exhibit bands 
running at the same molecular mass (compare lanes 7 & 9). It appears therefore 
that the N-terminal pIII secretion signal (2.1 kDa) is efficiently cleaved from 
pIII-K2C38-Tag. 
 
4.2.2.5 Morphology of E. coli expressing K2-CRAMP constructs 
Following from Section 4.2.2.3, Figure 4.6 shows photos taken of E. coli cells 
containing the various plasmids (Table 4.1) after 4 h induction. Constructs that 
exhibited negligible growth inhibition in Figure 4.4 exhibit a short, rod-like 
morphology, which was considered normal (Justice et al., 2008). In contrast, cells 
that targeted K2C18 and K2C38 to the periplasm, i.e. with the pIII secretion tag, are 
elongated. This increase in length is likely due to cell division being halted, an effect 
that has been observed during treatment of E. coli with AMPs such as PR-39, 
indolicidin and microcin 25 (Brogden, 2005).  
 
 
Figure 4.6: E. coli expressing growth-inhibiting K2C18 or K2C38 constructs have an 
elongated morphology. Photos taken after 4 h arabinose induction (0.05%) in LB medium 
at 37ºC at ~225 rpm. All uninduced cultures exhibited the same morphology, representative 
photo shown (- ara). Scale bar, 5 !m. 
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Cells from Figure 4.6 were inspected again after 21 h induction. While longer cells 
were still visible in the pBAD/gIII-K2C18 and pBAD-K2C38 cultures, these were 
now accompanied by cells with a more normal, short rod morphology. Due to the 
observed recovery of growth, K2C18 and K2C38 appear to exert a bacteriostatic 
rather than bactericidal effect when produced endogenously. Further indication of 
this was obtained by plating aliquots of cultures that had been induced for 4 h (cf. 
Figure 4.4) on arabinose-free LB agar containing carbenicillin to select for plasmid 
retention; preliminary data indicated that colony forming units (cfu) per OD600 unit 
were within the same order of magnitude for all constructs (data not shown). 
 
4.2.2.6 Seed growth curves of E. coli expressing K2-CRAMP constructs 
The apparent recovery of cultures expressing K2C18 and K2C38 was further 
explored by using samples induced for 21 h (see Figure 4.4) to seed fresh growth 
curves (Figure 4.7 A). Furthermore, uninduced samples were then taken from 
Figure 4.7 A after 21 h growth and used to seed a third growth curve (Figure 4.7 B), 
in the hope that uninduced cultures in Figure 4.7 A may have had time to “reset” in 
the absence of arabinose, and thus become responsive to induction once more. 
 
 
Figure 4.7: E. coli from pre-induced gIII-K2C18/K2C38 cultures does not respond to 
further arabinose induction (A), and are not reset to arabinose sensitivity after 
recovery in arabinose-free LB medium (B). Arabinose (0.05%) added to induce cultures 
at 0 h (dashed lines), incubated at 37ºC at ~225 rpm. Representative experiment shown 
(n = 2). 
 
The pBAD/gIII-A, pBADm, pBADm-K2C38-Tag and pBADm-K2C38* control 
constructs, which showed no inhibition of E. coli growth upon induction (Figure 4.4), 
gave similar growth curve profiles in both Figure 4.7 A and B. However, the 
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inhibiting constructs pBAD/gIII-K2C18 and pBAD/gIII-K2C38 no longer display 
retarded growth, but rather track their uninduced controls in both seeded growth 
curves. Arabinose-induced growth inhibition is therefore not reset in these 
constructs after recovery in arabinose-free medium. 
 
Some constructs (both induced and uninduced) exhibited initial growth lags in the 
seed growth curves. For example, pBAD/gIII-K2C18-Tag cells in Figure 4.7 A, when 
analysed microscopically, exhibited a number of filamented cells amongst normal 
short rods after 4 h induction (Figure 4.8). pBAD/gIII-K2C18* cells (Figure 4.7 B) 
had a similar mixed phenotype. In both cases, uninduced and induced samples 
were morphologically similar. 
 
 
Figure 4.8: E. coli from pre-induced cultures that exhibit growth curve lags contain 
filamented cells. Photos taken after 4 h post-inoculation in LB medium at 37ºC at ~225 
rpm. Uninduced (- ara) cultures shown, induced cultures exhibited the same morphology. 
Scale bar, 5 !m. 
 
Lastly, the addition of fresh carbenicillin (to select for plasmid retention) and/or 
arabinose during the early induction period, i.e. prior to 10 h, did nothing to restore 
growth-inhibition of bacteria containing the pBAD/gIII-K2C18-Tag construct (data 
not shown). However, if induced cultures were plated on arabinose-free LB agar 
after 4 h induction, and resultant colonies used as an inoculum for a new growth 
curve, the growth-inhibitory phenotype was restored (Figure 4.9). 
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Figure 4.9: E. coli from induced gIII-K2C18/K2C38 cultures are reset to arabinose 
sensitivity after recovery on arabinose-free LB agar. Cultures were induced for 4 h (cf. 
Figure 4.4), recovered on LB agar, and single colonies used as starter culture inoculums for 
this figure. Arabinose (0.05%) added to induce cultures at 0 h (dashed lines), incubated at 
37ºC at ~225 rpm. 
 
The growth curves in Figure 4.9 are similar to those initially observed in Figure 4.4 
(although the pBAD/gIII-A induced control lags slightly). This ability for the bacteria 
to “reset” on solid medium indicates that plasmid or genomic mutations are not 
responsible for the recovery of growth observed past ~10 h. It appears that E. coli is 
capable of adapting to the production and presence of toxic K2C18 and K2C38. 
This may be related to the persister effect, in which a small, stochastically 
generated sub-population of microbes in a genetically homogenous culture 
becomes tolerant to antimicrobial action (Lewis, 2007).  
 
4.2.2.7 Comparison to the persister effect 
The persister effect has been previously reported in E. coli harbouring a plasmid 
encoding the hok (host killing) peptide (Bej et al., 1988). Hok is a 52 amino acid 
peptide that kills the expressing host through inner cell membrane depolarisation, 
and forms part of the well-described hok/sok toxin-antitoxin pair that is responsible 
for retention of the R1 virulence plasmid in E. coli (Pecota et al., 2003). To 
determine if this effect is similar to that observed for K2C18 and K2C38 in Section 
4.2.2.6, the hok gene was cloned into pBAD/gIII and pBADm (see Section 2.6.1.3; a 
stop codon was included to prevent C-terminal hexa-histidine tag translation). 
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Furthermore, frame-shift mutations were generated after the start codon of the hok 
gene to serve as non-toxic controls. Growth curves in E. coli TOP10 (Figure 4.10 
A), as well as seed growth curves (Figure 4.10 B and C) were performed as for the 
K2C18 and K2C38 constructs previously. 
 
 
Figure 4.10: The persister effect also occurs during the induction of hok in E. coli. 
Arabinose (0.05%) added to induce cultures in LB medium at 0 h (dashed lines), incubated 
at 37ºC at ~225 rpm. A: Induction of hok suppresses E. coli growth initially before recovery 
results. B: E. coli from pre-induced hok cultures does not respond to further arabinose 
induction. C: E. coli containing hok plasmids are not reset to arabinose sensitivity after 
recovery in arabinose-free medium. HokFS, frame-shift negative control. Representative 
experiments shown (n = 2). 
 
The secreted and non-secreted forms of hok (blue/light blue lines in Figure 4.10) 
exhibited the same phenomenon as seen with K2C18 and K2C38 in Figure 4.7. A 
growth-inhibitory effect was seen in the initial growth curve (Figure 4.10 A), which is 
somewhat stronger and more immediate than that seen with K2C18 and K2C38 in 
Figure 4.4. However, using these arabinose-treated cultures to seed a fresh growth 
curve leads to a loss of response to fresh induction (Figure 4.10 B). When these 
uninduced cultures were used to seed a third growth curve, no resetting of a 
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response to arabinose was observed (Figure 4.10 C). Rather, both uninduced and 
induced hok versions grew at a similar rate, with an initial lag period seen before 
outgrowth. As with K2C18 and K2C38 in Figure 4.7, reasons for this are unclear. 
The frame-shift mutants (red/pink lines), on the other hand, exhibited the same 
non-inhibitory profile across all growth curves. 
 
4.2.3 Construction of vectors for AMP screen 
The endogenous expression of the AMPs K2C18 and K2C38 was characterised in 
Section 4.2.2. On solid medium, induced colonies were noticeably smaller in size 
than their controls when the AMP was targeted to the periplasm. In liquid medium, 
although recovery of growth during induction was observed after several hours, 
inhibition was seen during the early growth phase. These properties may be 
exploited to screen DNA libraries for novel AMPs if an appropriate set of expression 
vectors is created. 
 
4.2.3.1 Construction of pAMP/S 
The pBAD/gIII-A plasmid was modified (see Section 2.6.1.4) in order to make it 
suitable for the insertion of random lengths of DNA, as well as amenable to replica 
plating (Figure 4.11). For the first property, a new araBAD cloning site was 
constructed to allow for blunt-end insertion of DNA fragments via an AfeI site. 
Downstream stop codons in all three reading frames were also incorporated to 
ensure translation would be halted no matter what reading frame the DNA insert 
presented itself in. To aide replica plating, the lacZ operon was incorporated. 
Constitutively expressed, the encoded "-galactosidase can cleave exogenously 
supplied X-gal to give an insoluble blue product (Davies & Jacob, 1968). This gives 
the normally beige E. coli colonies an excellent contrast when plated on white 
membranes on X-gal medium, making them suitable for scanning and post-image 
processing. 
 
4.2.3.2 Construction of pAMP 
To screen for AMPs that only exhibit endogenous antimicrobial activity, i.e. act on 
intracellular targets, pAMP/S was modified (see Section 2.6.1.4) to remove the 
region coding for the N-terminal pIII secretion signal. Figure 4.11 shows schematics 
of the pAMP/S and pAMP vectors. 
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Figure 4.11: The pAMP/S and pAMP vectors used to screen for putative AMPs. Insert 
DNA may be blunt-end ligated into the AfeI site (underlined). A: pAMP/S, encodes the 
N-terminal pIII for targeting a peptide to the periplasm. The C-terminal serine residue of this 
18 aa secretion signal is indicated in bold (cleaved after this residue post-secretion). B: 
pAMP, lacks the pIII secretion signal, start codon indicated in bold. Stop codons are 
included for all three reading frames, indicated in bold (possible C-terminal residues also 
shown). 
 
4.2.4 Screening for novel putative AMPs 
4.2.4.1 Use of bdelloid rotifer and human genomic DNA libraries 
Genomic DNA (gDNA) from the bdelloid rotifer A. ricciae, as well as from a human 
source, was utilised as input DNA for ligation into pAMP/S and pAMP. 
Fragmentation of this gDNA to a suitable size range for encoding peptides was 
required: nebulisation (see Section 2.6.3) was employed due to its ability to induce 
extremely random DNA breakage without requiring specialist equipment (Quail, 
2005). Figure 4.12 A shows a representative agarose gel of the achieved fragment 
size range (100 to 900 bp, clustered around 350 bp), which is in line with the 
smallest achieved in the literature (Margulies et al., 2005). Ligation of these 
fragments into pAMP gave inserts with a typical size range of approximately 60 to 
400 bp, as revealed by colony PCR (Figure 4.12 B). If no internal stop codons fall 
in-frame, peptides between approximately 20 and 130 amino acids in length would 
be coded for. 
119 
 
Figure 4.12: Nebulisation of gDNA gives fragments centred around 350 bp in size, 
leading to inserts ranging from approximately 60 to 400 bp. A: Representative agarose 
gel of sheared A. ricciae gDNA. B: Colony PCR (see Section 2.2.5.2) shows the presence 
of inserts in 16 out of 23 colonies assayed. Empty plasmid results in a 300 bp band. WM, 
DNA ladder. 
 
4.2.4.2 Replica plating of pAMP/S and pAMP gDNA libraries 
Replica plating was carried out on white membranes using pAMP/S and pAMP 
gDNA libraries that had been transformed into E. coli TOP10 (see Section 2.6.4). 
To identify putative novel AMP hits, colony sizes were compared between replica 
membranes on plus/minus arabinose LB media (see Section 2.6.5). Those that 
exhibited a reduced size when induced were selected for further analysis. The 
protocol was designed to minimise false-positives derived from poor replica plating. 
For a colony to be considered a hit, its corresponding uninduced replicas on both 
the master and minus arabinose membranes were required to grow. A lack of 
proper colony transfer between the master and plus arabinose membrane could be 
ruled out if a colony grew on the minus arabinose membrane, which was the last to 
be replicated and hence the most likely to reveal experimental error. Figure 4.13 
shows a representative of replica membrane processing and the identification of 
hits. 
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Figure 4.13: Image processing of replica membranes to reveal colonies that may 
express a novel AMP. Representative experiment (n = 15) showing a pAMP/S human 
gDNA library. A: Scans of master, +ara and -ara replica membranes and subsequent image 
manipulation. B: Image overlay of +ara on -ara replica membrane. Potential hits arrowed. 
Ara, arabinose. 
 
Colonies that were not dispersed adequately on a replica membrane, i.e. those 
touching neighbours, were ignored. In total, approximately 3,500 discrete pAMP/S 
gDNA (~800 human, ~2,700 rotifer) and 1,400 discrete pAMP gDNA (~700 human, 
~700 rotifer) library colonies were analysed. A number of hits were observed. For 
the pAMP/S libraries, 11 human and 30 rotifer hits were selected for further 
analysis; for the pAMP libraries, 11 human and 8 rotifer hits were chosen. 
 
4.2.4.3 Growth curves of putative AMP library hits 
To verify that the 60 hit putative AMPs selected in Section 4.2.4.2 did inhibit E. coli 
growth like the model AMPs K2C18 and K2C38 in Section 4.2.2, and to further 
remove false-positives, the effect of induction in liquid LB was investigated. Cultures 
of E. coli TOP10 pAMP/S and pAMP hits were induced as per Section 2.3.1 and 
OD600 monitored over time. Figure 4.14 shows a representative set of growth curves 
obtained. 
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Figure 4.14: Growth curves of pAMP/S and pAMP gDNA library replica plate hits 
verify that ~77% possess inhibitory activity. Arabinose (0.05% final) added to induce 
cultures in LB medium at 0 h (dashed lines), incubated at 37ºC at ~225 rpm. H, human 
gDNA library hit; R, rotifer gDNA library hit. 
 
The empty pAMP/S and pAMP vector controls showed no toxicity when induced 
(see Figure 4.14 A), and the controls pBAD/gIII-K2C38* (targeted to the periplasm) 
and pBADm-K2C38* (retained in the cytoplasm) behaved as seen previously (cf. 
Figure 4.4). In addition, two colonies that exhibited no growth inhibition during a 
pAMP/S human gDNA library screen did not show any effect on growth in liquid 
culture (pAMP/S-Hneg1 & 2, Figure 4.14 D). However, 14 out of the 60 replica plate 
hits tested (~23%) also show no inhibition when induced, and thus appear to be 
false-positives. Although high, this false-positive rate is better than other in vivo 
AMP studies, where rates between 67% and 75% were observed (Loit et al., 2008; 
Cheng et al., 2009). Many of the putative AMP hits in this screen, be they targeted 
to the periplasm or not, showed a more immediate impact on growth than 
pBAD/gIII-K2C38* (Figure 4.14 A) in a manner more similar to Hok (cf. Figure 4.10 
A). Restoration of growth after approximately 10 h post-induction, also as seen with 
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Hok, was commonly observed. pAMP-H3 and pAMP-H11, however, did not recover. 
Furthermore, isolation of the plasmids from the hits in Figure 4.14 A and 
subsequent retransformation gave the same growth curve profile (see Appendix 3), 
confirming that the inhibitory agent is plasmid-encoded. 
 
Cells from Figure 4.14 A showed a variety of morphologies when examined after 
4 h induction (see Figure 4.15). While pAMP/S-H1 exhibited some long, filamented 
cells (cf. pBAD/gIII-K2C38*), most were only twice the normal rod length. The 
induced hit cultures contained cells that appeared slightly swollen, and double the 
length of the control strains; pAMP-H2 appeared to have visible inclusion bodies at 
each cell pole. 
 
 
Figure 4.15: E. coli expressing putative AMP hits exhibit varied morphology. Photos 
taken after 4 h arabinose induction (0.05%) in LB medium at 37ºC at ~225 rpm. All 
uninduced cultures exhibited the same morphology, representative photo shown (- ara). 
Scale bar, 5 !m. 
 
Furthermore, some of the pAMP/S and pAMP library hits showed indications of 
being initially bactericidal. Preliminary data indicated that although all cultures 
recovered after approximately 10 h induction, plating aliquots of cultures that had 
only been induced for 4 h on arabinose-free LB agar resulted in an approximate 
100-fold reduction in cfu for pAMP/S-1, pAMP/S-2, pAMP-H3 and pAMP-H4 in 
123 
comparison to the pAMP/S and pAMP controls (data not shown). Further 
investigation is required to confirm this effect. 
 
4.2.4.4 Bioinformatic analysis of pAMP/S and pAMP gDNA library hits 
A number of putative AMP hits from the replica plate screening (Section 4.2.4.2) 
that had been further validated by liquid culture growth curves (Section 4.2.4.3) had 
their gDNA insert isolated and sequenced. In total, 26 pAMP/S hits (8 from the 
human gDNA libraries, 18 rotifer) and 14 pAMP hits (9 human, 5 rotifer), 
representing an initial hit rate of approximately 0.8% of all library colonies examined 
(~5,000), were analysed as per Section 2.6.6. Table 4.2 summarises the findings; 
full DNA insert sequences are shown in Appendix 4. 
Name bp Peptide sequence (# aa) Q H ! A Accession # Name E-value Reading frame
pBAD/gIII-
K2C18*
114 TMGKKLKKIGQKIKNFFQKL (20) +7 -0.27 + +++ AF035680.1 CRAMP gene (Mus musculus 
[mouse])
2.60E-02 In-frame (aa 3-20)
pBAD/gIII-
K2C38*
54 TMAISRLAGLLRKGGEKIGKKLKKIGQKIKNFFQKLVPQPE (41) +9 -0.22 + +++ AF035680.1 CRAMP gene (M. musculus) 6.00E-16 In-frame (aa 4-41)
pAMP/S-H1 389 TMSRNAVESGRESNGEADGMQW (22) -2 -0.30 EF445003.1 NOL1/NOP2/Sun (NSUN6) 
gene (Homo sapiens)
1.00E-97 Intronic
pAMP/S-H2 130 TMSLLVLFQNKYDLKIEAIVQIEFWNRTRL (30) +1 -0.09 NG_007966.1 Cytochrome P450 (CYP4X1) 
gene (H. sapiens)
4.00E-21 Intronic
pAMP/S-H3 218
TMSVLNEFKSQCHLFVHAFIHQTLPECLPWAIYCTEQGRNGHSQLPHSRISSSSGG
VRKGNKHMKFSGILRMPSIPLSK (79)
+12 -0.13 + + AL591603.4 Chromosome 6 (H. sapiens) 2.00E-44 Non-coding
pAMP/S-H4 136 TMSKRYLGTRCLSLMWAKGDLRQIKMGKRGDKKE (34) +7 -0.36 + + AL158165.15 Chromosome 10 (H. sapiens) 4.00E-23 Non-coding
pAMP/S-H5 179 TMSFSKFLFLLHFIHLIFIH (20) +4 0.23 + AL35462.23 Chromosome 9 (H. sapiens) 3.00E-32 Non-coding
pAMP/S-H7 105 TMSERSRHERSYIVEFHLYAMFRLSQSTEIESR (33) +2 -0.30 + AC245260.1 Chromosome 8 (H. sapiens) 3.00E-15 Non-coding
pAMP/S-H8 384
TMSVIVLIYISTKKVQGFIFLHILASICVARHSDISHLNWGDAISHCSFDLHFSIG
DIEHLFICLFAIFMSSFEKCRFRSFAHFFNEVIRFFFLQS (96)
+7 0.04 + + AC207610.3 Chromosome 12 (H. sapiens) 3.00E-84 Non-coding
pAMP/S-H10 1186
TMSLWSDSMADVILILLNLLRLALWQSMWLILEYGPCTDEKDAYSMVEGYSVDVY 
(55)
-6 0.02 + AC067849.6 Chromosome 8 (H. sapiens) 0.00E+00 Non-coding
pAMP/S-R14 171
TMSKLNMQIIIGLVLIDIALFKSLEICKNICCKSNSLRSKALLDICLFLAAMICIS
AT (58)
+3 0.05 +
pAMP/S-R15 175
TMSRNSFSMLLLAINLIFLIVGLISIINNGKMENIFLQVNPKVILFTWYKQARRIY
ELVVIC (62)
+4 0.04 + +
pAMP/S-R17 235
TMSEDYFRRTLNIEQVDIRLIDENEIEAASIPNLEEILPGKPLIHFRHEPMISIRL
INRQPYSGHFEWTIPVINGDTVEKLG (82)
-3 -0.14 BC006060.1 Leucyl-tRNA synthetase gene 
(M. musculus)
3.00E-06 In-frame (aa 6-81)
pAMP/S-R20 164 TMSLHQTIVMCRKLLLNLFGFFIFGCISEFYYQRR (35) +4 -0.02 + AK371870.1 Hypothetical protein gene 
(Hordeum vulgare [barley])
5.00E-15 Wrong reading 
frame
pAMP/S-R21 367 TMSFEVI (7) -1 0.15
pAMP/S-R22 116 TMSYSKTITVKTNIIIGLTYQ (21) +2 -0.02
pAMP/S-R25 175
TMSLLYSLRRRCWPFVICFQRAMLLLTSAVGVFRIIIRLFFDLFSQTSWIFLE 
(53)
+4 0.02 +
Name bp Peptide sequence (# aa) Q H ! A Accession # Name E-value Reading frame
pAMP/S-R28 347
TMSEWKCTYSEYLAVERSVFETQMNNTRKVLPFYTRGIVDQQLSLFLSLSLFLSDS
ERASFK (62)
0 -0.15 +
pAMP/S-R30 145
TMSLATMLQIGAMLIFFTGHIIDTIGRRRSIHLITALLLITSLITQACLQFG 
(52)
+4 0.09 +
pAMP/S-R31 373
TMSIEIDLVLLIHIHTHTRVSLGIEIDLVLLIHIHTHTPVSLGIEIDLVLLIHIHT
HTPVSLGIEIDLVLLIHTYPHTPVSLGIEIDLVLLIHTYPHTPVSLGIEIDLVLLI
HTYPHTPVSLGIEIDC (128)
+2 0.12 AC139335.3
Chromosome 10 (M. 
musculus). Similar due to 
repetitiveness.
1.00E-17 Non-coding
pAMP/S-R32 238 TMSLFSLLSLSLSLLFFFYERNKK (24) +2 -0.01 +
pAMP/S-R33 108 TMSCWIFLHSLLYSIQVSFLRRFLLFLIPVPDKSDQRKCAK (41) +5 -0.07 +
pAMP/S-R34 168
TMSYFELNIRPCRSCSARRRRSIAAFSFRSMGRSSLYISVSGYKNERMLCILKTFF
SFKAK (61)
+11 -0.23 +
NM_00103259
0.1
Protofilament ribbon protein 
(pf-rib) gene (Ciona 
intestinalis [sea squirt])
9.00E-10
Wrong reading 
frame
pAMP/S-R36 199 TMSIATFCMLSLIFVTFHKPLVRNIWGTIKSLLNFIFYMRKKK (43) +8 -0.01 + +
pAMP/S-R37 132 TMSSHIIHFYSMELFHLCSCLFLDVGQYRIFVKSVTQHDNRARHIPLAK (49) +7 -0.08 +
pAMP/S-R39 123 TMSDRVTAFEFHNVYVLVSNFRYRLDVQEYIRSPSYSN (38) +1 -0.19
pAMP/S-R40 222
TMSELISKLFILYRSSELLISLSITSNSSASLACLVFEIEPFVPSKLSNLVLKFES
CSLI (60)
-1 0.03 +
pAMP/S-R41 161 TMSNLLLFQLCLNKKFNIVFSNSNVNMNLVLPVVVVDDKVVSLLPAKK (48) +3 -0.01 +
pAMP-R1 337 TMSFYVSFLLSFFALVTEQNIYQCSFVCLSPLLRLFIPFVDI (42) -1 0.14 +
pAMP-H2 383 TMSLFLFFFFF (11) 0 0.41 AC090383.4 Chromosome 18 (H. sapiens) 3.00E-86 Non-coding
pAMP-H3 334 TMSSLAEHYIQLKENVVSWNTDFGDDAQPRNRI (33) -1 -0.22 + + AC026887.9 Chromosome 10 (H. sapiens) 2.00E-70 Non-coding
pAMP-H4 268 TMSTWPILAALGFRTVFIFFGEEVM (25) -1 0.15 + AC020593.6 Chromosome 4 (H. sapiens) 6.00E-56 Non-coding
pAMP-H5 273
TMSNKNGCYQKPVPLLAVHCYLITTMMLSAGYLGLPLTTAEAWTLFAQMIFFSSSF
CFNYVHEGSGWRRPGRGRSGYSTEHNVYFFSILLTSIKAK (96)
+8 -0.04 + AC016877.11 Chromosome 8 (H. sapiens) 5.00E-58 Non-coding
pAMP-H6 362 TMSGGQGRGR (10) +2 -0.37 GU324919.1
Myosin heavy chain 6 (MYH6) 
gene (H. sapiens) 3.00E-80 Intronic
Name bp Peptide sequence (# aa) Q H ! A Accession # Name E-value Reading frame
pAMP-H8 404
TMSVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRV
RVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRV
RVRVRVRVRVRVRVRVRVRVRVRVRVLSK (141)
+68 -0.58 AC215217.2 Chromosome 10 (H. sapiens) 3.00E-94 Non-coding
pAMP-H9 304
TMSNKNKKCSLFSASLPAFVMFFGLFDNSHLTSKMTPHCGFHLHFPDSDVEHFFVY
VLAICMSSFEKCLFREFAPLTFFFLRQGLTLSPRLEYSGGISAHCNLCR (105)
+8 -0.04 + AL096701.14
Yeast Sfi1 homologue (SFI1) 
gene (H. sapiens) 7.00E-66 Intronic
pAMP-H11 176 TMSQREKESCLKNIFKNICGMIWNVTTFLPPPPRNIQEKLQNPSTLWE (48) +2 -0.19 + + AC153805.1 Chromosome 1 (H. sapiens) 6.00E-37 Non-coding
pAMP-H12 212
TMSLINKFYLFWQIHNLITLLAVSCKLLSSFGVFQMCRKPQVEEPKAKHTAFS 
(53)
+6 -0.04 + AL133383.10 Chromosome 1 (H. sapiens) 5.00E-40 Non-coding
pAMP-R13 690 TMSILQILYRVIFILNVIVVHIHYV (25) +3 0.20 + EU432546.1
Low density lipoprotein 
receptor (LDL_4) gene 
(Philodina roseola [rotifer])
7.00E-20
Wrong reading 
frame
pAMP-R14 362 TMSFKMKNHCISMFFRYEIFLKKKISWKNYSCVFEYVESCGLDKYYFIQRF (51) +6 -0.13 +
pAMP-R17 221
TMSYICKYMTRIVFRIQWSILAGMAFQTGVLFRLVWIDYRYLNSSSLIKSHVVSSF
SWDIMEPFTYFISYSTVFMA (76)
+4 0.03 +
XM_00308989
3.1
Hypothetical protein gene 
(Caenorhabditis remanei 
[nematode])
1.00E-06
In-frame (aa 
15-73)
pAMP-R18 129 TMS (3) 0 -0.06 EU643478.1
Telomeric repeat region 
(Adineta vaga [rotifer]) 2.00E-08 Non-coding
Table 4.2: Peptide sequence and properties of 26 pAMP/S and 14 pAMP gDNA library hits. Name, H (H. sapiens gDNA) and R (A. ricciae 
gDNA); bp; length of gDNA insert; Q, charge; H, mean hydrophobicity derived from Eisenberg’s consensus hydrophobicity scale (1984); !, 
predicted !-helix region by the Multivariate Linear Regression Combination method (Guermeur et al., 1999); A, potential amphipathic !-helix by 
helical wheel superimposition; Accession #, significant translated nucleotide query versus translated NCBI database BLAST hit (tBLASTx; see 
Section 2.4.4); E-value; expect value, lower values equate to a more significant BLAST hit; Reading frame, relevant aa region of the peptide in 
parentheses if in-frame. Amino acids encoded by the plasmid backbone are underlined for clarity.
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The insert length of the gDNA in each hit varied (range of 105 to 1,186 bp), as did 
the length of peptide encoded (range of 3 to 141 aa) (see Figure 4.16). The bimodal 
nature of Figure 4.16 A can be attributed to different gDNA nebulisation 
preparations, i.e. different lengths of insert. As a number of gDNA inserts contained 
in-frame stop codons, the median encoded peptide length of 48 aa was less than 
that predicted by the median gDNA insertion length of ~220 bp (approximately 
73 aa). Approximately 75% of the encoded products fell between the 10 to 62 aa 
peptide range, giving a suitable peptide size spread. 
 
 
Figure 4.16: Range of gDNA library insertion lengths and peptide lengths coded for 
(see Table 4.2). A: Insert DNA length. B: Peptide sequence length. 
 
Peptides in Table 4.2 with a mean hydrophobicity of -0.1 or less were considered to 
be truly hydrophilic, with 33% of the peptides meeting this criterion. These 
hydrophilic peptides were expected to be more amenable to downstream 
purification, i.e. soluble, as opposed to other very hydrophobic peptides (e.g. 
pAMP-H2, which is mostly phenylalanine and leucine). No significant bias for 
hydrophobicity was observed between the screening vectors or gDNA insert 
sources used. The charges of the peptides ranged from the anionic (-6 for 
pAMP/S-H10) to the cationic (+12 for pAMP/S-H3); for peptides <50 aa, the 
extremes were -2 for pAMP/S-H1 and +7 for pAMP/S-H4. Approximately 73% of the 
peptides analysed were cationic in charge. 
 
Of the 40 putative AMP sequences in Table 4.2, 30 are predicted to encode a 
peptide that contains an !-helical region. Peptides >25 aa were also predicted to 
contain unstructured regions, i.e. random coil and extended strand. However, only 7 
peptides were considered to possess a potentially amphipathic !-helical region 
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when projected on a helical wheel; most of these weakly so (see Figure 4.17). This 
indicates that the growth inhibitory mechanism of the putative AMPs may not be the 
same as that of the model amphipathic !-helical K2C18 control.  
 
 
Figure 4.17: Helical wheel projections of selected putative amphipathic AMP hits. 
Peptide sequences taken from Table 4.2, residue positions indicated. A: pAMP/S hits, i.e. 
targeted to the periplasm, including two regions of S-H4 (34 aa). B: pAMP hits. C: K2C18 
as an ideal amphipathic AMP reference. Hydrophilic face boundary indicated with dashed 
line, amino acids are colour coded: cationic (green), hydrophobic (yellow), anionic (purple) 
and uncharged hydrophilic (blue). 
 
BLAST analysis (tBLASTx; see Section 2.6.6) of the putative AMP encoding 
sequences in Table 4.2 was able to find genomic matches for all human-derived 
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DNA inserts (17 from 17), as opposed to the rotifer-derived set (7 from 23 gave 
moderately significant matches). As the genome of A. ricciae is not currently 
annotated (C. Boschetti, personal communication), this is unsurprising. Of those 24 
peptide sequences successfully matched, few were naturally in-frame with a known 
coding region; 19 were from non-coding or intronic regions instead. Three rotifer-
derived sequences were in the wrong reading frame, while two were in-frame 
(pAMP/S-R17 matching a mouse transfer RNA synthetase; pAMP-R17 a nematode 
hypothetical protein). 
 
Four peptides in Table 4.2 were predicted to encode very short peptides, which may 
be false-positives (<12 aa; pAMP/S-R21, pAMP-H2, pAMP-H6 and pAMP-R18). For 
example, pAMP-R18 possesses a stop codon as its first codon, with the next 
potential start codon (including the alternatives GTG and TTG [Blattner et al., 1997]) 
being too far from the ribosome binding site (31 bp) (Ringquist et al., 1992; Chen et 
al., 1994). pAMP-R18 thus only encodes the tripeptide Thr-Met-Ser; in contrast, the 
empty pAMP vector encodes Thr-Met-Ser-Ala-Lys, which has no effect on E. coli 
growth (see Figure 4.14 A). It was thought that perhaps the gDNA inserts of the 
above hits (available in Appendix 4) exerted their inhibitory effect as RNA 
transcripts instead, either by complementing and preventing the translation of an 
endogenous E. coli transcript (Gottesman, 2004; Morita et al., 2006) or by folding 
into an active secondary structure (Isaacs et al., 2006). While no significant 
transcript matches between the hit sequences and the E. coli DH10B genome were 
found, all transcript sequences were predicted to form a significant amount of 
secondary structure, i.e. intrasequence base pairing (Table 4.3). 
 
 
Table 4.3: Analysis of pAMP/S and pAMP hits that may be RNA-based effectors. aa, 
putative peptide length; bp, length of gDNA insert (see Appendix 4 for sequence); BLASTn; 
significant reverse complement nucleotide query versus E. coli DH10B genome (see 
Section 2.6.6); RNA 2º, prediction of a RNA secondary structure by RNAfold (Hofacker, 
2003). 
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4.2.5 Further exploration of novel putative AMP hits 
4.2.5.1 Frame-shift of pAMP/S library hits 
Analysis of the putative AMP hits in Section 4.2.4.4 revealed that some of the 
selected pAMP/S and pAMP plasmids only encoded very short peptides, indicating 
that their effect may instead be transcript related. To investigate whether or not this 
was also true for constructs that encoded longer peptides, several pAMP/S library 
hits were mutated to introduce a frame-shift mutation immediately downstream of 
the start codon (ATG to ATGG; see Section 2.6.7.1). It was reasoned that, if a 
frame-shifted construct maintained a negative effect on the growth rate of E. coli 
when induced, the wild-type encoded peptide would not be the cause. Cultures of 
E. coli TOP10 with frame-shifted pAMP/S hits were induced as in Section 4.2.4.3 
and OD600 monitored over time (Figure 4.18). 
 
 
Figure 4.18: Frame-shift mutation of several pAMP/S hits reveals that pAMP/S-H1 
retains inhibition of E. coli growth. Arabinose (0.05%) added to induce cultures in LB 
medium at 0 h (dashed lines), incubated at 37ºC at ~225 rpm. A: Wild-type growth curves. 
B: Frame-shift mutant growth curves. Representative experiments shown (n = 2).  
 
All of the frame-shifted pAMP/S hits analysed lost their growth inhibitory effect 
(other than the slight reduction in growth typically seen during arabinose induction) 
except for pAMP/S-H1, which retained activity. While this construct should encode a 
22 aa peptide (see Table 4.2), it appears to have an RNA-based effect instead. 
Point-mutations to remove the start codon (ATG to CTG) from the wild-type 
constructs listed in Figure 4.18 were also made, and resulted in similar growth 
curves to those observed above for the frame-shift mutations (data not shown). 
Analysis of the pAMP/S-H1 sequence as a possible RNA effector was carried out 
as per Section 4.2.4.4 above, but no potential E. coli antisense sequence or 
secondary structure was found. 
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4.2.5.2 Removal of the secretion signal from pAMP/S library hits 
The N-terminal pIII secretion signal used in pAMP/S allows for complete synthesis 
of the downstream peptide prior to secretion to the periplasm (Natale et al., 2008). 
This window of cytoplasmic retention time allows for the possibility that pAMP/S 
peptide hits have a cytoplasmic, rather than periplasmic, target. Previously it was 
established that K2C38 required the pIII secretion signal to exert an effect on E. coli 
growth; when this was removed, no inhibition was observed (see Figure 4.4). 
Removal of the pIII-encoding sequence (i.e. gIII) from the pAMP/S hits could thus 
confirm whether or not its target was periplasmic. Mutagenesis was conducted as 
per Section 2.6.7.3, and the resulting growth curves (as per Section 4.2.4.3) shown 
in Figure 4.19. 
 
 
Figure 4.19: Removal of the pIII secretion signal from several pAMP/S hits reveals 
some that retain inhibition of E. coli growth. Arabinose (0.05%) added to induce 
cultures in LB medium at 0 h (dashed lines), incubated at 37ºC at ~225 rpm. A: Wild-type 
growth curves. B: Mutants lacking the pIII secretion signal. 
 
Removal of the pIII secretion signal from pAMP/S-H2, pAMP/S-H3, pAMP/S-H4 and 
pAMP/S-R17 led to the loss of growth inhibition (see Figure 4.18 B), indicating that 
access to the periplasm is required for their activity. These may be truly exogenous 
hits. In contrast, pAMP/S-H5, pAMP/S-H8, pAMP/S-R14 and pAMP/S-R15 retained 
their original level of inhibitive activity without the pIII secretion signal. This indicates 
that the pAMP/S screen does not solely select for putative AMPs that act in the 
periplasm; intracellular activity is also isolated. 
 
4.2.5.3 Use of a different antibiotic selection marker 
The identified AMP hits, rather than having a truly antimicrobial function against 
their E. coli host, could instead interfere with the production or function of the 
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plasmid-encoded "-lactamase antibiotic resistance marker. This could lead to false 
positives in the AMP screening system by restoring E. coli sensitivity to carbenicillin. 
To briefly explore this, the "-lactamase operon (ampR) was replaced with the 
chloramphenicol acetyl transferase operon (chlR) in pAMP/S-H1 and pAMP/S-H5 
as per Section 2.6.7.2. Growth curves were then performed as in Section 4.2.4.3; 
no differences were observed with regards to the ampR controls (Figure 4.20). 
 
 
Figure 4.20: pAMP/S-H1 & pAMP/S-H5 still inhibit E. coli growth when a different 
antibiotic resistance marker is used. Arabinose (0.05%) added to induce cultures in LB 
medium at 0 h (dashed lines), incubated at 37ºC at ~225 rpm. chlR, chloramphenicol 
resistant; ampR, carbenicillin resistant. Representative experiment shown (n = 2). 
 
4.2.6 Validation of novel putative AMP hits 
4.2.6.1 Recombinant production of putative AMPs using CPD system 
The CPD system outlined in Chapter 3 was utilised in order to produce several of 
the pAMP/S hits identified in Section 4.2.4. Although their status as bona fide 
peptide hits that act periplasmically was not confirmed (see Section 4.2.5), it was 
reasoned that if these putative AMPs could be purified, and retained activity when 
added exogenously to E. coli, their target would most likely be membrane-relevant. 
To explore this, the coding sequences for nine pAMP/S hits were transferred to the 
pET28-CPD expression vector (see Section 2.6.8.1). The wild-type CPD cleavage 
sequence of Leu-Ala-Asp was retained in order to try to ensure suitable levels of 
recombinant protein production (see discussion in Section 3.3). After expression 
and purification (see Section 2.6.8.2 and 2.4.2 respectively), initial levels of 
antimicrobial activity for each putative AMP against E. coli TOP10 were assessed 
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using the antimicrobial liquid culture assay (see Section 2.5.3). Table 4.4 outlines 
the results. 
 
 
Table 4.4: Several pAMP/S hits were transferred to the CPD purification system, but 
no exogenous activity was observed. Common N-terminal residues Thr-Met-Ser 
removed, non-native C-terminal leucine (critical for CPD cleavage) indicated in bold. H, 
mean hydrophobicity (see Section 2.4.4); Hyphb., % of hydrophobic residues (F, I, L, N, V, 
W & Y); Expression, whole cell production of AMP-CPD fusion assessed by SDS-PAGE 
(data not shown); Purification, free AMP band detected by SDS-PAGE after CPD cleavage 
(data not shown); Activity, determined by any purification fraction completely inhibiting 
E. coli DH10B growth in LB medium after 18 h at 37ºC. 
 
Of the nine pAMP/S hits transferred to the pET28-CPD expression vector, only six 
were seen to successfully express the AMP-CPD fusion by SDS-PAGE analysis 
(data not shown). Of these, only three gave appreciable amounts of free AMP after 
on-column CPD cleavage, i.e. detected by SDS-PAGE (data not shown). Table 4.4 
indicates the mean hydrophobicity and percentage of hydrophobic residues of each 
peptide. It may be that overly hydrophobic peptides, with H values greater than -0.1 
(e.g. S-R25 and S-R32), are unsuitable for recombinant production. 
 
None of the putative AMPs observed in significant amounts post-cleavage (S-H3, 
S-H4 or S-R17) showed antimicrobial activity when added exogenously to E. coli. In 
contrast, the model AMP K2C18 completely inhibited growth (see Section 3.2.2.3). 
These putative AMPs may be inactive, or simply not concentrated enough to exert 
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an antimicrobial effect; concentration estimates in the initial cleavage fractions 
ranged from ~10 !M (S-R17) to ~60 !M (S-H4). In the antimicrobial liquid assay, 
this would equate to a working concentration range of ~1 to ~6 !M. To investigate 
further, chemically-synthesised versions of selected putative AMPs were 
purchased. 
 
4.2.6.2 Activity of chemically-synthesised putative AMPs 
Several AMP hits from Section 4.2.4 were chemically synthesised (see Section 
2.1.4) and used to challenge E. coli DH10B in an antimicrobial liquid culture assay 
(see Section 2.5.3). Due to synthesis costs, short peptides (<35 aa) were focused 
on. S-H1, which was discovered to exert its effect as a transcript rather than a 
peptide (see Figure 4.17), was used as a negative control. K2C18 and S-H4 were 
resuspended in sterile water, while S-H1, S-H5, H4 and R13 were resuspended in 
neat DMSO to aid solubility. DMSO alone was tolerated to 2.5% in the antimicrobial 
liquid culture assay, and therefore final dilutions below this concentration were 
used. Table 4.5 outlines the peptides, their properties, and any antimicrobial activity 
observed over a concentration range of ~50 !M to ~0.1 !M. 
 
 
Table 4.5: S-H4 exerts an antimicrobial effect against E. coli. Minimum inhibitory 
concentration (MIC) was determined as the concentration of peptide that completely 
inhibited E. coli DH10B growth in NB medium after 18 h at 37ºC. Experiment repeated at 
least in duplicate, average shown. Underlined residues encoded by pAMP/S or pAMP 
vector. Q, charge; H, mean hydrophobicity (see Section 2.4.4); Hyphb., % of hydrophobic 
residues (F, I, L, N, V, W & Y). 
 
The K2C18 positive control exhibited a potent MIC against E. coli as seen 
previously (Section 3.2.5); S-H1, acting as a negative control, showed no effect. 
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S-H4 (for amino acid analysis, see Appendix 5), previously established to require 
targeting to the periplasm for antimicrobial activity when expressed endogenously 
(Section 4.2.5.1), was found to inhibit growth. Agar plating of E. coli aliquots treated 
with S-H4 (31 !M) after 21 h gave no viable colonies in comparison to the negative 
control (S-H1), indicating cell death (data not shown; further confirmation is required 
to determine the minimal bactericidal concentration). H4 and R13, sourced from the 
intracellular pAMP library, showed no activity. This was not surprising, as the cell 
membrane was expected to block access to their putative intracellular targets. 
S-H5, which retained growth inhibitory properties in spite of the removal of its 
secretion signal (Section 4.2.5.2), also lacked antimicrobial activity for the same 
reason when added exogenously. Additionally, S-H4 was also observed to exert an 
antimicrobial effect on the Gram-negative bacterium Pseudomonas putida (MIC of 
11.6 !M) and the Gram-positive bacterium Bacillus subtilis (MIC of 31 !M), but not 
against the yeast Candida albicans. 
 
4.2.6.3 Synergy of hits with cell wall permeabilizing reagents 
The putative AMPs S-H5, H4 and R13 were hypothesised to require access to the 
cytoplasm for any antimicrobial effect to be seen. In order to facilitate this, the use 
of reagents that permeabilize the cell wall of E. coli was explored. The non-ionic 
detergent Nonidet P-40 (NP-40) is commonly used in the purification of membrane 
complexes (Fricke et al., 1999). Polymyxin B nonapeptide (PMBN), a truncation of 
the cationic polymyxin B antibiotic (produced by Bacillus polymyxa), has been used 
to selectively increase the permeability of the outer membrane of Gram-negative 
bacteria to other compounds while retaining cell viability (Vaara, 1992; Li et al., 
1998). Lastly, the model AMP K2C18, which is known to disrupt the outer 
membrane during self-mediated uptake (Sawyer et al., 1988), was selected. The 
three cell-permeabilizing reagents had their individual MICs against E. coli DH10B 
determined using the antimicrobial liquid culture assay (see Section 2.5.3): NP-40 
was toxic at 0.25%, PMBN at 4 !g/mL, and chemically-synthesised K2C18 at 
0.6 !M. These compounds were therefore used at the sub-lethal concentrations of 
0.01% (NP-40), 1 !g/mL (PMBN) and 0.23 !M (K2C18). Antimicrobial liquid culture 
assays were performed (see Section 2.5.3) in combination with the AMPs listed in 
Table 4.6. 
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Table 4.6: Effect of putative AMPs on growth of E. coli when used synergistically 
with cell-permeabilizing reagents. Putative AMP peptides used at ~50 !M; growth of 
E. coli DH10B (+ or -) was determined after incubation in NB medium for 18 h at 37ºC. 
Experiment repeated at least in duplicate, identical results achieved. Control, no peptide; 
Neg., no cell-permeabilizer.  
 
S-H4, as seen previously in Table 4.5, prevented E. coli growth under all conditions 
tested. While H4 and R13 showed no toxicity when used in combination with the 
cell-permeabilizers, S-H5 showed some potential when used in conjunction with 
PMBN. However, after an additional incubation past 18 h, turbidity was observed. 
This was corroborated by agar plating of S-H5 culture aliquots after 21 h; colonies 
resulted (data not shown). Curiously, the negative control S-H1 consistently showed 
activity when used with sub-lethal levels of K2C18. However, after an extended lag 
phase, growth was observed after an additional incubation as per S-H5 above. 
S-H4, on the other hand, retained its lethal effect under the same conditions. 
 
4.3 Discussion 
Earlier work revealed the potential of the inducible, autocleaving CPD domain as a 
fusion tag for the production of AMPs (see Chapter 3). However, it was found that 
the uncleaved K2C18-CPD fusion still possessed antimicrobial activity when added 
exogenously to E. coli. Although activity of K2C18-CPD and K2C18 at various 
concentrations was not compared, it is surprising that the fusion protein exhibits 
antimicrobial properties at all. Perhaps the entire fusion is able to transit the outer 
membrane via K2C18-promoted self-mediated uptake (see Section 3.1.2.2) in order 
to reach its inner membrane site of action (Gallo et al., 1997; Park et al., 2003). Or it 
may be that the CPD tag sterically hinders this translocation, and rather an 
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electrostatic interaction of the K2C18 domain with the outer membrane is sufficient 
to lead to cell death (Sawyer et al., 1988). Although the AMP domain forms only 
~8% of the fusion protein, the result in the work presented here is not without 
precedent. Tethering of magainin and bacteriocin derivatives to solid phase 
supports did not ameliorate their antimicrobial activity (Haynie et al., 1995; Hilpert et 
al., 2009). Furthermore, the fusion of a cellulose-binding domain (11.7 kDa) to the 
N-terminus of enterocin A (47 aa, a bacteriocin) did not significantly reduce 
antimicrobial activity (Klocke et al., 2005). More research is required to elucidate 
how an AMP may still function when part of a larger complex (Hilpert et al., 2009), 
especially with regard to the proposed mechanisms outlined in Figure 3.2. 
 
It thus appears that the lack of toxicity seen when expressing the K2C18-CPD 
fusion endogenously (Chapter 3) is primarily because of a lack of access to the 
periplasm (discussed further below), rather than any protective effect endowed by 
the C-terminal CPD domain. Confirmation of this was observed when the pIII 
secretion signal was inserted upstream of K2C18-CPD; when induced in vivo, a 
similar level of growth inhibition to pBAD/gIII-K2C38* (Figure 4.4) was observed 
(see Appendix 6). The fact that an AMP-CPD fusion may still exhibit activity is not 
without some value, especially when directed to the periplasm. A gDNA-CPD fusion 
library could still be very useful for screening, with any observed AMP hits being 
amenable to scaled-up recombinant production (minus secretion signal), as their 
viable expression and activity as a CPD fusion would presumably demonstrate. 
Additionally, the presence of a stable fusion partner could protect the AMP from 
host protease attack (Taguchi et al., 1994; Walker et al., 2001). However, with a 
randomly-sized DNA insert, there is no way to control for the correct read-through to 
the C-terminal CPD tag; only one in three inserts would allow for CPD to be 
translated in its correct reading frame. The presence of in-frame stop codons would 
also be unavoidable. For these reasons, further development appears limited to the 
optimisation of previously identified AMPs. 
 
Using the sensitive production host strategy and replica plating methodology, 40 
putative AMP hits were identified. Of the 24 that can be matched to sequences in 
the NCBI database, only 2 are found to be putatively in-frame with a natural protein 
(1 of which was hypothetical [pAMP-R17]). Although the sample number is small, 
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this indicates that the screen does not enrich for naturally-occurring reading frames 
with regard to AMP function. In contrast, Watt (2009) found that 15 out of 41 hits in 
a yeast two-hybrid screen for binders to the Mal intracellular adaptor protein were in 
their natural reading frame; however, the starting genomic source was 80% protein-
coding. In contrast, the human gDNA library used in this work is only approximately 
1.2% protein-coding sequence (International Human Genome Sequencing 
Consortium, 2004); the rotifer gDNA library protein-coding percentage is unknown, 
but expected to be higher (C. Boschetti, personal communication). 
 
The putative AMP hits pAMP/S-R21, pAMP-H2, pAMP-H6 and pAMP-R18 code for 
very short peptides (<12 aa). These may be false-positives, in that the encoded 
peptide is not responsible for the observed inhibition of growth (especially for the 
3 aa peptide encoded by pAMP-R18). It was hypothesised that the encoded mRNA 
transcript, which includes the entirety of the insert sequence (100s of bp), may 
instead be the effector entity. In addition, mutation studies revealed that the 22 aa 
encoded peptide of pAMP/S-H1 was not responsible for growth inhibition in vivo. No 
putative endogenous E. coli transcript binding partners were found for any of these 
five sequences, indicating against an antisense RNA effect (Gottesman, 2004; 
Morita et al., 2006). However, secondary structure for all but the pAMP/S-H1 RNA 
transcript was predicted. It may be that a putative secondary structure interferes 
with a critical cell function, or acts as a riboregulator using different parts of its 
primary sequence (Isaacs et al., 2006). In either case, the primary sequence of the 
transcript may not point towards an obvious binding partner or function, and further 
investigation is needed to determine how such transcripts affect E. coli. 
 
It is not entirely clear why the expression in vivo of an AMP does not lead to a 
bacteriostatic effect past approximately 10 h of induction. The persister 
phenomenon is one possible explanation (Lewis, 2007). The formation of these 
dormant cells, which possess a global decrease in metabolism and lack of cell 
division, can be encouraged in a homogenous culture through the overproduction of 
proteins that are toxic to a cell and inhibit growth, such as an AMP. Supporting this, 
the persister effect has been observed by others when E. coli is induced to express 
the toxic hok peptide (K. Gerdes, unpublished observation). It may be that 
intracellular expression of a toxic AMP causes an oscillation of protein synthesis 
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activity. As AMP production reaches toxic levels, global cellular processes and 
energy levels are affected and transcriptional/translational activity is reduced. As 
AMP levels fall within the cell, normal function resumes and the AMP is produced 
once more. The culture, in effect, becomes bacteriostatic. After ~10 h post-
induction, however, it appears that this stasis is broken: either production of the 
AMP is permanently muted, or the host cell becomes tolerant to its presence. The 
presence of an AMP during this “recovery” phase may be ascertained via Western 
blotting; however, this was not performed in the work presented here. Raventós et 
al. (2005) also observed a similar recovery phenomenon during AMP production in 
E. coli. Such an effect appears to last through seeding an induced culture into fresh 
medium and re-inducing, but cells appear slow to enter exponential growth after a 
further passage. The expression plasmid is not altered, as isolation and 
re-transformation into fresh bacteria gave the same result. In addition, the recovery 
of colonies on solid medium and subsequent use as a fresh inoculum restored the 
inhibitory growth curve profile, ruling out genomic adaptation. This epigenetic 
inheritance of tolerance to endogenous AMP production is similar to that of persister 
cell formation during treatment with ampicillin (Lewis, 2007). Both are a temporary 
state that is restored to sensitivity once the antimicrobial threat has been removed 
(on solid media at least in the work presented here). While a comprehensive 
bactericidal effect upon AMP induction in vivo was not observed, the initial 
bacteriostatic effect correlated with the exogenous activity of some peptides, i.e. 
K2C18 and the novel S-H4 (discussed below). 
 
The filamentation of E. coli seen when expressing periplasmically-targeted K2C18 
and K2C38 may be a typical stress response. This elongation is commonly 
observed in a variety of bacteria suffering DNA damage, the presence of an 
antibiotic, or nutritional limitation (Justice et al., 2008). For unknown reasons, this 
may promote survival of a sub-population of cells. In addition, LL-37 (closely related 
to K2C38; see Table 3.1) has recently been shown to target septum formation in the 
periplasm of E. coli (Sochacki et al., 2011). A lack of cell division may lead to 
tolerance, much as in the persister phenomenon outlined above. 
 
S-H4, a pAMP/S hit, was found to exhibit antimicrobial activity when added 
exogenously to E. coli. Out of the ~3,500 discrete pAMP/S colonies originally 
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screened, this represents an overall hit rate of approximately 0.03%. However, 
S-H4 was the only chemically-synthesised peptide expected to exhibit exogenous 
activity after frame-shift mutation and secretion signal removal investigations were 
performed (Section 4.2.5). The other hits, consisting of S-H2, S-H3 and S-R17, 
were not chemically-synthesised, and should be considered for further investigation. 
Although larger screens are required, proof-of-principle of this in vivo screening 
approach for AMPs has been shown. In previous work, Loit et al. (2008) claimed a 
hit rate of 0.002% when screening a random oligonucleotide library for AMPs, while 
Cheng et al. (2009) claimed a hit rate of 0.0004% when screening a wasp transcript 
library (i.e. complementary DNA). Both of these screens, however, had a large 
initial false-positive rate (67-75%) in comparison to the work presented here 
(~23%). 
 
S-H4, when expressed in E. coli, had a similar effect on the growth curve of E. coli 
as K2C38 when targeted to the periplasm (Figure 4.14). However, when produced 
recombinantly using the CPD system, S-H4 failed to show activity (at an estimated 
final concentration of 6 !M) against E. coli when tested in LB medium. While the 
chemically-synthesised version had a slightly higher MIC of 7.8 !M against E. coli 
grown in NB medium, this doubled to 15.5 !M when used in LB. It may be that the 
high salt concentration (171 mM) in LB mitigates the potency of S-H4. This has 
been seen for other AMPs, such as the cathelicidin LL-37 (Bowdish et al., 2005a). 
Thus, the lack of inhibitory effect seen when using the cleaved AMP fractions of 
recombinant S-H4 was probably due to a lack of sufficient peptide concentration. 
Interestingly, four of the pAMP/S hits encode peptides with cationic tails, of which 
S-H4 is one (see Table 4.7). This makes them structurally similar to the membrane-
lytic honeybee AMP melittin (26 aa). 
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Table 4.7: Peptide sequences of melittin and the novel putative AMP S-H4. Cationic 
residues in bold. 
 
Rather than possessing a regular distribution of hydrophobic and cationic residues 
over its length (such as K2C18), melittin has a largely hydrophobic N-terminus with 
a C-terminus enriched in cationic residues, and yet is highly potent as an AMP 
(Dathe & Wieprecht, 1999). It is important to recognise that AMPs that are not 
amphipathic along the entire length of an !-helix may be identified during the 
screening process, as well as AMPs that may not form a defined secondary 
structure at all.  
 
While it is easy to understand why an AMP that is toxic when produced 
endogenously may not be toxic when administered exogenously (i.e. the bacterial 
cell wall acts as a barrier to its target), it is not so clear with regards to an AMP that 
targets the inner membrane. A prime example is K2C18, which has had its inner 
membrane lytic ability confirmed both in vivo against E. coli and in vitro against 
vesicles that mimic the inner membrane (Gallo et al., 1997; Park et al., 2003). This 
negatively charged membrane is symmetrical in its leaflet composition (Ruiz et al., 
2006), so the origin of cationic AMP attack, either periplasmic or cytoplasmic, 
should not matter. Unless K2C38 (from which K2C18 is derived) is targeted to the 
periplasm with the pIII secretion signal, however, in vivo toxicity does not arise. The 
pI of K2C18 is predicted to be ~10.8, indicating that it will still be cationic in both the 
E. coli cytoplasm (pH 7.2 to 7.8) and periplasm (reflecting the LB medium, pH 5 to 
6.7) (Wilks & Slonczewski, 2007). It may be that the SecB chaperone, which can 
associate with nascent protein that is tagged with the pIII secretion signal (Natale et 
al., 2008), protects the AMP from cytoplasmic protease-mediated degradation 
(Maurizi, 1992). Furthermore, an increase in peptide length may lend such stability; 
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this could explain the lesser effect on growth of pIII-K2C18* versus pIII-K2C18-Tag 
in Figures 4.2 and 4.4. Subsequent secretion to the periplasm, which contains lower 
protease activity (Choi & Lee, 2004), may also give enough time for inhibition of 
growth to occur. Tentatively supporting this, less K2C38 is observed in a Western 
blot when the pIII secretion signal is removed (Figure 4.5). 
 
A number of putative AMP hits were identified that act cytoplasmically, both from 
the secreted and non-secreted screens. As mentioned above, such hits are not 
expected to show activity when added to E. coli exogenously, as it is unlikely they 
possess cell-penetrating activity. Indeed, this was observed for those putative 
AMPs purified and tested in this work, as well as previously for the toxic hok peptide 
(Pecota et al., 2003). The simultaneous addition of cell-permeabilizing reagents 
such as NP-40, PMBN or sub-lethal K2C18 did not lead to a toxic phenotype. In any 
case, synergy between an AMP and a cell-permeabilizing reagent is unlikely to be 
useful in practical applications due to unwanted side effects (Good et al., 2000). It 
would be better to focus on AMPs that exhibit intrinsic (and specific) lytic or cell 
penetrating activity. 
 
Future work could utilise different secretion signals to favour the isolation of 
periplasmically-active hits. For instance, a number of integral membrane proteins 
such as DsbA, TorT and TolB utilise the Sec pathway via the signal recognition 
particle (SRP) (Thie et al., 2008). SRP recognises and binds the secretion signal as 
it emerges from the ribosome, then pauses translation until the whole complex 
docks with the membrane-bound Sec-translocase complex (Natale et al., 2008). 
Translation resumes with the nascent protein being threaded into the periplasm. 
With this approach there would be little chance for an AMP to interact with potential 
cytoplasmic targets. In addition, knockouts of periplasmic proteases, such as DegP 
(Jones et al., 2002) and OmpT (Stumpe et al., 1998), may further allow 
accumulation of AMP in the periplasm. However, it is not strictly necessary, as a 
novel AMP has been successfully identified in the work presented here. Protease 
knockouts may lead instead to the identification of less potent entities, i.e. those 
requiring a greater concentration for efficacy. 
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In addition to the results presented in Section 4.2, the use of the yeasts 
Saccharomyces cerevisiae (West et al., 1984) and Pichia pastoris (Lee et al., 
2005b) to produce and secrete K2C18 in a trans-based assay was also explored 
(data not shown). The aim was to use the well-described S. cerevisiae ! mating 
factor secretion signal (Daly & Hearn, 2005) to drive secretion of a putative AMP 
library from yeast colonies plated on solid medium. A subsequent top agar overlay 
containing AMP-sensitive bacteria (e.g. E. coli) would reveal yeast clones producing 
novel AMPs, i.e. indicated by zones of growth inhibition. Not only could new AMPs 
be discovered via this trans-screen, but the eukaryotic yeast host (presumably 
tolerant to the AMP it produces) could then also be used for scaled-up peptide 
production. However, there are few previous examples of successful AMP secretion 
from yeast using episomal vectors, i.e. that do not integrate into the genome, as 
such integration is not amenable to high-throughput screening. Pediocin (12 aa, a 
bacteriocin) was produced in S. cerevisiae (Schoeman et al., 1999); and LL-37 and 
human !-defensin 5 (32 aa) in P. pastoris (Hong et al., 2007; Hsu et al., 2009). 
Unfortunately secreted K2C18 could not be successfully produced in either yeast: 
no growth inhibition of E. coli during top agar overlay of yeast colonies was seen. 
 
In conclusion, a recombinant production strategy in a sensitive bacterial host was 
used to screen genomic DNA libraries for peptides with AMP function. A number of 
hits were identified, and one (S-H4) proved successful when added exogenously to 
the host E. coli strain. The effect of endogenous AMP production on cell growth was 
assessed, and found to induce a persister-like phenomenon that lead to the 
recovery of cell viability. Further modifications to the in vivo screen for novel AMPs 
are required to minimise false-positives, i.e. effects mediated by transcripts, rather 
than peptides. The use of cell-permeabilizing reagents was not found to restore the 
function of AMPs that had putative intracellular targets. Periplasmically-active AMP 
hits should be focused on in the future, as these represent the best candidates for 
clinical development. 
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CHAPTER 5 – SCREENING FOR OTHER ACTIVITIES: 
ANTIAGGREGATION 
5.1 Introduction 
5.1.1 Brief history 
Proteins, the molecular workhorses of biology, predominantly require ordered 
folding to ensure correct function. While organisms have evolved a number of 
systems to aid this process, or remove misfolded products, i.e. chaperones and 
proteases (Plemper & Wolf, 1999; Schlieker et al., 2002), errors still occur and can 
lead to protein aggregation. This agglomeration, usually due to the exposure of 
hydrophobic side-chain regions in the hydrophilic cellular environment, may prove 
toxic and ultimately fatal to the cell or organism concerned (Dobson, 1999). In 
humans, a number of diseases are associated with protein misfolding and 
aggregation. For example, in Huntington’s disease the expansion of a codon repeat 
region in exon I of the huntingtin gene leads to an extended “sticky” patch of 
polyglutamine being coded for, which ultimately drives aggregation inside neuronal 
cells (Huntington's Disease Collaborative Research Group, 1993). Similarly, an 
increased polyalanine run length in the transcription factor Hox-D13 and 
subsequent aggregation leads to aggregation, culminating in the addition or fusion 
of digits (synpolydactyly syndrome) (Amiel et al., 2004). Other diseases in which 
aggregation is implicated include Parkinson’s disease, where the presynaptic-
associated protein !-synuclein can undergo aggregation, initiating Lewy body 
formation (aggregates) within neurons (Galvin et al., 1999); Creutzfeldt-Jakob 
disease, which is caused by the naturally produced prion protein being induced to 
change conformation by the disease prion variant and subsequent aggregation into 
amyloid plaques (Prusiner, 1998); and cystic fibrosis, in which a deletion of a single 
phenylalanine residue ("F508) from the cystic fibrosis transmembrane conductance 
regulator protein leads to improper folding, aggregation and a loss-of-function 
(Thomas et al., 1992).  
 
Another prominent aggregation-related condition is Alzheimer’s disease, a 
debilitating neuronal disorder that causes dementia and ultimately death (Selkoe, 
2002). The primary protein implicated in this disease is a peptide known as amyloid 
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# (A#), which may aggregate and lead to extracellular amyloid plaque formation in 
the brain (Walsh & Selkoe, 2007). While A# is seen as the predominant effector of 
Alzheimer’s disease, aggregation of the microtubule-associated protein tau is also 
associated with the condition (Brunden et al., 2009; Ittner & Götz, 2011). 
 
In 2009, 35.6 million cases of Alzheimer’s disease were reported worldwide, with 
this number expected to double by 2050 (Ittner & Götz, 2011). Current therapies, 
while able to alleviate the effects of the disease for a time, are unable to halt its 
progression (Gravitz, 2011). Therapies that are able to target the cause of 
Alzheimer’s disease are thus desired. 
 
5.1.2 Amyloid beta peptide (A#) 
5.1.2.1 A#40 and A#42 
A# is produced in two main variations of length, the predominant form being 40 
amino acids long (A#40), the other having an additional 2 residues at the 
C-terminus (A#42) (Walsh & Selkoe, 2007; DaSilva et al., 2010). Shorter lengths, 
such as A#39, are also possible (Jarrett et al., 1993). These small variations in 
length, heavily implicated in the aetiology of the disease (see Section 5.1.2.2), are 
formed by alternate processing of the Alzheimer’s precursor protein (APP; 87 kDa), 
a trans-membrane protein found in neurons and a number of other cell types 
(Walsh & Selkoe, 2007). Although the precise biological function of APP remains 
unknown, stepwise cleavage by membrane-bound aspartyl proteases processes 
the protein into smaller subunits, one of which is A# (De Strooper et al., 2010). At 
the first step of processing, #-secretase cleaves after residue 671 at the cell 
surface, releasing a substantial proportion of the N-terminus of APP into the 
extracellular milieu and leaving behind a C-terminal stub (De Strooper et al., 2010). 
This stub, in turn, is further cleaved at additional sites by the $-secretase complex 
within the membrane bilayer, resulting in the release of A# species of varying length 
(Carter et al., 2010). Point mutations around these cleavage regions are associated 
with familial Alzheimer’s, but the vast majority of cases are sporadic (Walsh & 
Selkoe, 2007). Indeed, production of A# is not abnormal in itself, as the peptides 
are found naturally throughout a human’s life at nanomolar concentrations in brain 
tissue or cerebrospinal fluid (Selkoe, 2002). 
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Exactly how A# peptides cause Alzheimer’s disease is still a matter of contention 
(see Section 5.1.2.2), but their propensity to self-recognise and aggregate is 
strongly implicated. Indeed, these peptides derive their name from their ability to 
generate amyloid fibrils, quaternary structures formed by protofilaments rich in 
#-sheet stacked in a parallel manner along an axis (DaSilva et al., 2010). These 
protofilament structures of A# may be further stabilised by intermolecular hydrogen 
bonding (Lührs et al., 2005). In Alzheimer’s disease, mature fibrils aggregate further 
to form amyloid plaques, the classic histological hallmark of the condition (Treusch 
et al., 2009). Such insoluble aggregates are essentially indestructible under 
physiological conditions due to a large number of hydrogen bonds shared between 
adjacent #-sheet regions (Dobson, 1999). 
 
 
Figure 5.1: A!40 and A!42 peptides with proposed secondary structures. Potential 
!-folds, formed by the central and C-terminal hydrophobic regions, are indicated by open 
arrows. When stacked, the axis of the protofilament protrudes from the page. The 
C-terminal dipeptide Ile-Ala, which A!40 lacks, is thought to adopt a different, or at least 
highly stabilised, !-fold confirmation. Amino acids are colour coded: cationic (green), 
hydrophobic (yellow), anionic (purple) and uncharged hydrophilic (blue). Figure adapted 
from DaSilva et al. (2010). 
 
Because of their propensity to aggregate both in vivo and in vitro, and consequent 
insolubility, fine-scale structures of A# have not been possible to obtain (Barrow & 
Zagorski, 1991). However, a mixture of circular dichroism spectroscopy and solid-
state nuclear magnetic resonance spectroscopy, combined with mutagenesis 
studies, has revealed some details (Hilbich et al., 1991; Lührs et al., 2005; DaSilva 
et al., 2010). Two main #-fold regions are formed in A# by the hydrophobic residues 
encompassing positions 17-21 and 30-40 (see Figure 5.1) (DaSilva et al., 2010). 
Compared to A#40, A#42 has a greater propensity to aggregate, at in vitro rates of 
hours versus days respectively (Jarrett et al., 1993). This is due to the additional 
147 
hydrophobic dipeptide Ile-Ala at the C-terminus of A#42, which may lead to a 
greater stabilisation of the dominant #-sheet region (Urbanc et al., 2004), or 
perhaps a second #-sheet confirmation being favoured (shown in Figure 5.1) 
(DaSilva et al., 2010). Finally, while the charged N-terminus of A# is not directly 
implicated in #-sheet formation, mutations to this region can prevent mature fibrils 
from forming, indicating that electrostatic interactions between the N-terminus and 
the #-fold regions may help stabilise mature fibril formation (Hilbich et al., 1991; 
DaSilva et al., 2010). 
 
5.1.2.2 A#42 in Alzheimer’s disease 
As mentioned in Section 5.1.2.1, aggregation of A# is heavily implicated in 
Alzheimer’s disease. Early observations that the brains of deceased sufferers were 
rich in amyloid plaque led to the hypothesis that the plaque itself was the causative 
agent of neuronal disruption (Roth et al., 1966). While the overproduction of A#40, 
or increased levels of the relatively low-abundance but aggressive aggregator 
A#42, is the root cause of plaques (Hardy & Selkoe, 2002), it is not clear that the 
plaques themselves are the effectors (Treusch et al., 2009; Ittner & Götz, 2011). 
Most frequently cited is the weak correlation observed between amyloid plaque 
levels and the onset of dementia, both in humans and in APP transgenic mouse 
models (Walsh & Selkoe, 2007). In humans, plaques are almost always present in 
the brains of healthy octogenarians, and even detectable in ~20% of cognitively 
normal people at an earlier age (Schnabel, 2011). But in neuronal cell cultures, 
aggregation of exogenously-added A# into fibrils was associated with toxicity (Pike 
et al., 1993), and brain extracts from APP transgenic mice (that exhibited amyloid 
plaques) induced amyloidosis and neuron pathogenesis in naïve mice when 
injected intracerebrally (Eisele et al., 2010). 
 
One proposed explanation for this is that low-order oligomeric A# species are 
instead responsible for toxicity, rather than mature amyloid fibrils (Walsh et al., 
2002). As these two A# forms are not mutually exclusive, such an explanation is not 
incompatible with the findings above (Walsh & Selkoe, 2007). Furthermore, the 
presence of soluble A# oligomers has been shown to be more closely correlated 
with memory loss (Kayed et al., 2003; Treusch et al., 2009). The oligomerisation of 
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A# represents a second pathway of aggregation that is distinct from 
amyloidogenesis (Figure 5.2). It may be that these oligomers display a larger 
surface area of hydrophobic patches than A# fibrils, bestowing a greater opportunity 
to interact and interfere with other neuronal components (Treusch et al., 2009). To 
tie these two aggregation pathways together, the formation of insoluble amyloid 
may instead serve as a protective mechanism to rid cells of the more reactive A# 
oligomers (Dobson, 1999; Hardy & Selkoe, 2002). Neuronal toxicity may result, 
however, if the cellular capacity to sequester A# oligomers into amyloid is 
exceeded, or the proteasome is overloaded and can no longer degrade soluble A# 
(Treusch et al., 2009). 
 
 
Figure 5.2: Two alternative pathways of amyloid !  aggregation, which are not 
mutually exclusive. One pathway leads from A! monomers to aggregation and 
amyloidosis; the other to small A! oligomers, which are now thought to be the main toxic 
species in Alzheimer’s disease. Figure adapted from Schnabel (2011).  
 
Early protofilaments of A# behave as intermediates between plaques and oligomers 
in that they can form both mature fibrils or dissociate back to low molecular weight 
species of A# (Walsh & Selkoe, 2007). A dynamic equilibrium between these 
aggregation states exists, with nucleation or “seed” events from monomers being 
the rate-limiting step (Selkoe, 2002; DaSilva et al., 2010). Furthermore, it has been 
observed that A# monomers are able to slough off mature fibrils to start this seeding 
process anew (Jan et al., 2008), and that the less abundant but more aggressively 
aggregating A#42 may seed the aggregation of A#40 (Jarrett et al., 1993). Indeed, 
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given that the major A# species in the brain is A#40, a small increase in the level of 
A#42 may be enough to set off an aggregation cascade into either oligomers or 
amyloid (DaSilva et al., 2010). The exact toxic oligomeric form(s), however, is hard 
to determine given the difficulty of isolating and studying discrete oligomeric states 
(Walsh et al., 2002; Bitan et al., 2005a). In mouse models, behavioural changes are 
associated with the appearance of A# nonamers and dodecamers (Lesné et al., 
2006). Other lower-order soluble oligomers, such as dimers (Shankar et al., 2008), 
have also been reported to be effectors (Carter et al., 2010). Given the above, 
isolating compounds that inhibit the initial stages of A# aggregation seems an 
attractive strategy, as it covers the gamut of possible aggregation states. 
 
While the form of A# that causes Alzheimer’s disease is still debated, so too are the 
exact mechanisms of neuronal cell death (Carter et al., 2010; Ittner & Götz, 2011). 
The synapse membrane and associated receptors appear to be a sensitive target 
(Selkoe, 2002; Ittner & Götz, 2011). A# association with synapse receptors, such as 
those for the neurotransmitters acetylcholine and glutamate, may lead to a loss of 
long-term potentiation and eventual neuronal death (Selkoe, 2002). There is even 
evidence that A# may functional as a lytic antimicrobial peptide (Soscia et al., 
2010), which could provide an immunoinflammatory explanation for neuronal 
membrane disruption (Carter et al., 2010). 
 
5.1.3 Screens for A#42 antiaggregants 
Some treatments for the symptoms of Alzheimer’s disease already exist, such as 
the small molecule drugs donepezil (trade name Aricept; Pfizer Inc.) and 
memantine (trade name Namenda; Forest Laboratories Inc.), which alter levels or 
responses to the neurotransmitters acetylcholine and glutamate respectively (Carter 
et al., 2010). Both mask the progression of dementia, but cannot ultimately cure 
Alzheimer’s disease. For this to occur, new treatments are needed that target the 
underlying causes of Alzheimer’s disease, i.e. protein aggregation. Possible 
approaches include decreasing A# production; stimulating the immune system to 
clear toxic A# forms from the brain; or inhibiting the aggregation process (all 
reviewed by Carter et al. [2010]). The work presented here focuses on generating a 
screen for the latter approach. 
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5.1.3.1 Small molecules and antibodies as antiaggregants 
A number of small molecules have been shown to inhibit aggregation of A# in vitro. 
For example, inositol-based compounds, as well as polyphenols from green tea 
(epigallocatechin-3-gallate) and turmeric (curcumin), inhibit fibril formation (Sato et 
al., 2006b; DaSilva et al., 2010). Furthermore, scyllo-inositol (a stereoisomer) is 
currently undergoing Phase II clinical trials after showing promising results in mouse 
models of Alzheimer’s disease (McLaurin et al., 2006). However, such small 
molecule antiaggregants are not the focus of the work presented here, and are 
reviewed elsewhere (Carter et al., 2010). 
 
Passive immunotherapy using antibodies raised against A# is also being pursued 
as a treatment option. This approach has shown promise in APP transgenic mice: 
synaptic dysfunction was somewhat prevented, even though amyloid plaque levels 
were not decreased (Dodart et al., 2002). Furthermore, A# toxicity towards neuronal 
cell cultures was ameliorated (Kayed et al., 2003). As a consequence, A# 
antibodies are now in clinical trials. Bapineuzumab (Pfizer Inc.), a monoclonal 
antibody that targets the N-terminus of A#, was seen to lower plaque levels in 
Phase II trials, however little overall positive effect on cognition was observed 
(Gravitz, 2011). This may be due to a lack of specificity towards oligomeric A#. To 
try to counter this, another monoclonal antibody, solanezumab (Eli Lilly and 
Company), has been raised against soluble A# (i.e. oligomeric) and is targeted 
against its central region (Gravitz, 2011). 
 
5.1.3.2 In vitro screening and animal models 
A#40 and A#42 may be chemically-synthesised and their aggregation observed in 
vitro, commonly by the monitoring of binding of thioflavin T (ThT), a dye that 
intercalates with amyloidic cross-# structures in a concentration-dependent manner 
(LeVine, 1993). For in vitro screening, putative antiaggregant compounds may be 
added to a freshly prepared A# solution and any reduction of ThT binding (and 
hence fibril formation) observed. However, some antiaggregants, e.g. inositol-based 
compounds, may allow for alternative A# aggregation into a fibril structure that ThT 
does not recognise, thus resulting in a “false” positive (Sato et al., 2006b; DaSilva et 
al., 2010). Techniques less amenable to throughput but more directly indicative of 
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aggregation state include electron microscopy, atomic force microscopy, and size-
exclusion chromatography (DaSilva et al., 2010). A large obstacle, however, when 
conducting in vitro studies of A# (especially A#42) is irreproducibility: truly 
monomeric A# is hard to isolate, as pre-existing aggregates are very difficult to 
remove from working stocks (Bitan & Teplow, 2005; Kim et al., 2006). In addition, 
chemically-synthesised A# is expensive to manufacture due to its propensity to 
aggregate and subsequent loss of solubility, currently costing ~£140 per mg 
(Sigma-Aldrich Company Ltd.). Alternatives are thus desired for high-throughput 
antiaggregation assays. 
 
Although animal models for the effects of A# aggregation serve an important 
purpose as pre-clinical validation tools, e.g. the APP transgenic mice mentioned in 
Section 5.1.2.2, these are not envisaged as high-throughput test beds. Animal 
models with a shorter generation time than mice do exist, but these are still limited 
(as yet) to profiling small sets of putative antiaggregants. For instance, various 
A#42 mutants have been expressed in the brains of the fruit fly Drosophila 
melanogaster, with a positive correlation being observed between their in vitro 
aggregation rate and in vivo toxicity (Luheshi et al., 2007). Similar mutational 
studies have been carried out in the nematode Caenorhabditis elegans, with 
muscle-expressed A#42 aggregating and eventually causing paralysis (Fay et al., 
1998). Harnessing these model organisms in high-throughput screens is a 
worthwhile goal, but simpler systems such as E. coli (see Section 5.1.3.4) may have 
greater immediate utility. 
 
5.1.3.3 Peptides as antiaggregants 
As A# self-recognises to aggregate, a number of attempts have been made to 
rationally design peptides that interfere with this process (Soto & Estrada, 2005). 
Known as #-breakers, these peptides are often homologous to the #-fold regions of 
A# (see Figure 5.1) and thus competitively interfere with intermolecular interactions 
between adjacent #-sheets (DaSilva et al., 2010). This, in effect, may inhibit the 
polymerisation of additional A# peptides at the end of a growing protofilament 
(Lührs et al., 2005). Alternatively, peptides may disrupt the cross-#-sheet hydrogen 
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bonding between A# protofilaments that is necessary for mature fibril formation 
(Sato et al., 2006b). 
 
Because of their homology to A#, however, a number of raw #-breaker sequences 
themselves aggregate, and thus are useless as therapeutics (DaSilva et al., 2010). 
To counter this, the addition of charged residues to such recognition elements can 
act as disrupters of further aggregation. When the pentapeptide KLVFF, 
homologous to amino acids 16 to 20 of A#, was C-terminally tagged with hexa-
lysine, it slowed the aggregation kinetics of A#39 in vitro and gave protection to 
neuronal cell line cultures in comparison to KLVFF alone (Pallitto et al., 1999). 
Furthermore, using a scrambled #-breaker sequence (VLFKF) also worked, 
indicating that an exact sequence match to A# was not required. An alternative to 
the use of a charged tag is to incorporate the disrupter element into the #-breaker 
recognition sequence itself. For example, incorporating a spatially constrained 
proline residue into the central hydrophobic recognition sequence of LVFFA 
(mutated to LPFFD) inhibited and dissolved amyloid formation in vitro, and 
prevented neuronal cell culture death on exposure to A# (Soto & Estrada, 2005). 
 
No peptide-based antiaggregation inhibitors, however, are currently in clinical trials 
due to stability and bioavailability reasons (DaSilva et al., 2010), with particular 
emphasis on their requirement to negotiate the blood-brain barrier (see 
Section 1.1.3.1). In order to overcome these problems, further work has been 
carried out to alter the peptide backbone of lead peptides, e.g. N-methylation 
(Gordon et al., 2001; Kokkoni et al., 2006), or to switch amino acids to their 
D-enantiomers (Findeis et al., 1999). It is hoped that such peptides will eventually 
prove clinically useful for the treatment of Alzheimer’s disease. In the meantime, it 
may be possible to find novel antiaggregant peptides through an in vivo screen if a 
suitable reporter system for the aggregation state of A# can be harnessed. 
 
5.1.3.4 Recombinant screen approaches 
In vitro solutions of chemically-synthesised A# are expensive and may already 
contain aggregates (see Section 5.1.3.2), so alternative approaches are desired. 
In vivo screening in systems such as E. coli is attractive: recombinant expression is 
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cheap and monomeric A# production must initially occur, thus allowing an 
opportunity for antiaggregants to interact at this key stage. Although using E. coli as 
a host by no means captures the native physiochemical environment of A#, it may 
prove useful as a first screen to identify putative antiaggregants. These may then be 
verified by additional in vitro and animal model experiments. 
 
A common approach to in vivo analysis of protein folding in E. coli (and hence 
solubility) is to couple the aggregation state of the protein of interest to the function 
of a reporter. Fluorescent proteins have been employed as C-terminal fusions for 
this purpose: aggregation of upstream proteins may lead to chromophore misfolding 
and consequent abrogation of fluorescence (Waldo et al., 1999). Supporting this, 
Waldo et al. (1999) found a strong correlation between the fluorescent output of 
green fluorescent protein (GFP) and the solubility state of aggregation-prone 
fusions such as bullfrog H-subunit ferritin or gene V protein mutants. 
!
Hecht and co-workers exploited this fluorescent folding reporter to study the 
aggregation of A#42 when expressed in E. coli (Figure 5.3). They found a good 
correlation between the in vitro aggregation state of A#42 and the in vivo 
fluorescent output of GFP, i.e. insolubility and a lack of fluorescence respectively 
(Wurth et al., 2002). Furthermore, mutations of A#42 that reduced its propensity to 
aggregate led to the restoration of chromophore fluorescence, and this also 
correlated with improved solubility as assessed by SDS-PAGE. Further work used 
this in vivo approach to screen a library of ~1,000 triazine-based small molecule 
drugs, and led to the identification of two compounds that inhibited A#42 
aggregation in vitro via the ThT assay and electron microscopy (Kim et al., 2006). 
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Figure 5.3: Fluorescence-based screen for antiaggregants using an A!42-GFP 
fusion. If a compound exhibits no antiaggregant activity, the A!42-GFP fusion protein 
misfolds due to A!42 aggregation, and no fluorescence output is observed. If A!42 
aggregation is inhibited, GFP (indicated in green) is able to fold and consequently 
fluoresce. Figure adapted from Kim et al. (2006). 
 
Moffet and co-workers used this A#42-GFP system to screen A#42-like peptides 
co-expressed in vivo for antiaggregant properties (Baine et al., 2009). As per the 
#-blocker approach (discussed in Section 5.1.3.3), these peptides were truncated 
mutants of the central or C-terminal hydrophobic regions of A#42 (see Figure 5.1) 
and incorporated aspartic acid mutations to interfere with further cross-# structures. 
A peptide that could partially restore A#42-GFP fluorescence was isolated 
(discussed below in Section 5.1.4.1). 
 
Other similar in vivo screens for A# solubility have also been used. Thomas and 
co-workers fused the !-fragment of #-galactosidase to the C-terminus of A#42, and 
found that aggregates were unable to complement the %-fragment in E. coli and 
hence could not cleave X-gal to give a blue output (Wigley et al., 2001). However, a 
downside of this approach is that the screen requires a fine degree of optimisation 
due to the !-fragment remaining accessible for complementation in large 
aggregates; thus, the range of sensitivity is small (3-fold at best). In another 
approach, DeLisa and co-workers utilised the twin-arginine translocation system 
(Tat; a Type II secretion pathway [Brüser, 2007]) as a reporter in E. coli. As the Tat 
system only exports properly folded and soluble proteins, A#42 (with an N-terminal 
Tat secretion signal) was fused to the N-terminus of #-lactamase (Bla), which 
confers resistance to ampicillin when localised to the periplasm. Aggregation of the 
A#42-Bla fusion prevented periplasmic export, and thus conferred ampicillin 
sensitivity (Fisher et al., 2006). Such a system can be used as a positive screen for 
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antiaggregants: if A#42-Bla is solubilised, growth in ampicillin-containing media can 
occur. Again, however, sensitivity was an issue, and consequently a fluorescent 
substrate of Bla had to be harnessed instead. This approach isolated four hits from 
the same combinatorial library of ~1,000 triazine scaffold variants used by Hecht 
and co-workers, one of which was the same (Lee et al., 2009). 
 
The above examples indicate the promise of utilising in vivo screens to isolate 
putative antiaggregants in a timely and cost effective manner. The work presented 
here aims to utilise such recombinant approaches to identify novel antiaggregant 
peptides. 
 
5.1.4 Recombinant screen considerations 
5.1.4.1 Antiaggregation controls 
For a non-aggregating positive control, the A#42 mutant GM6 was selected. 
Isolated by Wurth et al. (2002) in their original GFP fusion screen (see 
Section 5.1.3.4), GM6 contains a phenylalanine to serine mutation at position 19 
and a leucine to proline mutation at position 34, both of which serve to disrupt the 
core hydrophobic #-fold regions of A#42 (see Figure 5.1). As a consequence, the 
GM6-GFP fusion does not aggregate, and fluoresces well in vivo.  
 
In their A#42 antiaggregant peptide screen, Baine et al. (2009) isolated Peptide 2 
(Pep2), a 14 aa variant of the central hydrophobic region of A#42, which was able 
to double the fluorescence output of A#42-GFP when co-expressed. With a 
sequence of GKLDVVAEDAGSNK (mutations compared to A# underlined), this 
peptide likely complements A#42 but prevents further aggregation of cross-# 
structures through the steric hindrance imparted by the aspartic acid residue (see 
Section 5.1.2.3). Not only was Pep2 observed to depress A#42 aggregation in vitro 
through the ThT assay, it was also seen to disaggregate pre-existing fibrils (Baine 
et al., 2009). This peptide sequence was therefore picked as a positive peptide 
control for a de novo antiaggregant screen. 
 
As a novelty, a 16 kDa protein from the anhydrobiotic nematode Aphelenchus 
avenae, related to plant group 3 late embryogenesis abundant (LEA) proteins 
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(Browne et al., 2002), was also selected for study in this chapter. LEA proteins are 
implicated in the desiccation-tolerance of a large number of plants (specifically their 
seeds), as well as in some animals, and act to preserve cell component integrity in 
the “dry” state (Tunnacliffe & Wise, 2007). Functionally, LEA proteins may behave 
less like traditional chaperones and more as “molecular shields”, forming physical 
barriers between partially unfolded proteins to prevent their aggregation during 
desiccation (Goyal et al., 2005a; Chakrabortee et al., 2012). The LEA identified in 
A. avenae (designated AavLEA1; 143 aa) is highly hydrophilic and unstructured in 
solution (Goyal et al., 2003). Given its ability to prevent whole-cell proteome 
aggregation in vitro (Chakrabortee et al., 2007), its properties might allow it to 
interfere with A# aggregation if co-expressed in E. coli. Lending further evidence 
towards this, the use of rapeseed group 3 LEA proteins as C-terminal fusion tags of 
recalcitrant recombinant proteins somewhat alleviates inclusion body formation 
during expression in E. coli (Singh et al., 2009). 
 
5.1.4.2 Use of flow cytometry 
Previous approaches to the A#42-GFP screen in E. coli have involved analysing 
bacterial fluorescence in liquid medium using 96-well plates (Kim et al., 2006), or as 
colonies on solid medium (Baine et al., 2009). Although antiaggregant hits were 
identified by both Kim et al. (2006) and Baine et al. (2009), the dynamic range of 
signal output was low. At best, a two-fold increase in fluorescence output over 
background A#42-GFP was achieved. The use of flow cytometry may improve on 
this. Rather than relying on an average fluorometric reading from an entire cell 
population, this method assesses the output of cells on an individual basis, allowing 
for the possible concentration effects of E. coli cell size and replication state to be 
taken into account (Shapiro, 2003). This may give a greater sensitivity to the effect 
an antiaggregant may have on A#42-GFP fluorescence output. Importantly, such a 
single-cell approach is very much compatible with in vivo DNA library screening 
(discussed in Section 1.2.3), in which each cell encodes a different member of a 
putative antiaggregant peptide library. Fluorescence-activated cell sorting (FACS) 
could therefore be employed to separate putative hit cells, i.e. those with increased 
fluorescent output from the negative background, thus enabling the screening of 
antiaggregant peptide libraries in a high-throughput manner (Shapiro, 2003). 
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Given that the dynamic range between the effect of antiaggregants such as Pep2 
and background A#42-GFP fluorescence is low (see above), putative antiaggregant 
peptide hits in a flow cytometry screen may still be obscured by background noise. 
Measuring the ratio of cellular GFP output to an internal reference may aid in 
reducing this; such a ratiometric approach is commonly used in RNA microarray 
experiments, i.e. between a reference and an experimental sample (Schena et al., 
1995). To this end, constitutive expression of the red fluorescent protein mCherry 
(Shaner et al., 2004) was employed as an internal fluorescent reference. If 
A#42-GFP fluorescence increases relative to the mCherry standard, flow cytometry 
will reveal a shift along the X-axis of a plot of these two parameters (Figure 5.4). 
 
 
Figure 5.4: Ratiometric approach to identifying antiaggregants using flow cytometry. 
If a compound exhibits antiaggregant activity, the ratio of A!42-GFP:mCherry fluorescence 
will increase; mCherry acts as an internal standard. mCherry (red) and A!42-GFP (green) 
alone also plotted. 
 
While absolute A#42-GFP fluorescence per cell may vary under the same 
incubation conditions, the relative fluorescence to mCherry should remain constant. 
In addition, as synthesis rates of GFP have been reported to be relatively sensitive 
to plasmid copy number (varying 1.5 to 3-fold) (Kelly et al., 2009), mCherry may be 
incorporated into the same plasmid as A#42-EGFP to ensure an equal gene copy 
number between the two components. The only major variable remaining is the 
expressed DNA library member; therefore an increase in relative A#42-GFP 
fluorescence should be observed if a putative antiaggregant peptide is encoded.  
 
158 
5.1.4.3 Random oligonucleotide libraries 
While gDNA was used as an input to encode a peptide library in Chapter 4, here the 
use of chemically-synthesised random oligonucleotides was explored. Although the 
encoded random peptides may be unlikely to adopt a secondary structure 
(discussed in Section 1.2.2), this is not required for short length #-breakers (see 
Section 5.1.2.3). Furthermore, given that a match in overall physiochemical 
properties (e.g. hydrophobicity) is sufficient as opposed to an exact match of 
sequence (see Section 5.1.3.3), screening of randomly encoded peptides is not 
inappropriate. Aside from traditional #-breakers, other novel antiaggregant peptides 
may be identified.  
 
As proof-of-principle, oligonucleotides encoding 12 or 24 random amino acids 
(excluding the initiating methionine) were used. Random codons (NNN) were 
utilised, as although includes the possibility for internal stop codons to be 
incorporated, any restrictions (e.g. NNG/T to eliminate two of the three stop codons) 
will alter the codon bias for certain amino acids in E. coli (Walker et al., 2001). The 
potential sequence diversity of the aforementioned peptide libraries is huge: for the 
12 aa library, ~4.1x1015 combinations are possible; for the 24 aa library, ~1.7x1031. 
In reality, given the similar properties of some residues (e.g. the hydrophobicity of 
leucine and isoleucine), this diversity is lessened. Still, only a small fraction of this 
potential sequence space is likely to be explored during screening, and any hits 
may rather serve as templates for further optimisation. 
 
5.1.5 Summary 
While Chapters 3 and 4 dealt with antimicrobial peptides and screening for novel 
sequences that exhibited microbial toxicity, this chapter serves as further 
proof-of-principle that other, less readily-observable activities may also be screened 
for using an in vivo system. As an example, aggregation of the peptide A#, which is 
heavily implicated in the aetiology of Alzheimer’s disease, was studied. Peptides 
possessing antiaggregant properties may have the potential to attenuate clinical 
progression of the disease, or perhaps to prevent it if used prophylactically. A 
handful of antiaggregant peptides have already been reported, primarily being 
homologues to the key hydrophobic #-fold regions of A# that bind and competitively 
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interrupt aggregation of the same. Additional #-breakers, or novel antiaggregant 
peptide sequences, could prove useful for further development. As in vitro work with 
chemically-synthesised A# is expensive, using an in vivo screen of a peptide library 
in E. coli may allow for hit identification in a cost-effective manner. 
 
A#42-GFP fusions, when expressed in E. coli, aggregate and prevent the correct 
folding and fluorescence of the GFP domain. Restoration of fluorescence has 
previously been used as a basis for screening small molecules for antiaggregant 
properties. This approach was taken and applied to the screening of co-expressed 
random peptide libraries for putative antiaggregants. Specifically, flow cytometry 
was employed to ascertain the fluorescence state of the A#42-GFP fusion in single 
E. coli cells, with this being measured ratiometrically against a constitutively 
expressed fluorescent mCherry control. The antiaggregant peptides Pep2 and 
AavLEA1 were assessed for activity in this manner, and FACS initially trialled as a 
means of facilitating high-throughput screening. Screening libraries on solid medium 
was also conducted, with several putative antiaggregant hits subsequently 
assessed using flow cytometry. Further work is ongoing to verify these hits using 
traditional in vitro methodology. 
 
5.2 Results 
5.2.1 Construction of vectors for antiaggregant screen 
5.2.1.1 Construction of pAG2-A#42 
The pBADm plasmid was chosen as a chassis for the construction of the screening 
vector pAG2-A#42 (for details see Section 2.7.1). Three main operons formed the 
basis of the plasmid (Figure 5.5 A; full plasmid sequence in Appendix 7). Firstly, the 
coding sequence for the aggregator A#42-EGFP (enhanced GFP; taken from Baine 
et al. [2009]) was placed under tight control of the arabinose-inducible araBAD 
promoter (Guzman et al., 1995). Secondly, a “Library” operon was fabricated (see 
Appendix 8), featuring a strong constitutive promoter and SpeI/AfeI sites flanking 
the start codon for DNA library insertion and subsequent expression. Constitutive 
expression from the Library site should allow for putative antiaggregant peptide to 
build up in a cell prior to A#42-EGFP induction, thus maximising the chance that 
inhibitors of the earliest stages of A#42-EGFP aggregation may be identified (Kim et 
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al., 2006; Carter et al., 2010). Finally, mCherry was put under the control of a 
medium-strength constitutive promoter so that it could be consistently used as an 
internal standard to ratiometrically compare between the effects of putative 
antiaggregants on A#42-EGFP fluorescence output. As the origin of replication 
utilised by pAG2-A#42 (pBR322 origin) results in a low copy number of plasmids 
per cell (15 to 75) (Velappan et al., 2007), integration of genes on a single plasmid 
is important to minimise spurious ratiometric results due to gene copy variation. 
 
 
Figure 5.5: The pAG2-A!42 vector used to screen for putative antiaggregant 
peptides, and various control modifications. Insert DNA may be ligated into the Library 
site of pAG2-A!42 using either the SpeI site (start codon required) or AfeI site.                  
A: pAG2-A!42, with A!42-EGFP under control of the arabinose-inducible araBAD 
promoter, and the Library and mCherry operons constitutively expressed. Start and stop 
codons for all three Library insert reading frames are shown in bold (possible encoded 
C-terminal residues also indicated). Const.S, strong constitutive promoter; Const.M, 
medium constitutive promoter. B: Modifications made to pAG2-A!42 to create controls. 
Green indicates replacement at the araBAD site, white the Library site and red at mCherry. 
Crosses indicate removal of an operon. 
 
5.2.1.2 Construction of pAG2-A#42 controls 
Modifications were made to the pAG2-A#42 plasmid to generate a number of 
controls (Figure 5.5 B; see Section 2.7.2 for details). For a single, arabinose-
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inducible green fluorescence control, EGFP was inserted into the araBAD site of 
pBADm (pBADm-EGFP). pAG2-B, a precursor plasmid generated during the 
construction of pAG2-A#42, contained constitutively expressed mCherry and served 
as a single, red fluorescence control. The activity of the Library site could be 
assessed by the insertion of EGFP into pAG2-B (pAG2-B/EGFP). 
 
In addition, the A#42 domain of pAG2-A#42 was modified to incorporate the GM6 
mutations (F19S, L34P; Wurth et al. [2002]) to act as a non-aggregating, arabinose-
inducible double positive control, i.e. both green and red fluorescence (pAG2-GM6). 
Lastly, Pep2 and AavLEA1 were inserted into the Library site of pAG2-A#42 so that 
their effect on A#42-EGFP fluorescence/aggregation during co-expression could be 
assessed (pAG2-A#42-Pep2 and pAG2-A#42-AavLEA1 respectively). Some of the 
amino acid sequences of the constructs mentioned above are shown in Table 5.1. 
 
 
Table 5.1: The sequence of A!42 and the controls GM6, Pep2 and AavLEA1. The two 
hydrophobic regions of A!42 are underlined, with comparable mutations in GM6 and Pep2 
indicated in bold. The 11-mer repeat regions of AavLEA1 are also underlined (Goyal et al., 
2005b). MW, molecular mass. 
 
While homology between A#42 and GM6/Pep2 is obvious, any similarity to 
AavLEA1 is less so. Attempted alignment of the AavLEA1 amino acid sequence 
with A#42 revealed a small region of homology between the N-terminus of A#42 
and the second 11-mer repeat region of AavLEA1 (Figure 5.6), but not with the 
#-sheet critical hydrophobic regions (see Section 5.1.2.1). 
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Figure 5.6: The N-terminus of A!42 shares some homology with the second 11-mer 
repeat region of AavLEA1. Residue positions indicated. Star, indicates side-chain match; 
colon, indicates strong similarity between side-chains; period, indicates weak similarity 
between side-chains. ClustalW2 used to generate alignment (see Section 2.7.7). 
 
5.2.2 Profiling of pAG2-A#42 and controls 
5.2.2.1 Expression of pAG2-A#42 and controls 
The plasmid pAG2-A#42 and the controls pBADm-EGFP, pAG2-B, pAG2-B/EGFP, 
pAG2-A#42-Pep2, pAG2-A#42-AavLEA1 and pAG2-GM6 were transformed into 
E. coli DH10B cells. Expression from selected constructs was induced at 37ºC for 6 
h (see Section 2.3.1), and protein products analysed using SDS-PAGE (Figure 5.7). 
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Figure 5.7: Expression from pAG2-A!42 and selected controls. SDS-PAGE (glycine 
12%) of 6 h induction in E. coli DH10B at 37ºC, ~225 rpm. Expected band sizes: 
A!42-EGFP and GM6-EGFP, 32.6 kDa; mCherry/EGFP, 27 kDa; AavLEA1, 15.9 kDa, 
Pep2, 1.5 kDa. Equal volumes of cell culture were loaded (normalised to the same density 
via OD600). Whole-cell fractions represent both insoluble and soluble protein, clarified lysate 
soluble protein only. WM, molecular mass marker. 
 
It was hoped that there would be an obvious intensity difference between the 
A#42-EGFP band in the whole-cell fraction (a mix of soluble and insoluble protein; 
lane 4) and its equivalent in the clarified lysate fraction (soluble protein only; lane 
12). If A#42-EGFP aggregates, its band is only expected to be seen in lane 4. 
However, aside from AavLEA1 (lanes 6 & 14, arrow D), it is difficult to determine 
which, if any, of the bands in the 25 to 35 kDa region (arrows A to C) correspond to 
the expected sizes stated in the legend of Figure 5.7. Band C may be that of 
A#42-EGFP, as it is less intense in the soluble fraction of induced pAG2-A#42 
(compare lanes 4 & 12); however, this is unlikely, as the same band is equally 
present in samples not containing A#42-EGFP (e.g. lanes 10 & 11), and 
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furthermore is running at a lower weight than expected. In addition, there is no 
obvious intensity difference in the bands arrowed A to C between A#42-EGFP 
(lane 12) and the non-aggregating GM6-EGFP control (lane 15); GM6-EGFP is 
expected to be more soluble.  
 
Although interpretation of Figure 5.7 is unclear, Wurth et al. (2002) successfully 
demonstrated by SDS-PAGE that their A#42-GFP protein product was insoluble, 
while their non-aggregating mutant GM6-GFP appeared predominantly in soluble 
fractions. Furthermore, A#42-GFP was not observed to fluoresce, while GM6-GFP 
did (confirmed in Section 5.2.2.2 below). However, Wurth and co-workers’ 
A#42-GFP differed from the A#42-EGFP used in the work presented here (sourced 
from Baine et al. [2009]). The linker region between the A#42 sequence and the 
chromophore domain is 15 aa instead of 12 aa, and the GFP variant utilised is also 
different: Baine used EGFP, while Wurth used a GFP version containing mutations 
at five positions (Crameri et al., 1996). However, these differences are unlikely to 
explain any difference in solubility; further work utilising Western blotting with A#42-
specific antibodies is required to resolve this problem. 
 
5.2.2.2 Fluorescence microscopy of pAG2-A#42 and controls 
Although the exact expression and solubility properties of pAG2-A#42 and the 
control constructs could not be determined by SDS-PAGE, the next step was to 
assess their capability to produce fluorescence in E. coli. EGFP and mCherry 
fluorescence in induced cells was observed using fluorescence microscopy (see 
Section 2.7.4) after a 6 h induction (Figure 5.8). 
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Figure 5.8: Fluorescence microscopy of E. coli expressing pAG2-A!42 and controls. 
For each panel, from left to right: bright field, green fluorescence, red fluorescence. Photos 
taken after 6 h arabinose induction (0.05%) in LB medium at 37ºC at ~225 rpm. Both 
uninduced (- ara) and induced pAG2-A!42 samples shown (panels D & E). Green 
aggregates arrowed (panels F & G); EGFP photos overexposed to visualise (*), which 
leads to bleed-through of mCherry fluorescence. Scale bar, 5 !m. 
 
For the single green and single red controls (panels A & B), fluorescence was as 
expected as per Figure 5.5. However, green fluorescence from pBADm-EGFP cells 
was seen to bleach quickly; this was also the case for red fluorescence in all 
samples examined. The pAG2-A#42 vector, with A#42-EGFP both uninduced 
(panel D) and induced (panel E), exhibited no green fluorescence as desired. In 
contrast, the non-aggregating mutant GM6-EGFP exhibited diffuse green 
fluorescence when induced (panel H), indicating its solubility and confirming the 
work of Wurth et al. (2002). Importantly, the Library site of pAG2-A#42 was shown 
to be transcriptionally active, as inserted EGFP resulted in green fluorescence 
(panel C). In addition, similar observations were made of all samples after 23 h of 
induction (data not shown; however, for a 15 h induction, see Figure 5.18), 
indicating that longer incubation times did not affect the fluorescent state of the 
cells. 
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Interestingly, several cells containing pAG2-A#42-Pep2 and pAG2-A#42-AavLEA1 
(panels F & G) were seen under the microscope to possess single green 
fluorescent aggregates by eye; however, for photography, these images required 
overexposure and consequently led to bleed-through of mCherry fluorescence (for 
explanation see Section 2.7.4). While the majority of cells did not exhibit these 
aggregates, indicating against a homogenous effect, it may be that Pep2 and 
AavLEA1 are able to interfere with A#42-EGFP aggregation to a limited extent 
in vivo. This may provide enough time for EGFP to fold before subsequent A#42 
aggregation occurs. Furthermore, red fluorescence from pAG2-A#42-Pep2 and 
pAG2-A#42-AavLEA1 cells (panels F & G) appeared to be brighter than that from 
other samples, but still bleached as quickly. Related to this, centrifugation of these 
cultures also resulted in cell pellets with a brighter red than those of their 
counterparts (data not shown).  
 
Lastly, an additional observation of interest was that induced cells containing 
pAG2-A#42-AavLEA1 clumped together (see Section 5.2.2.3 below, and 
Figures 5.27 & 5.31 for photos). This was also observed in pAG2-A#42-Pep2 cells, 
but not to the same extent. 
 
5.2.2.3 Growth rates of pAG2-A#42 and controls 
The effect of induction of pAG2-A#42 and the various controls on the growth rate of 
E. coli in liquid LB was also ascertained. Cultures were induced as per 
Section 2.3.1 and OD600 monitored over time. Figure 5.9 shows the resulting growth 
curves. 
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Figure 5.9: pAG2-A!42 constructs containing inserts in the Library site exhibit a 
slight lag in growth. A: Uninduced. B: Arabinose (0.05%) added to induce cultures in LB 
medium at 0 h (dashed lines), incubated at 37ºC at ~225 rpm. 
 
All constructs seemed to grow normally and without any inhibition of growth rate. 
However, constructs containing inserts in the Library site, i.e. pAG2-B/EGFP (green 
line, red diamond), pAG2-A#42-Pep2 (dark blue line) and pAG2-A#42-AavLEA1 
(light blue line), showed a slight initial lag in entering exponential-phase growth. The 
effect was the seen in both uninduced and induced cultures. This may be due to the 
increased metabolic load imposed on these cells due to constitutive expression of a 
Library site insert. 
 
The OD600 of the pAG2-A#42-AavLEA1 culture was hard to accurately ascertain 
due to cell clumping, which was more apparent in the induced sample as opposed 
to the uninduced sample (Figure 5.10). Despite this, cell viability appeared 
unaffected. While cells were observed to settle out initially, turbidity was restored 
after several hours continued incubation. The pAG2-A#42-Pep2 culture also 
exhibited slight sedimentation, but nowhere near to the same extent as 
pAG2-A#42-AavLEA1. 
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Figure 5.10: Clumping of cells is visible in cultures containing pAG2-A!42-AavLEA1. 
Cultures grown as per Figure 5.9, photos taken after 4 h and 21.5 h induction. Cell 
clumping arrowed, prominent in pAG2-A!42-AavLEA1 (A) but not in pAG2-A!42-Pep2 (B). 
Ara, arabinose. 
 
5.2.2.4 Flow cytometry of pAG2-A#42 and controls 
To quantitatively assess EGFP and mCherry fluorescence levels, E. coli DH10B 
cells containing the various pAG2-A#42 constructs outlined in Figure 5.5 were 
induced for 22 h at 37ºC and analysed via flow cytometry (see Section 2.7.5.3). 
Figure 5.11 shows the resulting dot plots and observed median fluorescence 
intensities (MFI) for both EGFP and mCherry. 
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Figure 5.11: Flow cytometry dot plots from E. coli expressing pAG2-A!42 and 
controls. Cultures induced for 22 h at 37ºC at ~225 rpm before analysis of EGFP and 
mCherry fluorescence. A: Initial gating scheme used on all samples (B to G) to doublet 
discriminate (G1 & G2; pAG2-A!42 cells shown as a representative; see Section 2.7.5.1). 
B to G: Dot plots for each sample with the same RoI (triangle, with % cells indicated) as the 
right-most plot of A. At least 35,000 total events were recorded for each dot plot (blue 
highest density, red lowest), representatives shown (n = 3). MFI, median fluorescence 
intensity (arbitrary units) for whole plot: EGFP (green bullet), mCherry (red bullet). 
 
A region of interest (RoI), with a left-most border running parallel to the axis of the 
pAG2-A#42 plot (panel A; see also Section 5.1.4.2), was set on the right-most 
border of the observed pAG2-A#42 cell cluster and adjusted so that cells from the 
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single-fluorescence controls (panels B & C) did not fall within it. Approximately 1% 
of pAG2-A#42 cells were allowed to enter this RoI, providing a comparison between 
this sample (pAG2-A#42) and the various controls. For the non-aggregating 
pAG2-B/EGFP (panel D) and pAG2-GM6 (panel G) samples, the majority of cells 
exhibited greater EGFP fluorescence than pAG2-A#42, thus moving along the 
X-axis and falling into the RoI. This also occurred for the cells co-expressing Pep2 
and AavLEA1 (panels E & F), but to a lesser extent. Figure 5.12 plots the observed 
MFIs for each sample, as well as showing the EGFP:mCherry ratios for 
comparison. 
 
 
Figure 5.12: MFIs from E. coli expressing pAG2-A!42 and controls. Data taken from 
representative plots shown in Figure 5.11 (n = 1). MFI, median fluorescence intensity; error 
bars represent coefficient of variation (see Section 2.7.5.4). 
 
The median A#42-EGFP fluorescence output from pAG2-A#42-Pep2 was seen to 
be twice that of pAG2-A#42 alone (panel A), with a tight coefficient of variation 
(CV), i.e. spread of data. This finding is in line with that observed by Baine et al. 
(2009) during their original work on Pep2. Furthermore, AavLEA1 seems to have a 
similar effect, signalling its potential as an A#42 antiaggregant. However, neither of 
these constructs comes close to matching the non-aggregating pAG2-GM6 control, 
which shows a ~6-fold increase in EGFP output. This serves as a further indicator 
that Pep2 and AavLEA1 may only serve as rate, rather than absolute, inhibitors of 
A#42 aggregation in vivo (see Section 5.2.2.2). The green positive control, 
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pBADm-EGFP, did not express well in this work, but given that pAG2-B/EGFP and 
pAG2-GM6 performed as expected (Figure 5.5), this was not remedied. 
 
With regards to comparison of the A#42-EGFP:mCherry ratios (panel B), they serve 
to confirm the median A#42-EGFP readings. It is worth noting, however, that 
mCherry levels are quite varied over the samples. For instance, the mCherry MFI 
for pAG2-A#42 alone is approximately twice that observed for pAG2-GM6, with a 
CV value indicating a large spread of data. This indicates that the use of mCherry 
as an internal in vivo standard is not as robust as initially envisaged. 
 
Next, in order to see if cells containing the positive controls could easily be detected 
amongst a negative background prior to FACS, cultures of “empty” pAG2-A#42 
bacteria were spiked with cultures of pAG2-A#42-Pep2, pAG2-A#42-AavLEA1 or 
pAG2-GM6. Samples were created such that 100% (i.e. the positive control alone), 
50%, 10% or 1% of the culture was derived from a particular spike source. 
Figure 5.13 shows dot plots of the observed fluorescence outputs for each spiked 
sample. 
 
172 
 
 
 
Figure 5.13: Flow cytometry dot plots from E. coli expressing pAG2-A!42 spiked with 
pAG2-GM6, pAG2-A!42-Pep2 or pAG2-A!42-AavLEA1 cultures. Cultures induced 
separately for 17 h at 37ºC at ~225 rpm before spiking. Samples gated and analysed as per 
Figure 5.11. For pAG2-A!42 alone, 1.03% of cells fell into the RoI (panel D). n = 1. 
 
The percentage of cells falling into the RoI for the positive controls alone (panels 
A1, B1 & C1) was observed to be less than that seen in Figure 5.11. The two 
experiments were conducted in the same manner but on different days; such a 
difference has been commonly observed due to biological and machine variance 
between measurement times (Kelly et al., 2009). Furthermore, all spikes with 
pAG2-A#42-Pep2 indicate a higher percentage of cells in the RoI than 
pAG2-A#42-Pep2 alone (panels A1-A4). The same applies for 
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pAG2-A#42-AavLEA1 (panels B1-B4). Taken together, this noise indicates that 
isolating novel peptide hits with similar activity levels to Pep2/AavLEA1 in a library 
screen through a single gating step would be difficult to achieve using FACS. 
Instead, multiple rounds of FACS would be required to try to enrich for hit cells with 
the brightest A#42-EGFP output. For any hits exhibiting greater EGFP 
fluorescence, however, a single sort may prove adequate: pAG2-GM6 cells can 
clearly be seen in panel C4 (arrowed), separate from the “empty” pAG2-A#42 
background (cf. panel D). 
 
The next step was to construct random DNA library inserts for insertion into 
pAG2-A#42, and use FACS to attempt to enrich and isolate putative antiaggregant 
hits. 
 
5.2.3 Using FACS to screen for novel antiaggregant peptides 
5.2.3.1 Creation of random DNA library 
Oligonucleotides consisting of 74 or 110 bp were purchased as templates for the 
creation of random DNA libraries for insertion into pAG2-A#42. These single-
stranded DNA sequences contained a large run of random bases (36 or 72 bp; see 
Table 5.2) encoding either 12 or 24 amino acids if translated (excluding the initiating 
methionine and ignoring internal stop codons). To facilitate the insertion process, 
the 5’ and 3’ terminals of the oligonucleotides were conserved, containing a SpeI or 
AfeI site respectively. In-frame start and stop codons were also included 
(Table 5.2). However, synthesis of these oligonucleotides was difficult (personal 
communication, Sigma-Aldrich Company Ltd.), and consequently the number of 
random bases incorporated could not be absolutely guaranteed. Although 
translation frame-shifts could occur, the pAG2-A#42 plasmid was designed to 
include stop codons in all possible reading frames downstream of the Library 
insertion point. Only two to five additional amino acids may be incorporated at the 
C-terminus if a frame-shift occurs (see Figure 5.5). 
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Table 5.2: Random oligonucleotides used to create libraries encoding random 
peptides up to 13 or 25 amino acids in length. The name of the oligonucleotide reflects 
its total length in base pairs. N, random base. 
 
Limited PCR amplification from the oligonucleotides was performed (see Section 
2.7.3) to try to ensure library diversity by minimising any reaction bias towards a 
particular sequence. The 10 pmol of oligonucleotide used as a template, when 
multiplied by Avogadro’s number, equates to a potential ~6x1012 different 
sequences. Given that only 1x104 to 1x105 different library members were to be 
screened during any one FACS run, a large buffer exists against any potential 
reduction in sequence diversity. Aliquots from each generated library were 
subsequently ligated into the pAG2-A#42 vector via the SpeI and AfeI sites of the 
Library site and transformed into E. coli DH10B. 
 
5.2.3.2 Plasmid stability and assessment of library insertion 
During attempts to insert the random DNA libraries into pAG2-A#42, large numbers 
of unwanted negative background colonies were obtained after each 
transformation. Colony numbers (thousands) were indistinguishable between insert 
ligation plates and those of negative controls, i.e. no insert, transformed with 
SpeI/AfeI digested pAG2-A#42 plasmid. It was hypothesised that the pAG2-A#42 
vector may suffer from instability due to the presence of identical sequence regions, 
such as the rrnB terminator used in all three of the araBAD, Library and mCherry 
operons (see Appendix 7). This could allow for homologous recombination and 
therefore potential plasmid truncation to occur, possibly resulting in the removal of 
the Library site and hence loss of sensitivity to SpeI/AfeI digestion. Although the 
DH10B strain used in this work is a recA1 mutant (inactivating E. coli’s major DNA 
recombinase), unwanted recombination events may still occur (Kawashima et al., 
1984). 
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To explore this possibility, SpeI/AfeI digested pAG2-A#42 was gel-extracted (see 
Section 2.2.2) to separate it from any putative recombinant/undigested plasmid, and 
then directly transformed (without ligation) into DH10B cells. Colonies still resulted, 
but in their hundreds rather than thousands as noted earlier. Two of these resultant 
negative control colonies were cultured so that their plasmids could be subjected to 
restriction digestion analysis (Figure 5.14). 
 
 
Figure 5.14: Restriction digestion analysis of negative control plasmids indicates 
pAG2-A!42 suffers from sequence instability. Orig., original pAG2-A!42 plasmid; Neg., 
plasmid isolated from a negative control colony. Desired band sizes for wild-type 
pAG2-A!42: NcoI/AfeI/SpeI/EcoRV, 2,809, 1,279, 984, 931 & 11 bp; AfeI, SpeI or both, 
~6,010 bp. WM, DNA ladder. 
 
Wild-type pAG2-A#42 was expected to possess bands that summed to ~6 kbp in 
size. While the original plasmid (Orig.; lane 2) and the second negative control 
plasmid (Neg. #2; lane 4) met this criteria when multiply digested, the first negative 
control plasmid (Neg. #1; lane 3) was seen to lack the SpeI and AfeI sites 
(confirmed lanes 7 to 14) between the two NcoI sites of pAG2-A#42. If full-length, 
the largest NcoI-related band should be ~4.1 kbp; instead it was observed to be 
~3.7 kbp (lane 3). These observations indicate that Neg. #1 lacks a ~400 bp region 
that encompasses the Library site. Analysis of the sequence of pAG2-A#42 
(Appendix 7) shows that the 5’ ends of the homologous rrnB terminator regions of 
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the araBAD site and the Library site are ~330 bp apart, indicating that these are the 
probable recombination sites. 
 
Furthermore, it should be remembered that plasmids Neg. #1 and Neg. #2 both 
originated from the same transformation using the Orig. plasmid (lane 1). The 
restriction digest profile of Orig. (lane 2), however, appears identical to that of Neg. 
#2 (lane 4) in Figure 5.14; no trace of the Neg. #1 (lane 3) profile is seen. This 
indicates that any truncated plasmid is only present in minute (picogram) amounts, 
as nanogram quantities of DNA are required for detection using ethidium bromide 
(Section 2.2.7; Sambrook & Russell [2001]). While gel-extraction of SpeI/AfeI 
digested pAG2-A#42 led to a reduction in negative background colonies, it seems 
impossible to completely remove the undesired truncated plasmid. Upon close 
examination of Figure 5.14, a faint band of relaxed Neg. #1 plasmid can be seen to 
run just below the 6 kbp marker (lanes 7 to 9; arrowed). As this runs at a similar 
size to SpeI/AfeI digested pAG2-A#42 (lane 10), contamination and co-purification 
may occur during the gel-extraction process. New truncation events may also occur. 
Nevertheless, ligation of the random DNA libraries into gel-extracted pAG2-A#42 
was trialled again to determine the success rate of insertion. Approximately 75% of 
colonies were found to contain a desired insert in the Library site, as revealed by 
colony PCR (Figure 5.15). Given that negative background colonies containing 
truncation products should not exhibit any increase in A#42-EGFP fluorescence, 
this situation was deemed acceptable enough to proceed with screening. 
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Figure 5.15: Profile of random DNA library inserts ligated into the Library site of 
gel-extracted pAG2-A!42. Colony PCR (Section 2.2.5.2) shows the presence of inserts in 
9 out of 12 colonies assayed. Empty plasmid should result in a 333 bp band; 74 library 
insert, 372 bp; 110 library insert, 408 bp. Neg., colonies from a negative control 
transformation plate; WM, DNA ladder. 
 
Of additional note, colonies picked from a negative control transformation plate 
(lanes 1 & 2) exhibited a faint band running at ~575 bp. This is an artefact most 
likely endowed by truncated plasmid: if a Library site was present, a band of 333 bp 
was expected. Other negative colonies (lanes 4, 7 & 14) gave a similar profile. 
 
5.2.3.3 FACS of pAG2-A#42-74 and pAG2-A#42-110 libraries 
Two libraries (approximately 25,000 colonies each) from pAG2-A#42-74 (encoding 
a 12 aa random peptide) or pAG2-A#42-110 (encoding a 24 aa random peptide) 
ligations were prepared, with plate incubation taking place at 30ºC to ensure a small 
colony size and hence high plate density. Colonies were pooled and resuspended 
as per Section 2.7.5.2. In addition, a similar resuspension of “empty” pAG2-A#42 
colonies was prepared, and subsequently spiked with several colonies of either 
pAG2-A#42-Pep2, pAG2-A#42-AavLEA1 or pAG2-GM6 to act as positive controls 
(a ~1x10-4 dilution/0.01% spike; see Table 5.3). It was noted that colonies of 
pAG2-A#42-Pep2 and pAG2-A#42-AavLEA1 alone were smaller than those of the 
74 and 110 library colonies (see Section 5.2.2.3), so incubation was continued until 
approximate size parity was achieved. 
 
Inoculums from the above preparations were induced for ~15 h at 30ºC and 
subjected to FACS (see Section 2.7.5.3). Approximately 1x106 cells were analysed 
per sample, with the top 1% of A#42-EGFP fluorescence from each sample being 
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gated and adjusted individually (as per Section 5.2.2.4) prior to sorting into fresh 
medium (approximately 1x104 cells captured). To enrich for high A#42-EGFP 
fluorescence, these sorted cultures were directly induced and sorted again for a 
total of three sorts. Figure 5.16 outlines the workflow and shows the resulting dot 
plots. 
 
 
Figure 5.16: Flow cytometry dot plots from FACS of E. coli expressing pAG2-A!42 
random peptide libraries and spiked controls. Cultures induced for between 11-15 h at 
30ºC at ~225 rpm. Gating was as per Figure 5.11; cells with the top 1% of A!42-EGFP 
fluorescence that exceeded mCherry background fluorescence were sorted into fresh 
medium (~1x106 cells screened per sample). Although this top 1% gate was adjusted for 
each sample sorted, the same RoI (calibrated in each row to pAG2-A!42 alone [column A]) 
is shown for the purposes of comparison between FACS rounds. n = 1. 
 
To easily detect enrichment and allow for comparison, the RoI for each round of 
FACS in Figure 5.16 is shown as calibrated to the pAG2-A#42 control (column A; 
shifted to top 1% for each sort). For the spiked positive control cultures, there are 
indications of enrichment occurring after Sort #2 for the Pep2 and AavLEA1 
samples (columns D & E), as the percentage of cells falling into the RoI increases 
above 1%. This is also seen for the brighter EGFP output of GM6 (column F, 
arrowed). This experiment was not repeated, however, therefore any possible 
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enrichment effects are indicative only. With regards to the random peptide libraries, 
after Sort #1 a small sub-population of cells with brighter A#42-EGFP fluorescence 
was seen in the pAG2-A#42-74 and pAG2-A#42-110 library samples (columns B & 
C, arrowed). After Sort #2, these populations were predominant, but appeared to 
have low levels of mCherry fluorescence (MFIs of 7.84 and 8.12 respectively, 
compared to 28.76 for the pAG2-A#42 control). After Sort #3, work was halted to 
investigate this problem further (see Section 5.2.3.4 below). Furthermore, the 
incubation temperature of 30ºC used during the rounds of FACS was seen to have 
an effect on A#42-EGFP output: the difference between pAG2-GM6 and 
pAG2-A#42 fluorescence shrank from ~6-fold (Section 5.2.2.4) to ~2-fold (e.g. in 
Pre-sort #3, EGFP MFIs of 290.23 and 113.48 respectively). This reduction in 
dynamic range could be explained by a decrease in the rate of A#42 aggregation in 
vivo at this lower temperature, thus allowing sufficient time for some EGFP to fold.  
 
Before continuing to employ FACS as a screening methodology, it was worth 
considering the expected enrichment after each round of sorting. If each positive 
spike is gated for sorting as per the RoI used in Figure 5.16, i.e. ~1% of background 
cells falling into the RoI, then ~10,000 negative cells will be obtained from the 
sorting of 1x106 cells (see Section 2.7.5.3). If it is conservatively estimated that only 
~5% of pAG2-A#42-Pep2/AavLEA1 cells meet the same RoI criteria, i.e. a 5-fold 
enrichment, then only 5 positive cells would be selected for from a 1x10-4 starting 
dilution (e.g. 5% of 1x106 cells sorted multiplied by 1x10-4). This number runs 
perilously close to being lost in background noise, and is similar for the 
pAG2-A#42-74/110 libraries. Sorting ten-fold more cells would be desirable, i.e. 
1x107, but time-consuming (~45 min per run). In addition, given that cells containing 
inserts were seen to be slow to enter exponential phase growth (e.g. pAG2-A#42-
Pep2/AavLEA1; see Section 5.2.2.3), any positive cells may be outcompeted at the 
very first round of sorting by “empty” pAG2-A#42. For GM6, ~35% of cells will 
conservatively fall in the RoI, resulting in 35 positive cells being successfully 
selected. Using the above assumptions of enrichment, i.e. 5-fold for Pep2/AavLEA1 
(as well as for a single putative hit from the ~25,000 colony pAG2-A#42-74/110 
libraries, i.e. a 4x10-5 starting dilution) and 35-fold for GM6, the percentage of true 
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positive cells in a population after each round of FACS can be estimated 
(Table 5.3). 
 
 
Table 5.3: Estimated levels of enrichment after rounds of FACS. Positive cell % of total 
cell population calculated as the enrichment factor to the power of n sorts, multiplied by the 
initial cell dilution expressed. Assumptions: % of positive cells that fall into sorting gate: 
pAG2-A!42-74/110/Pep2/AavLEA1, 5%; pAG2-GM6, 35%. Starting dilutions: 
pAG2-A!42-74/110 libraries, 4x10-5; pAG2-A!42-Pep2/AavLEA1 and pAG2-GM6, 1x10-4. 
The consequent reduction of negative cells in the total population during subsequent FACS 
rounds is ignored, as is any growth disadvantage incurred by positive cells (see Section 
5.2.2.3). 
 
It can be seen that at least six rounds of FACS would be required to enrich the 
Pep2 and AavLEA1 spikes to near homogeneity; at three rounds, only ~1.25% of 
cells in the post-sort culture are expected to be truly positive. With regards to Figure 
5.16, such numbers would be lost in the pAG2-A#42 negative background 
(cf. Figure 5.13). The situation is similar for the pAG2-A#42-74/110 libraries, where 
theoretically 1 potential hit could be present amongst the ~25,000 library colonies 
screened (a starting dilution of 4x10-5). For the GM6 spike, three rounds would be 
sufficient: only a small fraction is seen in Figure 5.16 after Sort #2 (column F, 
arrowed), as pAG2-GM6 cells are only expected to make up ~12% of the total 
population at this stage (multiplied by the 35% expected RoI event rate, this 
equates to ~4.3% of total cells). 
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5.2.3.4 Further analysis of FACS data 
As Section 5.2.3.3 indicated, E. coli cells containing members of the pAG2-A#42-74 
and pAG2-A#42-110 libraries were enriched for increased green fluorescence over 
the course of three rounds of FACS, with a correlated decline in red fluorescence. It 
appeared that plasmid instability was not just confined to the Library region (see 
Section 5.2.3.2). Upon fluorescence microscopy examination (Section 2.7.4), cells 
with bright green fluorescence were observed (Figure 5.17 A), but always lacked 
mCherry fluorescence. Those with dim green fluorescence were found to be 
mCherry positive. In addition, bright green fluorescence was seen to be constitutive, 
as samples plated on solid medium after the final round of FACS gave colonies that 
continued to fluoresce, despite the lack of inductive agent (Figure 5.17 B). It seems 
that a recombination event between the EGFP and mCherry coding regions of 
pAG2-A#42 occurred and was enriched for; Figure 5.17 C shows a rare split colony 
event arising on solid medium. However, a lack of mCherry fluorescence from such 
cells should have resulted in their rejection by the gating criteria used in 
Section 5.2.3.3. Re-examination of the pAG2-A#42-74/110 cell populations in 
pre-sort #3 of Figure 5.16 (columns B & C, arrowed), however, shows this not to be 
the case, as a large number of EGFP-bright cells breach the mCherry cut-off and 
fall into the RoI. If FACS were to be performed again, this gating criterion must be 
more stringent. 
 
 
Figure 5.17: FACS of E. coli expressing pAG2-A!42 libraries enriches for mutant 
recombinants. For each panel, from left to right: bright field, green fluorescence, red 
fluorescence. A: Cells with bright green fluorescence lack red fluorescence (circled).          
B & C: Cells plated on non-inducing medium give rise to colonies exhibiting plasmid 
recombination. Photos taken after 11 h arabinose induction (0.05%; + ara) in LB medium at 
37ºC at ~225 rpm (panel A) or 16 h at 37ºC without arabinose (panels B & C; - ara). Scale 
bar, 5 !m (panel A) or 250 !m (panels B & C). 
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Section 5.2.3.3 also indicated an effect of temperature on the aggregation kinetics 
of A#42-EGFP. To briefly explore this, several control cultures were induced at 
either 30ºC or 37ºC for 15 h and examined using fluorescence microscopy (see 
Section 2.7.4). At 30ºC, pAG2-A#42 cells showed dim fluorescence, whereas at 
37ºC no fluorescence was seen (Figure 5.18 A & B). Despite this, the in vivo effect 
of Pep2 and AavLEA1 on A#42-EGFP aggregation can again be seen (panels C 
& E; cf. Figure 5.8): the slower aggregation kinetics at 30ºC simply makes their 
effects more pronounced. 
 
 
Figure 5.18: E. coli expressing pAG2-A!42 and controls fluoresce brighter green at 
30ºC than at 37ºC. For each panel, from left to right: bright field, green fluorescence, red 
fluorescence. Photos taken after 15 h arabinose induction (0.05%) in LB medium at 30ºC 
(left column) or 37ºC (right column) at ~225 rpm. Green aggregates arrowed (panels C, E 
& F). Scale bar, 5 !m. 
 
Lastly, colonies that resulted from plating out the pAG2-A#42-74/110 and spiked 
libraries after the third round of FACS in Section 5.2.3.3 were analysed for the 
presence of insert in their Library site (Figure 5.19; pAG2-GM6 samples contained 
no Library insert, so were not examined). Before selection, colonies were examined 
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via microscopy to confirm that they were fluorescently “normal”, i.e. did not exhibit 
constitutive green fluorescence. In addition, two such constitutive green mutants 
were also analysed. 
 
 
Figure 5.19: Profile of Library site inserts after three rounds of FACS. Colony PCR 
(Section 2.2.5.2) shows the presence of inserts in 8 out of 12 pAG2-A!42-74/110 colonies 
assayed, and in 0 out of 14 pAG2-A!42-Pep2/AavLEA1 spiked samples. Empty plasmid 
should result in a 333 bp band; 74 library insert, 372 bp; 110 library insert, 408 bp; Pep2, 
370 bp; AavLEA1, 754 bp. G, constitutive green fluorescent mutant; WM, DNA ladder. 
 
All isolated colonies from the pAG2-A#42-Pep2 and pAG2-A#42-AavLEA1 spiked 
samples were found to contain the “empty” pAG2-A#42 plasmid (lanes 16 to 30); as 
expected, no Pep2 or AavLEA1 insertions were detected at such an early stage of 
enrichment (see Section 5.4.3.3). In addition, the constitutive green mutants 
(lanes 7 & 14) exhibited the ~575 bp artefact band, previously seen to be typical of 
plasmids lacking the Library site (Section 5.2.3.2). Further analysis of these mutants 
was not conducted. 
 
Finally, inserts from the sorted libraries of pAG2-A#42-74 (lanes 4 & 5) and 
pAG2-A#42-110 (lanes 10 to 13) were sequenced to check for any possibility of 
homogeneity at this early stage. Every sequence was found to vary (data not 
shown). This, together with the lack of positive control isolation from the positive 
control pAG2-A#42-Pep2/AavLEA1 spikes, confirmed that the FACS selection 
criteria used were not stringent enough to resolve true hits from background noise 
over the number of sorts conducted. Given that a much larger number of sorting 
rounds are required (see Section 5.2.3.3), and that potential positive hits may be 
outcompeted during culture growth (Section 5.2.2.3), FACS seems ill-suited to this 
particular screen. A simpler approach of screening library members directly on solid 
medium was instead investigated. 
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5.2.4 Using solid medium to screen for novel antiaggregant peptides 
To solve the twin problems of multiple FACS rounds being required to enrich a hit 
while contending with potential out-competition during growth by negative 
background cells (Section 5.2.3.4), pAG2-A#42 library members may instead be 
spatially isolated and induced as colonies on solid medium. Those containing 
successful Library site inserts would merely grow to a smaller size in a given time 
(as mentioned in Section 5.2.3.3), and colonies with the highest levels of EGFP 
fluorescence may be selected for further analysis using more sensitive techniques 
such as flow cytometry. 
 
5.2.4.1 Fluorescence of colonies expressing pAG2-A#42 and controls  
To test the solid medium screening approach, cultures of pAG2-A#42 and the 
various controls were plated on inductive LB agar (0.05% arabinose) and incubated 
for ~16 h at 37ºC. In addition, cultures of “empty” pAG2-A#42 were spiked at a ratio 
of 9:1 with cultures of pAG2-A#42-Pep2, pAG2-A#42-AavLEA1 or pAG2-GM6 to 
ascertain whether or not these positive control colonies could be readily identified 
from a negative background. Resultant colonies were examined by fluorescence 
microscopy (Figure 5.20). 
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Figure 5.20: Fluorescence microscopy of E. coli colonies expressing pAG2-A!42 and 
controls. For each panel, from left to right: bright field, green fluorescence, red 
fluorescence. Arrows indicate putative hit colonies in pAG2-A!42 samples spiked with 
indicated controls at a ratio of 9:1. Photos taken after 19 h arabinose induction (0.05%) on 
LB agar at 37ºC, then 2 h at ~23ºC. Scale bar, 250 !m. 
 
While pAG2-A#42 exhibited faint green fluorescence (panel A), encouragingly the 
pAG2-A#42-AavLEA1 colonies appeared noticeably brighter (panel C). It was, 
however, difficult to interpret an effect given by pAG2-A#42-Pep2 (panel B). With 
regards to the sample spikes, putative hit colonies were also detected amongst the 
background of pAG2-A#42 colonies, even for Pep2 (panels E to G, arrowed). 
Furthermore, all colonies examined also expressed mCherry, indicating against 
undesired plasmid recombination events. 
 
It should be noted that the time delay between removing the plates from incubation 
at 37ºC and inspecting them at room temperature (~23ºC) improved the contrast 
between negative and positive colonies (Figure 5.21). Leaving the plates at ~23ºC 
for 5 h before imaging, rather than 2 h, allowed for a green fluorescence output 
difference to be more clearly seen between pAG2-A#42 and pAG2-A#42-Pep2 
(panel E). This effect was especially pronounced for the pAG2-A#42-AavLEA1 
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construct (panel C), which became as bright as the non-aggregating pAG2-GM6 
control (panel D). This increased amount of green fluorescence was likely due not 
only to a reduced frequency of encounter between A#42-EGFP molecules (hence a 
decrease in A#42 aggregation; see Section 5.2.3.4), but also because of a reduced 
stability of hydrophobic forces at lower temperatures (Chandler, 2005). The same 
effect was also seen when plates were incubated at 30ºC instead of 37ºC (data not 
shown). 
 
 
Figure 5.21: Fluorescence microscopy of E. coli colonies expressing pAG2-A!42 and 
controls: 5 h at ~23ºC. Same as Figure 5.20, but photos taken after 5 h at ~23ºC 
post-37ºC incubation. *, marker pen artefact. Scale bar, 250 !m. 
 
Next, the overall green fluorescence from each spiked plate was photographed and 
the images processed as per Section 2.7.6 to emphasise colonies with the brightest 
output (Figure 5.22). At least ten hits identified in this manner were manually 
verified using fluorescence microscopy as above; all showed a level of green 
fluorescence greater than that of adjacent negative colonies. Note that colonies are 
required to be of a reasonable size (>0.5 mm in diameter), as otherwise the 
fluorescence signal was lost to the camera. Panel C illustrates this, with colony size 
being reduced due to a high cell density. 
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Figure 5.22: Fluorescence image processing of induced pAG2-A!42 E. coli colonies 
spiked with indicated controls. Colonies highlighted in red indicate putative hits in 
pAG2-A!42 samples spiked with indicated controls at a ratio of 9:1. Note that the dynamic 
range between background and hit is greater for the pAG2-GM6 spike (panel C), hence a 
greater contrast. Photos taken after 19 h arabinose induction (0.05%) on LB agar at 37ºC, 
then ~4 h at ~23ºC. Scale bar, 10 mm. 
 
To confirm correct colony identification, selected hits from the spiked plates shown 
in Figure 5.22 were analysed for the presence of the appropriate Pep2 or AavLEA1 
Library site insert by colony PCR. (pAG2-GM6 hits could not be identified in this 
manner, as the construct contains no insert.) Negative colonies (i.e. those with 
background levels of green fluorescence) were not analysed. Figure 5.23 shows 
that 4 from 5 of the selected pAG2-A#42-Pep2 hits contained the correct insert 
(lanes 3 to 7), while for pAG2-A#42-AavLEA1 (lanes 11 to 15) the success rate was 
5 from 5. The fluorescence imaging and colony PCR results together confirm and 
extend the work of Wurth et al. (2002) and Baine et al. (2009), indicating that 
screening in vivo peptide libraries using solid medium is a pursuable strategy. 
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Figure 5.23: Profile of hit colonies identified by fluorescence image analysis. Colony 
PCR (Section 2.2.5.2) shows the presence of inserts in 4 out of 5 pAG2-A!42-Pep2 spiked 
hits, and in 5 out of 5 pAG2-A!42-AavLEA1 spiked hits. Empty plasmid should result in a 
333 bp band; Pep2, 370 bp; AavLEA1, 754 bp. WM, DNA ladder. 
 
5.2.4.2 Screening for novel antiaggregant peptides 
The ligated pAG2-A#42-74 and pAG2-A#42-110 libraries generated in 
Section 5.2.3.1 were transformed again into E. coli DHB10 and induced on agar as 
per Section 2.7.3. Approximately 38,000 pAG2-A#42-74 and 36,000 
pAG2-A#42-110 colonies were generated and imaged as per Section 2.7.6 to try to 
identify colonies with an above-background green fluorescence output 
(Figure 5.24 A & B). A number of putative hits were identified, and of these 114 
(~0.15% of total) were manually verified using fluorescence microscopy 
(Section 2.7.4), with mCherry expression also being confirmed (Figure 5.24 C & D). 
This represented an initial hit rate of approximately 0.21%, as only ~75% of the 
~74,000 total colonies plated were expected to contain library inserts (due to 
contaminating recombinant plasmid; see Section 5.2.3.2 for explanation). In 
addition, some mutant recombinants were observed at a frequency of one or two 
colonies per plate, i.e. bright green fluorescence without red fluorescence (see 
Section 5.2.3.4). While these colonies upset the contrast of the image acquisition 
process (see panel B), they did not ultimately interfere with the screen. The hit 
colonies visualised in panels C & D were not pursued further due to their adjacency 
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to negative colonies; rather, these images serve as further confirmation that the 
screening methodology is able to isolate putative antiaggregation events. 
 
 
Figure 5.24: Fluorescence image processing of induced pAG2-A!42 E. coli colonies 
reveals those that may express a novel antiaggregant. Representative experiment 
shown. Colonies highlighted in red indicate putative hits; those numerically labelled were 
investigated further (negative controls are lettered). In panel B, x denotes a bright green hit 
with no red fluorescence (an undesired recombinant), which increased the contrast of the 
image. Arrows indicate examples of hit colonies under fluorescence microscopy. Photos 
taken after 16 h arabinose induction (0.05%) on LB agar at 37ºC, then ~3.5 h at ~23ºC. 
Representative photos shown (n = 20 plates per library); scale bar, 10 mm (panels A & B) 
or 250 !m (panels C & D). 
 
5.2.4.3 Validation through flow cytometry 
Of the putative antiaggregant hits identified in Section 5.2.4.2, nine pAG2-A#42-74 
and nine pAG2-A#42-110 colonies were selected for further analysis using flow 
cytometry. In addition, two pAG2-A#42-74 and three pAG2-A#42-110 colonies that 
showed no signs of increased A#42-EGFP fluorescence were selected as negative 
controls (e.g. labelled “B” in Figure 5.24 A & B). Cultures were induced for 14 h at 
37ºC and analysed as per Section 2.7.5.1, with a delay of ~2 h at ~23ºC before flow 
cytometry to try to maximise green fluorescence output (see Section 5.2.4.1). The 
resulting dot plots for several samples are shown in Figure 5.25 (see Appendix 10 
for all dot plots obtained). 
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Figure 5.25: Flow cytometry dot plots from E. coli expressing pAG2-A!42-74 and 
pAG2-A!42-110 library hits and controls. Cultures induced for 14 h at 37ºC at ~225 rpm 
before analysis of EGFP and mCherry fluorescence. 100,000 total events recorded, initial 
doublet discrimination (data not shown) and RoI covering top ~1% of pAG2-A!42 
EGFP:mCherry ratio performed as per Figure 5.11. Dot plot densities: blue (highest), red 
(lowest). Median fluorescence intensity (arbitrary units) shown for whole plot: EGFP (green 
bullet), mCherry (red bullet). Representative plots shown (n = 3). 
 
A RoI was set for pAG2-A#42 as per Section 5.2.2.4 so that the top ~1% of its 
EGFP:mCherry ratio was selected (panel A1). However, the positive controls 
pAG2-A#42-Pep2/AavLEA1 (panels A2 & A3) did not show any shift along the 
X-axis as per Figure 5.11. While their raw green MFI values were above that of 
pAG2-A#42, they were less than the two-fold extent that was expected. However, 
the negative library controls (74-B1-B in panel A5 shown as a representative 
example) performed similarly to pAG2-A#42, although 74-A1-A exhibited a positive 
shift with 9.39% of cells falling into the RoI (see Appendix 10). With regards to the 
pAG2-A#42-74/110 library hits, all exhibited greater than background A#42-EGFP 
fluorescence, showing that their behaviour in liquid culture is similar to that 
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observed during their selection on solid medium. An exception to this was 74-C1-1 
(panel B5; although panels B2 & B3 show no increase in RoI %, they do exhibit an 
increase in EGFP output), which was akin to the pAG2-A#42 control. While no hits 
exhibited an effect as dramatic as that of the non-aggregating pAG2-GM6 control, 
110-A1-4, 110-C3-3 and 110-C3-7 appeared relatively strong (row C). Figure 5.26 
plots the observed MFIs for all of the samples, as well as the EGFP:mCherry ratios 
for comparison. 
 
 
Figure 5.26: MFIs from E. coli expressing pAG2-A!42-74 and pAG2-A!42-110 library 
hits and controls. Ranked by EGFP fluorescence, data taken from representative plots 
shown in Figure 5.25 (n = 1). Median fluorescence intensities: EGFP (green bars), mCherry 
(red bars); EGFP:mCherry ratio (yellow dots). Highlighted labels: selected controls (yellow), 
clumping cultures (red), example of bright red fluorescence (blue). Error bars represent 
robust coefficient of variation (see Section 2.7.5.4). 
 
The dotted line in Figure 5.26 represents a stringency cut-off for potentially 
significant EGFP:mCherry ratios: while most of the negative controls fall below this, 
74-A1-A (highlighted yellow) rivals many of the putative hits. Aside from the non-
aggregating pAG2-GM6 controls, only three constructs were seen to exhibit ratios 
exceeding this high threshold: 110-C3-3, 110-C3-7 and 110-A1-4 (arrowed). 
Furthermore, as in Section 5.2.2.4, mCherry fluorescence was seen to vary widely; 
for example, there was an approximate 3-fold difference between 110-B1-3 
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(highlighted blue; Figure 5.25 C2) and the pAG2-A#42 control. In many similar 
cases, this increase in mCherry fluorescence nullified any gain in A#42-EGFP 
output with respect to the ratiometric approach. 
 
A number of constructs (highlighted red) were observed to consistently exhibit cell 
clumping in liquid culture under both inducing and non-inducing conditions. While 
similar to that seen with pAG2-A#42-AavLEA1 (Section 5.2.2.3), clumping in these 
samples was more severe: in the case of 74-B2-6, cells sedimented to the bottom 
of the incubation vessel, with little turbidity visible in the strata above even during 
shaking incubation (Figure 5.27). However, turbidity in the upper strata was 
restored after several hours of additional incubation, and cell viability in all cases 
was unaffected. Immediately before flow cytometry, clumping cultures were 
thoroughly vortexed to aid dispersion, and the initial gating criteria ensured that only 
single cells were analysed (see Section 2.7.5.1). 
 
 
Figure 5.27: Examples of clumping in pAG2-A!42-74 and pAG2-A!42-110 cultures.  
A: Photo taken after ~16 h incubation in LB medium (without arabinose) at 37ºC at 
~225 rpm. Sedimentation arrowed; note the greater clarity of the 74-B2-6 sample. B: Photo 
of clumping cells grown as above, but after 3 h incubation. Scale bar, 5 !m. 
 
After several repeats, the severity of clumping was ranked as follows: 110-C3-3 > 
74-B1-3 > 110-A1-4 > 74-B2-6 > 110-C2-3 > AavLEA1. Interestingly, some of these 
“clumpers” also exhibited high levels of mCherry fluorescence (see Figure 5.26). In 
an attempt to further normalise the observed mCherry levels, a gate encompassing 
cells with a narrow range of mCherry MFI was created, and the corresponding 
EGFP fluorescence levels analysed (Figure 5.28). 
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Figure 5.28: Histograms of EGFP fluorescence with/without gating a narrow segment 
of mCherry fluorescence. Data taken from representative plots shown in Figure 5.25 
(n = 1), with rows 2 & 3 giving the mCherry (red bullet) and EGFP (green bullet) median 
fluorescence intensities (arbitrary units) respectively. mCherry fluorescence gated as per 
narrow band indicated in row 2, corresponding EGFP fluorescence shown in row 1. 
Histograms (blue) overlaid on that of pAG2-A!42 (pink) for comparison. 
 
For comparison, the selected histograms are shown overlaid on that of pAG2-A#42; 
in rows 1 (mCherry gate) and 3 (ungated), a RoI is also indicated to highlight any 
comparative increase in EGFP fluorescence. While the non-aggregating pAG2-GM6 
control exhibited a positive shift in EGFP fluorescence no matter if it was gated (B1) 
or not (B3), putative hits such as 72-B2-6 and 110-A3-5 revealed a commensurate 
drop in EGFP output when their increased mCherry levels were normalised to 
pAG2-A#42 (C1 & D1). 110-C3-3, on the other hand, retained a slight increase in 
EGFP output (E1). Figure 5.29 plots the mCherry-normalised MFIs for all of the 
putative hits and controls, as well as their adjusted EGFP:mCherry ratios. 
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Figure 5.29: MFIs from E. coli expressing pAG2-A!42-74 and pAG2-A!42-110 library 
hits and controls: gated to a small segment of mCherry fluorescence. Ranked by 
EGFP fluorescence, data taken from representative plots shown in Figure 5.25 (n = 1). 
Median fluorescence intensities: EGFP (green bars), mCherry (red bars); EGFP:mCherry 
ratio (yellow dots). Highlighted labels: selected controls (yellow), clumping cultures (red), 
example of bright red fluorescence from Figure 5.26 (blue). Error bars represent robust 
coefficient of variation (see Section 2.7.5.4). 
 
Using the same stringency cut-off as Figure 5.26 (dotted line; the EGFP:mCherry 
ratio of the negative control 74-A1-A), the same three hits of 110-C3-3, 110-C3-7 
and 110-A1-4 were again seen to outperform EGFP fluorescence from the 
pAG2-A#42 control. This indicates that assessing the EGFP:mCherry ratio in the 
first instance is adequate to judge the potential of a hit without resorting to 
additional gating criteria. Interestingly, constructs that exhibited cell clumping 
(highlighted in red) showed a relative increase in their normalised fluorescence ratio 
that correlated with an increased severity of clumping (ranked beneath Figure 5.27). 
pAG2-A#42-Pep2/AavLEA1, on the other hand, showed negligible improvement in 
EGFP output, with their ratios remaining similar to that of pAG2-A#42 alone. As 
alluded to earlier in Section 5.2.2.4, this variance between different experiments 
may make isolating true antiaggregant hits difficult. To try to achieve a consensus, 
the plasmids from each hit were isolated, retransformed into fresh E. coli DH10B, 
and subsequently induced and analysed by flow cytometry as per Section 2.7.5.1 
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separately on three consecutive days using the same parameters. Figure 5.30 plots 
the mean of the MFIs observed, as well as their EGFP:mCherry ratios. 
 
 
Figure 5.30: Mean MFIs from three repeats of E. coli expressing pAG2-A!42-74 and 
pAG2-A!42-110 library hits and controls. Cultures induced and analysed as per Figure 
5.25, ranked by EGFP fluorescence. Mean fluorescence intensities: EGFP (green bars), 
mCherry (red bars); mean EGFP:mCherry ratio (yellow dots). Highlighted labels: selected 
controls (yellow), clumping cultures (red). Error bars represent 1 standard deviation (n = 3). 
 
Despite being carried out under the same conditions, mCherry levels were seen to 
fluctuate greatly in some samples (such as 110-A3-5, 74-B2-6 and 74-B1-B) over 
the three repeats. When the stringency cut-off (dotted line) is set to the negative 
control exhibiting the highest mean EGFP:mCherry ratio (110-B1-B, highlighted 
yellow), several samples were seen to outperform, including two of those identified 
initially in Figure 5.26. While reproducibility seems to be an issue with this assay, hit 
trends can be detected. 
 
5.2.4.4 Fluorescence microscopy of library hits 
During the conduction of flow cytometry for Figure 5.30, E. coli expressing 
pAG2-A#42-74/110 library hits were inspected using fluorescence microscopy (see 
Section 2.7.4). A selection of these are shown in Figure 5.31. 
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Figure 5.31: E. coli expressing pAG2-A!42 library hits possess green fluorescent 
aggregates. For panels A to D, from left to right: bright field, green fluorescence, red 
fluorescence. Panels E & F show green fluorescence filter only, exposure adjusted to allow 
mCherry bleed-through (see Section 2.7.4). Photos taken after 14 h arabinose induction 
(0.05%) in LB medium at 37ºC at ~225 rpm, then several hours at ~23ºC. Green 
aggregates arrowed (panels B, C & D). Representative photos shown (n = 3); scale bar, 
5 !m. 
 
Many cells (but by no means the majority) in each hit culture were observed to 
possess a single, punctate green fluorescent aggregate at one pole, as observed 
earlier during induction of the pAG2-A#42-Pep2 and pAG2-A#42-AavLEA1 controls 
in Figures 5.8 & 5.18. This is best demonstrated in panel E, while panel F serves to 
show the same in an example of clumping cells (110-A1-4). Furthermore, cells 
exhibiting brighter mCherry fluorescence appeared more likely to contain these 
aggregates (e.g. panels C & D). For the negative controls, however, this was not 
seen to be the case (e.g. panel A). 
 
5.2.4.5 Bioinformatic analysis of library hits 
The putative antiaggregant hits from colony screening (Section 5.2.4.2) had their 
DNA insert sequenced and analysed as per Section 2.7.7. Table 5.4 summarises 
the findings; for full DNA insert sequences, see Appendix 9. 
Name bp GC Peptide sequence (# aa) Composition Q H Hyphb. Culture notes
A!42 126 50% DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA (42) Gly/Val (14%)
Ala (10%)
0 -0.01 38%
GM6 126 52% DAEFRHDSGYEVHHQKLVSFAEDVGSNKGAIIGPMVGGVVIA (42) Gly/Val (14%)
Ala (10%)
0 -0.05 33%
Pep2 42 46%               QKLDVVAEDAGSNK (14) Asp/Gly/Lys/Val (14%) -1 -0.25 21% Bright red pellet
AavLEA1 426 63%
SSQQNQNRQGEQQEQGYMEAAKEKVVNAWESTKETLSSTAQAAAEKTAEF
RDSAGETIRDLTGQAQEKGQEFKERAGEKAEETKQRAGEKMDETKQRAGE
MRENAGQKMEEYKQQGKGKAEELRDTAAEKLHQAGEKVKGRD (142)
Glu (18%)
Ala (13%)
Lys (12%)
-3 -0.40 12%
Minor cell clumping, bright red 
pellet
74-B1-3 36 57% PGKRAKRTGRW (11) Arg (27%)
Gly/Lys (18%)
+5 -0.61 9% Cell clumping, bright red pellet
74-B1-5 36 64% TPGGWIPLQRNG (12) Gly (25%)
Pro (17%)
+1 -0.10 25%
74-B2-6 36 71% AQGRGRDCSGGR (12) Gly (33%)
Arg (25%)
+2 -0.50 0% Cell clumping, bright red pellet
74-B4-3 36 69%
RVGGGPAG (8)
No other potential ORFs
Gly (44%) +1 -0.05 12%
74-C1-1 36 62%
GLH (3)
No other potential ORFs
- +1 0.09 33%
74-C3-1 53 55% EPGKGPNDFGKH (12) Gly (25%)
Lys/Pro (17%)
+1 -0.30 8%
74-C4-1 36 69% ARKPVGRRATRG (12) Arg (33%)
Ala/Gly (17%)
+5 -0.58 8%
74-C4-3 36 67% VAGAGGGNSQAP (12) Gly (33%)
Ala (25%)
0 0.02 8%
74-C4-4 52 60% CRRDQRARHQRG (12) Arg (42%)
Gln (16%)
+5 -0.90 0%
74-A1-A 97 62% SRNVGGRGLRRR (12) Arg (42%)
Gly (25%)
+5 -0.67 17% Negative control
74-B1-B 36 67% VHLPRGLVVRER (12) Arg/Val (25%)
Leu (17%)
+3 -0.29 42% Negative control
Name bp GC Peptide sequence (# aa) Composition Q H Hyphb. Culture notes
110-A1-1 71 57%
LACGRCR (7)
Alternative ORF: ATG 15 bp from RBS
WSVQVMDRMCGNTTDPQGNGG (21)
Arg/Cys (29%)
Alt. ORF:
Gly (19%)
+2
Alt. ORF:
-1
-0.35
Alt. ORF:
-0.18
14%
Alt. ORF:
24%
110-A1-4 88 60% RMCGNSVGRSVWVSGRVAQRTSGR (24) Arg (21%)
Gly/Ser/Val (17%)
+5 -0.31 25% Cell clumping, bright red pellet
110-A3-5 167 62%
AV (2)
Alternative ORF: ATG 8 bp from putative RBS
GHGAGRKWMKR (11)
-
Alt. ORF:
Gly (27%)
0
Alt. ORF:
+5
0.39
Alt. ORF:
-0.43
50%
Alt. ORF:
18%
Bright red pellet
110-B1-3 78 69%
DAKRG (5)
Alternative ORF: ATG 11 bp from RBS
LSVDSSPAGVGMGGRAGARHGRGEA (25)
Alt. ORF:
Gly (27%)
Arg/Lys (18%)
+1
Alt. ORF:
+2
-0.63
Alt. ORF:
-0.15
0%
Alt. ORF:
16%
Bright red pellet
110-C2-2 72 51% RDTELWQYKDGCRCVVGVGWDRYS (24) Arg/Asp/Gly/Val (13%) 0 -0.28 33%
110-C2-3 72 62%
(0)
Alternative ORF: GTG 9 bp from RBS
RRFGVVSLRGREKRALRGGRGDVMKR (26)
Alt. ORF:
Arg (31%)
Gly (19%)
Alt. ORF:
+8
Alt. ORF:
-0.51
Alt. ORF:
27% Cell clumping, bright red pellet
110-C3-3 72 55% LDRGLVDREYSRRGQAFGQLCARG (24)
Arg (21%)
Gly (17%)
Leu (13%)
+2 -0.35 25% Cell clumping, bright red pellet
110-C3-7 72 65% GQGCRMVNDPHKRARGRGRRGSQG (24) Arg/Gly (25%) +7 -0.54 8%
110-C4-3 72 46% RPGSVDSEQTSVLLKSSFRVYKDS (24) Ser (25%)
Val (13%)
+1 -0.28 29%
110-A1-A 72 49%
GE (2)
No other potential ORFs
- -1 -0.23 0% Negative control
110-B1-B 72 55% GETTSVRTA (9) Thr (33%) 0 -0.24 11% Negative control
110-C1-C 72 54% SAPCIMGSGRCGVLDSVNFRSRST (24) Ser (21%)
Arg/Gly (13%)
+2 -0.17 25% Negative control
Table 5.4: Peptide sequence and properties of pAG2-A!42 random DNA library hits. Name, 74 (36 bp random DNA library) and 110 (72 
bp random DNA library); bp; actual length of DNA insert (excluding start and stop codons); GC, content % of random DNA insert; ORF, open 
reading frame; RBS, ribosome binding site; Composition, % of predominant amino acids; Q, charge; H, mean hydrophobicity derived from 
Eisenberg’s consensus hydrophobicity scale (1984); Hyphb., % of hydrophobic residues (F, I, L, N, V, W & Y); Culture notes, anything 
significant noted during the screening process. Amino acids encoded by the plasmid backbone, as opposed to the random DNA insert, are 
underlined for clarity.
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Insert DNA lengths between the start and stop codons were mostly as expected: 
36 bp for the 74 library, and 72 bp for the 110 library (see Section 5.2.3.1). Other 
lengths were also seen, e.g. double insertion events in 74-A1-A (97 bp) and 
110-A3-5 (167 bp). The GC bias of the DNA of the 18 sequenced putative hits, at 
an average of 61%, was relatively high. This may have been a consequence of the 
amino acids favoured for antiaggregant properties by the screen. For example, 
arginine and glycine were particularly prominent in all hit peptides, and the 
corresponding codons for these amino acids are GC rich. However, inserts from the 
negative controls revealed a similar average GC content (~62%). PCR amplification 
during library generation may have introduced such a bias; or, given the difficulty of 
synthesising the random oligonucleotides (see Section 5.2.3.1), a high GC content 
could have been favoured from the beginning.  
 
The desired peptide lengths of 12 aa and 24 aa (for the 74 and 110 libraries 
respectively, discounting the initiating methionine [Ben-Bassat et al., 1987]) were 
not always achieved. As the length of random base pairs increased, so did the 
probability of an internal stop codon being incorporated: for the 74 library, ~44% of 
peptides were predicted to possess an internal stop codon, while for the 110 library 
the probability rose to ~68% (see Section 2.7.7 for calculation). However, the actual 
number of peptides incorporating internal stop codons was seen to be less than 
predicted: ~27% for the 74 library and ~50% for the 110 library respectively, most 
likely due to the high GC sequence bias observed (stop codons being TA rich). As a 
result of internal stop codons, a number of peptides were predicted to encode very 
short peptides, potentially representing false positives. For instance, 74-C1-1 only 
encoded 3 aa; this most likely explains why its fluorescence output was similar to 
that of the pAG2-A#42 control when analysed by flow cytometry (see 
Section 5.2.4.3). However, for a number of truncated sequences (e.g. 110-C2-3), an 
alternative ORF could be identified (see Appendix 9). This potentially allows for a 
longer peptide product to be produced. 
  
In general, the putative hit peptides were cationic (average charge of +3) and 
largely hydrophilic (mean hydrophobicity of -0.33; average hydrophobic residue 
content of 17%). This differed little from the negative controls (average charge of 
+3, mean hydrophobicity of -0.34; average hydrophobic residue content of 24%). 
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None of these properties correlated with an increased effect of a peptide on 
A#42-EGFP fluorescence output in vivo (see Section 5.2.4.3). Additionally, while all 
culture samples had pink coloured pellets when centrifuged (due to mCherry 
expression), a number exhibited a noticeably brighter shade of red. These 
observations unsurprisingly correlated with high mCherry fluorescence levels 
observed during flow cytometry (e.g. 74-B2-6 & 110-A3-5). 
 
In order to try to identify potential #-breaker hits (see Section 5.1.3.3), the putative 
hit peptides and negative controls were aligned pairwise with A#42 (Figure 5.32). 
Although average hit peptide hydrophobicity was low (see above), sequences that 
might potentially complement the hydrophobic #-fold regions of A#42 (17-21 and 
30-42) were focused on. 
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Figure 5.32: Pairwise alignment of putative antiaggregants to A!42 reveals little 
homology. Residue positions indicated. Green dots represent hydrophobic region hits, 
while blue dots represent putative !-turn region hits. Colon, indicates similarity between 
side-chains; altO, alternative ORF. EMBOSS Matcher used to generate alignments (see 
Section 2.7.7). 
 
While the putative antiaggregants contained plenty of cationic residues that may act 
as #-fold disrupter elements (Soto & Estrada, 2005), there were few obvious 
hydrophobic regions of homology (green dots) to act as recognition elements 
between these hits and the A#42 sequence. Indeed, the negative control 74-B1-B 
showed as much homology to the C-terminal hydrophobic region of A#42 as did the 
hit 110-C2-2. Other peptides (blue dots), such as 110-C3-3, showed homology with 
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the putative #-turn region between residues 25-29 (DaSilva et al., 2010). These 
could potentially interfere with intermolecular #-sheet hydrogen bonding and thus 
aggregation, as disruption of a salt bridge formed between Asp23 and Lys28 of 
adjacent A# peptides has been shown to ameliorate fibril formation (Lührs et al., 
2005). Alternatively to acting as traditional #-breakers, it may be that the hit 
peptides interfere with cross-#-sheet interactions between A#42-EGFP 
protofilaments (see Section 5.1.2.1). Sato et al. (2006b) showed that the IxGxMxG 
motif, found at the C-terminus of A#42, formed “glycine grooves” running along the 
axis of one outer face of a protofilament. The deployment of peptides incorporating 
a complementary GxFxGxF motif bound these grooves, and in combination with 
hydrophilic residues at the “x” positions, inhibited mature fibril formation. However, 
examination of the putative antiaggregant hits in Table 5.4 reveals that only 
110-A1-4 and 110-C3-3 possess something similar to this motif (10SxWxSxR16 and 
18GxLxAxG24 respectively). Although these hits exhibited an increase in A#42-EGFP 
output during flow cytometry trials (Section 5.2.4.3), as well as exhibiting green 
fluorescent aggregates (Section 5.2.4.4), it is unlikely that the above may be their 
mode of operation; if A#42-EGFP is able to aggregate into protofibrils before any 
therapeutic effect takes place, EGFP would not be expected to fold correctly and 
hence fluoresce. 
 
Next, in order to try to identify any shared regions of homology between the hit 
peptides themselves, their sequences were aligned (Table 5.5). 
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Table 5.5: Sequence alignment of putative antiaggregant peptides. Sequence length 
indicated. Amino acids are colour coded: cationic (pink), hydrophobic (red), anionic (blue) 
and uncharged hydrophilic (green). altORF, alternative ORF. ClustalW2 used to generate 
alignment (see Section 2.7.7). 
 
While no obvious motif appears common between all of the hit peptides, some more 
local alignments can be discerned. At the top of Table 5.5, a good level of homology 
can be seen between the peptides 74-B1-3 and 110-C2-3-altORF; these two 
constructs (the second harnessing a putative alternative ORF; see Table 5.4) show 
similar levels of fluorescence in E. coli (Figure 5.30, left-most on X-axis), and both 
exhibit the cell clumping phenotype. 74-C4-1 is also somewhat homologous to 
these peptides, but does not display the clumping phenomenon. Peptides 74-B2-6, 
110-C3-7 and 110-A1-1 (middle of table) also share a region of homology, but do 
not have similar fluorescence or phenotypic profiles. 
 
Lastly, hit constructs seen to possess the cell clumping phenotype (Table 5.4) were 
aligned in isolation in a further attempt to find a common motif (Table 5.6). 
 
 
Table 5.6: Sequence alignment of peptides from clumping constructs. Sequence 
length indicated. Amino acids are colour coded: cationic (pink), hydrophobic (red), anionic 
(blue) and uncharged hydrophilic (green). Star, indicates side-chain match; altORF, 
alternative ORF. ClustalW2 used to generate alignment (see Section 2.7.7). 
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Aside from 74-B1-3 and the alternative ORF of 110-C2-3 (mentioned above), no 
other regions of obvious homology were found. While Table 5.4 revealed that all 
“clumping” peptides contained a high proportion of arginine and glycine, e.g. 
74-B1-3 (Arg 27%, Gly 18%) and 110-C3-3 (Arg 21%, Gly 17%), so do many other 
“non-clumping” peptides, e.g. 74-C4-1 (Arg 33%, Gly 17%) and 110-C3-7 (Arg 25%, 
Gly 25%). It is thus hard to find a common denominator that links these peptides. 
 
5.2.4.6 Selection of putative antiaggregant peptides for in vitro analysis 
Several putative antiaggregant peptides were selected to be chemically-synthesised 
based on their performance in vivo as assessed by flow cytometry (Section 5.2.4.3). 
A range of peptides was chosen (Table 5.7), including those whose constructs 
exhibited cell clumping. It was envisaged that these peptides would be assessed 
in vitro for their ability to influence A#42 aggregation via the ThT assay (LeVine, 
1993) as per Baine et al. (2009), with Pep2 serving as a positive control. However, 
time constraints did not permit this. 
 
 
Table 5.7: Putative antiaggregant peptides selected for in vitro characterisation. 
Composition, % of predominant amino acids; Q, charge; H, mean hydrophobicity derived 
from Eisenberg’s consensus hydrophobicity scale (1984); Hyphb., % of hydrophobic 
residues (F, I, L, N, V, W & Y); Culture notes, anything significant noted during the 
screening process. 
 
Collaborators in the laboratory of Prof Yizhi Zheng (College of Life Science, 
Shenzhen University, China) are currently pursuing these experiments. Preliminary 
results indicate that the peptides 110-A1-4 and 110-C3-7 have a moderate effect on 
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the rate of A#42 aggregation, similar to that of the positive control 
epigallocatechin-3-gallate (EGCG; a polyphenol from green tea) (Ehrnhoefer et al., 
2008). The remaining peptides, including Pep2, appear to have no effect. 
 
5.3 Discussion 
High-throughput screens that dispense with the need for expensive and 
cumbersome synthetic A# peptide are desired to aid in the isolation of novel 
antiaggregants (Lansbury, 2001). The use of an in vivo recombinant fluorescent 
reporter for the aggregation state of A#, first outlined by Wurth et al. (2002), has 
been coupled in this work to the concurrent constitutive production of peptides to 
screen for those possessing novel antiaggregant activity. In an attempt to introduce 
greater robustness, mCherry was also co-expressed as an internal fluorescence 
standard to allow for ratiometric comparison between samples. 
 
One of the key advantages of the pAG2-A#42 screen is that, as A# expression is 
inducible, inhibitors of the earliest events of A# aggregation can potentially be 
identified: this renders moot what particular oligomeric state is most toxic (Carter et 
al., 2010). However, given that a heterologous system to the human brain is being 
used, the clinical activity of any peptide hits identified is putative. Although no 
absolute prevention of A#42-EGFP aggregation was observed in E. coli (cf. the 
non-aggregating GM6-EGFP control), this was in line with previous screens that 
used a similar reporter system (Kim et al., 2006; Baine et al., 2009). A ~2-fold 
increase in A#42-EGFP fluorescence is the best previously reported effect for a 
peptide-based inhibitor, i.e. Pep2 (Baine et al., 2009), as opposed to a ~6-fold 
increase observed with GM6-EGFP. In this work, several putative antiaggregant 
hits, such as 110-A1-4 and 110-C3-7, were seen to exhibit similar if not greater 
increases in A#42-EGFP output in comparison to Pep2. Despite the internal 
mCherry standard output fluctuating in some samples, these peptides exhibited 
consistently higher EGFP:mCherry ratios than the negative controls. In addition, the 
desiccation-implicated “molecular shield” AavLEA1 (Goyal et al., 2005a) also 
showed a similar effect to Pep2. While not a peptide, the in vitro activity of AavLEA1 
against A#42 would be interesting to ascertain. 
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Together with the concurrent observation of punctate green fluorescent aggregates 
in E. coli host cells, modest increases in A#42-EGFP output indicated that at least a 
reduction in the rate of A#42 aggregation was achievable in vivo. It was initially 
hoped that diffuse green fluorescence could be restored to the E. coli host, i.e. like 
that observed for the non-aggregating GM6-EGFP control. However, the 
observation of green fluorescent aggregates, both in the Pep2 and AavLEA1 
controls and several hits, indicates that A#42-EGFP aggregation is only inhibited 
sufficiently enough to allow EGFP to fold in some cells. Once folded, the 
chromophore is stable; subsequent aggregation still results in fluorescent particles 
(Waldo et al., 1999). Similar patterns of discrete aggregation to the work presented 
here are also observed with stress-denatured proteins (Zietkiewicz & Liberek, 
2010), which often localise at the cell poles of a bacterium. An explanation for this 
localisation is that it partitions dead-end and potentially toxic products away from 
the critical nucleoid region of a bacterium (Winkler et al., 2010), as well as allowing 
for asymmetric inheritance of an aggregate burden during cell division to a single 
daughter cell (Treusch et al., 2009). Overall, this increases the fitness of the 
bacterial population as a whole. Non-inhibited A#42-EGFP is also expected to 
aggregate and localise in the same manner; however, a lack of fluorescence 
prevents direct visualisation. It would be interesting to assess the structure of both 
inhibited/uninhibited A#42-EGFP at the nanometre scale using electron microscopy, 
as observations on the actual physical state (rather than implied) of such A# fusions 
have yet to be reported. 
 
The use of FACS was originally envisaged to conduct the antiaggregant peptide 
library screen, but unfortunately proved unmanageable. Three factors were 
primarily responsible for this. Firstly, the low dynamic range between background 
negative cells and the positive control (~2-fold at best for Pep2) led to poor gating of 
rare positive events; multiple rounds of FACS (six-plus) would be required to enrich 
a single hit from a small (~1x104) library. Secondly, while the above is an 
inconvenient but not insurmountable obstacle, the pAG2-A#42 plasmid exhibited 
partial instability, resulting in a minute but incurable background population of 
negative background constructs, as well as rare instances of constitutive green 
fluorescence that could be inappropriately enriched during FACS. To remediate 
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this, redesign of the pAG2-A#42 vector is required to ensure that the operational 
sequences used are sufficiently heterologous to discourage recombination. Lastly, 
E. coli containing inserts in the pAG2-A#42 Library site exhibited a slower entry into 
exponential growth compared to “empty” pAG2-A#42, potentially leading to any 
positive hits being out-competed in culture by negative background cells. If all of 
these problems these could be eliminated the FACS approach may become viable. 
Instead, the approach of directly inducing and screening pAG2-A#42 library 
colonies was utilised (Wurth et al., 2002; Baine et al., 2009). While this mitigated 
the problems of undesired plasmid recombination and background cells, it could not 
solve the lack of dynamic range between the A#42-EGFP output from negative and 
positive cells. 
 
While flow cytometry of E. coli expressing the putative hits was used to further 
validate the primary colony screen, it also revealed that mCherry fluorescence 
levels, rather than being uniformly stable, varied between different library members. 
For example, a ~2-fold difference in mCherry output was observed between 
110-B1-3 and the “empty” pAG2-A#42 control. This put the reliability of using 
constitutively expressed mCherry as a ratiometric standard in doubt. Why such 
variance occurred is unclear, but some general comments can be made. Firstly, 
vector construction is often assumed to be a “plug and play” affair, where discrete 
encoding sequences can be inserted or removed in isolation. However, as synthetic 
biologists are realising, biological systems are inherently noisy (Kelly et al., 2009). 
“Parts” are not insulated from each other, and as a consequence may work 
unpredictably under different configurations and conditions (Kwok, 2010). Although 
all variables aside from the random DNA library insert were closely controlled to 
ensure experimental homogeneity, variability between even the same samples run 
on different days was observed (e.g. 110-A3-5). Despite such variation, trends can 
still be discerned between sample runs: Endy and co-workers concluded the same 
while assessing promoter activity using a fluorescent reporter, as measurements 
varied by ~2-fold when made by separate research groups despite following the 
same protocol (Kelly et al., 2009). 
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Curiously, several putative antiaggregant constructs were seen to exhibit cell 
clumping during growth in liquid medium. Ranging from severe (110-C3-3) to minor 
(AavLEA1), this condition led to partial sedimentation, with small (~50 to ~250 !m) 
bacterial clumps being visible under the microscope. Although this did not affect cell 
viability, it was less than ideal for the dispersal of single cells during flow cytometry 
analysis. A tentative explanation of this phenomenon is that clumping was induced 
by soluble A#42-EGFP, i.e. the by-product of an active antiaggregant effect. As 
A#42 has previously been shown to exhibit an antimicrobial effect against E. coli 
(Soscia et al., 2010), perhaps the A#42-EGFP fusion possessed a similar activity: 
E. coli cell clumping has previously been observed as a stress response to 
antibiotics (e.g. tobramycin) (Hoffman et al., 2005). However, there were no other 
similarities seen between this work and that conducted with AMPs in Chapter 4, i.e. 
a reduced growth rate during intracellular production. And although an increase in 
A#42-EGFP fluorescence was observed in most of the clumping constructs during 
induction, lending some support to the theory of a soluble A#42-EGFP effect, the 
clumping phenomenon was also observed when A#42-EGFP expression was not 
induced. Given the tightness of araBAD repression in the absence of arabinose 
(Guzman et al., 1995), it is unlikely that soluble A#42-EGFP is the cause of cell 
clumping. Instead, this phenotype is most likely to be a stress response to the 
constitutive expression of particular peptides from the Library site; however, no 
common homology was found between the five implicated putative peptides. Aside 
from antibiotics, cell clumping has also been observed as a response to general 
stresses such as changes in pH and heat shock (Zhang et al., 2007); unfavourable 
peptide expression may thus be another effector. A few membrane proteins, such 
as antigen 43 (Kjaergaard et al., 2000) and curli CsgA (Barnhart & Chapman, 
2006), are implicated as agents of cell clumping and biofilm formation. Perhaps 
investigating any up-regulation of these products in the clumping constructs could 
prove informative. However, with regards to antigen 43 expression, E. coli colony 
morphology is described as being “frizzy” (a distinctly ruffled surface) (Kjaergaard et 
al., 2000): in the work presented here, colony morphologies were indistinguishable 
between normal and clumping constructs (data not shown). Lastly, while the 
AavLEA1 control was seen to endow minor levels of clumping, other members of 
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the Tunnacliffe laboratory have not reported such an effect when recombinantly 
expressing this protein in other E. coli cell lines. 
 
The sequences of the eighteen putative antiaggregant peptide hits profiled in this 
work were found to have little homology with the A#42 peptide, indicating that their 
mode of action is probably not that of a traditional homologous #-blocker (Soto & 
Estrada, 2005). Furthermore, runs of three or more hydrophobic residues were rare, 
indicating against any putative hydrophobic interactions with the #-strand regions of 
A#42. An explanation of how these putative antiaggregant peptides interact with 
A#42 is not immediately obvious, especially given the lack of overall homology 
between them. It may be that they have other effects on fluorescent output, such as 
by facilitating chromophore folding without preventing A#42 aggregation (Baine et 
al., 2009). While this theory may explain the observed increase in mCherry 
fluorescence seen in several constructs, it does not quite fit. Pep2, which exhibited 
a concurrent in vivo increase in mCherry fluorescence alongside that of 
A#42-EGFP, also displayed green fluorescent aggregates in a minority of cells. 
Baine et al. (2009) previously showed that, while lacking a large influence in vivo 
(the fluorescence morphology was not mentioned), Pep2 had an impressive 
antiaggregant effect on A#42 alone in vitro during ThT assays (LeVine, 1993). As 
green fluorescent aggregates were also seen in a number of cells expressing 
putative hits, similar antiaggregation behaviour of these to Pep2 in vitro was 
predicted. 
 
Although preliminary in vitro results from collaborators indicated that 110-A1-4 and 
110-C3-7 moderately retard the rate of A#42 aggregation, surprisingly the positive 
control Pep2 was not seen to exhibit any antiaggregant activity (Y. Zheng, personal 
communication). The use of electron microscopy to visualise any aggregate 
morphology affect may be more informative (Sato et al., 2006b). Interestingly, for 
some antiaggregants, the use of ThT to assess a compound’s activity against A# 
may not be truly indicative of function (Pallitto et al., 1999). For example, the small 
molecule inositol, despite being shown to induce #-sheet structure in A#42 by 
binding ThT, is still able to inhibit overall fibril formation (DaSilva et al., 2010). 
Electron microscopy revealed that small and apparently non-toxic oligomers are 
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instead formed in the presence of scyllo-inositol (DaSilva et al., 2010). If the 
formation of such oligomers prevents EGFP from folding, the in vivo screen 
described in this work may miss peptides that act in a similar manner. If some of the 
hit peptides can be satisfactorily validated in vitro, future work may involve testing 
putative antiaggregant peptides in neuronal cell models to ascertain if they prevent 
A# toxicity, and then perhaps in animal models such as APP transgenic mice 
(Walsh & Selkoe, 2007). However, any antiaggregant peptides also need to be 
capable of uptake across the blood-brain barrier and potentially into neurons 
themselves (Hartmann et al., 1997; Walsh et al., 2002). Such bioavailability 
problems (reviewed in Section 1.1.2 and 1.1.3.1) remain to be surmounted. 
 
A number of putative hits were predicted to only encode extremely short peptides 
(<6 aa), and consequently were not expected to be able to exhibit any 
antiaggregant activity in vivo due to short product half-life (Maurizi, 1992). However, 
closer examination of these putative false-positives revealed that alternative reading 
frames were present. For example, in 110-C2-3 a stop codon was predicted to 
immediately halt translation after initiation at the original start codon; however, an 
alternative start codon for a 26 aa product was present in close proximity to the 
RBS (see Appendix 9). Although peptide production from this alternative ORF (or 
indeed any ORF) was not directly confirmed, this explanation is not without merit 
given that 110-C2-3 exhibited a homologous alternative peptide sequence to 
74-B1-3 as well as a similar in vivo performance. Further investigation in vitro using 
such predicted alternative peptides could confirm whether or not they are true hits. 
74-C1-1, on the other hand, looked to be a true false-positive from the colony 
screen. Encoding 3 aa before an in-frame stop codon was reached, no other ORFs 
could be identified. Unsurprisingly, this construct performed no differently from the 
“empty” pAG2-A#42 control during flow cytometry. 
 
While the work presented here has focused on the internal production of 
antiaggregant peptides in vivo, the system is also amenable to use in a liquid 
culture well-plate format to assay exogenously added compounds as per Kim et al. 
(2006) and Baine et al. (2009). In addition, the A#42-EGFP aggregator operon may 
be replaced with other aggregating proteins, such as those implicated in 
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Huntington’s or Parkinson’s disease (see Section 5.1.1). Preliminary data from 
fusing EGFP to the N-terminus of exon I of the huntingtin gene found fluorescent 
aggregates form over several hours post-induction; however, total fluorescence 
output per cell was equivalent to that of EGFP alone (data not shown). It is thus 
important to note that, if the aggregation rate of the target is slower than that of the 
folding of EGFP (approximately 0.5 to 1.5 h [Waldo et al., 1999]), the screen loses 
its sensitivity as fluorescent aggregates are capable of producing similar total 
amounts of fluorescence per cell as diffuse EGFP. 
 
Further improvements to the screen could involve tweaking either the aggregation 
rate of the A# component or the sensitivity of the chromophore domain to 
aggregation events. For instance, using a less-aggressively aggregating form of A#, 
such as A#40 or A#41, may allow for an antiaggregant effect to be better observed. 
Similarly, Wurth et al. (2002) identified a number of other A#42 mutants alongside 
GM6 that still aggregate, but at slower rates than that of the wild-type. With regards 
to the fluorescent reporter, Waldo and co-workers, who initially described the GFP 
folding reporter assay (Waldo et al., 1999), have generated a new range of 
split-GFP variants with a decreased sensitivity to aggregation events (Cabantous et 
al., 2008). Either of these two approaches may potentially increase the dynamic 
range between a positive and negative event. 
 
Finally, in a therapeutic sense, absolute prevention of A#42 aggregation may be 
unnecessary: if aggregation can be sufficiently slowed, perhaps toxic products can 
be more easily cleared by the brain’s natural degredative machinery (Walker et al., 
2001). For similar reasons an ultimate cure, while desired, may too be redundant. 
As Alzheimer’s disease appears to be an inevitable consequence of increased life 
expectancy (Schnabel, 2011), the production of a viable antiaggregant drug that 
delays the onset of symptoms for ~30 years may render the problem moot. 
Unfortunately, most patients who are recruited into clinical trials of potential 
antiaggregants already exhibit mild-to-moderate progression of the disease 
(Sheridan, 2009), thus making true assessment of efficacy difficult. A focus of using 
antiaggregants prophylactically, rather than curatively, is then the next-best 
strategy. Choosing when to start such a treatment, however, is problematic, as 
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plaques are observed to form 10 to 15 years prior to symptom onset (Gravitz, 
2011). If the presence of plaques were used as a biomarker and somehow 
identified at the earliest possible stage (histological analysis not being practical), 
perhaps a prophylactic strategy may be able to prolong symptom onset past 
probable life expectancy. 
 
In conclusion, an A# antiaggregant peptide screening vector was constructed, with 
the fluorescent output of A#42-EGFP linked to its aggregation state. As a novelty, 
constitutively expressed mCherry was also encoded to act as a constant internal 
control for ratiometric comparison. DNA libraries encoding a maximum of either 12 
or 24 random amino acids were co-expressed and screened for members that 
increased A#42-EGFP fluorescence. Although FACS was originally envisaged as 
the method for isolating putative antiaggregant hits, this proved to be infeasible 
mainly due to a low dynamic range between positive cells and background noise. 
Instead, screening was conducted via imaging colonies on solid medium and 
subsequent validation through flow cytometry. While several peptide hits exceeded 
or were comparable to the effect of the positive control Pep2 in vivo, restoration of 
EGFP fluorescence to the same level as the non-aggregating GM6 control was not 
achieved. Surprisingly, some peptides (including Pep2) were also found to influence 
mCherry output, suggesting alternative modes of action. Further in vitro validation of 
the putative antiaggregant peptide hits is being carried out by collaborators, with 
110-A1-4 and 110-C3-7 showing initial signs of promise in slowing the rate of A#42 
aggregation. 
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CHAPTER 6 – FINAL DISCUSSION 
This dissertation has been concerned with exploring the use of in vivo DNA library 
screens to identify sequences that encode novel bioactive peptides. Specifically, the 
activities of antimicrobials and antiaggregants were focused on, with the emphasis 
being primarily on the former. In Chapter 3, the recently described CPD tag (Shen 
et al., 2009) was used in E. coli to recombinantly produce the model linear 
cathelicidin K2C18 (Shin et al., 2000) in a simple and straightforward manner. 
Several variants were also generated and confirmed to exhibit antimicrobial activity 
against a panel of microbial species. The worth of the CPD production system was 
thus established for AMP optimisation and structure/function studies. 
 
Chapter 4 employed E. coli in an in vivo cis-based whole-cell screen to isolate novel 
AMPs from sheared genomic DNA libraries. Utilising a replica-plating methodology, 
a number of endogenously expressed hits were identified that required secretion to 
the periplasm for activity to occur, suggesting a membrane-specific site of action 
similar to that of K2C18. Chemical synthesis of one such novel AMP (S-H4) 
revealed the presence of moderate antimicrobial activity, establishing proof-of-
principle for this screen. 
 
Finally, as a second in vivo screen example, Chapter 5 investigated the use of an 
EGFP fusion for reporting the aggregation status of A! (Wurth et al., 2002), which is 
heavily implicated in Alzheimer’s disease (Walsh & Selkoe, 2007). Using a colony 
screen, random DNA libraries were assayed for sequences that encoded peptides 
possessing putative antiaggregant properties, and the hits were subsequently 
assessed using flow cytometry. Furthermore, the use of an internal ratiometric 
standard (mCherry) was investigated to allow for more robust comparison between 
the effect of each putative antiaggregant. Although the ratiometric approach did not 
perform as desired, a number of positive hits were identified. Further in vitro 
validation of several chemically-synthesised hits is ongoing with collaborators. 
 
During this dissertation, a two-step workflow for cost-effective and high-throughput 
discovery of bioactive peptides has become apparent. Firstly, recombinant 
production of peptides should be conducted in a suitable model organism, utilising 
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DNA libraries as the input encoding source. Importantly for the purpose of 
screening, peptide production is coupled in vivo to a measurable output for the 
desired activity. Thus, each host cell represents an individual test-tube for the 
assessment of a specific library member; and as long as positive cells can be 
subsequently isolated, the encoded peptide sequence can easily be deduced from 
the DNA insert. In addition, the ability for this peptide-producing “living laboratory” to 
self-replicate may allow for the recovery of sufficient recombinant peptide for 
purification and further in vitro validation. While this was achieved for several 
peptides using the CPD system in Chapter 3, a number of putative AMP hits in 
Chapter 4 were unable to be produced in this manner. 
 
The above served as a reminder that successful recombinant peptide production to 
a meaningful yield is context-specific, and cannot be accurately predicted a priori. 
Therefore, the second step of the workflow is to chemically synthesise selected hit 
peptides for further validation. Solid-phase peptide synthesis is a mature technology 
that can be performed generically, and for relatively short runs of amino acids such 
as peptides, remains the gold-standard (Lax, 2010). While in vitro validation using 
synthetic peptides is required to confirm the accuracy of a screen, chemical 
synthesis is also likely to be the production method of choice for any hits that 
proceed to clinical trials. Manufacturing robustness, quality assurance, regulatory 
compliance and the fact that such production can be easily outsourced are all 
factors in favour of this approach (Pichereau & Allary, 2006; Lax, 2010). 
 
Rather than being employed directly in a screen from the beginning, however, 
chemically-synthesised peptides are more suited towards optimising known 
sequences at a small scale. This is due to the prohibitive cost of individual peptide 
synthesis: libraries consisting of up to ~1x104 members are the current practical 
limit, even with the aid of miniaturisation and robotics (Hilpert et al., 2005; 
Rathinakumar et al., 2009). Recombinant systems can easily and cheaply exceed 
this limit, with 5x106 members being theoretically feasible from a single standard 
transformation of E. coli (assuming 109 cfu/ug DNA, with 5 ng transformed). As with 
any screen, the power is in the numbers. The larger a library analysed, the higher 
the likelihood that a potential candidate peptide will be identified. While the 
antimicrobial and antiaggregant assays presented here utilised small libraries 
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(~1x104) as proof-of-principle, they are compatible with off-the-shelf equipment such 
as colony pickers and automated handling systems, the use of which is ultimately 
required for the realisation of high-throughput screening (Raventós et al., 2005). 
 
Other recombinant production systems are available for use as hosts for in vivo 
screens, but do not match the robustness and ease of use ascribed to E. coli 
(Baneyx, 1999). Yeasts are capable of the generation of similarly large libraries (in 
excess of 1x109 members), as well as stable protein secretion (Raventós et al., 
2005). However, experiments with S. cerevisiae and P. pastoris to produce K2C18 
in this dissertation failed to produce significant yields as opposed to the use of 
E. coli. Mammalian cell systems, while commonly used for the production of many 
proteinaceous therapeutics (Wurm, 2004), are unwieldy and time-consuming with 
regards to library transfection and screening (Kaykas & Moon, 2004; Li et al., 2010). 
 
The use of other hosts does hold appeal for certain screens, however. For instance, 
in the AMP screen outlined in Chapter 4, using bacterial strains other than E. coli as 
a production chassis could allow peptides with specificity towards important 
pathogens to be discovered. Genetically tractable and attenuated relatives of 
antibiotic-resistant “superbugs” exist, such as Pseudomonas aeruginosa (West et 
al., 1994) and Salmonella enterica serovar Typhimurium (Widmaier et al., 2009; 
Medina et al., 2011). Furthermore, the use of Gram-positives such as Bacillus 
subtilis (Brockmeier et al., 2006) or Bacillus megatarium (Malten et al., 2006) could 
be better suited towards the search for novel AMPs that act exogenously. With the 
transit of only a single membrane required for protein secretion, the use of the Sec 
pathway as described in Chapter 4 should be sufficient to export peptides into the 
extracellular milieu (Fu et al., 2007). However, secretion of heterologous proteins 
can be unpredictable due to the presence of quality control and “feeding” proteases 
co-secreted by the bacterium (Harwood & Cranenburgh, 2008). 
 
If E. coli is to remain the host of choice for the AMP screen, further improvements 
could be made with regards to generating exogenously acting hits. Given that the 
Sec system, although well described (Saier, 2006), does not guarantee peptide 
secretion past the periplasm (Ni & Chen, 2009), alternative but lesser proven 
secretion pathways represent further avenues for investigation. One such candidate 
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is the ATP-binding cassette Type I system used by pathogenic E. coli to secrete the 
toxin haemolysin (110 kDa; Gentschev et al. [2002]); another is the Type V system, 
specifically the serine protease autotransporters of the Enterobacteriaceae class 
(SPATEs, ~110 kDa; Yen et al. [2008]). Both are able to secrete protein through the 
inner and outer membranes of E. coli using dedicated molecular machinery: in the 
case of SPATEs, this is encoded within the protein itself (hence the autotransporter 
moniker). However, these systems (especially the SPATEs [Jong et al., 2010]) are 
not well described for heterologous protein production. Furthermore, they both 
require conserved C-terminal secretion signals: any insertion of DNA upstream for 
screening may introduce disrupting frame-shifts or internal stop codons, preventing 
proper translation and secretion. A known exception to this is the colicin V toxin 
(9 kDa, Type I system); its secretion signal is N-terminal (Hwang et al., 1997). By 
incorporating the dedicated secretion machinery (ClvA and ClvB, in combination 
with the endogenous outer membrane protein TolC [Hwang et al., 1997]) into a 
screening vector, such a system could be trialled for AMP secretion; again, 
however, its ability to cope with heterologous protein remains to be seen. 
 
Regarding future screen development, other lessons learnt from this dissertation 
should be applied. Drawing from the AMP screen again, it has been postulated that 
virtually every peptide that possesses a net positive charge and a few hydrophobic 
residues will display antimicrobial activity if assayed in common buffers or dilute 
media (Hancock & Sahl, 2006). Although the novel sequence of S-H4 exhibited 
antimicrobial activity in high-salt LB media in a similar manner to the known AMP 
K2C18, it is pertinent to note that not every hit identified can be expected to show 
clinical efficacy (even discounting stability and bioavailability issues [Vlieghe et al., 
2010]). To better facilitate this, the next generation of screens should try to replicate 
as closely as possible the physiochemical environment in which the peptides will 
ultimately be deployed. For AMPs, if the end use is topical (e.g. treatment of cystic 
fibrosis infections), this means modelling high-salt epithelial environments (Knowles 
et al., 1997); or for systemic use, the use of appropriately cation- and serum-
adjusted broths to simulate conditions in the blood (Wiegand et al., 2008). For A! 
antiaggregants, the employment of media that replicates the properties of 
cerebrospinal fluid would be desirable (Wishart et al., 2008), although as the screen 
takes place in the E. coli host’s cytoplasm it is difficult to optimise this further. At the  
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very least, if a screen cannot be made physiologically relevant, it should contain 
strong positive controls that show a good correlation between screen activity and 
clinical efficacy (if these exist for peptides; if not, small molecule drugs may be 
employed instead). In this manner novel peptide candidates with similar in vivo 
profiles can be identified and proceed to be validated piecemeal in other systems. 
 
A greater emphasis on trans-acting systems, in which the production host does not 
double as the test organism, has been suggested as a further advance towards the 
goal of creating more robust screens (Raventós et al., 2005). In this approach, each 
library clone acts as a miniature peptide production system, with aliquots 
subsequently taken and added to the assay proper. To simplify peptide recovery, 
however, secretion is required: and even if reliably achieved, the peptide may be 
diluted below the concentration required for activity. Additional processing 
techniques are thus necessary to recover and concentrate a peptide prior to testing, 
which is not particularly amenable to high-throughput screening. Complicating a 
screen with such additional processing steps negates the main advantage of in vivo 
screening: self-contained peptide production combined with activity assessment in a 
discrete self-replicating entity. If the two are separated, the recombinant approach is 
of comparable utility to that of harnessing chemically-synthesised peptides at the 
initial stages of a screen. 
 
Looking ahead, it is clear that therapeutic peptides have a promising future. 
Although they currently suffer from the twin problems of poor bioavailability and 
stability (Vlieghe et al., 2010), this has not prevented them from filling valuable 
clinical niches worth approximately US$13 billion in 2010 (Reichert et al., 2010). 
While strategies for protecting peptides from breakdown continue to be developed 
(McGregor, 2008), it seems reasonable to continue the search for novel bioactive 
peptides to develop the art for eventual deployment into clinical trials. At the very 
least, “low hanging” targets can continue to be focused upon: profitable hormonal 
analogues (Loffet, 2002), antimicrobial peptides for use as topical or antifouling 
agents (Hancock & Sahl, 2006), and even cosmetic product supplements 
(Pichereau & Allary, 2006) all represent areas of significant interest. It is hoped that 
the work contained in this dissertation has shown that simple microbial systems can 
be used towards these developmental ends. 
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APPENDICES 
Appendix 1 
Mass spectrometry result for recombinant K2C18 (Section 3.2.2.3). The expected 
mass of K2C18 without initiating methionine was 2,146.4 Da; observed was 2,146.3 
Da. This confirms that K2C18 lacked the initiating methionine. 
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Appendix 2 
Amino acid analysis results for recombinant K2C18 and MCC18 analogues (see 
Section 3.2.4.2). Note that asparagine and glutamine are hydrolysed to aspartic 
acid and glutamic acid respectively, so are counted in this manner in the output. 
The indole ring of tryptophan is destroyed during hydrolysis, so this amino acid is 
not identified. Some amino acids are excluded from the analysis of a particular run 
(e.g. MCC18) as contaminants in the peptide solution result in poor fits to the true 
expected values. Exclusion of such contaminating amino acids allows a more 
accurate concentration of the desired peptide to be measured. 
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Appendix 3 
Growth curve of pBAD/gIII-Calm-Tag (see Section 4.2.2.3), performed as per Figure 
4.4 except with 50 mL culture volume in 250 mL shake flasks. pIII-tagged 
calmodulin (pBAD/gIII-Calm-Tag), which is targeted to the periplasm, shows the 
same level of growth inhibition when induced as the pBAD/gIII-A control. 
 
 
 
Growth curves of retransformed hits from Figure 4.14 A (see Section 4.2.4.3), 
performed as per Figure 4.14 except with 25 mL culture volume in 50 mL shake 
tubes. Similar growth profiles to Figure 4.1.4 A are observed, confirming that the 
effector agent is plasmid encoded. 
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Appendix 4 
DNA sequences inserted into the pAMP/S or pAMP AfeI site are shown, as well as 
the predicted translation product (Section 4.2.4.4). For pAMP/S peptides, only 
residues downstream of the pIII secretion signal cleavage site are shown, i.e. TMS 
onwards. For pAMP peptides, the initiating methionine is assumed to be removed 
(Ben-Bassat et al., 1987); the same N-terminal residues of TMS result. Plasmid-
contributed residues, i.e. those outside the insert DNA, are underlined. 
 
pAMP/S-H1 
389 bp  
CGGAATGCAGTGGAGAGTGGAAGAGAATCGAATGGCGAAGCGGATGGAATGCAGTGGTGAACAGAATG
GAATGGAGGATGGTATGGAGAATGAAATGGAGTGGAGAATGGAATGGAAGGGAGCATGGAATGGAATG
GAGAATGGAATGGAATGGAGAATGGAATGAAATGGAATGGAGAATGGAATGGAATAGAGAATGGAATG
GAATAGAGCATGGAATGGAATGGAGAATAGAATGGAAGGGAGAATGGAATGGAATGGAAAGGATGATG
GTATGGAGAATGGAATGGACAGTGGAATGAATGGAATGGAGAATGGAATGGAAGATGGATTGGAACGG
AGAATGGAATAGAGTGGAGAATGGAAAAGAGCGGAATGGAATGGAGAAT 
22 aa 
TMSRNAVESGRESNGEADGMQW 
 
pAMP/S-H2 
130 bp 
TTACTTGTCTTATTTCAAAATAAATATGATTTAAAAATTGAAGCCATTGTACAAATAGAGTTTTGGAA
TAGAACTCGTTTATAAATCAGAGACCACTCACAGGAATGTTCTTCAGCCCCTTTGAAAGGTG 
30 aa 
TMSLLVLFQNKYDLKIEAIVQIEFWNRTRL 
 
pAMP/S-H3 
218 bp 
GTTTTAAATGAATTCAAAAGTCAGTGTCATCTGTTTGTTCATGCATTCATCCATCAAACATTACCTGA
GTGTTTACCATGGGCCATATACTGCACTGAACAAGGGAGAAACGGTCATTCTCAGCTCCCACATTCAA
GGATTTCATCCTCTAGTGGAGGAGTCAGGAAAGGAAATAAGCATATGAAGTTCTCTGGGATACTTCGT
ATGCCTAGTATTCC 
79 aa 
TMSVLNEFKSQCHLFVHAFIHQTLPECLPWAIYCTEQGRNGHSQLPHSRISSSSGGVRKGNKHMKFSG
ILRMPSIPLSK 
 
pAMP/S-H4 
136 bp 
AAAAGGTACCTTGGTACCCGATGCCTGTCCCTTATGTGGGCCAAGGGAGACCTGAGACAAATAAAAAT
GGGGAAAAGAGGGGACAAGAAGGAGTGATTGTTAGAGAGGCTGTCTGAATAATGCTTTATCAAAATAA 
34 aa 
TMSKRYLGTRCLSLMWAKGDLRQIKMGKRGDKKE 
 
 
pAMP/S-H5 
179 bp 
TTCTCTAAATTTCTGTTCTTGCTTCATTTCATTCATTTGATCTTCATTCACTGATACCCTTTCTTCCA
GTTGATCAAATTGGCTACTGAAGCTTGTGCATTCGTCACGTAGTTCTTGTGCCATGGTTTTCAGCTCC
ATCAGGTCATTTAAGGACTTCTCTACACTGGTTATTCTAGTTA 
20aa 
TMSFSKFLFLLHFIHLIFIH 
 
pAMP/S-H7 
105 bp 
GAAAGAAGCAGACATGAAAGGTCATATATTGTAGAATTCCATTTATATGCAATGTTCAGACTAAGCCA
ATCGACAGAGATAGAAAGTAGATGAGAGGTTTCCAAC 
33 aa 
TMSERSRHERSYIVEFHLYAMFRLSQSTEIESR 
238 
pAMP/S-H8 
384 bp 
GTGATTGTACTAATTTACATTTCTACTAAGAAGGTCCAAGGGTTTATTTTTCTTCACATTCTTGCTAG
CATTTGTGTTGCCCGTCATTCCGATATAAGCCATTTGAACTGGGGTGATGCTATATCTCATTGCAGTT
TTGACTTGCATTTCTCTATTGGTGATATTGAGCACCTTTTCATATGCCTGTTTGCCATTTTTATGTCT
TCTTTTGAGAAATGTCGATTCAGATCTTTTGCCCATTTTTTCAATGAGGTTATTAGATTTTTTTTCCT
ACAGAGTTGATTGAGCTACTTATGTATTCTGATTATGAATCCCTTGTCAGATGGGTGGTTTGCAAATA
TTTTCTCTTATTCTGTGGGTTGTCTCTTCCCTGAGTTGATTGTT 
96 aa 
TMSVIVLIYISTKKVQGFIFLHILASICVARHSDISHLNWGDAISHCSFDLHFSIGDIEHLFICLFAI
FMSSFEKCRFRSFAHFFNEVIRFFFLQS 
 
pAMP/S-H10 
1186 bp 
CTGTGGTCTGATAGCATGGCTGATGTGATTTTGATACTTTTGAACTTACTGAGACTTGCTTTATGGCA
GAGCATGTGGTTAATCTTGGAGTATGGTCCATGTACAGATGAGAAGGATGCATATTCTATGGTTGAGG
GGTATTCTGTAGATGTGTATTAGATACAATGGGTCAAGTGTCAAATTTACATCCAGAATATTTTTGTT
AGTATTCTGCCTCAATGATCTGTCTAATGTTGTCAGTGGGGTGTTGAAGTTCCTCACTATTATTGTGT
GGCTACCTATGTCTTTTTGCAGGTTGAGAATTACTTGTTTTATGAATCTGGATGCTCCATTGTTAGGT
GTGTATACATTTAGCATAGTTAAGTCTTCTTTTTGAATTGAACCTTTTATCATTATATAATGCCCTTC
TTTGTTCTTTTCTACTGATTTCATTGGCTATGTGCCTTATTATATTGGCTAGGACTTCCAGTATTATT
TTGAATAGGTGTGGTGACAGAGATCATCTTTGCCTTGTTCCTGATCTTAAGGAGATAGCATTCACCAT
TAAGCGTAAAATCTATTTACATTTAATGTGATTATTGATATGGTTTGACTGACTGCAACCATTTTTCT
ATTTGTTTTCTATATATCCCATGTCTCTTTTGTTTCTCTGTTCCTCCTCTCTTTTGTGTTATTTTCTC
GCATATCATTTTAATTCCTTTGTTGGTTTCTTTAAACTACATTTTTTAGTTACTTCATGTTTCCTCAA
GAGATCTTAATTCATTATAATCTAATTCAGATTAATAATAACTTAATTCCATGATAATATGAAAATTT
GCTTCTATATAGCTCCATTTCCTCCCTCTACATTTGTGGTATTATTGACATATATGTTTTAAGTGCAT
CACAGCAATGTTTATGAATATTGTTTTATGTAATTTTTAAAAAATCAGTTTGGAAACACACACACACA
TATAGAGAGAGAGAGATAGATAATATACTTAGGTAATTACCTTTATCTGTGAAATGTAATTCTTTGTG
TGGACTCAAGTTACCCTCTTGTATTTCCTTTGACTTGAAGGTCTTTCTTTAGCATTTCTTATAAGACA
GATCTGTTAGCAATGCACTCTTTGTTTACCTGGAAATAACTTTATTTCTATTCATCATCAAAGGATAG
TTTTATTGAATGCAATAATCTTGATTGACA 
55 aa 
TMSLWSDSMADVILILLNLLRLALWQSMWLILEYGPCTDEKDAYSMVEGYSVDVY 
 
pAMP/S-R14 
171 bp 
AAATTAAATATGCAAATAATCATTGGCCTGGTGCTAATAGACATTGCTTTGTTCAAATCACTGGAGAT
TTGCAAGAACATTTGTTGTAAATCAAACTCATTGAGATCGAAGGCACTTTTAGACATTTGTCTATTTT
TAGCAGCCATGATTTGTATTAGCGCAACATAGACT 
58 aa 
TMSKLNMQIIIGLVLIDIALFKSLEICKNICCKSNSLRSKALLDICLFLAAMICISAT 
 
pAMP/S-R15 
175 bp 
CGGAACTCATTTTCAATGCTTCTACTCGCTATCAACTTGATCTTTCTAATTGTTGGACTGATCTCGAT
TATCAACAATGGAAAGATGGAAAATATTTTCCTGCAAGTAAACCCAAAGGTAATATTGTTTACATGGT
ACAAACAGGCGAGAAGAATCTACGAACTCGTTGTGATAT 
62 aa 
TMSRNSFSMLLLAINLIFLIVGLISIINNGKMENIFLQVNPKVILFTWYKQARRIYELVVIC 
 
pAMP/S-R17 
235 bp 
GAAGATTATTTTCGACGAACGTTGAATATCGAACAAGTGGACATCCGTTTGATTGATGAAAATGAAAT
TGAAGCAGCGAGTATTCCCAATCTGGAAGAGATTTTACCTGGAAAGCCATTGATTCATTTTCGACATG
AACCAATGATTTCCATTCGTTTGATTAATCGACAACCTTATTCTGGTCATTTTGAATGGACTATTCCG
GTGATCAATGGTGATACCGTGGAGAAATTGG 
82 aa 
TMSEDYFRRTLNIEQVDIRLIDENEIEAASIPNLEEILPGKPLIHFRHEPMISIRLINRQPYSGHFEW
TIPVINGDTVEKLG 
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pAMP/S-R20 
164 bp 
CTGCATCAAACCATTGTTATGTGTAGAAAATTGCTGTTGAATCTTTTTGGTTTCTTTATCTTTGGGTG
TATCAGCGAATTTTACTACCAAAGGAGATGAACAGCCCTAATAGATAGGAATATTAATTATGTAATAT
GATGAATAATTCAGAATTTAACCTCCAT 
35 aa 
TMSLHQTIVMCRKLLLNLFGFFIFGCISEFYYQRR 
 
pAMP/S-R21 
367 bp 
TTTGAAGTTATCTGATTAAGATATAATGGGAAGCCATATGATATGGGATAGATGTATGCATTTGGTCT
AACAGTAAGTGAGAAAGAATGTAAACGTCGAATTGAATAATAAACTTGATGTCTGTTTCGAATATGAT
TGATGTGTACGTGAGAATATGTTGTATATGTTTGAAGAGAAATTTCAAGAGGAACTTTTCGGACTCTA
AGAAGTGCAGGTTTGCTTGGCATTGTCTTTCTGTTCAATTGAAAATATGTTGCCTAGTGTCTTTGCAA
GAGAATTGTGAGAACCAAAGGAATAGATGACGCTACTTATTGTATATAACCATTGTACTGTTTCGTTT
ATCATTCCATATTACTATTCTTTTGAA 
7 aa 
TMSFEVI 
 
pAMP/S-R22 
116 bp 
TACAGCAAAACAATCACTGTAAAGACAAACATAATCATCGGATTGACTTACCAGTAACAGCATCTTGG
TGTTTCTTACGGAGTTGAGCAGCTGTGGCTTCATGTTGAAGATTAGCT 
21 aa 
TMSYSKTITVKTNIIIGLTYQ 
 
pAMP/S-R25 
175 bp 
TTATTATATTCATTGAGACGTCGTTGCTGGCCGTTCGTGATATGTTTTCAAAGGGCGATGCTATTACT
CACTTCAGCTGTTGGAGTTTTCCGAATAATCATTCGACTTTTCTTCGATCTTTTTAGTCAAACCTCGT
GGATCTTTTTGGAATGAATTAGCAATCTTCATGGATTCG 
53 aa 
TMSLLYSLRRRCWPFVICFQRAMLLLTSAVGVFRIIIRLFFDLFSQTSWIFLE 
 
pAMP/S-R28 
347 bp 
GAATGGAAATGTACTTACTCGGAGTATCTTGCGGTTGAGAGAAGTGTGTTTGAAACTCAGATGAACAA
TACTAGGAAAGTATTGCCTTTTTATACGAGAGGCATTGTTGACCAACAACTATCTCTTTTTCTTTCTC
TCTCCCTCTTCCTGAGCGATAGCGAAAGGGCGTCATTTAAATGAATTATATATTGTCGAAGGATTATC
ATTGTTGGGCACGAGTCTGTCCGCCCTGTTTTAACGATTGGATCATTCACGTTCAATCTTTCGATCCT
TGCTCTGTGCATACATATATATATATCTCTATCTAAACAGAATAAATAAAGGGCGAATGACACGTGTA
ATTAGTT 
62 aa 
TMSEWKCTYSEYLAVERSVFETQMNNTRKVLPFYTRGIVDQQLSLFLSLSLFLSDSERASFK 
 
pAMP/S-R30 
145 bp 
CTTGCAACTATGTTGCAAATAGGTGCAATGTTAATCTTCTTCACTGGACATATCATAGATACGATTGG
ACGTCGTCGATCGATTCATTTAATAACTGCTCTGCTCTTAATAACCTCGTTGATTACACAAGCATGCT
TACAATTCG 
52 aa 
TMSLATMLQIGAMLIFFTGHIIDTIGRRRSIHLITALLLITSLITQACLQFG 
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pAMP/S-R31 
373 bp 
ATAGAAATAGATTTAGTTTTACTTATCCATATACACACCCACACCCGTGTGAGTTTAGGAATAGAAAT
AGATTTAGTTTTACTTATACATATACACACCCACACCCCTGTGAGTTTAGGAATAGAAATAGATTTAG
TTTTACTTATCCATATACACACCCACACCCCTGTGAGTTTAGGAATAGAAATAGATTTAGTTCTACTT
ATACATACATACCCCCACACCCCTGTGAGTTTAGGAATAGAAATAGATTTAGTTTTACTTATACATAC
ATACCCCCACACCCCTGTGAGTTTAGGAATAGAAATAGATTTAGTTTTACTTATACATACATACCCCC
ACACCCCTGTGAGTTTAGGAATAGAAATAGATT 
128 aa 
TMSIEIDLVLLIHIHTHTRVSLGIEIDLVLLIHIHTHTPVSLGIEIDLVLLIHIHTHTPVSLGIEIDL
VLLIHTYPHTPVSLGIEIDLVLLIHTYPHTPVSLGIEIDLVLLIHTYPHTPVSLGIEIDC 
 
pAMP/S-R32 
238 bp 
CTCTTTTCCCTTCTCTCTCTCTCTCTTTCTCTTTTATTTTTCTTTTACGAACGAAACAAGAAATAATA
ATATGCGTTGATGTGTCCGAGACTAGCATAGAGAAAGAGAGAAAGAAGAGCGATTAGAAAAGGGGAGA
AAGAAAAGGAGACCTTTCGTTTACATACATTACCATGCCATCACTCAAGATGCCGTTTTCCTTTTCCT
TTCGAAACTATCTATTCTTTTTTTTCGAAAACAT 
24 aa 
TMSLFSLLSLSLSLLFFFYERNKK 
 
pAMP/S-R33 
108 bp 
TGTTGGATTTTTTTGCATTCCCTTTTATATTCCATTCAGGTAAGTTTTTTAAGGCGCTTTTTGCTTTT
CCTTATACCAGTGCCAGACAAATCCGATCAGCGAAAATGT 
41 aa 
TMSCWIFLHSLLYSIQVSFLRRFLLFLIPVPDKSDQRKCAK 
 
pAMP/S-R34 
168 bp 
TATTTCGAATTGAATATTCGACCTTGCCGTTCTTGTTCTGCGCGACGACGTCGTTCAATCGCAGCTTT
CTCTTTCAGATCGATGGGAAGATCGAGTTTATACATATCTGTCTCCGGATATAAGAATGAAAGAATGT
TGTGTATATTAAAAACTTTCTTCTCCTTCAAA 
61 aa 
TMSYFELNIRPCRSCSARRRRSIAAFSFRSMGRSSLYISVSGYKNERMLCILKTFFSFKAK 
 
pAMP/S-R36 
199 bp 
ATAGCCACTTTTTGCATGCTTTCGCTGATCTTTGTTACCTTTCACAAGCCATTAGTAAGAAACATTTG
GGGAACGATAAAATCATTATTGAATTTTATCTTTTATATGCGTAAAAAGAAGTGAAATTAAGTAAGTA
TGATGCGTAGTATTGATTTATGTGATCACATTCTTATCTGATCCAAGGTATTTTATGACTGCA 
43 aa 
TMSIATFCMLSLIFVTFHKPLVRNIWGTIKSLLNFIFYMRKKK 
 
pAMP/S-R37 
132 bp 
TCACATATTATTCACTTCTACTCAATGGAGTTATTCCACCTCTGCTCATGTTTATTTTTGGATGTTGG
ACAGTACAGAATATTCGTAAAGTCCGTCACGCAACACGACAATCGGGCTCGACACATTCCGCTG 
49 aa 
TMSSHIIHFYSMELFHLCSCLFLDVGQYRIFVKSVTQHDNRARHIPLAK 
 
pAMP/S-R39 
123 bp 
GACCGTGTTACTGCGTTTGAGTTTCACAACGTCTACGTTTTAGTAAGCAATTTTCGATATAGACTAGA
TGTTCAAGAGTATATTCGATCGCCAAGTTATTCAAACTAACTAGAATGTCATTTA 
38 aa 
TMSDRVTAFEFHNVYVLVSNFRYRLDVQEYIRSPSYSN 
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pAMP/S-R40 
222 bp 
GAGTTGATTTCAAAACTTTTCATTTTGTATAGATCGTCTGAACTTTTGATTTCACTGAGTATAACGTC
TAATTCTTCCGCTTCGTTAGCTTGCTTAGTGTTTGAAATTGAACCTTTTGTGCCAAGTAAACTATCAA
ACTTGGTGCTCAAGTTCGAAAGTTGTTCGCTCATATAAAGCAGTTGCTGTTGAAATTGGTGCTCATTT
GATGGCGAGAAAGACGAA 
60 aa 
TMSELISKLFILYRSSELLISLSITSNSSASLACLVFEIEPFVPSKLSNLVLKFESCSLI 
 
pAMP/S-R41 
161 bp 
AACTTGTTGCTGTTCCAGTTGTGCCTAAACAAGAAATTTAACATCGTGTTCTCGAATAGCAATGTGAA
TATGAATTTAGTTTTACCAGTTGTAGTTGTCGACGACAAAGTCGTATCACTTCTACCAGCAAAAAAAT
AGATAGGCACAGTGATCGCTCCGAT 
48 aa 
TMSNLLLFQLCLNKKFNIVFSNSNVNMNLVLPVVVVDDKVVSLLPAKK 
 
pAMP-R1 
337 bp 
TTCTATGTCTCTTTTTTACTTTCTTTCTTCGCTTTGGTAACAGAGCAGAATATATACCAGTGTTCGTT
CGTTTGTCTGTCTCCTCTTTTGCGCCTCTTTATCCCTTTCGTTGACATTTGACATCTGCTGTTGCTTG
ATGCATACGTATGTAGAGATGTGTGCAGATATATACATGTACATTTACTTACTTTCGAACAAAAAAAA
GAAGTAACTGGGTCACACTATACAATCGAAGGACAATGACGCAGCACATAATCTTTCGGTTTCTCTTT
TCTTTACTCCATCAATTTCAGATTTATCTTCCAATGAACTAAGACGAAAGGACGTTATTATCAAA 
42 aa 
TMSFYVSFLLSFFALVTEQNIYQCSFVCLSPLLRLFIPFVDI 
 
pAMP-H2 
383 bp 
CTTTTTCTTTTCTTTTTTTTTTTTTGAGACAGGGCCTCACTCTGTCTCACAGGCTGGAGTGCAATGGC
ACATTCTTGGCTCACTGCAGCCTCTGCCTCCCGGGTTCTAGCAATTCTCATGCCTCAGCCTCCCAAGT
AGCTGAGATTACAGGCATGCACCACAATGCCCGGCTAACTTCTGTATTTTTAGTAGAGACAGGGTTTT
GCCATGTTGGTTGGGCTGGCCTCGAATTCCTGACTTCAAGTGATCTGTCCATCTCGGCCTCCCAAAGT
GCTGGGATTACAGGCATGAGCCACCACGCATGGCCCTGCCTTCTTGAGATTCTTGCTGAGACTGTACA
AGGCGTTGACTCTTGTCTAATCTTTTGCACTGCTCCTCTGTCT 
11 aa 
TMSLFLFFFFF 
 
pAMP-H3 
334 bp 
AGTTTAGCGGAACATTACATACAATTGAAAGAGAATGTGGTGAGCTGGAACACAGATTTTGGAGATGA
TGCCCAACCGAGAAACAGAATATGAGAGGTGAAGTGACATGGAATAGATCTAACTTAGGTCTAGCTAA
ATTCCTAGTGGAAAGGAGAAAGAGAATGGGGGAAAGTCAATATAAGAGCAGCTAATAACCAAGAACTT
TTCAGAACTGATAAAAGGTAGAAACAAAAATCCACATATTCAGGGATCCAGATGAATTCCAAGCAGTG
AAAATAAAAATCAATCTAAACTTGGAAGCACCATAGTGATAAATGCAGAACACCAAAGACAA 
33 aa 
TMSSLAEHYIQLKENVVSWNTDFGDDAQPRNRI 
 
pAMP-H4 
268 bp 
ACCTGGCCAATATTGGCAGCTTTAGGCTTCAGAACTGTTTTTATCTTTTTTGGTGAGGAGGTCATGTA
ATGTAAAGCAGGGGAGGTGTTTTGTGTTTCCCACCTTGCAGAGTAAGGTGGCTTGTATCAGAAGAAAA
TGAATTCTACATTAATAAAAGGGCAGAGAAGAAAGAAGTTCCTTGGATTAGATTGATTTAGTTATTCC
AAAATGTATACATATATCAAAATATCGGCCTGGCATGGTGGCTCACACCTGTCATCCCAACACT 
25 aa 
TMSTWPILAALGFRTVFIFFGEEVM 
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pAMP-H5 
273 bp 
AACAAAAATGGCTGTTATCAAAAGCCAGTGCCTCTCCTGGCTGTTCACTGTTACCTCATTACAACCAT
GATGTTATCTGCTGGGTATCTGGGTTTACCACTGACCACAGCAGAGGCTTGGACATTATTTGCTCAAA
TGATTTTCTTCTCCTCTTCCTTTTGTTTTAATTATGTGCATGAGGGATCAGGCTGGCGCAGGCCGGGT
CGGGGTAGGAGTGGTTATTCCACAGAGCACAATGTGTACTTTTTCAGCATTCTACTTACTTCCATAAA
G 
96 aa 
TMSNKNGCYQKPVPLLAVHCYLITTMMLSAGYLGLPLTTAEAWTLFAQMIFFSSSFCFNYVHEGSGWR
RPGRGRSGYSTEHNVYFFSILLTSIKAK 
 
pAMP-H6 
362 bp 
GGAGGGCAGGGAAGGGGCAGGTAGAGTTGGGAAAGGGAGGGAGGGGCAGGGAGGGGTAAGGGACGGGG
TGAATGGAGGAAGGGAGGACAGGGAGCAGGGAGAGAAGAGAAGTCAGCAAGGACCAAGGAGTGAACCC
AGAGGAAGTGAAAGGGTAGAAGAGGGGCCCTGGCAGGGGCTCCAGTAACAAGGAGGAGGGAGGGTGGC
AGGGGAGTGACACATGGGAGATGGGGAGGCAAATAAAGAGGAGAAGGCAAAGACAAGCCGAGGGAGGA
GTGGAGAGAAGGGTGGAGAAGGAGTGAGGTGTGTGACTGCACAGGGAGGCGAGAGGAGACGCAGGTGG
TCTTGGGAGGGAAGCGAGAGGG 
10 aa 
TMSGGQGRGR 
 
pAMP-H8 
404 bp 
GTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGT
TAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTA
GGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGG
GTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGT
TAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTA
GGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGT 
141 aa 
TMSVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRV
RVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRVRV
RVLSK 
 
pAMP-H9 
304 bp 
AATAAAAATAAAAAGTGTTCCCTTTTCTCTGCTTCCTTGCCAGCATTTGTTATGTTTTTTGGTCTTTT
TGACAACAGTCACCTAACAAGTAAGATGACACCTCATTGTGGTTTTCATTTGCATTTTCCTGATAGTG
ATGTTGAGCATTTCTTCGTATATGTGTTAGCCATTTGTATGTCTTCTTTTGAGAAATGTCTATTCAGA
GAATTTGCTCCCCTCACTTTTTTTTTTTTGAGACAGGGTCTCACTCTGTCACCCAGGCTGGAGTACAG
TGGTGGGATCTCAGCTCACTGCAACCTCTGCC 
105 aa 
TMSNKNKKCSLFSASLPAFVMFFGLFDNSHLTSKMTPHCGFHLHFPDSDVEHFFVYVLAICMSSFEKC
LFREFAPLTFFFLRQGLTLSPRLEYSGGISAHCNLCR 
 
pAMP-H11 
176 bp 
CAGAGAGAAAAAGAGAGTTGCTTAAAGAACATATTTAAAAACATTTGTGGTATGATATGGAATGTGAC
CACCTTCCTCCCACCTCCACCAAGAAATATTCAGGAAAAGCTACAAAACCCATCAACGCTTTGGGAGT
AAAGGATGTGGAGAAATTGGAACTTTCATGCACCGTGGGT 
48 aa 
TMSQREKESCLKNIFKNICGMIWNVTTFLPPPPRNIQEKLQNPSTLWE 
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pAMP-H12 
212 bp 
CTAATTAATAAGTTTTATTTATTTTGGCAAATACACAATTTAATTACTTTACTAGCTGTTAGCTGCAA
ACTGCTTAGCTCCTTTGGAGTTTTTCAAATGTGCAGAAAACCTCAGGTGGAAGAGCCCAAAGCAAAAC
ACACCGCTTTTTCCTGATAACGGCATTTTCCAGACGTCATTTTCCCAGCTGTCAGAGTGTGATAAAAG
GCTTGGGT 
53 aa 
TMSLINKFYLFWQIHNLITLLAVSCKLLSSFGVFQMCRKPQVEEPKAKHTAFS 
 
pAMP-R13 
690 bp 
ATACTTCAAATTCTTTATCGTGTTATATTCATATTAAATGTAATCGTGGTCCATATCCATTATGTTTA
GATTGGACTGAAGTTTGTGATGGAAAATTTGATTGTCTTGATGGTCCATTTGATGAAGAACATTGTAC
ACAAATTGATAATGATTATGAGATTCATAAGAGTACATTAAAAATCGATGGATTTCCCGATAATCTTC
TTGGTTATCCACCTATTGTTTATCTTGAAGATGTTAAATGTCATGAATCACCTTTAACAAGTTCTTGT
ACGAAATCACGTCAAAAACAATTATTCGAAGCAATGTTTTCTATCAAAGATAATTCAACAACAGATAA
TTGTTGGTCAGCATTTAAATGTATTTTACCAATATCAATATCATTAGGTTCAATTTGTAATAGTTTTT
GTTCAAATGATAATTGTCTTGAAATTATTGAAGATGAATGTCCATCAATGTTTTATATACCAATTATT
CCTATTCTATTTACTAATATATATTTTGCTTATGAAAAACTCGATTCAAAAATGTTCAATCATGGACT
ATTTCAACATCCTTATATTTGTTATAATGATTCTCGTTACGATAAGTATTTTACTAATGAATCAGTAC
TATTATTTCATTCGAGAAAATGTTTTCGTTACAAGACTTCAAATACAAATCATATTTTTGATTTGAAA
TATTTACAAT 
25 aa 
TMSILQILYRVIFILNVIVVHIHYV 
 
pAMP-R14 
362 bp 
TTCAAAATGAAAAACCACTGTATATCGATGTTTTTCCGGTATGAAATCTTTTTGAAGAAAAAAATTTC
ATGGAAGAACTATTCATGTGTTTTTGAATACGTAGAATCGTGTGGGCTCGACAAATATTACTTTATAC
AACGGTTTTGATCAGCCAACAGATGTGACGCGTATGGAATTTCCAACATACGGTAATTGTTTTTCATT
TATTTGGAATACAACATCACCAAACAAATTAATCATTGAATCGAAGAAAAATCATCAGGTATGTACTA
ATTGTTCGATCGAATTTCGGAATTATTTCTGTTTTATCATAGATCGGAAAGCTAATGTTCGATATGTT
ACCATTATGTAATAGTATTCAG 
51 aa 
TMSFKMKNHCISMFFRYEIFLKKKISWKNYSCVFEYVESCGLDKYYFIQRF 
 
pAMP-R17 
221 bp 
TACATTTGTAAATATATGACACGAATCGTTTTCAGGATTCAATGGTCAATTCTGGCAGGAATGGCTTT
TCAAACTGGTGTATTGTTTCGATTAGTGTGGATTGACTACAGGTATTTGAATTCTTCATCTCTTATCA
AATCACACGTTGTTTCTTCCTTTAGTTGGGATATTATGGAACCTTTCACATACTTCATTTCGTATTCA
ACTGTATTTATGGCTTA 
76 aa 
TMSYICKYMTRIVFRIQWSILAGMAFQTGVLFRLVWIDYRYLNSSSLIKSHVVSSFSWDIMEPFTYFI
SYSTVFMA 
 
pAMP-R18 
129 bp 
TAGTTAATAGAATGAAAACGGTGGGTGTGAGGGTGGGTGGGTGTGGGTGAGGGTGTGGGTGAGTTTGA
AAATAGGAAAGAAAGAATCTCAAGATTAGAAATCTTTTCGTCTGTTCACAAAAATCTCTAT 
3 aa 
TMS 
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Appendix 5 
Amino acid analysis result for chemically-synthesised S-H4 (Section 4.2.6.2). Note 
that asparagine and glutamine are hydrolysed to aspartic acid and glutamic acid 
respectively, so are counted in this manner in the output. The indole ring of 
tryptophan is destroyed during hydrolysis, so this amino acid is not identified. 
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Appendix 6 
Growth curve of pBAD/gIII-K2C18-CPD (see Section 4.3), performed as per Section 
4.2.2.3 (n = 2, representative shown) and overlaid on Figure 4.4. The growth 
inhibitory effect of K2C18 tagged at the C-terminus with CPD falls between that of 
pBAD/gIII-K2C38* and pBAD/gIII-K2C18*. 
 
 
246 
Appendix 7 
The 6,013 bp sequence of plasmid pAG2-A!42 (Section 5.2.1.1). Includes 
mutations to vector (backbone is pBAD/gIII-A) acquired during construction 
(G1603T, deletion of T at position 1905); these are in regions of the plasmid that 
are not predicted to have any function. The A!42-EGFP gene (Baine et al., 2009) 
contains the arabinose-inducible araBAD promoter; the Library gene contains a 
strong constitutive promoter (BBa_J23119); and the mCherry gene contains a 
medium constitutive promoter (BBa_J23101). All genes share similar terminator 
regions, i.e. E. coli rrnB operon T1/T2 terminators (underlined). 
 
Key for coding regions: A!42 Linker EGFP mCherry Library ATG 
 
AAGAAACCAATTGTCCATATTGCATCAGACATTGCCGTCACTGCGTCTTTTACTGGCTCTTCTCGCTAACCAAA
CCGGTAACCCCGCTTATTAAAAGCATTCTGTAACAAAGCGGGACCAAAGCCATGACAAAAACGCGTAACAAAAG
TGTCTATAATCACGGCAGAAAAGTCCACATTGATTATTTGCACGGCGTCACACTTTGCTATGCCATAGCATTTT
TATCCATAAGATTAGCGGATCCTACCTGACGCTTTTTATCGCAACTCTCTACTGTTTCTCCATACCCGTTTTTT
GGGCTAACAGGAGGAATTAACCATGGATGCGGAATTTCGCCATGATTCTGGCTATGAAGTGCATCATCAGAAAC
TGGTGTTTTTTGCGGAAGATGTGGGCTCTAACAAAGGCGCGATTATTGGCCTGATGGTGGGCGGCGTGGTGATT
GCGGGATCCGCTGGCTCCGCTGCTGGTTCTGGCGAATCCCATATGGTGAGCAAGGGCGAGGAGCTGTTCACCGG
GGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGG
GCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACC
CTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTT
CAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCC
GCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGAC
GGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAA
GAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACC
AGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTG
AGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGG
CATGGACGAGCTGTACAAGTAAACGGTCTCCAGCTTGGCTGTTTTGGCGGATGAGAGAAGATTTTCAGCCTGAT
ACAGATTAAATCAGAACGCAGAAGCGGTCTGATAAAACAGAATTTGCCTGGCGGCAGTAGCGCGGTGGTCCCAC
CTGACCCCATGCCGAACTCAGAAGTGAAACGCCGTAGCGCCGATGGTAGTGTGGGGTCTCCCCATGCGAGAGTA
GGGAACTGCCAGGCATCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGT
CGGTGAACGCTCTCCTGAGTAGGACAAATCCGCCGGGAGCGGATTTGAACGTTGCGAAGCTTGACAGCTAGCTC
AGTCCTAGGTATAATGCTAGCTACTCCGCAAAGAGGAGAAAACTAGTATGAGCGCTGACTAGGTGAGACGTCAG
GCGACGTGCCTGGCTGCAGTAGCGCGGTGGTCCCACCTGACCCCATGCCGAACTCAGAAGTGAAACGCCGTAGC
GCCGATGGTAGTGTGGGGTCTCCCCATGCGAGAGTAGGGAACTGCCAGGCATCAAATAAAACGAAAGGCTCAGT
CGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGGTGAACGCTCTCCTCCGCCATAAACTGCCAGGCATC
AAATTAAGCAGAAGGCCATCCTGACGGATGGCCTTTTTGCGTTTCTACAAACTCTTTTGTTTATTTTTCTAAAT
ACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTA
TGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCA
GAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAA
CAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTAT
GTGGCGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGAC
TTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGC
CATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTT
TTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAAC
GACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTAC
TCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCC
TTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTG
GGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAA
TAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATAC
TTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACC
AAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGA
TCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGG
ATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTA
GTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTT
ACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGG
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CGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGA
TACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGG
CAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGT
TTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGC
AACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGA
TTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCG
AGTCAGTGAGCGAGGAAGCGGAAGAGCGCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTCACAC
CGCATATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGTATACACTCCGCTATCGCTT
TACAGCTAGCTCAGTCCTAGGTATTATGCTAGCTACTAGAGAAAGAGGAGAAATACTAGATGGTGAGCAAGGGC
GAGGAGGATAACATGGCCATCATCAAGGAGTTCATGCGCTTCAAGGTGCACATGGAGGGCTCCGTGAACGGCCA
CGAGTTCGAGATCGAGGGCGAGGGCGAGGGCCGCCCCTACGAGGGCACCCAGACCGCCAAGCTGAAGGTGACCA
AGGGTGGCCCCCTGCCCTTCGCCTGGGACATCCTGTCCCCTCAGTTCATGTACGGCTCCAAGGCCTACGTGAAG
CACCCCGCCGACATCCCCGACTACTTGAAGCTGTCCTTCCCCGAGGGCTTCAAGTGGGAGCGCGTGATGAACTT
CGAGGACGGCGGCGTGGTGACCGTGACCCAGGACTCCTCCTTGCAGGACGGCGAGTTCATCTACAAGGTGAAGC
TGCGCGGCACCAACTTCCCCTCCGACGGCCCCGTAATGCAGAAGAAGACCATGGGCTGGGAGGCCTCCTCCGAG
CGGATGTACCCCGAGGACGGCGCCCTGAAGGGCGAGATCAAGCAGAGGCTGAAGCTGAAGGACGGCGGCCACTA
CGACGCTGAGGTCAAGACCACCTACAAGGCCAAGAAGCCCGTGCAGCTGCCCGGCGCCTACAACGTCAACATCA
AGTTGGACATCACCTCCCACAACGAGGACTACACCATCGTGGAACAGTACGAACGCGCCGAGGGCCGCCACTCC
ACCGGCGGCATGGACGAGCTGTACAAGTAATAATACTAGAGCCAGGCATCAAATAAAACGAAAGGCTCAGTCGA
AAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGGTGAACGCTCTCTACTAGAGTCACACTGGCTCACCTTCG
GGTGGGCCTTTCTGCGTTTATAGGTCATGGCTGCGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGG
GCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTC
ACCGTCATCACCGAAACGCGCGAGGCAGCAGATCAATTCGCGCGCGAAGGCGAAGCGGCATGCATAATGTGCCT
GTCAAATGGACGAAGCAGGGATTCTGCAAACCCTATGCTACTCCGTCAAGCCGTCAATTGTCTGATTCGTTACC
AATTATGACAACTTGACGGCTACATCATTCACTTTTTCTTCACAACCGGCACGGAACTCGCTCGGGCTGGCCCC
GGTGCATTTTTTAAATACCCGCGAGAAATAGAGTTGATCGTCAAAACCAACATTGCGACCGACGGTGGCGATAG
GCATCCGGGTGGTGCTCAAAAGCAGCTTCGCCTGGCTGATACGTTGGTCCTCGCGCCAGCTTAAGACGCTAATC
CCTAACTGCTGGCGGAAAAGATGTGACAGACGCGACGGCGACAAGCAAACATGCTGTGCGACGCTGGCGATATC
AAAATTGCTGTCTGCCAGGTGATCGCTGATGTACTGACAAGCCTCGCGTACCCGATTATCCATCGGTGGATGGA
GCGACTCGTTAATCGCTTCCATGCGCCGCAGTAACAATTGCTCAAGCAGATTTATCGCCAGCAGCTCCGAATAG
CGCCCTTCCCCTTGCCCGGCGTTAATGATTTGCCCAAACAGGTCGCTGAAATGCGGCTGGTGCGCTTCATCCGG
GCGAAAGAACCCCGTATTGGCAAATATTGACGGCCAGTTAAGCCATTCATGCCAGTAGGCGCGCGGACGAAAGT
AAACCCACTGGTGATACCATTCGCGAGCCTCCGGATGACGACCGTAGTGATGAATCTCTCCTGGCGGGAACAGC
AAAATATCACCCGGTCGGCAAACAAATTCTCGTCCCTGATTTTTCACCACCCCCTGACCGCGAATGGTGAGATT
GAGAATATAACCTTTCATTCCCAGCGGTCGGTCGATAAAAAAATCGAGATAACCGTTGGCCTCAATCGGCGTTA
AACCCGCCACCAGATGGGCATTAAACGAGTATCCCGGCAGCAGGGGATCATTTTGCGCTTCAGCCATACTTTTC
ATACTCCCGCCATTCAGAG 
 
Translated (295 aa): 
MDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIAGSAGSAAGSGESHMVSKGEELFTGVVPILVE
LDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPEG
YVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNF
KIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITLGMDELYK* 
 
The linker is nearly the same as that used by Waldo et al. (1999) in their GFP 
folding reporter, except GSAGSAAGSGEF has been modified to 
GSAGSAAGSGESHMV, making it 3 aa longer. 
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Appendix 8 
The 228 bp sequence of the Library site of plasmid pAG2-A!42 (Section 5.2.1.1). 
Regions in order of notation: BBa_J23119 constitutive promoter (highlighted), 
BBa_B0034 ribosome binding site (highlighted), SpeI site (underlined), start codon 
(bold), AfeI site (underlined), stop codons for all three reading frames (bold), rrnB 
T1 & T2 transcriptional terminators (highlighted). 
 
TTGACAGCTAGCTCAGTCCTAGGTATAATGCTAGCTACTCCGCAAAGAGGAGAAAACTAGT
ATGAGCGCTGACTAGGTGAGACGTCAGGCGACGTGCCTGGCTGCAGTAGCGCGGTGGTCCC
ACCTGACCCCATGCCGAACTCAGAAGTGAAACGCCGTAGCGCCGATGGTAGTGTGGGGTCT
CCCCATGCGAGAGTAGGGAACTGCCAGGCATCAAATAAAACGAAAGGCTCAGTCGAAAGAC
TGGGCCTTTCGTTTTATCTGTTGTTTGTCGGTGAACGCTCTCCT 
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Appendix 9 
Random DNA sequences inserted into the pAG2-A!42 Library SpeI/AfeI site are 
shown (between the fixed start and stop codons), as well as the predicted 
translation product(s). A number of constructs may contain additional open reading 
frames (ORFs), including the use of alternative start codons such as GTG (Blattner 
et al., 1997); these are underlined where applicable. In the case of 
pAG2-A!42-110-A3-5, an additional putative RBS is highlighted (Ringquist et al., 
1992; Chen et al., 1994). For the original Library site RBS and distance from the 
start codon (7 bp), see Appendix 8. Some peptides contain plasmid-contributed 
residues, i.e. those outside the insert DNA sequence (underlined). The initiating 
methionine is also assumed to be removed (Ben-Bassat et al., 1987).  
 
For properties of the peptides, see Section 5.2.4.5. 
 
A!42 
126 bp 
GATGCGGAATTTCGCCATGATTCTGGCTATGAAGTGCATCATCAGAAACTGGTGTTTTTTGCGGAAGA
TGTGGGCTCTAACAAAGGCGCGATTATTGGCCTGATGGTGGGCGGCGTGGTGATTGCG 
42 aa 
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA 
 
GM6 
 126 bp 
GATGCGGAATTTCGCCATGATTCTGGCTATGAAGTGCATCATCAGAAACTGGTGTCTTTTGCGGAAGA
TGTGGGCTCTAACAAAGGCGCGATTATTGGCCCGATGGTGGGCGGCGTGGTGATTGCG 
42 aa 
DAEFRHDSGYEVHHQKLVSFAEDVGSNKGAIIGPMVGGVVIA 
Mutations in comparison to A!42 indicated in bold. 
 
pAG2-A!42-Pep2 
 42 bp 
CAGAAACTGGATGTGGTAGCGGAAGATGCTGGCTCTAACAAA 
14 aa 
QKLDVVAEDAGSNK 
 
pAG2-A!42-AavLEA1 
426 bp 
TCCTCTCAGCAGAACCAGAACCGACAGGGTGAGCAGCAGGAGCAGGGCTACATGGAGGCGGCCAAGGA
GAAGGTCGTCAACGCATGGGAGAGCACGAAGGAAACCCTCTCGAGCACGGCTCAAGCGGCCGCCGAGA
AGACGGCTGAGTTTCGCGATTCCGCCGGTGAGACCATCCGTGACCTGACCGGACAGGCGCAGGAGAAG
GGTCAGGAGTTCAAGGAGCGCGCTGGCGAGAAGGCAGAGGAGACGAAGCAGCGTGCCGGGGAGAAGAT
GGATGAGACCAAGCAGCGGGCTGGCGAAATGCGCGAGAACGCGGGCCAGAAGATGGAGGAGTACAAGC
AGCAGGGCAAGGGCAAGGCCGAGGAGCTTCGCGACACTGCCGCCGAGAAGCTCCACCAGGCTGGCGAG
AAGGTCAAGGGCCGCGAC 
142 aa 
SSQQNQNRQGEQQEQGYMEAAKEKVVNAWESTKETLSSTAQAAAEKTAEFRDSAGETIRDLTGQAQEK
GQEFKERAGEKAEETKQRAGEKMDETKQRAGEMRENAGQKMEEYKQQGKGKAEELRDTAAEKLHQAGE
KVKGRD 
 
pAG2-A!42-74-B1-3 
36 bp 
CCAGGGAAGAGGGCGAAACGAACAGGGAGGTGGTAG 
11 aa 
PGKRAKRTGRW 
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pAG2-A!42-74-B1-5 
36 bp 
ACTCCGGGGGGATGGATACCCCTGCAGCGCAACGGG 
12 aa 
TPGGWIPLQRNG 
 
pAG2-A!42-74-B2-6 
36 bp 
GCCCAGGGACGGGGGCGCGATTGCAGCGGAGGCAGG 
12 aa 
AQGRGRDCSGGR 
 
pAG2-A!42-74-B4-3 
36 bp 
AGGGTCGGGGGAGGCCCAGCGGGGTAGGACGCCTCT 
8 aa 
RVGGGPAG 
No other potential ORFs. 
 
pAG2-A!42-74-C1-1 
36 bp 
GGACTCCACTAAGTCGGCGGCTGCGGGGCAGTCAGA 
3 aa 
GLH 
No other potential ORFs. 
 
pAG2-A!42-74-C3-1 
53 bp 
GAGCCAGGGAAGGGTCCCAACGACTTCGGCAAACATTGAAGCGCATCGGATCA 
12 aa 
EPGKGPNDFGKH 
 
pAG2-A!42-74-C4-1 
36 bp 
GCACGGAAGCCAGTGGGCCGACGAGCGACACGGGGG 
12 aa 
ARKPVGRRATRG 
 
pAG2-A!42-74-C4-3 
36 bp 
GTGGCGGGGGCGGGAGGAGGCAATTCCCAGGCTCCA 
12 aa 
VAGAGGGNSQAP 
 
pAG2-A!42-74-C4-4 
52 bp 
TGCAGGAGGGATCAAAGAGCCCGGCACCAGAGAGGCTGAAGCGCATCGGATC 
12 aa 
CRRDQRARHQRG 
 
pAG2-A!42-74-A1-A 
97 bp 
AGCAGAAACGTTGGCGGGCGTGGCCTGCGGCGCCGTTGAAGCGCACGCTGCGACTAGTATGTGAGGGG
GGTTTTGGGCTGCTTGTTTGGGGGGTGGT 
12 aa 
SRNVGGRGLRRR 
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pAG2-A!42-74-B1-B 
36 bp 
GTGCACCTGCCACGGGGGCTGGTGGTCCGGGAACGT 
12 aa 
VHLPRGLVVRER 
 
pAG2-A!42-110-A1-1 
71 bp 
TTGGCATGTGGTCGGTGCAGGTGATGGATAGGATGTGTGGTAACACCACAGACCCCCAGGGAAACGGC
GGG 
8 aa 
LACGRCR 
Alternative ORF, using ATG 15 bp downstream of RBS: 
21 aa 
WSVQVMDRMCGNTTDPQGNGG 
 
pAG2-A!42-110-A1-4 
88 bp 
CGGATGTGTGGGAATAGTGTCGGGCGGTCGGTGTGGGTTTCGGGTAGGGTAGCTCAAAGGACGAGCGG
ACGGTGAAGCGCATCGGATC 
24 aa 
RMCGNSVGRSVWVSGRVAQRTSGR 
 
pAG2-A!42-110-A3-5 
167 bp 
GCCGTGTAGTTCGTGGAGAGGGACGAAGACAGCTAGCGCCGAGGGATGCTCTGCCCCAGCCGCCCCGT
GTTTTGAAGCGCACGCTGCGACTAGTATGCGCAACAATTGGAGCCAAGCAGACCAGAGAAGGGACGAC
GCGATGGGGCACGGGGCGGGCAGGAAGTGGA 
2 aa 
AV 
Alternative ORF, using ATG 8 bp downstream of a putative RBS (highlighted above): 
11 aa 
GHGAGRKWMKR 
 
pAG2-A!42-110-B1-3 
78 bp 
GATGCTAAGCGTGGATAGTTCGCCGGCAGGGGTTGGCATGGGCGGGCGAGCAGGGGCCCGACACGGGC
GGGGTGAAGC 
5 aa 
DAKRG 
Alternative ORF, using ATG 11 bp downstream of RBS: 
25 aa 
LSVDSSPAGVGMGGRAGARHGRGEA 
 
pAG2-A!42-110-C2-2 
72 bp 
CGGGACACGGAGCTGTGGCAGTACAAGGATGGTTGTAGATGTGTAGTAGGGGTTGGATGGGATCGCTA
TAGT 
24 aa 
RDTELWQYKDGCRCVVGVGWDRYS 
 
pAG2-A!42-110-C2-3 
72 bp 
GTGAGGCGCTTCGGGGTCGTCTCTCTCAGAGGACGAGAGAAGAGAGCATTGCGGGGGGGCAGGGGCGA
TGTCA 
0 aa 
* 
Alternative ORF, using GTG 9 bp downstream of RBS: 
26 aa 
RRFGVVSLRGREKRALRGGRGDVMKR 
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pAG2-A!42-110-C3-3 
72 bp 
CTAGACAGGGGTTTGGTGGACAGGGAGTATAGTCGCAGGGGTCAAGCTTTTGGGCAGTTATGCGCAAG
GGGG 
24 aa 
LDRGLVDREYSRRGQAFGQLCARG 
 
pAG2-A!42-110-C3-7 
72 bp 
GGGCAGGGTTGCCGCATGGTCAATGACCCTCATAAGAGGGCGCGGGGGAGAGGTAGGCGAGGGAGCCA
GGGG 
24 aa 
GQGCRMVNDPHKRARGRGRRGSQG 
 
pAG2-A!42-110-C4-3 
72 bp 
CGGCCTGGGTCGGTTGATTCTGAACAGACGAGTGTTTTGTTGAAATCTTCCTTTCGGGTATACAAGGA
CAGT 
24 aa 
RPGSVDSEQTSVLLKSSFRVYKDS 
 
pAG2-A!42-110-A1-A 
72 bp 
GGCGAATAGATCGCTTGGCGGGAGCGGGAGCGAGTGGGAAAGAACGATTTCATAGACAATTTTTAGTG
TGGA 
2 aa 
GE 
No other potential ORFs. 
 
pAG2-A!42-110-B1-B 
72 bp 
GGTGAAACGACTAGTGTGCGAACGGCGTAGTGGATTCAGGAGTCGGAGTCGATGGGTGTGGTGATCCG
CTTG 
9 aa 
GETTSVRTA 
 
pAG2-A!42-110-C1-C 
72 bp 
AGTGCGCCTTGTATTATGGGATCGGGGCGTTGTGGGGTTTTAGACTCGGTCAACTTTCGCTCCCGCAG
TACC 
24 aa 
SAPCIMGSGRCGVLDSVNFRSRST 
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Appendix 10 
Flow cytometry dot plots of analysed putative antiaggregant hits from the 
pAG2-A!42-74 and pAG2-A!42-110 libraries (Section 5.2.4.3). This analysis was 
repeated a total of 3 times; one representative run is shown. Cultures induced for 
14 h at 37ºC at ~225 rpm before analysis of EGFP and mCherry fluorescence. 
100,000 total events recorded per plot (red highest density, blue lowest), then an 
initial gating scheme was used on all samples to doublet discriminate (see Section 
2.7.5.1 and Section 5.2.2.4). A region of interest was calibrated as per Section 
5.2.2.4. Median fluorescence intensity (arbitrary units) shown for whole plot: EGFP 
(green bullet), mCherry (red bullet). 
 
 
 
Continued over page. 
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